<SEC-DOCUMENT>0001125345-22-000090.txt : 20220808
<SEC-HEADER>0001125345-22-000090.hdr.sgml : 20220808
<ACCEPTANCE-DATETIME>20220808160458
ACCESSION NUMBER:		0001125345-22-000090
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		51
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220808
DATE AS OF CHANGE:		20220808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		221144289

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mgnx-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:c76f9653-d31d-4b72-a3cc-7cc008424052,g:58338f7a-a7b2-4bbd-85aa-a2b62be307be,d:01067eced90d451488548dfbb9077922--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:mgnx="http://macrogenics.com/20220630" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mgnx-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80L2ZyYWc6NWI1NzFlNDBjZDE5NDNiYjkxNmMxZjFmYmExN2VlYjYvdGFibGU6YThiZTQ1YzIzMGNjNDkxMTgwMjQyYmUzMThjOWVlNzkvdGFibGVyYW5nZTphOGJlNDVjMjMwY2M0OTExODAyNDJiZTMxOGM5ZWU3OV8yLTEtMS0xLTQ2MzM4_468d7ef4-50b9-49c1-a2bc-15656b57b7ff">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80L2ZyYWc6NWI1NzFlNDBjZDE5NDNiYjkxNmMxZjFmYmExN2VlYjYvdGFibGU6YThiZTQ1YzIzMGNjNDkxMTgwMjQyYmUzMThjOWVlNzkvdGFibGVyYW5nZTphOGJlNDVjMjMwY2M0OTExODAyNDJiZTMxOGM5ZWU3OV80LTEtMS0xLTQ2MzM4_f048a2b3-3031-456f-bd94-dcc17050f18f">2022</ix:nonNumeric><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80L2ZyYWc6NWI1NzFlNDBjZDE5NDNiYjkxNmMxZjFmYmExN2VlYjYvdGFibGU6YThiZTQ1YzIzMGNjNDkxMTgwMjQyYmUzMThjOWVlNzkvdGFibGVyYW5nZTphOGJlNDVjMjMwY2M0OTExODAyNDJiZTMxOGM5ZWU3OV81LTEtMS0xLTQ2MzM4_b82b2222-8717-4d3c-a8ba-0c4d7f7a1972">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80L2ZyYWc6NWI1NzFlNDBjZDE5NDNiYjkxNmMxZjFmYmExN2VlYjYvdGV4dHJlZ2lvbjo1YjU3MWU0MGNkMTk0M2JiOTE2YzFmMWZiYTE3ZWViNl8xMzA_dda1eef6-9d56-481f-875b-112ed6a31123">0001125345</ix:nonNumeric><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80L2ZyYWc6NWI1NzFlNDBjZDE5NDNiYjkxNmMxZjFmYmExN2VlYjYvdGV4dHJlZ2lvbjo1YjU3MWU0MGNkMTk0M2JiOTE2YzFmMWZiYTE3ZWViNl8xMzI_f362e2bb-45dd-45e1-b11c-a6f2ce89ae3a">--12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mgnx-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic86da2ca86ec48249282e0c8b9afcedb_I20220803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i111ca364d8d9452c98412cfc77554d5c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i1aa36d71f2554ec7ac421732f1d56211_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1474e19bd49641ca95f1df5b97ffda84_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c5b5f80fcf64edf9a7ce9cdd569016c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5520922931f84525b041ec1a665396db_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70f2b39b029e4400ab336e9eb752d124_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6157a5193cc4e70a8fa23f4827f2dbb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if15ff1812c10442899e2cf54325cbfe9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b3615a23c9c49bc81b71aa860b0c3fa_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ca289337e7c4ed690151a7e54c4fc70_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide2e659901eb4ab195007de738bac04a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7335a3b467a240e1858fea3db99d4a4d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d787d37774e49e1915ebd2702c26bdb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d736da8f18d4111a5767bccb6535145_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idebaf5ecdd6c4fea8b83671370499c05_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d4bdfd68712460f823d1bf125c86b3f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03eb5525f9b94ed7873d9f8250b3cca6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6975b1f7488c45198ae9150fbe3b8c7b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0c69bb719c3497d90be7f759811e800_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaff1f4fb6ef74e32a52bbd7c4bb14937_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5305ed22a6544700a6decb559d43709a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9409a0811aab41deb09d84f3c21fdd0f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02e4e511353d4dd8adc8ee7f27200377_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9193ad0c43c49adb87caf0bb8cc1a6a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia01bbab25f694758af9fdb20e188c211_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6af280d8c83413794a1f147acb2c7b5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84633159b9d94cbaba6793f1e6477f84_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09ff33671d854a77b9d0d807ec309f96_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c6e7b24f80040eab49e7800603cd599_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eb8f9dc25b944a7aafb7dd67b63c8eb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id238f32381334840b79f44311e1018c2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i421f9269a5cb42afa04a5399caed4fd6_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1913ba16a654f48bcf967f37f5fb82a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie08c6695ec9b444685aa4d16e4738d38_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eccd5582ce54a15822ae39c44fefe89_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2528ec96deee48b9987b5e9d12b2014b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7860cbece44418a8ff3040d49e386e3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15f04b0e26d44b449fc94c3e591045a1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a41dc55370a496293ef975cede85db1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4e23f5d9b7e42e6af2e22c7b835b9ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i315ea40550944380a8a795ffaf599935_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d1da529eb6147c8bcc77a537372ae17_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28c3d485a47347b8a63e5c0279d3d948_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2bddaadb46348c0b4ffff238bc156b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f8510121d6c43aa911e2ac76934ed91_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id01dffdb96844c10acb64f346aef127a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d5a5adb662d4445b57b4f674696d537_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2ba53e0fd1a4ee8bf3144621333cc43_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc5b069d236c47748328d17bca6c1d10_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3b3a5a72fdd4b3da840a570e5af718b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5451c73989d1424e9f9e8846cbf00e5c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ebb9cbc861e4a39b4be17cc2b7ea234_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33615ead81b149f3b55531f86d45463c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i705e1bd323d14eb592155589c5b08fec_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5296297226cf40d094b2d74708621179_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c0b210150ec456fa3744f3cc68cea51_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8484507c9a614dbabce63ba8e51bfce5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbfc2b733cfd4233983a58b4045191a4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d08ce914c5c47fd8befe84917164ba8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie06048008ce14472b49e66e78b382b06_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71939f0c66ac4a5da0b6b7b12b9d9d10_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88719d0849ae41bd9b947552c67ca2c2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ef21de7a8c14c07a9a31936ea4dcc72_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f2cf382a17b4e04bc62223c9662497b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaee5df7c6fd24644b6271803fce2aae2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3209e333ef1b4efc9f643a26585398bb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cacffd890924583aaf540298dbf7a8c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74bfe05c99f446cba0ad613ef542784b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic926423ab3114b2784c30e3020c5be6e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2edf905318ec4cc88d408a7710dfea8b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i412eca49d41d47de87d3a53713b8e50e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9708b71437741bc98bf41f57791fef6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c140531ab074f03aea8d010a367b9b3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i232d1bddbda24a9786d7b4e89ec55bfc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7d4f9b1948e4f9c8fc832ab374f303c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e22930bedfe4f48b55574f1491fe4b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5c4c855042e4bc586a5317d9125cfe4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dfffc601f2c44cf829806a11359034d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie88ae8b3089f4d8bbd25cc1cecc99d47_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8d60276ffc34955ab0ae2df036b1032_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64bbb463b56f459e848a5399c786db9b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad0c041aa4bc458e8e7d118fe4c9e08f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied25e1f92b644194804e5004a17b2d7d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id44b34a1bd494162bed536c9eb0de155_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75ac06ceb7484bb8bd34e4033c4faf19_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19535bf1b5074b99b2df151eb4bc4d31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5bf3535880a4ceb822d925ba094e608_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib610d63458364b959341d2c275fc3966_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79d5f7405cf1437c9d2766b6093531d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i250e6d1dd1d14d73a9e40891670e7259_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19fed250b414468dbaf9d90c31a31e26_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae8184b5fd91450ea18de2dae673882c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa546adbe93e4c63a396fe25106b66ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31aa193c0dfc4403bbdb295edc147c6e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia56c7c0c5dd64063ade2d2b387b7f6c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ae83217782a49f581625143e7d04f9d_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6b440df4f4e426d8d698f7cb5f42342_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99f0316ba50d4c39a9c3d29ef8473c34_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d0a69ad66bb4c0b8b17295ffe63c014_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6417b05cf7d64d0bb5cc9aa0b049314b_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1adbba07b474f27be0bcec58c6f439a_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8862965ac7c74eaa91fbf299dcefad53_I20210615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbbb27e355214928b77e2fc758f95088_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id672cb9284434e3a9202e6f51f077bac_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00c0c8a5e81842d6ad36655e19d61684_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b2a073d3c794192a595450d0028cae4_D20180101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96f7ff3791204451aedc226872ae5fcb_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d06233b12574a07a62e6512ccf7e4fb_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i61b3c4379d88468da27af3737a110d8c_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="performanceobligation"><xbrli:measure>mgnx:performanceObligation</xbrli:measure></xbrli:unit><xbrli:context id="i5c253e1b8d354889a4ce47f6161201e6_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf96f2f2d3bb4019aab8b83995fbefb6_D20170101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id33701a0fbcb45c99cf26d0167b17df9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76d65ceb505a48e1acdee1cd35c24fd7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8427f430b14a43c5a0c839c84cd2fac8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d2a0a32c3bf4466ba347ecd77c315eb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i252d416a130b4aef83acef014a242473_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i868d68accdbb4b1baea1ef30a6c728af_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie30a746971b840fa954d23a4bd59f89e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6171432917614920af3bc0adaae45923_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib69d294a237f46dbb406c9df90ddc345_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012SupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1434bddbeff34ada94d5f3a35035e034_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012SupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib07fdf3f2fc0440ca7f2e21164cc1d94_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012SupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if65110ca3e22439a98fecb99c1d702d2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012SupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b2807234912469ba06c538de023e4f5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27227311568a45f2b51cd61543ae9030_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8e1dffc03b44a83ab8e292584fd3d5b_D20200701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5b94f0e0eeb4a01aea4900a9c756dd1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb889204b9fb4dcc80d0bb9f95f21240_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6983323f60e4a67818ce6a331b74360_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fbf626084c549ea9aa5a07ec92ed81d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c76ddf33fdb445c8361740c1a5a1d36_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20167305bd354a7886c63d0edbe908a2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icba2317be6d9465d9e494fbbc525bc2c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55649e5833464f0ca12e4ad111b17c07_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ca75e3ff4904b2a89f832e75c1ca3da_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea8d6ea8007a4fedb1d035394ed7db3f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c3f1cf70f6e49f2a38e855d5b0e46c2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66ee9789245a4404aaebbe85e877994a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94bc3a3ceb5941fb8aa911e2ffb733eb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70ebe69ee2214b73974336b7a5727cc9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa61f3996c3c405984b11d51d65bf3ae_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05e7befa8e9d45b6893dabb2ea11e658_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae3a758cac9b4c67ac48b3d949bb81ab_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98ee39cd1bfe4c6fadfe480718e3ef13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f16bac8141c4383a00685b230199498_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i613268f3651e4fae832a1050b7bc8c75_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i702fa2d64613432cba42480b770b9427_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i460b9af7b2724b7e931ef3fcbb896107_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c06d5991f5342a9bc4118c142fb5a68_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6784addc67c4bffab8c458f3a96daaf_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i118a870a47a847ab9a59d307cf7a8dec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief27732f4ac54730a699b2393bb54497_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcd59b18a37243bfb09019e459954829_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c7222aea8cc4fe58941ee0a062a32d5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7f623bc792547a1a41b06a0787a398e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20c8da099331485ba579926bf66c0d17_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2497d88ae95c4519b39b87d1ba7cdeb7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic969da273e7b44dba3060478dc9568ab_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e4dca55397644a2849eaef94593433c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63be51e66fd743578dd0ea8c55b930fc_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9537b5eb6ae949c28d9293e9e3ce85f9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i427113310e024f5eb793d1e86f25cad4_D20220101-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic55bd316cd91463e82b7d37fc8a0975a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ee85754d5014401ad61235f662351ae_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i096d5137725d40148157656180087db8_D20150915-20150915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-15</xbrli:startDate><xbrli:endDate>2015-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="molecule"><xbrli:measure>mgnx:Molecule</xbrli:measure></xbrli:unit><xbrli:context id="i772a42253ce1405785340b3edb6899da_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4a0eb4c0fe649c482ed64bbcf0d0b11_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f9782aefce248e491b1017c418c61ad_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i655cea49e809491ba22491fc3a7a1477_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d1bdfd0b85f4ac79e062c9afd027395_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5806f140f2fb4121a04208d77d725e5d_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bb8e7382f584403b0bd73897bfafdc4_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5c46189a60a4d9e98d6758e10e520b4_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i164a86dfd80c4e50a7e23e302c1c0bf0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43fa69d5c22045ddbb94dd1e3a59d966_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:A2003StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i978da7f614aa4ea690dbff8c9356eb6d_I20131031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf3d70a2fb43424cb1591bef0c3534e4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d1a4774b1f345f19d161adf566fb6fd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5499db67d8414a0fbbfbf13e986ae6dd_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb0c8219b14e42c7aad0de17683ccf63_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if743a9b99df64882ac59cc7cf3cb3f2b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i133be2faddae4492b069093a43dfefae_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2c0a615ad08480184a8698a62ebdc4b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1253c83d5764ca2869c6ae3052e19ad_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e41bc1a29374b0f95aa6bf490e51d76_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39128793661549b8bdf32a8a1cc51c91_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7ffcf2243504d388387524c69d636c3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i424f99869a384d90912972e1c1b09528_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd329807983e4f3cb3e69df9ae058545_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5649fb8ec294f408a306886c4a94ba6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacfa9386b3a3414bbb61ae3690fcdc16_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1104b4f510e448a6aafaae0d08700a68_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a101c2276a549c7b6f9656b0b6d6551_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fd134611cfd4590aae18ff1ca79c965_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i01067eced90d451488548dfbb9077922_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGV4dHJlZ2lvbjphN2VmYTY2ZDMzYzA0NGM0YTUzNDM1NjM4YTY2NzkyNl84Mg_1310d4d9-2340-4362-9c91-cd2096cbe633">10-Q</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.337%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6ZmRkOWMzY2U1NzU2NGYyN2EwMTU5ZjNmYzNjNzliNzIvdGFibGVyYW5nZTpmZGQ5YzNjZTU3NTY0ZjI3YTAxNTlmM2ZjM2M3OWI3Ml8wLTAtMS0xLTQ2MzM4_8f2dccd2-7adb-4958-a3ab-7cff28027a1b">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGV4dHJlZ2lvbjphN2VmYTY2ZDMzYzA0NGM0YTUzNDM1NjM4YTY2NzkyNl8xMTc_c8822f59-1890-4e34-af85-ddc249310c98">June 30, 2022</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.337%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6NzFhN2E0YmJmNDMxNDAyMjgwMzBkNTgwOWRmYWE5YmUvdGFibGVyYW5nZTo3MWE3YTRiYmY0MzE0MDIyODAzMGQ1ODA5ZGZhYTliZV8wLTAtMS0xLTQ2MzM4_3fdcf9ce-9c40-49ac-9cd3-38b30789cbe4">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGV4dHJlZ2lvbjphN2VmYTY2ZDMzYzA0NGM0YTUzNDM1NjM4YTY2NzkyNl8yMDg_a404f032-c559-441d-ae1f-aa1037c877ea">001-36112</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGV4dHJlZ2lvbjphN2VmYTY2ZDMzYzA0NGM0YTUzNDM1NjM4YTY2NzkyNl8yMTE_103320ad-fa36-4537-ab22-45c0e53fc11d">MACROGENICS, INC.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6Y2YyZjM4NjAxZmYxNDc0OGE0MjAzMTYwZmI1ZThkMTUvdGFibGVyYW5nZTpjZjJmMzg2MDFmZjE0NzQ4YTQyMDMxNjBmYjVlOGQxNV8wLTAtMS0xLTQ2MzM4_ad9799d9-39f2-4508-9044-ee4b303e0d8c">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6Y2YyZjM4NjAxZmYxNDc0OGE0MjAzMTYwZmI1ZThkMTUvdGFibGVyYW5nZTpjZjJmMzg2MDFmZjE0NzQ4YTQyMDMxNjBmYjVlOGQxNV8wLTEtMS0xLTQ2MzM4_96517f0f-bdd8-4ce9-9915-fac6240ab2c2">06-1591613</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6Y2YyZjM4NjAxZmYxNDc0OGE0MjAzMTYwZmI1ZThkMTUvdGFibGVyYW5nZTpjZjJmMzg2MDFmZjE0NzQ4YTQyMDMxNjBmYjVlOGQxNV8zLTAtMS0xLTQ2MzM4L3RleHRyZWdpb246NGI3M2FmMWQ2NzU5NDNlZWIzZTBmOTczZDQ3ZmE0Y2ZfNQ_36636e0d-6904-4828-8fa8-a7b4701c21be">9704 Medical Center Drive</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6Y2YyZjM4NjAxZmYxNDc0OGE0MjAzMTYwZmI1ZThkMTUvdGFibGVyYW5nZTpjZjJmMzg2MDFmZjE0NzQ4YTQyMDMxNjBmYjVlOGQxNV8zLTAtMS0xLTQ2MzM4L3RleHRyZWdpb246NGI3M2FmMWQ2NzU5NDNlZWIzZTBmOTczZDQ3ZmE0Y2ZfOA_26e02701-8f7d-4c50-ab15-3e16661acbfe">Rockville</ix:nonNumeric>, <ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6Y2YyZjM4NjAxZmYxNDc0OGE0MjAzMTYwZmI1ZThkMTUvdGFibGVyYW5nZTpjZjJmMzg2MDFmZjE0NzQ4YTQyMDMxNjBmYjVlOGQxNV8zLTAtMS0xLTQ2MzM4L3RleHRyZWdpb246NGI3M2FmMWQ2NzU5NDNlZWIzZTBmOTczZDQ3ZmE0Y2ZfMTI_4301dde7-d345-440e-8a45-bced3fc0c839">Maryland</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6Y2YyZjM4NjAxZmYxNDc0OGE0MjAzMTYwZmI1ZThkMTUvdGFibGVyYW5nZTpjZjJmMzg2MDFmZjE0NzQ4YTQyMDMxNjBmYjVlOGQxNV8zLTEtMS0xLTQ2MzM4_9758677b-8a41-4fc9-a839-1901cc711e87">20850</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Zip code)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGV4dHJlZ2lvbjphN2VmYTY2ZDMzYzA0NGM0YTUzNDM1NjM4YTY2NzkyNl8yNzA_ce00e72c-1d49-4834-bc46-aabbab472816">301</ix:nonNumeric>-<ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGV4dHJlZ2lvbjphN2VmYTY2ZDMzYzA0NGM0YTUzNDM1NjM4YTY2NzkyNl8yNzM_e3948d22-65d1-433f-b7ba-15720c8305fe">251-5172</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant's telephone number, including area code)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:36.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6MjBiMDFlYzExMWY3NDdkMWEyY2MwNjY1OWJhNWRlOTkvdGFibGVyYW5nZToyMGIwMWVjMTExZjc0N2QxYTJjYzA2NjU5YmE1ZGU5OV8xLTAtMS0xLTQ2MzM4_840ac799-ee87-425c-af4f-857a41238d76">Common Stock, par value $0.01 per share</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6MjBiMDFlYzExMWY3NDdkMWEyY2MwNjY1OWJhNWRlOTkvdGFibGVyYW5nZToyMGIwMWVjMTExZjc0N2QxYTJjYzA2NjU5YmE1ZGU5OV8xLTEtMS0xLTQ2MzM4_496ddbf6-f680-44d0-8a7e-228d079c157c">MGNX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6MjBiMDFlYzExMWY3NDdkMWEyY2MwNjY1OWJhNWRlOTkvdGFibGVyYW5nZToyMGIwMWVjMTExZjc0N2QxYTJjYzA2NjU5YmE1ZGU5OV8xLTItMS0xLTQ2MzM4_ee52d341-e802-4323-8a21-7c2a313c2b3e">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGV4dHJlZ2lvbjphN2VmYTY2ZDMzYzA0NGM0YTUzNDM1NjM4YTY2NzkyNl8xOTE3_5309a683-6290-40e4-a47d-aa17d4df3a9f">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGV4dHJlZ2lvbjphN2VmYTY2ZDMzYzA0NGM0YTUzNDM1NjM4YTY2NzkyNl8xOTE1_b8c85808-13de-479d-adf6-5d302040ce7a">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "accelerated filer," "large accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:23.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6NzM5YjAyNzUwMjI2NDdjNzlhMDc5ZGM3NDhmZWZjYWYvdGFibGVyYW5nZTo3MzliMDI3NTAyMjY0N2M3OWEwNzlkYzc0OGZlZmNhZl8wLTAtMS0xLTQ2MzM4_3f80b6fe-cc9d-4f4f-a84e-42259f78d498">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6NzM5YjAyNzUwMjI2NDdjNzlhMDc5ZGM3NDhmZWZjYWYvdGFibGVyYW5nZTo3MzliMDI3NTAyMjY0N2M3OWEwNzlkYzc0OGZlZmNhZl8yLTMtMS0xLTQ2MzM4_a17ca926-7690-4ecf-b15a-66e5dcb1ffa6">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6NzM5YjAyNzUwMjI2NDdjNzlhMDc5ZGM3NDhmZWZjYWYvdGFibGVyYW5nZTo3MzliMDI3NTAyMjY0N2M3OWEwNzlkYzc0OGZlZmNhZl80LTEtMS0xLTQ2MzM4_3106c86d-7047-486f-b262-77dc85597840">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160; &#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGV4dHJlZ2lvbjphN2VmYTY2ZDMzYzA0NGM0YTUzNDM1NjM4YTY2NzkyNl8xOTE2_a47a48de-03f3-4ff9-b831-4d337c113bd0">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of August&#160;3, 2022, <ix:nonFraction unitRef="shares" contextRef="ic86da2ca86ec48249282e0c8b9afcedb_I20220803" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGV4dHJlZ2lvbjphN2VmYTY2ZDMzYzA0NGM0YTUzNDM1NjM4YTY2NzkyNl8xODI4_e2d7041a-424d-4a96-8c5b-5abe61c59d67">61,458,790</ix:nonFraction> shares of the registrant's common stock, par value $0.01 per share, were outstanding.</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i01067eced90d451488548dfbb9077922_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:23.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_13">FINANCIAL INFORMATION</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_16">Financial Statements</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_19">Consolidated Balance Sheets at</a> June&#160;30, 2022 (unaudited) and December&#160;31, 2021</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_22">Consolidated Statements of Operations and Comprehensive Loss for the three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_22"> and si</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_22">x</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_22"> months ended</a> June&#160;30, 2022<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_22"> and </a>June&#160;30, 2021<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_22"> (unaudited)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_25">Consolidated Statements of Stockholders' Equity for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_25">and six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_25">months ended </a>June&#160;30, 2022<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_25"> and </a>June&#160;30, 2021<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_25"> (unaudited)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_28">Consolidated Statements of Cash Flows for the</a> six<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_28"> months ended </a>June&#160;30, 2022<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_28"> and </a>June&#160;30, 2021<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_28"> (unaudited)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_31">Notes to Consolidated Financial Statements (unaudited)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_61">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_79">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_82">Controls and Procedures</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;II.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_85">OTHER INFORMATION</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_88">Legal Proceedings</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_91">Risk Factors</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_94">Exhibits</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01067eced90d451488548dfbb9077922_97">Signatures</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i01067eced90d451488548dfbb9077922_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Quarterly Report on Form 10-Q. Forward-looking statements can often be identified by the use of terminology such as "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under "Item 1A. Risk Factors" of our Annual Report on Form 10-K for the year ended December&#160;31, 2021 and "Part II, Item 1A. Risk Factors" of this Quarterly Report on Form 10-Q), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements:</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional capital through the capital markets or through one or more corporate partnerships, equity offerings, debt financings, collaborations, licensing arrangements or asset sales and the availability of financing to fund the development of our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to develop and commercialize our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcomes of our ongoing and planned clinical trials and the timing of those outcomes, including when clinical trials will be initiated or completed, and when data will be reported or regulatory filings will be made;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates and the labeling for any approved products;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to implement and realize expected cost savings from our restructuring plan;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding commercial prospects of or product revenues from MARGENZA and our product candidates if approved;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity and duration of the impact of the COVID-19 global pandemic, geopolitical tensions, and macroeconomic conditions on our business, operations, clinical programs, manufacturing, financial results and other aspects of our business;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding product candidates currently being developed by our collaborators;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into new collaborations or to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits and future operation of our existing collaborations; </span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recover the investment in our manufacturing capabilities;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our products;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant competition in our industry;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of litigation and the failure to successfully defend lawsuits and other claims against us and our expectations regarding the outcome of any regulatory or legal proceedings;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic, political and other risks associated with our international operations;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to receive research funding and achieve anticipated milestones under our collaborations;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect and enforce patents and other intellectual property;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss or retirement of key members of management;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to successfully execute our growth strategy, including any delays in our planned future growth; and</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to maintain effective internal controls.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i01067eced90d451488548dfbb9077922_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i01067eced90d451488548dfbb9077922_16"></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="i01067eced90d451488548dfbb9077922_19"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfNC0xLTEtMS00NjMzOA_65b04186-e803-4372-b126-a718ea3c9677">21,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfNC0zLTEtMS00NjMzOA_34e9748f-464b-46f1-9c7d-1f47d6e7d436">123,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfNS0xLTEtMS00NjMzOA_e3558d0d-b695-400e-8954-f998ee818a10">112,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfNS0zLTEtMS00NjMzOA_7e4979ac-016a-4fb8-8216-9e6c3ac78d58">120,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfNi0xLTEtMS00NjMzOA_88821d5e-e8a7-4d0c-96e9-dc5da56e0359">18,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfNi0zLTEtMS00NjMzOA_5ae277bc-0487-416f-9517-2c1a4c9bd7a3">10,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfNy0xLTEtMS00NjMzOA_35d96bba-23aa-466e-84c3-bd1041e516b6">2,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfNy0zLTEtMS00NjMzOA_1b12d84d-b966-4904-9f6f-130b875d688a">4,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfOC0xLTEtMS00NjMzOA_6a287449-c1aa-4771-9e85-02446eaa731b">12,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfOC0zLTEtMS00NjMzOA_e36d706b-f615-435f-afaf-47bc564e8112">21,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTAtMS0xLTEtNDYzMzg_a6524dc4-16bc-4357-acab-ce5978d8b7b0">167,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTAtMy0xLTEtNDYzMzg_e5261b62-5fdd-44bd-bb14-d1ab13136ee0">279,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTEtMS0xLTEtNDYzMzg_9c126235-ab8d-476c-ba52-a6cf24e61fe1">34,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTEtMy0xLTEtNDYzMzg_fb506c84-a25e-42f7-b7c9-d76a2d798cfa">37,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTMtMS0xLTEtNDYzMzg_a020a7b5-a68d-4010-b93f-8762d3398351">16,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTMtMy0xLTEtNDYzMzg_b93f78f9-659c-482d-b4e9-5c6997d25992">18,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTQtMS0xLTEtNDYzMzg_951d132f-e925-4d4f-9c79-b05007c576cd">218,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTQtMy0xLTEtNDYzMzg_21f604c6-13e3-412d-bdc8-17617601bc74">335,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTgtMS0xLTEtNDYzMzg_2f91c9c6-f85c-4943-b83a-c2053ed785dd">2,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTgtMy0xLTEtNDYzMzg_03b5d3a3-05c5-48e2-940d-a8a42b513e1d">15,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTktMS0xLTEtNDYzMzg_1f71d94b-c626-4a66-98a0-2f63c6fc4730">31,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTktMy0xLTEtNDYzMzg_90b8cdee-5459-411a-a0d7-38c53e0bf482">33,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjAtMS0xLTEtNDYzMzg_7268d3e5-e150-4888-a51d-3b2ccae200c8">11,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjAtMy0xLTEtNDYzMzg_6c1291e3-99bd-4d24-8e88-ee331cc66cf2">20,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjEtMS0xLTEtNDYzMzg_45b57871-7ca8-4630-8042-bc5e988a72ab">4,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjEtMy0xLTEtNDYzMzg_dbb489a2-e435-4165-acec-63d0db7e0a96">4,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjMtMS0xLTEtNDYzMzg_4a5ef22e-ce69-464f-8444-aa84a7ae38f1">50,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjMtMy0xLTEtNDYzMzg_3b239871-5309-41df-962b-d1d481512546">74,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjQtMS0xLTEtNDYzMzg_be11d5c5-29dc-47f8-b586-beba9ff51c05">6,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjQtMy0xLTEtNDYzMzg_d890e641-807e-43f6-9c7c-8a066d19bee4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjUtMS0xLTEtNDYzMzg_183305dc-58fe-47d8-913f-377af2a769db">18,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjUtMy0xLTEtNDYzMzg_d6bbf29b-e4d4-4830-b8d9-710cbbb0e0c8">20,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjYtMS0xLTEtNDYzMzg_1e3aa09c-d70a-4a74-a660-89b33abcc477">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjYtMy0xLTEtNDYzMzg_8f541a53-4eaf-41c0-b9a9-c3fa045d17f6">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjctMS0xLTEtNDYzMzg_96bb88a8-6141-4a08-81ab-966c408329aa">75,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjctMy0xLTEtNDYzMzg_66963f2a-e941-4373-bd19-e095feeca133">95,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjktMC0xLTEtNDYzMzgvdGV4dHJlZ2lvbjpjYmU3Y2EzZWNiNDA0ZmFiYjJiOWYxMmMwNTk5ZDAzZF8xOA_277b6099-cb74-4a7c-8f3b-0a3e7e1aaad3"><ix:nonFraction unitRef="usdPerShare" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjktMC0xLTEtNDYzMzgvdGV4dHJlZ2lvbjpjYmU3Y2EzZWNiNDA0ZmFiYjJiOWYxMmMwNTk5ZDAzZF8xOA_9396ead0-5846-46cb-a5dc-532c57c81f64">0.01</ix:nonFraction></ix:nonFraction> par value -- <ix:nonFraction unitRef="shares" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjktMC0xLTEtNDYzMzgvdGV4dHJlZ2lvbjpjYmU3Y2EzZWNiNDA0ZmFiYjJiOWYxMmMwNTk5ZDAzZF8zNA_d9151642-c4aa-407d-8672-781322b0c1ec"><ix:nonFraction unitRef="shares" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjktMC0xLTEtNDYzMzgvdGV4dHJlZ2lvbjpjYmU3Y2EzZWNiNDA0ZmFiYjJiOWYxMmMwNTk5ZDAzZF8zNA_fcfe45e1-e4c5-44cc-abed-bc476f98f087">125,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjktMC0xLTEtNDYzMzgvdGV4dHJlZ2lvbjpjYmU3Y2EzZWNiNDA0ZmFiYjJiOWYxMmMwNTk5ZDAzZF81Ng_99074007-bb9d-4ead-977e-82ef0280ef6f">61,458,790</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjktMC0xLTEtNDYzMzgvdGV4dHJlZ2lvbjpjYmU3Y2EzZWNiNDA0ZmFiYjJiOWYxMmMwNTk5ZDAzZF82Mw_a5e49d7d-daa1-4265-971d-661e4e753453">61,307,428</ix:nonFraction> shares outstanding at June&#160;30, 2022 and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjktMS0xLTEtNDYzMzg_afe67535-82b3-4fdc-98ea-4eb846dbc9b8">615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjktMy0xLTEtNDYzMzg_7b53442f-09aa-44d3-931d-2faa07b91c9c">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMzAtMS0xLTEtNDYzMzg_10e2365f-e6c5-492c-8aa3-be6a65e03b11">1,223,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMzAtMy0xLTEtNDYzMzg_07c0e3f3-2909-44ee-96f5-75a0ea96a9d4">1,213,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMzEtMS0xLTEtNDYzMzg_d37e1372-0569-49dd-8319-02a7ae0f7a13">326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMzEtMy0xLTEtNDYzMzg_8b44290c-1a6c-4b69-8a06-8098229a203d">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMzItMS0xLTEtNDYzMzg_231d5b18-857b-4d27-b5ec-41b38a3b8f95">1,081,683</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMzItMy0xLTEtNDYzMzg_d16b849c-0bce-4de9-9454-0c2ad052c76c">973,936</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMzMtMS0xLTEtNDYzMzg_cbfe408b-c2e0-442d-8596-78cf68ceae00">142,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMzMtMy0xLTEtNDYzMzg_96e856ef-fcfc-41de-b31d-f12e4294267f">239,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMzQtMS0xLTEtNDYzMzg_e8c79946-3e40-483a-8243-a8cd8bc61e7d">218,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMzQtMy0xLTEtNDYzMzg_a7382893-c3f6-4808-9ca1-06a55c52e152">335,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i01067eced90d451488548dfbb9077922_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.354%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative and other agreements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aa36d71f2554ec7ac421732f1d56211_D20220401-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMy0xLTEtMS00NjMzOA_3c6b7c68-f4ce-467b-af96-4e4c62257b3b">16,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1474e19bd49641ca95f1df5b97ffda84_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMy0zLTEtMS00NjMzOA_faf0a04b-0298-446a-92d6-4450ef5944ab">27,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c5b5f80fcf64edf9a7ce9cdd569016c_D20220101-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMy01LTEtMS00NjMzOA_f3d87405-f1a5-4bfa-ae7e-57c97018c56c">23,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5520922931f84525b041ec1a665396db_D20210101-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMy03LTEtMS00NjMzOA_0a96bf69-454f-48ef-ac5f-0d8c9d6c009e">42,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70f2b39b029e4400ab336e9eb752d124_D20220401-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNC0xLTEtMS00NjMzOA_94401956-be3e-46ef-bb2e-ba2345c07d8c">4,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6157a5193cc4e70a8fa23f4827f2dbb_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNC0zLTEtMS00NjMzOA_4d043f07-5903-424f-81a3-f4bdc92b5043">3,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if15ff1812c10442899e2cf54325cbfe9_D20220101-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNC01LTEtMS00NjMzOA_55e5050b-a8d3-4c2c-9f28-e412746c01c2">8,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3615a23c9c49bc81b71aa860b0c3fa_D20210101-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNC03LTEtMS00NjMzOA_5bd8fec9-7be5-4c44-b1b7-5223f1aff821">4,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca289337e7c4ed690151a7e54c4fc70_D20220401-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNS0xLTEtMS00NzY3MA_6a457ccd-38d9-42ce-a06d-57e5c8dfbf31">3,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide2e659901eb4ab195007de738bac04a_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNS0zLTEtMS00NzY3Nw_67b24d5d-758d-4408-b22e-a59173028b04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7335a3b467a240e1858fea3db99d4a4d_D20220101-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNS01LTEtMS00NzY4NA_33fa4f66-8d7b-4344-bb34-f95536df869f">3,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d787d37774e49e1915ebd2702c26bdb_D20210101-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNS03LTEtMS00NzY5MQ_29097958-9d33-4594-ae7c-b6a206ddfb56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d736da8f18d4111a5767bccb6535145_D20220401-20220630" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNS0xLTEtMS00NjMzOA_86bebe78-f53c-4459-b02e-bc66e0923568">480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idebaf5ecdd6c4fea8b83671370499c05_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNS0zLTEtMS00NjMzOA_50a35b06-6005-4ab8-9671-4328b0e1177c">386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d4bdfd68712460f823d1bf125c86b3f_D20220101-20220630" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNS01LTEtMS00NjMzOA_6bbb0bd3-9405-426b-a46d-1ce04908e7c0">908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03eb5525f9b94ed7873d9f8250b3cca6_D20210101-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNS03LTEtMS00NjMzOA_b3641e14-1c1e-491d-939c-447f98c7470a">1,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNi0xLTEtMS00NjMzOA_b198e8ec-2fee-4a75-a799-47df3e66b049">26,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNi0zLTEtMS00NjMzOA_bbbb8bcd-691c-4ad2-a6a2-fcf7d9be00a2">30,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNi01LTEtMS00NjMzOA_414d4af0-322f-438f-8fe4-8a91929ca505">37,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNi03LTEtMS00NjMzOA_1c9d8a9f-ac6b-43dd-a89b-1a62be7fc64f">47,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfOC0xLTEtMS00NjMzOA_26bbc01b-1a75-4c10-8a38-243f927b2510">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfOC0zLTEtMS00NjMzOA_ebfe5ca1-6959-41f3-944c-4bed82ee7de5">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfOC01LTEtMS00NjMzOA_73829530-84f0-48f2-acee-192becc8b087">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfOC03LTEtMS00NjMzOA_08c8d1a7-b4e1-4f79-b6b0-4843322149a7">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of manufacturing services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630" decimals="-3" name="mgnx:CostOfManufacturingServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTAtMS0xLTEtNDg5MTk_2321441d-a7cc-460c-912d-05cb66a6850e">2,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630" decimals="-3" name="mgnx:CostOfManufacturingServices" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTAtMy0xLTEtNDg4NjE_7d2a3d0b-5db5-4da2-ab6c-7db58281ce75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" name="mgnx:CostOfManufacturingServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTAtNS0xLTEtNDg5MjY_301f7ba9-9438-48bb-9587-d91d4da6e26e">2,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="mgnx:CostOfManufacturingServices" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTAtNy0xLTEtNDg4Njg_21caaeee-3ef5-4703-9c8d-d5755c7530dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfOS0xLTEtMS00NjMzOA_e12bf92f-033b-4eb7-bd12-a924565f46cc">51,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfOS0zLTEtMS00NjMzOA_2ca593d2-9dae-4afe-909f-011ff21e0c96">55,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfOS01LTEtMS00NjMzOA_001aeb49-7acb-41cd-9861-5225e9bda07a">113,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfOS03LTEtMS00NjMzOA_1073845a-4eda-4b64-b0b0-862dd16a9438">108,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTAtMS0xLTEtNDYzMzg_5dd235d6-fda9-45be-bdac-2a65a8abb4dc">13,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTAtMy0xLTEtNDYzMzg_eddb83e2-8dc5-46be-9992-9f8fd73f53f9">15,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTAtNS0xLTEtNDYzMzg_fde2ab81-b08a-44af-b973-e91d7b7c519b">29,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTAtNy0xLTEtNDYzMzg_4adaeb34-0391-4346-8d5f-b10f9dccc232">30,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTEtMS0xLTEtNDYzMzg_80ce15cd-7f7d-4f23-a161-17266fbad26c">67,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTEtMy0xLTEtNDYzMzg_a700a42d-af91-4f0f-be6d-8014caf818b3">71,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTEtNS0xLTEtNDYzMzg_21f1a69b-40b0-45bb-b963-0a7fbe68e004">145,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTEtNy0xLTEtNDYzMzg_35e5fabe-8893-40fc-9e9b-04a9fbdacbe4">139,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTItMS0xLTEtNDYzMzg_63ec869a-650d-4688-83df-cd5f837fac97">41,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTItMy0xLTEtNDYzMzg_d966b3de-ea80-478f-9fad-cc33b89c32c3">40,279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTItNS0xLTEtNDYzMzg_29bae111-bf5c-4075-86bb-4c2950640bce">108,446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTItNy0xLTEtNDYzMzg_684b6f56-4f76-4d93-b226-5e53c008f8dd">91,572</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTMtMS0xLTEtNDYzMzg_b52fa179-7591-44a7-938b-8fd615b1e68e">504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTMtMy0xLTEtNDYzMzg_da44ca30-4988-4cd5-8647-c0de4269eb65">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTMtNS0xLTEtNDYzMzg_aa728027-6fd5-4099-8350-f7ac4ea84247">699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTMtNy0xLTEtNDYzMzg_cb751312-13bf-4876-aa1d-949ea745e61c">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTQtMS0xLTEtNDYzMzg_6455e493-4243-4bed-8148-20a9d24abf89">41,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTQtMy0xLTEtNDYzMzg_72b0f0c3-9b4c-4913-8acd-d32590bbf537">39,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTQtNS0xLTEtNDYzMzg_e4df569d-ced5-450e-be4a-685382ae1f74">107,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTQtNy0xLTEtNDYzMzg_ebe5022a-ccff-4201-af34-9ab2a7234b28">91,207</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTYtMS0xLTEtNDYzMzg_4662572e-3511-4bbe-be82-d8d0288cd494">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTYtMy0xLTEtNDYzMzg_a20203aa-b929-4591-8da5-b6077d0ccb4b">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTYtNS0xLTEtNDYzMzg_ebf18ff9-be1a-4501-b3fa-a63a9ba24ebf">265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTYtNy0xLTEtNDYzMzg_d9ca0614-7324-4c40-878b-a09eaab27fd6">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTctMS0xLTEtNDYzMzg_5e0aca22-e9db-4080-ab0d-882e29442d1f">41,347</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTctMy0xLTEtNDYzMzg_b22599c1-8d61-404e-859a-536270f3c88b">39,945</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTctNS0xLTEtNDYzMzg_c98c431e-f137-4169-ac4a-34f36e22e21d">108,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTctNy0xLTEtNDYzMzg_7eb6c9c8-a11d-4a2c-8204-e3f0c4497bab">91,199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTktMS0xLTEtNDYzMzg_0999c159-2dc5-45fc-882e-ce10876c4f5a"><ix:nonFraction unitRef="usdPerShare" contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTktMS0xLTEtNDYzMzg_c0f11a93-a1f9-4eeb-a7e7-96a976c584f0">0.67</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTktMy0xLTEtNDYzMzg_6f93673a-dcb1-43f2-ac11-6d6b3e8424b7"><ix:nonFraction unitRef="usdPerShare" contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTktMy0xLTEtNDYzMzg_a596322c-4e0b-485b-8ae5-445f40db5c68">0.66</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTktNS0xLTEtNDYzMzg_a038e543-375b-4d5c-be13-a389074eae30"><ix:nonFraction unitRef="usdPerShare" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTktNS0xLTEtNDYzMzg_e4e96c58-43dc-48f5-b820-6276ef40b117">1.76</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTktNy0xLTEtNDYzMzg_4acf468c-249e-40d7-ba04-2b0e0dc0626a"><ix:nonFraction unitRef="usdPerShare" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTktNy0xLTEtNDYzMzg_ac63542d-352c-42de-9fce-f3f8e7b2ffa7">1.56</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMjAtMS0xLTEtNDYzMzg_6c819133-30b6-468d-b7c6-5900a861aa36"><ix:nonFraction unitRef="shares" contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMjAtMS0xLTEtNDYzMzg_9c44e4a4-fd2d-4791-bd24-e1b423775ba2">61,384,943</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMjAtMy0xLTEtNDYzMzg_46479fff-02d5-4a87-824b-aec52e2ad78d"><ix:nonFraction unitRef="shares" contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMjAtMy0xLTEtNDYzMzg_9e9ad83e-78f5-472d-8dce-c9ec8ff25ae4">60,068,315</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMjAtNS0xLTEtNDYzMzg_0528b377-01fe-4413-9232-47b8fbaaeb73"><ix:nonFraction unitRef="shares" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMjAtNS0xLTEtNDYzMzg_b0b6b442-50c2-4e9a-bbb2-4e293d5169eb">61,354,721</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMjAtNy0xLTEtNDYzMzg_a3407051-af21-4573-baa5-5f1d4212ec84"><ix:nonFraction unitRef="shares" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMjAtNy0xLTEtNDYzMzg_c87ef2f1-82ef-440f-8ace-239c2d0607df">58,643,496</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i01067eced90d451488548dfbb9077922_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.968%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.689%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6975b1f7488c45198ae9150fbe3b8c7b_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMi0xLTEtMS00NjMzOA_e1cba271-f88a-41c3-96a4-68f66c08cff8">61,307,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6975b1f7488c45198ae9150fbe3b8c7b_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMi0zLTEtMS00NjMzOA_54834788-ce19-427f-b7f8-26233f789e16">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c69bb719c3497d90be7f759811e800_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMi05LTEtMS00NjMzOA_6d491f36-7d38-4052-98b0-7ee779d40db7">1,213,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaff1f4fb6ef74e32a52bbd7c4bb14937_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMi0xMS0xLTEtNDYzMzg_c2e12ba6-0fe8-475c-95fc-e248cc677520">973,936</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5305ed22a6544700a6decb559d43709a_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMi0xMy0xLTEtNDYzMzg_3e0f843c-50e7-4bf6-b9d1-42b40cb9710c">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMi0xNS0xLTEtNDYzMzg_9f8cf8b7-0738-4c4c-aaee-64009d07b867">239,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9409a0811aab41deb09d84f3c21fdd0f_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMy05LTEtMS00NjMzOA_d6e8c439-2859-4043-aa2e-276537b68e77">5,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02e4e511353d4dd8adc8ee7f27200377_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMy0xNS0xLTEtNDYzMzg_bd267a44-6a59-43f9-b552-c48d1825a314">5,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9193ad0c43c49adb87caf0bb8cc1a6a_D20220101-20220331" decimals="INF" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfNS0xLTEtMS00NjMzOA_db1b9826-f818-4dff-ab55-8ef5215f26b7">25,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9409a0811aab41deb09d84f3c21fdd0f_D20220101-20220331" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfNS05LTEtMS00NjMzOA_a245b256-3dea-44e0-9f98-2d7ebcaa5549">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02e4e511353d4dd8adc8ee7f27200377_D20220101-20220331" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfNS0xNS0xLTEtNDYzMzg_d5aa40d7-99f5-4300-af02-5c3f0b41917e">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia01bbab25f694758af9fdb20e188c211_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfNi0xMy0xLTEtNDYzMzg_a59337ba-260d-478b-9b8d-ad7f1ebbabfe">222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02e4e511353d4dd8adc8ee7f27200377_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfNi0xNS0xLTEtNDYzMzg_2b9d1e79-bce5-4f6d-9576-69c5e781c31f">222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6af280d8c83413794a1f147acb2c7b5_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfNy0xMS0xLTEtNDYzMzg_516c4cd3-3277-4a6e-9219-d4ab909a1a28">66,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02e4e511353d4dd8adc8ee7f27200377_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfNy0xNS0xLTEtNDYzMzg_5699ef13-71da-4666-ac8e-07dc0d187a10">66,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i84633159b9d94cbaba6793f1e6477f84_I20220331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfOC0xLTEtMS00NjMzOA_d34c75a2-4f77-49b9-92c2-e46dabf997f1">61,333,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84633159b9d94cbaba6793f1e6477f84_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfOC0zLTEtMS00NjMzOA_9ca469e8-337a-4d60-9ac9-bbc8d4ab0150">613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ff33671d854a77b9d0d807ec309f96_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfOC05LTEtMS00NjMzOA_d937f7b7-69bf-42c0-a6d6-9d1aa2973da2">1,218,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c6e7b24f80040eab49e7800603cd599_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfOC0xMS0xLTEtNDYzMzg_2c1774e1-f0d0-4002-874e-56f5ddd5ebe0">1,040,379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1eb8f9dc25b944a7aafb7dd67b63c8eb_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfOC0xMy0xLTEtNDYzMzg_72f82d4f-950c-4135-8a7f-1f42d53823fe">283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id238f32381334840b79f44311e1018c2_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfOC0xNS0xLTEtNDYzMzg_050e93b4-0dde-42fc-988e-56e003833f20">178,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i421f9269a5cb42afa04a5399caed4fd6_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfOS05LTEtMS00NjMzOA_3f1ffd3e-0449-44e4-a74e-0ee421ce14f1">5,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfOS0xNS0xLTEtNDYzMzg_4a3fa00f-8732-49f4-9eff-93b54ff2f1d3">5,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1913ba16a654f48bcf967f37f5fb82a_D20220401-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTAtMS0xLTEtNDYzMzg_ce49b1c6-02e5-48e9-bce6-806a2a04f883">125,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1913ba16a654f48bcf967f37f5fb82a_D20220401-20220630" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTAtMy0xLTEtNDYzMzg_c121a679-d6da-455e-8118-4d1709b4a2df">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i421f9269a5cb42afa04a5399caed4fd6_D20220401-20220630" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTAtOS0xLTEtNDYzMzg_104e2705-d810-4bb4-ba94-7f7263456bde">262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTAtMTUtMS0xLTQ2MzM4_04648101-c7cb-45bd-921d-a044a6805941">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie08c6695ec9b444685aa4d16e4738d38_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTEtMTMtMS0xLTQ2MzM4_39b26de3-291e-407a-b43c-6f43505aa32e">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTEtMTUtMS0xLTQ2MzM4_6b74218b-8839-4728-a80a-6f93a3b155cf">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4eccd5582ce54a15822ae39c44fefe89_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTItMTEtMS0xLTQ2MzM4_1fb7c134-a726-462d-b941-30d0539b72e2">41,304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTItMTUtMS0xLTQ2MzM4_7c86aa44-517c-46ec-afdd-caf70e2c5e44">41,304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2528ec96deee48b9987b5e9d12b2014b_I20220630" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTMtMS0xLTEtNDYzMzg_0af9feb8-354a-40c0-a33d-f715743d87af">61,458,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2528ec96deee48b9987b5e9d12b2014b_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTMtMy0xLTEtNDYzMzg_38fff79d-6fa0-4574-9a9c-39ffeaad2a57">615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7860cbece44418a8ff3040d49e386e3_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTMtOS0xLTEtNDYzMzg_a803006b-73f5-4bbc-8faa-ee68c7d3bf35">1,223,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15f04b0e26d44b449fc94c3e591045a1_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTMtMTEtMS0xLTQ2MzM4_e2b35fa7-f9b5-42bc-b423-79ff909f46d7">1,081,683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a41dc55370a496293ef975cede85db1_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTMtMTMtMS0xLTQ2MzM4_e4df4d67-7f55-4740-b238-06fed943e6ef">326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTMtMTUtMS0xLTQ2MzM4_b94f598e-48ed-49e9-b3f8-27aea3107354">142,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:34.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.379%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.093%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4e23f5d9b7e42e6af2e22c7b835b9ef_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMi0xLTEtMS00NjMzOA_bac1ac86-1464-4dc8-88db-adcaf25b8f6c">56,244,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4e23f5d9b7e42e6af2e22c7b835b9ef_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMi0zLTEtMS00NjMzOA_8c6bba0d-93ed-4092-9d82-f7d57f322e1b">562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i315ea40550944380a8a795ffaf599935_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMi05LTEtMS00NjMzOA_777e2415-ba51-4c13-bf0e-ad2a8ed08a2b">1,067,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d1da529eb6147c8bcc77a537372ae17_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMi0xMS0xLTEtNDYzMzg_3f4d52a2-7343-45ce-8ac8-ed67e75ae918">771,821</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28c3d485a47347b8a63e5c0279d3d948_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMi0xMy0xLTEtNDYzMzg_23b51ab3-5291-415b-b1d0-7aa3c916dbee">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2bddaadb46348c0b4ffff238bc156b4_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMi0xNS0xLTEtNDYzMzg_9abe92c1-700f-400a-b371-bf739fae0a1f">295,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f8510121d6c43aa911e2ac76934ed91_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMy05LTEtMS00NjMzOA_7083759e-5d7b-49cf-b4a5-a0e900f8d134">5,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id01dffdb96844c10acb64f346aef127a_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMy0xNS0xLTEtNDYzMzg_c7f7187a-85dc-4561-9838-045e88ac5288">5,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4d5a5adb662d4445b57b4f674696d537_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNC0xLTEtMS00NjMzOA_1df0b446-013c-4749-b61c-f822fda7f8c7">3,622,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5a5adb662d4445b57b4f674696d537_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNC0zLTEtMS00NjMzOA_863a83f4-bb24-4c55-b71b-94cc7c70d95e">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f8510121d6c43aa911e2ac76934ed91_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNC05LTEtMS00NjMzOA_2c7e9896-a522-4d2e-a254-4b997e0db422">98,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id01dffdb96844c10acb64f346aef127a_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNC0xNS0xLTEtNDYzMzg_e9d21300-d1d7-41b3-bf73-8a20f94651c0">98,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4d5a5adb662d4445b57b4f674696d537_D20210101-20210331" decimals="INF" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNS0xLTEtMS00NjMzOA_e7f1dca7-6319-4e09-930a-0f0a0eff2bd7">144,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5a5adb662d4445b57b4f674696d537_D20210101-20210331" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNS0zLTEtMS00NjMzOA_333f86fe-2187-4bc4-9806-8d0a0c6eb9ff">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f8510121d6c43aa911e2ac76934ed91_D20210101-20210331" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNS05LTEtMS00NjMzOA_0c66b768-69e5-4d1c-b90e-cae8cb06529a">2,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id01dffdb96844c10acb64f346aef127a_D20210101-20210331" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNS0xNS0xLTEtNDYzMzg_0eddb424-7f38-4ecf-bf0c-6c5a2674bfdb">2,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba53e0fd1a4ee8bf3144621333cc43_D20210101-20210331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNi0xMy0xLTEtNDYzMzg_5f52ed42-51a8-4ed8-9ba5-cfb38c2aef1f">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id01dffdb96844c10acb64f346aef127a_D20210101-20210331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNi0xNS0xLTEtNDYzMzg_84bfcabb-e38c-4d15-bb97-1e241ef93947">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc5b069d236c47748328d17bca6c1d10_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNy0xMS0xLTEtNDYzMzg_2bde6926-c29b-4a2e-8a75-75101a677f04">51,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id01dffdb96844c10acb64f346aef127a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNy0xNS0xLTEtNDYzMzg_2d91f96a-8d96-42d0-908b-4e71514062c7">51,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3b3a5a72fdd4b3da840a570e5af718b_I20210331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfOC0xLTEtMS00NjMzOA_584b1938-460b-4382-b00d-77409e00a4a2">60,011,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b3a5a72fdd4b3da840a570e5af718b_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfOC0zLTEtMS00NjMzOA_f2f74a71-b00f-4a6b-9cf2-96da2ac344a2">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5451c73989d1424e9f9e8846cbf00e5c_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfOC05LTEtMS00NjMzOA_58fd71b8-48cc-4931-bc1f-19e2a24d0722">1,173,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ebb9cbc861e4a39b4be17cc2b7ea234_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfOC0xMS0xLTEtNDYzMzg_ef3c6ebd-1277-4f2e-94ae-88693c4fe002">823,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33615ead81b149f3b55531f86d45463c_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfOC0xMy0xLTEtNDYzMzg_e7e66a92-8cef-4f85-8dd9-eb231b1d8c05">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i705e1bd323d14eb592155589c5b08fec_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfOC0xNS0xLTEtNDYzMzg_cbb66890-7c89-4ba1-a149-1fe912b81cb1">350,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5296297226cf40d094b2d74708621179_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfOS05LTEtMS00NjMzOA_26ef0176-52d4-4f32-a0bf-e21aab90da16">6,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfOS0xNS0xLTEtNDYzMzg_a0f9c07f-9c3e-4781-9929-3d9744bf1ba3">6,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c0b210150ec456fa3744f3cc68cea51_D20210401-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTEtMS0xLTEtNDYzMzg_273d509b-dcb2-42be-ae3e-e6783c7b314a">122,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c0b210150ec456fa3744f3cc68cea51_D20210401-20210630" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTEtMy0xLTEtNDYzMzg_b3391e70-71e8-45ac-8eb2-2ea88b15800c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5296297226cf40d094b2d74708621179_D20210401-20210630" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTEtOS0xLTEtNDYzMzg_a0d3129b-942b-4b84-85d2-4c23ae9a32ee">2,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTEtMTUtMS0xLTQ2MzM4_1c7d4a8c-d62f-48d4-b59e-c55cc4639eb2">2,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8484507c9a614dbabce63ba8e51bfce5_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTItMTMtMS0xLTQ2MzM4_9e0f85c0-85c6-4624-a3fe-a4a94c57d7e4">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTItMTUtMS0xLTQ2MzM4_c24c86ea-4ac9-4776-8db1-edb57356cdff">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbfc2b733cfd4233983a58b4045191a4_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTMtMTEtMS0xLTQ2MzM4_c1445376-b0f6-42d8-b7a0-e384990577b9">39,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTMtMTUtMS0xLTQ2MzM4_6d2131b5-44a0-40e4-a2b4-9bdfe23cfdc4">39,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d08ce914c5c47fd8befe84917164ba8_I20210630" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTQtMS0xLTEtNDYzMzg_d9b2e37c-1f9f-4d00-8308-a577df3ec57f">60,133,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d08ce914c5c47fd8befe84917164ba8_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTQtMy0xLTEtNDYzMzg_1bb910d1-4421-42f2-9796-01adda63cf13">601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie06048008ce14472b49e66e78b382b06_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTQtOS0xLTEtNDYzMzg_2295cbaa-6e2b-474a-a6e3-be96c77ad5cf">1,181,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71939f0c66ac4a5da0b6b7b12b9d9d10_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTQtMTEtMS0xLTQ2MzM4_8d9893b2-1561-4070-992a-2e53429e4310">863,028</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88719d0849ae41bd9b947552c67ca2c2_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTQtMTMtMS0xLTQ2MzM4_9a1dd26f-bcd6-4582-8889-f52ac96aaf46">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ef21de7a8c14c07a9a31936ea4dcc72_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTQtMTUtMS0xLTQ2MzM4_3e565114-9d11-4004-a239-893e6661932f">319,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i01067eced90d451488548dfbb9077922_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.275%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMy0xLTEtMS00NjMzOA_fa27f00b-ac9a-4a9a-a8ff-42aa46c4f2d6">107,747</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMy0zLTEtMS00NjMzOA_2c21cf79-409f-4b4c-8f0d-5c063752887f">91,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfNS0xLTEtMS00NjMzOA_a4c567b5-34da-404b-9cb7-2c076c8374dc">5,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfNS0zLTEtMS00NjMzOA_b4390d9e-074f-4955-8e6f-0d96c4d381f2">5,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums and discounts on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfNi0xLTEtMS00NjMzOA_4d9e3948-925f-4290-84fa-cd51f1fd9323">628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfNi0zLTEtMS00NjMzOA_1be72ba7-3af2-441a-ab29-e7118de1210a">808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfNy0xLTEtMS00NjMzOA_416f9860-47a8-41a0-b721-518709414bde">10,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfNy0zLTEtMS00NjMzOA_bc9e301d-3ee2-4ecf-ac18-34db32034f9b">11,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfOS0xLTEtMS00ODk1OQ_54b75062-1c41-42cc-a861-0e9975b38726">1,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfOS0zLTEtMS00ODk2Mw_fcb58b34-441e-4ac4-a782-70ee9cc85c4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTAtMS0xLTEtNDYzMzg_e7f74467-0633-4666-a8e3-eaa9a3a0ea82">7,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTAtMy0xLTEtNDYzMzg_8decb833-5808-4030-be7d-cdd5948ded7b">22,166</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTEtMS0xLTEtNDYzMzg_9acbb54a-c3fb-4787-be35-1915b3639939">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTEtMy0xLTEtNDYzMzg_f20f98b1-c687-466d-8722-6469890bf1e9">6,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTItMS0xLTEtNDYzMzg_8ca9afe5-8365-4d55-96df-a628185ef8d4">8,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTItMy0xLTEtNDYzMzg_ecf20fa5-3ad6-471e-8e74-3fa3bdacf709">974</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTMtMS0xLTEtNDYzMzg_f17ce1bc-4029-4091-9815-003252aa6008">1,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTMtMy0xLTEtNDYzMzg_2114a806-1662-4cbc-9733-69dc1ba24937">4,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTQtMS0xLTEtNDYzMzg_0d429979-6439-4ea8-8651-95fc684af0f7">12,896</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTQtMy0xLTEtNDYzMzg_1fb3bbd1-6d8a-4aff-b7f0-54f99c5f0bbc">1,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTUtMS0xLTEtNDYzMzg_baeddc22-98d2-4515-b212-213bfe7072e4">1,697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTUtMy0xLTEtNDYzMzg_4cb1b6de-1f07-4d50-80d0-06c931b67a54">5,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTYtMS0xLTEtNDYzMzg_81087d9d-814f-4190-820a-75fdc17c1219">2,264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTYtMy0xLTEtNDYzMzg_887a59ed-27dd-4117-8d06-30e223dd7039">1,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTctMS0xLTEtNDYzMzg_f6ec885c-8154-474f-9900-6789021f5a76">2,918</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTctMy0xLTEtNDYzMzg_1c671772-75d9-449a-8dd4-06eb03722088">18,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTktMS0xLTEtNDYzMzg_f9ddf948-89bc-4287-a391-65709452d39e">106,857</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTktMy0xLTEtNDYzMzg_bf006fb2-473c-4a0a-ae3f-872d637cdbf6">74,726</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjEtMS0xLTEtNDYzMzg_ee2f16df-6382-4f26-bf0c-b210d1a88a8f">75,457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjEtMy0xLTEtNDYzMzg_6d500778-3b08-4713-80e3-a45cf68be1ed">117,546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale and maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjItMS0xLTEtNDYzMzg_e3a156a7-7ce0-415c-a87d-bd7be5e18053">82,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjItMy0xLTEtNDYzMzg_20492185-ac09-4e2a-a14e-97d26d1084f3">99,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjMtMS0xLTEtNDYzMzg_64b957e8-2387-4849-bb9e-c87ec4ed444e">2,426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjMtMy0xLTEtNDYzMzg_dfda879e-f31f-456d-9631-3621f2e42b27">2,693</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjQtMS0xLTEtNDYzMzg_17a84a3b-817d-4e4d-a40d-bfcfd585643d">4,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjQtMy0xLTEtNDYzMzg_703e5100-0d58-48dd-ae4a-2172b7dcb809">20,439</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjYtMS0xLTEtNDYzMzg_e04e559c-a1d2-4c71-b5a9-ced7d2ef316d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjYtMy0xLTEtNDYzMzg_3bb419a5-69df-4cd4-bf5e-f3d4d6eab88f">98,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises and ESPP Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjctMS0xLTEtNDYzMzg_293914da-6252-438a-b8ec-e41559979e78">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjctMy0xLTEtNDYzMzg_f0bd9d80-59ff-41b3-ab0a-ff8f52a3a9be">4,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjktMS0xLTEtNDYzMzg_eb8e84a3-87c0-4699-ba59-f707352a8976">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjktMy0xLTEtNDYzMzg_29524fe5-65a2-4d27-8682-3c63982216f2">103,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMzAtMS0xLTEtNDYzMzg_a2149d1b-4c4a-405d-b997-cbd975644a76">102,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMzAtMy0xLTEtNDYzMzg_2f485143-9717-4175-a6f6-5b375aa563fd">7,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMzEtMS0xLTEtNDYzMzg_c9412291-2859-4b68-9e19-dd24f9ef1013">123,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2bddaadb46348c0b4ffff238bc156b4_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMzEtMy0xLTEtNDYzMzg_d1d6c83c-6dca-4e3a-add8-5c1fb1b25b9c">181,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMzItMS0xLTEtNDYzMzg_6786cb00-fba7-453d-b6f8-006665ed259f">21,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ef21de7a8c14c07a9a31936ea4dcc72_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMzItMy0xLTEtNDYzMzg_e02cbb32-f440-4740-a89f-96868ae8fb22">188,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software included in accounts payable or accruals</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMzUtMS0xLTEtNDYzMzg_96afb170-1199-4d3e-a495-9e99314a6df2">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMzUtMy0xLTEtNDYzMzg_c73a089e-833c-4cb2-84bc-cdb1de795def">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i01067eced90d451488548dfbb9077922_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div id="i01067eced90d451488548dfbb9077922_34"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8zNC9mcmFnOmUzOGJkZWM2MTkyYjRkOWY4NGNhYmFiNzEyOTlhNmFkL3RleHRyZWdpb246ZTM4YmRlYzYxOTJiNGQ5Zjg0Y2FiYWI3MTI5OWE2YWRfNDc0OA_5f32166f-f12e-44d2-a765-7b38519a5f39" continuedAt="ie146553ccd024fc9803ab47c15775683" escape="true">Nature of Operations</ix:nonNumeric></span></div><ix:continuation id="ie146553ccd024fc9803ab47c15775683" continuedAt="iab4c2f37f79e4976aec9ce862ad088fb"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of the business</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company has a pipeline of product candidates being evaluated in clinical trials sponsored by the Company or its collaborators.  These product candidates include multiple immuno-oncology programs, some of which were created primarily using the Company&#8217;s proprietary, antibody-based technology platforms. The Company believes its product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.  In March 2021, the Company and its commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.  </span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future success of the Company is dependent on its ability to identify and develop its product candidates, and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company&#8217;s stockholders&#8217; equity and working capital, and accordingly, its ability to execute its future operating plans.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings, revenue from its multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases (NIAID).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews the Company&#8217;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#8217;s working capital.   The Company plans to meet its future operating requirements by generating revenue from current and future strategic collaborations or other arrangements, and product sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities.  If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, reduce other operating expenses, and/or downsize its organization. It is considered probable that the Company can successfully implement efforts to manage uncommitted spending and carry out necessary cost saving measures, including from our recently announced corporate restructuring plan. Therefore, based on the Company&#8217;s most recent cash flow forecast, the Company believes its current resources are sufficient to fund its operating plans for a minimum of twelve months from the date that this Quarterly Report on Form 10-Q was filed.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to the Company's business, the COVID-19 pandemic and geopolitical tensions, including the ongoing military conflict between Russia and Ukraine and the related sanctions imposed against Russia, and related global slowdown of economic activity, decades-high inflation, rising interest rates and a potential recession in the United States might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to these uncertainties, the Company will continue to evaluate the nature and extent of the impact of these uncertainties on its business and financial position.</span></div><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8zNC9mcmFnOmUzOGJkZWM2MTkyYjRkOWY4NGNhYmFiNzEyOTlhNmFkL3RleHRyZWdpb246ZTM4YmRlYzYxOTJiNGQ5Zjg0Y2FiYWI3MTI5OWE2YWRfNDc0Nw_14c11a22-fd72-4a89-ae15-425b87d00d29" continuedAt="i237ffaf1be7d4095836d603aa7a56649" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iab4c2f37f79e4976aec9ce862ad088fb"><ix:continuation id="i237ffaf1be7d4095836d603aa7a56649">The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2021 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 24, 2022.</ix:continuation></ix:continuation></span></div><div id="i01067eced90d451488548dfbb9077922_37"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 2. <ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8zNy9mcmFnOmEwNGM0ZWU0ODVhZDRlNTM4NGY0NDIzYjhmMDEwMGJhL3RleHRyZWdpb246YTA0YzRlZTQ4NWFkNGU1Mzg0ZjQ0MjNiOGYwMTAwYmFfNTQy_7de62a48-f43a-47af-b4a9-d5de6e1d77bc" continuedAt="i4aa6b3c8e59c450ea5801be7c2c3331a" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i4aa6b3c8e59c450ea5801be7c2c3331a"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, there have been no material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021. </span></div><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8zNy9mcmFnOmEwNGM0ZWU0ODVhZDRlNTM4NGY0NDIzYjhmMDEwMGJhL3RleHRyZWdpb246YTA0YzRlZTQ4NWFkNGU1Mzg0ZjQ0MjNiOGYwMTAwYmFfNTQz_f7b07221-615e-4900-984b-fd84fd0bd29f" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements that were issued or became effective since the issuance of the Company&#8217;s 2021 Annual Report on Form 10-K that had, or are expected to have, a material impact on its consolidated financial position, results of operations or cash flows.</span></div></ix:nonNumeric></ix:continuation><div id="i01067eced90d451488548dfbb9077922_40"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RleHRyZWdpb246NGRjYzBmODQwOTJiNDRjNjlmODQ0Yzc2YWNhYjc4OThfMjgzNQ_d7195371-75c9-4d79-a474-c8ec1545a97a" continuedAt="ifa97a03213c04a988eb49d2e987e705e" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="ifa97a03213c04a988eb49d2e987e705e" continuedAt="i2a47b50dfbb943188b4e024db2f0ab6a"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RleHRyZWdpb246NGRjYzBmODQwOTJiNDRjNjlmODQ0Yzc2YWNhYjc4OThfMjgzNw_a2807062-75b1-4b1f-902a-b563d8cafb28" continuedAt="i07dc7cbc5e8e427abc0955f5112aa20a" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i07dc7cbc5e8e427abc0955f5112aa20a" continuedAt="ib103ee1c96f9467bb71bb10a9c45c35a">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. </ix:continuation></span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib103ee1c96f9467bb71bb10a9c45c35a">There were no transfers between levels during the periods presented.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i2a47b50dfbb943188b4e024db2f0ab6a"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RleHRyZWdpb246NGRjYzBmODQwOTJiNDRjNjlmODQ0Yzc2YWNhYjc4OThfMjgzOA_f3c2b9a5-50a3-4d89-ab18-b23d304144ac" escape="true"><div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:15pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2cf382a17b4e04bc62223c9662497b_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfMy0xLTEtMS00NjMzOA_42c57048-f72d-4e72-a30f-b53f09c07922">8,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaee5df7c6fd24644b6271803fce2aae2_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfMy0zLTEtMS00NjMzOA_1b98da6f-9404-4eac-9c92-d3cb4aacf517">8,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3209e333ef1b4efc9f643a26585398bb_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfMy01LTEtMS00NjMzOA_189e9aed-48e1-4bbf-8494-6aedd14f3618">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cacffd890924583aaf540298dbf7a8c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfNC0xLTEtMS00NjMzOA_df16fad1-af9a-46cf-9d79-dc606d67726f">105,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74bfe05c99f446cba0ad613ef542784b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfNC0zLTEtMS00NjMzOA_1d2e92f1-7fe5-4ec5-b0ae-8e26565bfcce">105,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic926423ab3114b2784c30e3020c5be6e_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfNC01LTEtMS00NjMzOA_4178096e-fe73-492c-9c5a-1af6428a397f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2edf905318ec4cc88d408a7710dfea8b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfNi0xLTEtMS00NjMzOA_8d58f5bb-593c-4f52-8e25-17d35ff46949">6,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i412eca49d41d47de87d3a53713b8e50e_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfNi0zLTEtMS00NjMzOA_af22fcaf-4b6f-42d9-95f5-a74349376fc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9708b71437741bc98bf41f57791fef6_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfNi01LTEtMS00NjMzOA_49228d56-bed4-479c-b198-69bef53391e3">6,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c140531ab074f03aea8d010a367b9b3_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfOC0xLTEtMS00NjMzOA_4d3811e0-6874-443a-99b2-d4c3a87710a8">120,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i232d1bddbda24a9786d7b4e89ec55bfc_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfOC0zLTEtMS00NjMzOA_1d703f98-533f-4926-b510-660360ba23a4">113,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d4f9b1948e4f9c8fc832ab374f303c_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfOC01LTEtMS00NjMzOA_8c1857e8-0a4a-42e5-9995-65f0fd42083a">6,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e22930bedfe4f48b55574f1491fe4b8_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfMy0xLTEtMS00NjMzOA_c567eff5-89d3-4930-a18e-78b9c510c579">17,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c4c855042e4bc586a5317d9125cfe4_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfMy0zLTEtMS00NjMzOA_a4ae6fe7-b6a3-49dd-8c29-253eb1ca9703">17,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dfffc601f2c44cf829806a11359034d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfMy01LTEtMS00NjMzOA_4e7c282d-c098-4c52-9f4f-770965ca7d61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88ae8b3089f4d8bbd25cc1cecc99d47_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfNC0xLTEtMS00NjMzOA_887fda57-5b88-44f8-8f75-4b23e2bd2555">81,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8d60276ffc34955ab0ae2df036b1032_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfNC0zLTEtMS00NjMzOA_2a61449d-181a-4ac4-b577-21f734f03126">81,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64bbb463b56f459e848a5399c786db9b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfNC01LTEtMS00NjMzOA_5fcfb166-fad3-4920-a29a-a52deae5a81a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad0c041aa4bc458e8e7d118fe4c9e08f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfNS0xLTEtMS00NjMzOA_f8c9a62a-ac02-4b90-889f-fce82ecee5f9">7,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied25e1f92b644194804e5004a17b2d7d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfNS0zLTEtMS00NjMzOA_645d7fb0-9dbe-4586-a25d-396e83465d28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id44b34a1bd494162bed536c9eb0de155_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfNS01LTEtMS00NjMzOA_0a7164e9-bce9-4397-ab1e-e36d0420200f">7,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75ac06ceb7484bb8bd34e4033c4faf19_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfNi0xLTEtMS00NjMzOA_61052d84-6dfc-4834-b7b4-5f0166d3ce65">37,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19535bf1b5074b99b2df151eb4bc4d31_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfNi0zLTEtMS00NjMzOA_00e4ad52-219c-4afe-b1d5-7778ed2f924b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bf3535880a4ceb822d925ba094e608_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfNi01LTEtMS00NjMzOA_9fbcc2cc-6db5-4cb9-8e8b-89e984d5dc60">37,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib610d63458364b959341d2c275fc3966_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfOC0xLTEtMS00NjMzOA_b3fe431e-6857-46f5-8508-fae66ff674c8">143,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79d5f7405cf1437c9d2766b6093531d1_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfOC0zLTEtMS00NjMzOA_517302f9-b7de-40cb-b7e3-5b1a9606209b">98,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i250e6d1dd1d14d73a9e40891670e7259_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfOC01LTEtMS00NjMzOA_1bdd9dea-d2a2-4b32-9a4d-0d7a57eb2c2c">45,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at June&#160;30, 2022 includes approximately $<ix:nonFraction unitRef="usd" contextRef="i7c140531ab074f03aea8d010a367b9b3_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RleHRyZWdpb246NGRjYzBmODQwOTJiNDRjNjlmODQ0Yzc2YWNhYjc4OThfMjYxNg_fb401f12-12e9-4ae3-a998-994551636d8d">8.2</ix:nonFraction> million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2021 includes approximately $<ix:nonFraction unitRef="usd" contextRef="ib610d63458364b959341d2c275fc3966_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RleHRyZWdpb246NGRjYzBmODQwOTJiNDRjNjlmODQ0Yzc2YWNhYjc4OThfMjc2MQ_22d28a00-6d0b-488a-87f6-dd737a98dd8d">23.2</ix:nonFraction> million reported in cash and cash equivalents on the consolidated balance sheet.</span></div></ix:nonNumeric></ix:continuation><div id="i01067eced90d451488548dfbb9077922_43"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RleHRyZWdpb246MDBhNDFkYzQ4MDdmNDJjNjk1ZDhmZTI1ODg2OTBjZDNfMTAzMQ_59b7cf79-1e06-4c6f-86c2-b54986776754" continuedAt="ic4e59a24ae564d3e9ded344d9de1e923" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="ic4e59a24ae564d3e9ded344d9de1e923" continuedAt="ibf7671e81237409bbd6c9f51522a872c"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RleHRyZWdpb246MDBhNDFkYzQ4MDdmNDJjNjk1ZDhmZTI1ODg2OTBjZDNfMTAzMg_a9edcc7a-a9b2-4b63-939a-f2c1050bcbed" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's marketable debt securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.724%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fed250b414468dbaf9d90c31a31e26_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfMi0xLTEtMS00NjMzOA_a2a51e58-0f10-49d4-8b44-164b694db821">106,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fed250b414468dbaf9d90c31a31e26_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfMi0zLTEtMS00NjMzOA_40f624db-336a-48fb-aa1c-08ccde76f84c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19fed250b414468dbaf9d90c31a31e26_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfMi01LTEtMS00NjMzOA_daa8ea74-828e-4927-96ed-49fc2639f8ed">310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fed250b414468dbaf9d90c31a31e26_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfMi03LTEtMS00NjMzOA_a3201264-d270-4cc4-a3ac-88286801d2fd">105,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8184b5fd91450ea18de2dae673882c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfNC0xLTEtMS00NjMzOA_93601b40-0bb6-46b2-b802-261f5a7f82d3">6,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8184b5fd91450ea18de2dae673882c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfNC0zLTEtMS00NjMzOA_318b452b-22e6-401f-8722-88e5b47f9b6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae8184b5fd91450ea18de2dae673882c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfNC01LTEtMS00NjMzOA_8df716b7-8193-4eb2-b871-ce941f34c169">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8184b5fd91450ea18de2dae673882c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfNC03LTEtMS00NjMzOA_75d39dc4-43bc-45a8-8e72-2ced8068e7ad">6,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfNS0xLTEtMS00NjMzOA_dd6d3af1-2979-426e-8a8b-fd214ac82a66">112,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfNS0zLTEtMS00NjMzOA_c283abd5-f0a6-4dca-9bd4-77b754ff8462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfNS01LTEtMS00NjMzOA_494fd5f8-f217-45b7-bb58-e3a80bd1d787">325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfNS03LTEtMS00NjMzOA_69a97c9f-3eb6-42a9-9ed0-f3d7f2c3c7e5">112,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa546adbe93e4c63a396fe25106b66ae_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfMi0xLTEtMS00NjMzOA_5a25d741-9aca-407f-a298-e5f3c41c5c18">81,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa546adbe93e4c63a396fe25106b66ae_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfMi0zLTEtMS00NjMzOA_7bba65b4-bc75-4c22-a377-d56894d7efe4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa546adbe93e4c63a396fe25106b66ae_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfMi01LTEtMS00NjMzOA_53f6427f-b876-4fca-840a-a0d5f0388256">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa546adbe93e4c63a396fe25106b66ae_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfMi03LTEtMS00NjMzOA_3d150ac7-a952-45d7-8d6c-bc29ecbf98be">81,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31aa193c0dfc4403bbdb295edc147c6e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfMy0xLTEtMS00NjMzOA_7ea17476-5a6b-4bab-9690-0ce567f794eb">7,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31aa193c0dfc4403bbdb295edc147c6e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfMy0zLTEtMS00NjMzOA_2d4c7634-c4bf-4a12-9ffe-d3f82247e7e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31aa193c0dfc4403bbdb295edc147c6e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfMy01LTEtMS00NjMzOA_3b863339-1f73-4508-aacb-16bfcce543ef">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31aa193c0dfc4403bbdb295edc147c6e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfMy03LTEtMS00NjMzOA_b57c2832-df2a-4e18-acbb-650cb20cd4e2">7,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia56c7c0c5dd64063ade2d2b387b7f6c1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfNC0xLTEtMS00NjMzOA_0983feae-d097-4dfc-95e3-06d0047b7e38">31,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia56c7c0c5dd64063ade2d2b387b7f6c1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfNC0zLTEtMS00NjMzOA_0911f48c-702f-4274-ae97-ba8f7fe1ee49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia56c7c0c5dd64063ade2d2b387b7f6c1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfNC01LTEtMS00NjMzOA_8ed7f4f2-dd83-4ed5-81c2-a3f2ea477eb3">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia56c7c0c5dd64063ade2d2b387b7f6c1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfNC03LTEtMS00NjMzOA_91e0dbc5-0772-4f48-aed4-7e7543ac8610">31,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfNS0xLTEtMS00NjMzOA_c42a49f0-fe4e-4463-a67e-d1f24ddcb53a">120,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfNS0zLTEtMS00NjMzOA_c26186fc-d848-4e56-b138-ce0146852b90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfNS01LTEtMS00NjMzOA_3bfe6cc8-c6fb-45aa-8e09-c35af95daa75">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfNS03LTEtMS00NjMzOA_7737bdbc-a5e3-437d-9ef5-791e375ef2a1">120,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All available-for-sale marketable debt securities held as of June&#160;30, 2022 and December&#160;31, 2021 had contractual maturities of less than one year.  All of the Company's available-for-sale marketable debt securities in an unrealized loss position as of June&#160;30, 2022 and December&#160;31, 2021 were in a loss position for less than twelve months.&#160; Unrealized losses on available-for-sale debt securities as of June&#160;30, 2022 and December&#160;31, 2021 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, <ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RleHRyZWdpb246MDBhNDFkYzQ4MDdmNDJjNjk1ZDhmZTI1ODg2OTBjZDNfNjgw_6465684a-e58e-4368-8c1e-b8d512d9deca"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RleHRyZWdpb246MDBhNDFkYzQ4MDdmNDJjNjk1ZDhmZTI1ODg2OTBjZDNfNjgw_ac03c959-efd2-4f4d-ba67-d4d6c690063f">no</ix:nonFraction></ix:nonFraction> allowance for credit losses related to the Company's available-for-sale debt securities was recorded </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibf7671e81237409bbd6c9f51522a872c">for any periods presented. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</ix:continuation> </span></div><div id="i01067eced90d451488548dfbb9077922_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80Ni9mcmFnOjFlNmJlNTgyMGFmZjRmZWM4ODdmMTA0YzU0NzRjMGI1L3RleHRyZWdpb246MWU2YmU1ODIwYWZmNGZlYzg4N2YxMDRjNTQ3NGMwYjVfNTc3_82fe0337-f198-4dce-8554-f91b26273368" continuedAt="id3975a9462d141a9abedb739444aa49d" escape="true">Inventory, Net</ix:nonNumeric></span></div><ix:continuation id="id3975a9462d141a9abedb739444aa49d" continuedAt="i0c83621ba3094ab6a57136d701468e5c"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80Ni9mcmFnOjFlNmJlNTgyMGFmZjRmZWM4ODdmMTA0YzU0NzRjMGI1L3RleHRyZWdpb246MWU2YmU1ODIwYWZmNGZlYzg4N2YxMDRjNTQ3NGMwYjVfNTc4_5bab22af-84c7-43d3-b9e8-25a3d8624c4a" escape="true"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's net inventory (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80Ni9mcmFnOjFlNmJlNTgyMGFmZjRmZWM4ODdmMTA0YzU0NzRjMGI1L3RhYmxlOjQ5MDIwMmQ5ZTViMTRjNzA5YWMwOTUxMDI1N2VkODY0L3RhYmxlcmFuZ2U6NDkwMjAyZDllNWIxNGM3MDlhYzA5NTEwMjU3ZWQ4NjRfMi0xLTEtMS00NjMzOA_fdf3741e-d8ee-419b-97eb-64f466298412">2,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80Ni9mcmFnOjFlNmJlNTgyMGFmZjRmZWM4ODdmMTA0YzU0NzRjMGI1L3RhYmxlOjQ5MDIwMmQ5ZTViMTRjNzA5YWMwOTUxMDI1N2VkODY0L3RhYmxlcmFuZ2U6NDkwMjAyZDllNWIxNGM3MDlhYzA5NTEwMjU3ZWQ4NjRfMi0zLTEtMS00NjMzOA_e8dc7d1e-817b-4300-bf7c-ce5116e9cb48">3,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80Ni9mcmFnOjFlNmJlNTgyMGFmZjRmZWM4ODdmMTA0YzU0NzRjMGI1L3RhYmxlOjQ5MDIwMmQ5ZTViMTRjNzA5YWMwOTUxMDI1N2VkODY0L3RhYmxlcmFuZ2U6NDkwMjAyZDllNWIxNGM3MDlhYzA5NTEwMjU3ZWQ4NjRfMy0xLTEtMS00NjMzOA_cf0360b2-dcbc-4d4a-beb2-a12c1793f6f9">718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80Ni9mcmFnOjFlNmJlNTgyMGFmZjRmZWM4ODdmMTA0YzU0NzRjMGI1L3RhYmxlOjQ5MDIwMmQ5ZTViMTRjNzA5YWMwOTUxMDI1N2VkODY0L3RhYmxlcmFuZ2U6NDkwMjAyZDllNWIxNGM3MDlhYzA5NTEwMjU3ZWQ4NjRfMy0zLTEtMS00NjMzOA_c71894a4-fcc2-4787-8456-4b005b613f4b">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80Ni9mcmFnOjFlNmJlNTgyMGFmZjRmZWM4ODdmMTA0YzU0NzRjMGI1L3RhYmxlOjQ5MDIwMmQ5ZTViMTRjNzA5YWMwOTUxMDI1N2VkODY0L3RhYmxlcmFuZ2U6NDkwMjAyZDllNWIxNGM3MDlhYzA5NTEwMjU3ZWQ4NjRfNC0xLTEtMS00NjMzOA_579abe10-f061-49f8-a203-3111b0794538">2,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80Ni9mcmFnOjFlNmJlNTgyMGFmZjRmZWM4ODdmMTA0YzU0NzRjMGI1L3RhYmxlOjQ5MDIwMmQ5ZTViMTRjNzA5YWMwOTUxMDI1N2VkODY0L3RhYmxlcmFuZ2U6NDkwMjAyZDllNWIxNGM3MDlhYzA5NTEwMjU3ZWQ4NjRfNC0zLTEtMS00NjMzOA_fcd5f3d4-eee5-49c0-8349-3944d150ac89">4,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:31.5pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0c83621ba3094ab6a57136d701468e5c">Prior to U.S. Food and Drug Administration (FDA) approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of June&#160;30, 2022 and December&#160;31, 2021 is net of a reserve of  $<ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80Ni9mcmFnOjFlNmJlNTgyMGFmZjRmZWM4ODdmMTA0YzU0NzRjMGI1L3RleHRyZWdpb246MWU2YmU1ODIwYWZmNGZlYzg4N2YxMDRjNTQ3NGMwYjVfNTQ5NzU1ODE0NDY5_4b64848a-6ec3-4a0d-9a1f-1e7ed3c911f6">3.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80Ni9mcmFnOjFlNmJlNTgyMGFmZjRmZWM4ODdmMTA0YzU0NzRjMGI1L3RleHRyZWdpb246MWU2YmU1ODIwYWZmNGZlYzg4N2YxMDRjNTQ3NGMwYjVfNTQ5NzU1ODE0NDg4_071f2d9a-80b2-4c6e-ac77-bcbe511083a4">2.0</ix:nonFraction>&#160;million, respectively, for unsaleable inventory.</ix:continuation> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i01067eced90d451488548dfbb9077922_49"></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfMTc2MQ_328772ea-040e-4fd2-bc59-2870b7e2dd4d" continuedAt="i57e2236cfb5a44f597b2a5a1f489c2bc" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="i57e2236cfb5a44f597b2a5a1f489c2bc"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $<ix:nonFraction unitRef="usd" contextRef="i0ae83217782a49f581625143e7d04f9d_D20201101-20201130" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfMjE4_641eb9f1-b935-45a4-a415-3c1a14335214">100.0</ix:nonFraction> million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. The shares that were sold under the Sales Agreement were issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 4, 2020.  During the six months ended June 30, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="ia6b440df4f4e426d8d698f7cb5f42342_D20211001-20211231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfNTk0_029b17cf-eb77-43ab-b978-2e1fb20992af">3,622,186</ix:nonFraction> shares of common stock at a weighted average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i99f0316ba50d4c39a9c3d29ef8473c34_I20211231" decimals="2" name="us-gaap:SaleOfStockPricePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfNjYx_3350ec51-9f1b-4d47-9333-379c5408cce4">27.60</ix:nonFraction>, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ia6b440df4f4e426d8d698f7cb5f42342_D20211001-20211231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfNzA4_09385fad-56ac-4b08-a03e-bc134b8d209c">98.2</ix:nonFraction> million, net of underwriting discounts and commissions and other offering expenses. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increases the amount of the Company&#8217;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i0ae83217782a49f581625143e7d04f9d_D20201101-20201130" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfMTA0MA_6f6b7c56-93b7-49da-9181-270437f4a3ca">100.0</ix:nonFraction>&#160;million to an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i5d0a69ad66bb4c0b8b17295ffe63c014_D20210401-20210430" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfMTA4Mw_93a7e7f9-dd99-43e7-bb88-488b27d66b8f">300.0</ix:nonFraction>&#160;million.  The Company has not sold any shares of common stock related to Amendment No. 1 to the Sales Agreement as of June&#160;30, 2022.  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the consideration for the rights granted to Zai Lab US LLC under the collaboration and license agreement described more fully in Note 7, Revenue, the Company and Zai Lab US LLC entered into a separate stock purchase agreement (Stock Purchase Agreement) in June 2021.  Under this Stock Purchase Agreement, Zai Lab US LLC paid the Company approximately $<ix:nonFraction unitRef="usd" contextRef="i6417b05cf7d64d0bb5cc9aa0b049314b_D20210601-20210630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfMTU2NA_1654a8e2-386d-4e81-8aef-bfdb45e97215">30.0</ix:nonFraction> million to purchase <ix:nonFraction unitRef="shares" contextRef="ia1adbba07b474f27be0bcec58c6f439a_D20210601-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfMTU3OQ_3648aea6-91ca-448e-b952-aa1ddb406952">958,467</ix:nonFraction> newly issued shares of the Company's common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfMTY0Mw_8c22cd83-d639-4902-87d3-328ab0983266">0.01</ix:nonFraction>, at a fixed price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8862965ac7c74eaa91fbf299dcefad53_I20210615" decimals="2" name="us-gaap:SaleOfStockPricePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfMTY2Nw_972312f8-bb52-4500-967a-6a5c6158dca1">31.30</ix:nonFraction> which represented a $<ix:nonFraction unitRef="usd" contextRef="ibbbb27e355214928b77e2fc758f95088_D20210601-20210630" decimals="-5" name="mgnx:PremiumReceivedOnStockPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfMTY5MA_c0781a70-2663-47df-a039-9ccb7ebe5ad7">10.4</ix:nonFraction> million premium over the share price on the Stock Purchase Agreement date.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i01067eced90d451488548dfbb9077922_52"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzMzMTM_a4dbddba-ffe2-4224-bfe9-707d7fe775f3" continuedAt="i911bedf9024e4c429337c6c40484b701" escape="true">Revenue </ix:nonNumeric></span></div><ix:continuation id="i911bedf9024e4c429337c6c40484b701" continuedAt="id18b40849f03495da354c050e23e5694"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborative and Other Agreements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte Corporation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte License Agreement</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab.  Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="id672cb9284434e3a9202e6f51f077bac_D20180101-20180930" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNjc5_f400404f-acfd-41a8-892e-4452a4f37e28">150.0</ix:nonFraction> million in 2017. In July 2021, Incyte announced that the FDA had issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal. Incyte&#8217;s announcement indicated that the FDA determined that additional data are needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte was reviewing the CRL and would discuss next steps with the FDA. Incyte subsequently withdrew its European application for marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal. Incyte has stated it is pursuing development of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="id18b40849f03495da354c050e23e5694" continuedAt="i7e78cdaba95344f4b01912a1fc7f42ab"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">retifanlimab in potentially registration-enabling studies beyond squamous cell carcinoma of the anal canal, including in patients with MSI-high endometrial cancer, Merkel cell carcinoma and non-small cell lung cancer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline. In April 2022, the Company and Incyte executed an amendment to the Incyte License Agreement to add a milestone for U.S. approval of retifanlimab in a specific indication and to exclude certain other regulatory and development achievements with retifanlimab in this same indication from the milestone events of the Incyte License Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, as amended, Incyte will lead global development of retifanlimab.  Assuming successful development and commercialization by Incyte, the Company could receive up to $<ix:nonFraction unitRef="usd" contextRef="i00c0c8a5e81842d6ad36655e19d61684_I20181231" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTk3OA_07a677c4-2e0a-45bd-aacd-1d3e1ce38c02">435.0</ix:nonFraction> million in development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i00c0c8a5e81842d6ad36655e19d61684_I20181231" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjAzMg_920f7115-fa64-49e1-8f3e-02662d52d95b">330.0</ix:nonFraction> million in commercial milestones. From the inception of the Incyte License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="i8b2a073d3c794192a595450d0028cae4_D20180101-20220630" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjE1MQ_315918c6-a00a-4355-a87e-bef90e350fb5">70.0</ix:nonFraction> million in development milestones under the Incyte License Agreement. In July 2022, the Company and Incyte further amended the Incyte License Agreement to reflect changes related to the payment of certain milestones and the Company received $<ix:nonFraction unitRef="usd" contextRef="i96f7ff3791204451aedc226872ae5fcb_I20220701" decimals="-5" name="mgnx:TwoAdditionalMilestoneIncyteLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNDA1OTM_5aed2386-df07-4091-a339-dddc7ff1ed72">30.0</ix:nonFraction> million in milestone payments from Incyte.  If retifanlimab is approved and commercialized, the Company would be eligible to receive tiered royalties of <ix:nonFraction unitRef="number" contextRef="i5d06233b12574a07a62e6512ccf7e4fb_D20180101-20180930" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjMyNg_7fc96a79-882c-4a95-bf5b-2f237727f3f3">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i61b3c4379d88468da27af3737a110d8c_D20180101-20180930" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjMzMg_aa1c1242-b575-4dd2-a922-c522027e0a5b">24</ix:nonFraction>% on any global net sales.  The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte License Agreement under the provisions of Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606) and identified the following <ix:nonFraction unitRef="performanceobligation" contextRef="i00c0c8a5e81842d6ad36655e19d61684_I20181231" decimals="INF" name="mgnx:NumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjk3Nw_3d5c8416-b25f-4bfa-a6d1-d2c8bcc139d6">two</ix:nonFraction> performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte License Agreement at inception was $<ix:nonFraction unitRef="usd" contextRef="i00c0c8a5e81842d6ad36655e19d61684_I20181231" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzc2NA_2cdca3a3-c59c-4bee-871e-8780dfe74787">154.0</ix:nonFraction> million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. From 2018 through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, it became probable that a significant reversal of cumulative revenue would not occur for development milestones totaling $<ix:nonFraction unitRef="usd" contextRef="i8b2a073d3c794192a595450d0028cae4_D20180101-20220630" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTM0Mw_315918c6-a00a-4355-a87e-bef90e350fb5">70.0</ix:nonFraction> million related to </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical and regulatory activities related to the further advancement of retifanlimab, including Incyte&#8217;s initiation of a Phase 3 clinical trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Therefore, the associated consideration was added to the estimated transaction price and was recognized as revenue</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="i5c253e1b8d354889a4ce47f6161201e6_D20180101-20180930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTY0OQ_37272679-8d81-4c73-9f00-c5924d28b2e3">150.0</ix:nonFraction> million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $<ix:nonFraction unitRef="usd" contextRef="idf96f2f2d3bb4019aab8b83995fbefb6_D20170101-20181231" decimals="-5" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTc3Mw_caf74ba3-62fa-4c8d-9859-a9c0c52ecdb8">4.0</ix:nonFraction> million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018. <ix:nonFraction unitRef="usd" contextRef="id33701a0fbcb45c99cf26d0167b17df9_D20220401-20220630" decimals="INF" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODUxNTEw_ae720bae-3518-4d4f-ad92-cdb9bf2b56a5"><ix:nonFraction unitRef="usd" contextRef="i76d65ceb505a48e1acdee1cd35c24fd7_D20220101-20220630" decimals="INF" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODUxNTEw_e9bb9f30-3447-4a83-aee9-6f5219d050aa">No</ix:nonFraction></ix:nonFraction> revenue was recognized under the Incyte License Agreement during the three and  six months ended June 30, 2022.  $<ix:nonFraction unitRef="usd" contextRef="i8427f430b14a43c5a0c839c84cd2fac8_D20210401-20210630" decimals="INF" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODUxNTAz_2c0bdd1e-ad99-4854-b62b-028e9cfedad4">5.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3d2a0a32c3bf4466ba347ecd77c315eb_D20210101-20210630" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTk3Nw_d4251426-5d83-421f-bfa4-a8da6a1cf6f7">15.0</ix:nonFraction> million in milestone revenue was recognized under the Incyte License Agreement during the three and six months ended June 30, 2021, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Clinical Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into an agreement with Incyte, under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement).  The Company evaluated the Incyte Clinical Supply Agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i7e78cdaba95344f4b01912a1fc7f42ab" continuedAt="if290b5f7670542cdbf096c5124c3c52f"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the manufacturing services.  During the three months ended June 30, 2022 and 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i252d416a130b4aef83acef014a242473_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNzEzNw_482fe0aa-7f08-4ec0-b800-6482338d39f9">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i868d68accdbb4b1baea1ef30a6c728af_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNzE0NA_3456ac5d-a124-45f3-97cf-ed86873ef485">0.7</ix:nonFraction> million, respectively, for services performed under the Incyte Clinical Supply Agreement.   During the six months ended June 30, 2022 and 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ie30a746971b840fa954d23a4bd59f89e_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ3NDI0_b597ccf5-c6a8-4b90-b171-f76171a3a751">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6171432917614920af3bc0adaae45923_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ3NDMy_0d4a4467-dd63-4313-8d04-b9058c22877f">0.8</ix:nonFraction> million, respectively, for services performed under the Incyte Clinical Supply Agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Commercial Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#8217;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated the Incyte Commercial Supply Agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor costs incurred) related to the manufacturing services.  During the three months ended June 30, 2022 and 2021,  the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ib69d294a237f46dbb406c9df90ddc345_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ3MjQ5_c1445df8-cbca-4c2e-8df0-7132dc3ec0dd">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1434bddbeff34ada94d5f3a35035e034_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ3NDU5_8f8d5eb1-e8ee-44b3-aa12-1acb16212362">2.8</ix:nonFraction>&#160;million, respectively, for services performed under the Incyte Commercial Supply Agreement.  During the six months ended June 30, 2022 and 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ib07fdf3f2fc0440ca7f2e21164cc1d94_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ3NDg1_6d35627b-e534-4137-8d71-d654e53c00d5">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if65110ca3e22439a98fecb99c1d702d2_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ3NDk0_720996c7-ff27-43d2-bafe-0efbb8cd8146">5.9</ix:nonFraction>&#160;million, respectively, for services performed under the Incyte Commercial Supply Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab Limited</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Zai Lab Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab)  under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab, a bispecific DART&#174; molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development of these molecules in its territory.  Zai Lab has informed the Company that they have decided to discontinue development of tebotelimab for indications they were enrolling in their territory and is evaluating future development plans in other indications.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i1b2807234912469ba06c538de023e4f5_D20180101-20181231" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfOTQyMw_7caf07d1-8fda-4e4c-8973-97f3ae7cc5e0">25.0</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="i1b2807234912469ba06c538de023e4f5_D20180101-20181231" decimals="-5" name="mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfOTQyNw_675ff960-7be6-4904-8d67-83ea948f8cc1">22.5</ix:nonFraction> million after netting value-added tax withholdings of $<ix:nonFraction unitRef="usd" contextRef="i1b2807234912469ba06c538de023e4f5_D20180101-20181231" decimals="-5" name="mgnx:NonrefundablePaymentTaxWithholding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfOTQ3Ng_74169b4c-904c-4699-99f4-8188d073057c">2.5</ix:nonFraction> million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $<ix:nonFraction unitRef="usd" contextRef="i27227311568a45f2b51cd61543ae9030_I20201231" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfOTYyMg_b80efafe-65df-4080-b062-7f6d269dd74a">140.0</ix:nonFraction> million in development and regulatory milestones, of which the Company has earned $<ix:nonFraction unitRef="usd" contextRef="ic8e1dffc03b44a83ab8e292584fd3d5b_D20200701-20220630" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfOTY5OQ_e5ee53fa-c867-4b50-9339-f412768dcb4a">9.0</ix:nonFraction> million through June&#160;30, 2022. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to <ix:nonFraction unitRef="number" contextRef="id5b94f0e0eeb4a01aea4900a9c756dd1_D20180101-20181231" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfOTgxMA_66fd1980-872a-47a5-9094-efef93bb1775">20</ix:nonFraction>% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and <ix:nonFraction unitRef="number" contextRef="icb889204b9fb4dcc80d0bb9f95f21240_D20180101-20181231" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfOTkzMw_17e67937-e5c7-4987-a769-fb44b42b80b3">10</ix:nonFraction>% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2018 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $<ix:nonFraction unitRef="usd" contextRef="i1b2807234912469ba06c538de023e4f5_D20180101-20181231" decimals="-5" name="mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTEyMzg_675ff960-7be6-4904-8d67-83ea948f8cc1">22.5</ix:nonFraction> million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="if290b5f7670542cdbf096c5124c3c52f" continuedAt="id9a8a7a4d35b4f9a8beedb170ea95d74"><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.  From 2020 through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, it became probable that a significant reversal of cumulative revenue would not occur for development and regulatory milestones totaling $<ix:nonFraction unitRef="usd" contextRef="ic8e1dffc03b44a83ab8e292584fd3d5b_D20200701-20220630" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTI2MTQ_e5ee53fa-c867-4b50-9339-f412768dcb4a">9.0</ix:nonFraction> million.  Therefore, the associated consideration was added to the estimated transaction price and was recognized as revenue</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Of this </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ic8e1dffc03b44a83ab8e292584fd3d5b_D20200701-20220630" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTI3NDM_e5ee53fa-c867-4b50-9339-f412768dcb4a">9.0</ix:nonFraction> million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ic6983323f60e4a67818ce6a331b74360_D20220101-20220630" decimals="-5" name="mgnx:MillstoneRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTI3NDc_c64386df-d4fe-4182-ba12-e12aad50fc5a">5.0</ix:nonFraction> million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was recognized as revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the six months ended June 30, 2022. During the three and six months ended June 30, 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i3fbf626084c549ea9aa5a07ec92ed81d_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ4NjEx_d11ebc05-7fdb-40be-b43e-2c82fbd315ec">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic6983323f60e4a67818ce6a331b74360_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODUxODkx_b7d22d93-6bbc-4b26-badc-0107edb2b19b">5.4</ix:nonFraction>&#160;million, respectively, under the 2018 Zai Lab Agreement.  <ix:nonFraction unitRef="usd" contextRef="i7c76ddf33fdb445c8361740c1a5a1d36_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTI3OTI_697f1e7b-4294-44ba-ba25-fa24d0245fc8"><ix:nonFraction unitRef="usd" contextRef="i20167305bd354a7886c63d0edbe908a2_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTI3OTI_99c7f746-d10e-4b29-902e-4acb3d7da6da">No</ix:nonFraction></ix:nonFraction> revenue was recognized during the three and six months ended June 30, 2021 under the 2018 Zai Lab Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zai Lab Clinical Supply Agreements</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements). The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab.  The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing service. During the three months ended June 30, 2022 and 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="icba2317be6d9465d9e494fbbc525bc2c_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTM5ODU_d6807320-04e0-4783-a21c-f5797b4eca43">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i55649e5833464f0ca12e4ad111b17c07_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTM5OTI_fc56fce2-94ce-4885-a19d-774d166235e0">0.5</ix:nonFraction> million, respectively, related to the Zai Lab Clinical Supply Agreements. During the six months ended June 30, 2022 and 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i0ca75e3ff4904b2a89f832e75c1ca3da_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ3NzYx_2d41180a-5231-4d85-8cb2-00d1eb5802eb">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iea8d6ea8007a4fedb1d035394ed7db3f_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ3NzY5_49f3a62a-c20a-4a19-8062-de6777d765d5">1.6</ix:nonFraction> million, respectively, related to the Zai Lab Clinical Supply Agreements. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Zai Lab Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates the Company&#8217;s DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by the Company. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while the Company receives commercial rights in all other territories. Under the Lead Program, Zai Lab received an option upon reaching a predefined clinical milestone to convert the regional arrangement into a global 50/50 profit share. If Zai Lab elects such option, Zai Lab is to pay the Company $<ix:nonFraction unitRef="usd" contextRef="i8862965ac7c74eaa91fbf299dcefad53_I20210615" decimals="-5" name="mgnx:OptInFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTUwNjU_3219d673-3573-491b-b296-e86d32b904c7">85.0</ix:nonFraction>&#160;million plus any research costs incurred by both parties as of the option election date. Zai Lab also obtained exclusive, global licenses from the Company to develop, manufacture and commercialize two additional molecules. Zai Lab granted the Company a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to the Company.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Zai Lab Agreement, the Lead Program includes joint research and development services by both the Company and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with the Company to perform research and development services in the future. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i6417b05cf7d64d0bb5cc9aa0b049314b_D20210601-20210630" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTU4MjU_bb2de008-f42e-48fc-8182-3aa7a8bef68e">25.0</ix:nonFraction>&#160;million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into the Stock Purchase Agreement whereby Zai Lab paid the Company approximately $<ix:nonFraction unitRef="usd" contextRef="i6417b05cf7d64d0bb5cc9aa0b049314b_D20210601-20210630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTYwNTM_1654a8e2-386d-4e81-8aef-bfdb45e97215">30.0</ix:nonFraction> million to purchase shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTYxMTY_8b30ca84-6404-4d48-9b96-b8228d6e491e">0.01</ix:nonFraction>, at a fixed price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8862965ac7c74eaa91fbf299dcefad53_I20210615" decimals="2" name="us-gaap:SaleOfStockPricePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTYxNDA_972312f8-bb52-4500-967a-6a5c6158dca1">31.30</ix:nonFraction> which represented a $<ix:nonFraction unitRef="usd" contextRef="ibbbb27e355214928b77e2fc758f95088_D20210601-20210630" decimals="-5" name="mgnx:PremiumReceivedOnStockPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTYxNjM_c0781a70-2663-47df-a039-9ccb7ebe5ad7">10.4</ix:nonFraction> million premium over the share price on the Stock Purchase Agreement date. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful development and commercialization of the Programs, the Company could receive up to approximately $<ix:nonFraction unitRef="usd" contextRef="i8862965ac7c74eaa91fbf299dcefad53_I20210615" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTYzNTE_0c101153-1a15-42cd-b512-8e45d6296d22">800.0</ix:nonFraction>&#160;million in development and regulatory milestones and $<ix:nonFraction unitRef="usd" contextRef="i8862965ac7c74eaa91fbf299dcefad53_I20210615" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTYzOTk_6e1cc9ed-2670-4657-beab-03dfeb1a1edc">600.0</ix:nonFraction>&#160;million in commercial milestones. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of low double digit teens on annual net sales of certain specified products and of mid-single digits to low double digit teens on annual net sales of other specified products in Zai Lab&#8217;s territory, which may be subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, the Company may also receive reimbursements from Zai Lab for certain research and development costs incurred by the Company. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="id9a8a7a4d35b4f9a8beedb170ea95d74" continuedAt="ic6b5e4ecba15427e8fa3f3aef8f0804c"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#8217;s territory for each Program and (ii) certain research and development activities for the Lead Program. The Company determined that for the Lead Program, the license is not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#8217;s significant expertise in this area and as such, the research and development services are expected to significantly modify and customize the license. Therefore, for the Lead Program, the license and the services were combined into a single performance obligation. Since the other programs each represent distinct intellectual property and there are no other services included in the 2021 Zai Lab Agreement related to these licenses, each license is considered to be a distinct performance obligation. As such, there are four performance obligations included in the 2021 Zai Lab Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the estimated transaction price is $<ix:nonFraction unitRef="usd" contextRef="i8862965ac7c74eaa91fbf299dcefad53_I20210615" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTgxNTI_86bd2e68-fc13-4baf-8ebe-9645618caf9a">40.4</ix:nonFraction> million, consisting of the $<ix:nonFraction unitRef="usd" contextRef="i6417b05cf7d64d0bb5cc9aa0b049314b_D20210601-20210630" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTgxNzQ_4bcbb36f-994d-4612-9dfb-10c29a4154ae">25.0</ix:nonFraction> million upfront payment, the $<ix:nonFraction unitRef="usd" contextRef="ibbbb27e355214928b77e2fc758f95088_D20210601-20210630" decimals="-5" name="mgnx:PremiumReceivedOnStockPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTgxOTg_07d56a3f-7f51-4442-881b-3bcea7d28d3b">10.4</ix:nonFraction> million premium related to the purchase of the Company&#8217;s common stock, and the $<ix:nonFraction unitRef="usd" contextRef="i6417b05cf7d64d0bb5cc9aa0b049314b_D20210601-20210630" decimals="-5" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTgyNzI_b1a55e7e-8755-4f23-a3ab-1530ca25dab4">5.0</ix:nonFraction> million estimated reimbursement by Zai Lab for research and development activities for the Lead Program. The potential milestone payments were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company will re-assess the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $<ix:nonFraction unitRef="usd" contextRef="i8862965ac7c74eaa91fbf299dcefad53_I20210615" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTkxNDQ_bd3116a6-7e59-4b9a-a80a-6ac6ea09bc9a">40.4</ix:nonFraction> million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believes a market participant is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#8217;s estimate of the probability of success for each Program. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to the Lead Program license and related research and development services performance obligation is being recognized over time as the research and development activities are performed. The Company will utilize a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in June 2021.  During the three months ended June 30, 2022 and 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i3c3f1cf70f6e49f2a38e855d5b0e46c2_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjc0ODc3OTEwNDg1OA_d5c02f43-5e16-49ca-a4cb-87d77ede8048">14.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i66ee9789245a4404aaebbe85e877994a_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjc0ODc3OTEwNDg2Ng_41217e69-e5e1-4a03-a9c2-4d721af9456c">14.4</ix:nonFraction> million, respectively, under the 2021 Zai Lab Agreement. During the six months ended June 30, 2022 and 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i94bc3a3ceb5941fb8aa911e2ffb733eb_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjc0ODc3OTEwNDk0OA_8c660914-c543-40e9-a0ab-7166b31d757e">15.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i70ebe69ee2214b73974336b7a5727cc9_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjc0ODc3OTEwNDk1Ng_bf016e66-33f6-4573-876e-7818f6e9a3f5">14.4</ix:nonFraction> million, respectively, under the 2021 Zai Lab Agreement. As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022, $<ix:nonFraction unitRef="usd" contextRef="iaa61f3996c3c405984b11d51d65bf3ae_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjA0OTc_b250bcc5-d3c5-43e7-bc9b-825f85a1e122">1.8</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenue was deferred under the agreement, all of which was current. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i05e7befa8e9d45b6893dabb2ea11e658_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjA1ODE_9e656788-3d80-4c08-9456-3096b55a98d5">16.1</ix:nonFraction> million in revenue was deferred, all of which was current.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Biotech, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a research collaboration and license agreement with Janssen Biotech, Inc. (Janssen) to develop a novel DART molecule (Janssen Agreement).  The research collaboration will incorporate the Company&#8217;s proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the Janssen Agreement, Janssen paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="iae3a758cac9b4c67ac48b3d949bb81ab_D20201201-20201231" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjExMTI_7aaaa680-87f3-4cec-809d-a2ac98a2b452">20.0</ix:nonFraction>&#160;million and will be responsible for funding all research and development expenses. The Company will also be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i98ee39cd1bfe4c6fadfe480718e3ef13_I20211231" decimals="-5" name="mgnx:PotentialMilestonePaymentsAndRoyaltiesOnProductSales" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjEyNDE_dd067549-0a31-4c1e-8d0b-76fc55a2f608">312.0</ix:nonFraction>&#160;million in potential milestone payments and tiered royalties of up to <ix:nonFraction unitRef="number" contextRef="iae3a758cac9b4c67ac48b3d949bb81ab_D20201201-20201231" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjEzMDY_4eedd710-e892-4ce6-8d58-ccd83ddb53f4">10</ix:nonFraction>% on worldwide product sales. </span><span style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Janssen an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term. The Company evaluated the Janssen Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i)  a license to develop the preclinical bispecific molecule and (ii) performing certain research and development activities during the research term. The Company determined that the license and research and development activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as Janssen could benefit from the license on its own without the Company&#8217;s involvement during the research term.  The Company determined that the transaction price of the Janssen Agreement at inception was $<ix:nonFraction unitRef="usd" contextRef="i98ee39cd1bfe4c6fadfe480718e3ef13_I20211231" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjIzODU_1c579e4f-0434-4abd-9edc-b3b5fde07453">22.2</ix:nonFraction>&#160;million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for research and development activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ic6b5e4ecba15427e8fa3f3aef8f0804c" continuedAt="i9dd64a3caee947de8f70915e939d98ad"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">considering similar collaboration and license agreements as well as current market conditions. The standalone selling price for agreed-upon research and development activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. This variable consideration is fully constrained until the Company begins its work under the performance obligation.  The potential milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Janssen and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="i8f16bac8141c4383a00685b230199498_D20201201-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjQwMDA_c74fb630-21b1-4c1b-8ed6-46a7e4308346">20.0</ix:nonFraction>&#160;million allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Janssen in December 2020. The $<ix:nonFraction unitRef="usd" contextRef="iae3a758cac9b4c67ac48b3d949bb81ab_D20201201-20201231" decimals="-5" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjQxMzQ_6bf40b98-0db6-41b8-afee-9898b13f3017">2.2</ix:nonFraction>&#160;million allocated to the research and development activities is being recognized over the Company&#8217;s involvement in the research term, which is estimated to be less than two years. During the three months ended June 30, 2022 and 2021, the Company recognized revenue of  $<ix:nonFraction unitRef="usd" contextRef="i613268f3651e4fae832a1050b7bc8c75_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ4ODM5_5c00daa7-48d1-4fdb-903c-825b793ae2c0">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i702fa2d64613432cba42480b770b9427_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ4ODQ4_85551497-75a9-46c9-870f-3fb0790fe403">0.6</ix:nonFraction>&#160;million, respectively, for research and development activities performed under the Janssen Agreement.  During the six months ended June 30, 2022, and 2021 the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i460b9af7b2724b7e931ef3fcbb896107_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ5MTgw_a9adddd9-e45c-4bbc-b72c-a6ef69c620ce">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8c06d5991f5342a9bc4118c142fb5a68_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ4MDQ2_a44ec199-9860-438e-be45-8f0357e6db34">0.9</ix:nonFraction>&#160;million, respectively, for research and development activities performed under the Janssen Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I-Mab Biopharma</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I-Mab License Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab License Agreement).  I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the I-Mab License Agreement, I-Mab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ie6784addc67c4bffab8c458f3a96daaf_D20200101-20200930" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjUxODQ_defba850-5a76-413c-84a4-da0d3835d641">15.0</ix:nonFraction> million.  Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $<ix:nonFraction unitRef="usd" contextRef="i118a870a47a847ab9a59d307cf7a8dec_I20201231" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjUyOTM_6485fd6c-f92c-4d55-a3a6-f561b545063c">135.0</ix:nonFraction> million in development and regulatory milestones, of which $<ix:nonFraction unitRef="usd" contextRef="ief27732f4ac54730a699b2393bb54497_D20220101-20220630" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjUzNDc_4d7211fe-0a46-492d-965e-57770bed8139">5.0</ix:nonFraction>&#160;million has been earned from the inception of the I-Mab License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, I-Mab would pay the Company tiered royalties ranging from mid-teens to <ix:nonFraction unitRef="number" contextRef="ibcd59b18a37243bfb09019e459954829_D20200101-20200930" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjU1MTM_509a0e49-ec4b-436d-a964-cf81831fbd6a">20</ix:nonFraction>% on annual net sales in I-Mab's territory.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the I-Mab License Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i) an exclusive license to develop and commercialize enoblituzumab in I-Mab&#8217;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $<ix:nonFraction unitRef="usd" contextRef="ie6784addc67c4bffab8c458f3a96daaf_D20200101-20200930" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjYzMjA_defba850-5a76-413c-84a4-da0d3835d641">15.0</ix:nonFraction> million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $<ix:nonFraction unitRef="usd" contextRef="ie6784addc67c4bffab8c458f3a96daaf_D20200101-20200930" decimals="-5" name="mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjY3MzU_d6608013-55ff-4f4c-bd81-9621dc5eb8d5">1.0</ix:nonFraction> million. I-Mab paid the Company for the cost of this study as the costs were incurred and I-Mab received a one-time credit of eighty percent of the total amount of such costs against the milestone achieved during 2021. The Company reassessed the transaction price as it became probable that a significant reversal of cumulative revenue would not occur for a $<ix:nonFraction unitRef="usd" contextRef="i8c7222aea8cc4fe58941ee0a062a32d5_D20220101-20220331" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjcwODg_36237875-7c46-425d-9631-bcf6d6d37d08">5.0</ix:nonFraction>&#160;million milestone ($<ix:nonFraction unitRef="usd" contextRef="ia7f623bc792547a1a41b06a0787a398e_I20211231" decimals="-5" name="mgnx:OneTimeMillstoneCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjcxMDI_282fd9cc-3c0f-462d-aecb-6e6f6faebf36">4.5</ix:nonFraction>&#160;million after netting a one-time credit as described above) related to development progress of enoblituzumab, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue during 2021. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Revenue under the I-Mab License Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations.  During the three months ended June </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i9dd64a3caee947de8f70915e939d98ad" continuedAt="i9826254e18cc4f4ea38b140b56bbd558"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30, 2022 and 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i20c8da099331485ba579926bf66c0d17_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ4MzI5_66cb7a9c-6cb6-4d6d-87a1-2f35695f087c">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2497d88ae95c4519b39b87d1ba7cdeb7_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ4MzMz_f9fc1529-f56d-4d3f-8109-86eaa2405c96">1.9</ix:nonFraction> million, respectively, under the I-Mab License Agreement. During the six months ended June 30, 2022 and 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ief27732f4ac54730a699b2393bb54497_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjg0Nzc_c7d77ede-bf8a-4582-aea9-67ac2a423b81">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic969da273e7b44dba3060478dc9568ab_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjg0ODQ_74ca725a-a927-494a-9cf6-b7ae7c507c7e">2.5</ix:nonFraction> million, respectively, under the I-Mab License Agreement. As of June&#160;30, 2022, $<ix:nonFraction unitRef="usd" contextRef="i9e4dca55397644a2849eaef94593433c_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjg1NDc_c2181c18-57a3-4103-99c0-81aa92b539d8">3.8</ix:nonFraction> million in revenue was deferred under the I-Mab License Agreement, all of which was current. As of December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="ia7f623bc792547a1a41b06a0787a398e_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjg2NDU_8d31441b-62f8-4b57-8454-2c0ecc7ea14f">4.5</ix:nonFraction> million in revenue was deferred under the I-Mab License Agreement, all of which was current.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I-Mab Clinical Supply Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into an agreement under which the Company is to perform development and manufacturing services for I-Mab&#8217;s clinical needs of enoblituzumab (I-Mab Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of enoblituzumab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the three and six months ended June 30, 2022, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i63be51e66fd743578dd0ea8c55b930fc_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODUxOTI1_43490112-8872-4e90-9672-be7ff3b78bea">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9537b5eb6ae949c28d9293e9e3ce85f9_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ4MzM5_48c58e4f-c625-4aea-99b7-483fcfc12be6">1.1</ix:nonFraction> million, respectively, for research and development activities performed under the I-Mab Clinical Supply Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing Services Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Incyte (Incyte Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Incyte bulk drug substance over a three-year period at one of the Company&#8217;s manufacturing facilities. Under the terms of the Incyte Manufacturing and Clinical Supply Agreement, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i427113310e024f5eb793d1e86f25cad4_D20220101-20220731" decimals="-3" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzAzNDM_ce09b26e-a9da-4732-beb9-3b7619816408">10.0</ix:nonFraction>&#160;million and is eligible to receive annual fixed payments paid quarterly over the term of the contract totaling $<ix:nonFraction unitRef="usd" contextRef="ic55bd316cd91463e82b7d37fc8a0975a_I20220630" decimals="-5" name="mgnx:TotalAnnualFixedPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzA0NDk_ed0d3122-b9f4-4e70-9101-f9bcd567f500">14.4</ix:nonFraction>&#160;million. The Company will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte Manufacturing and Clinical Supply Agreement under the provisions of ASC 606 and identified one performance obligation to provide manufacturing runs to Incyte, as and when requested by Incyte, over the term of the contract that is part of a series of goods and services. The Company determined that the transaction price at inception consists of the upfront payment received of $<ix:nonFraction unitRef="usd" contextRef="i427113310e024f5eb793d1e86f25cad4_D20220101-20220731" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzEwMDg_1568fd57-9e94-4d90-a7e5-7499e51ebd11">10.0</ix:nonFraction>&#160;million and the annual fixed payments totaling $<ix:nonFraction unitRef="usd" contextRef="ic55bd316cd91463e82b7d37fc8a0975a_I20220630" decimals="-5" name="mgnx:TotalAnnualFixedPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzEwNTA_ca217ec8-4401-455f-ae70-5930c6e3167c">14.4</ix:nonFraction>&#160;million.   The Company will recognize revenue over time on a straight-line basis as the manufacturing services are provided to Incyte, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Incyte will be allocated to the related manufacturing activities and will be recognized as revenue as those activities occur.  Materials purchased by the Company to manufacture the product for Incyte are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i7ee85754d5014401ad61235f662351ae_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ4MzQ1_8edf5d7b-8498-4c9d-828d-21992150b213">4.0</ix:nonFraction>&#160;million under the Incyte Manufacturing and Clinical Supply Agreement during each of the three and six month periods ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ic55bd316cd91463e82b7d37fc8a0975a_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzIwMjg_997403e0-2c37-41bf-a99a-feb00d40898a">9.5</ix:nonFraction>&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ic55bd316cd91463e82b7d37fc8a0975a_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzIwNzc_2db20a13-acb2-451d-bbc3-1ae32d6d19de">3.3</ix:nonFraction>&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ic55bd316cd91463e82b7d37fc8a0975a_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzIxMDU_ccf66020-3579-4de3-b10f-bfce8b98c9e9">6.2</ix:nonFraction>&#160;million </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of which was non-current.  </span></div><div style="margin-bottom:6pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to <ix:nonFraction unitRef="molecule" contextRef="i096d5137725d40148157656180087db8_D20150915-20150915" decimals="INF" name="mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzIzNjQ_5a90fa90-e00e-4c73-9c07-93be2aec44c0">two</ix:nonFraction> DART molecules, MGD014 and MGD020 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9826254e18cc4f4ea38b140b56bbd558">Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of June&#160;30, 2022 is $<ix:nonFraction unitRef="usd" contextRef="i772a42253ce1405785340b3edb6899da_D20220101-20220630" decimals="-5" name="mgnx:TotalPotentialValueUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzMwNzY_ac226585-68ba-40e5-8b26-56e1dc86f4e1">25.1</ix:nonFraction>&#160;million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in July 2023. During the three months ended June 30, 2022 and 2021, the Company recognized revenue under the NIAID Contract of $<ix:nonFraction unitRef="usd" contextRef="ib4a0eb4c0fe649c482ed64bbcf0d0b11_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ4NDc4_c44ee503-1e92-492b-9b61-9c78b050c515">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3f9782aefce248e491b1017c418c61ad_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ4NDc0_2352e710-4074-4f83-a501-c232cbfff82b">0.4</ix:nonFraction> million, respectively.   During the six months ended June 30, 2022 and 2021, the Company recognized revenue under the NIAID Contract of $<ix:nonFraction unitRef="usd" contextRef="i655cea49e809491ba22491fc3a7a1477_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzMyODM_cec48d56-74fa-41e1-9140-9c0f1ebf556d">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7d1bdfd0b85f4ac79e062c9afd027395_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzMyOTM_a452e580-40c3-4a0b-bc6a-48486b757cd5">1.2</ix:nonFraction> million, respectively.</ix:continuation>  </span></div><div id="i01067eced90d451488548dfbb9077922_55"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNTI2OQ_10bfd651-9990-4de0-bcc0-8ed70c2d5e7c" continuedAt="i0636c0ce63c94f1096f7da6ee3f96d41" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i0636c0ce63c94f1096f7da6ee3f96d41" continuedAt="iae81c8ee1a7346e4b380c3514b1da45c"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved <ix:nonFraction unitRef="shares" contextRef="i5806f140f2fb4121a04208d77d725e5d_I20170531" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNDI3_46b2ec8d-da86-4411-ad69-b484b4140ce8">800,000</ix:nonFraction> shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="i0bb8e7382f584403b0bd73897bfafdc4_D20170501-20170531" decimals="INF" name="mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNjI2_d2c330b5-5538-48d8-98c5-44ff4ede28d7">10</ix:nonFraction>% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for <ix:nonNumeric contextRef="id5c46189a60a4d9e98d6758e10e520b4_D20170501-20170531" name="mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNzY5NjU4MTM5OTkxMg_94fc549e-5e23-4bd6-bbd7-dd55da615d4f">six-month</ix:nonNumeric> offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at <ix:nonFraction unitRef="number" contextRef="i0bb8e7382f584403b0bd73897bfafdc4_D20170501-20170531" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfODcy_2449551a-3c35-44a3-98d1-ac50156d3658">85</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on the last day of the offering period.  During the six months ended June&#160;30, 2022, <ix:nonFraction unitRef="shares" contextRef="i164a86dfd80c4e50a7e23e302c1c0bf0_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfMTAwMg_5d9d58ec-e003-4498-94fe-040948e161b0">65,125</ix:nonFraction> shares of common stock were purchased under the 2016 ESPP.   </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Option Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of June&#160;30, 2022, under the 2003 Plan, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i43fa69d5c22045ddbb94dd1e3a59d966_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfMTkyMw_99816722-a687-4ea1-be85-5e3b021d37eb">105,282</ix:nonFraction> shares of common stock outstanding.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&#160;&#160;The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) <ix:nonFraction unitRef="shares" contextRef="i978da7f614aa4ea690dbff8c9356eb6d_I20131031" decimals="INF" name="mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfMjM2MA_cb485ef2-1f60-415d-aa2a-65aa033cf483">1,960,168</ix:nonFraction> shares, (b) <ix:nonFraction unitRef="number" contextRef="idf3d70a2fb43424cb1591bef0c3534e4_D20220101-20220630" decimals="3" name="mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfMjM3NQ_84d47d59-97ae-456d-b452-02bdc49d1993">4.0</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Company's Board of Directors. During the six months ended June&#160;30, 2022, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to <ix:nonFraction unitRef="shares" contextRef="i3d1a4774b1f345f19d161adf566fb6fd_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfMjcyNw_33146162-fd45-45b7-9652-7cfdfa2d77ff">15,816,949</ix:nonFraction>.&#160;&#160; If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards.  As of June&#160;30, 2022, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i3d1a4774b1f345f19d161adf566fb6fd_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfMzMwMw_3835582c-cd44-42f6-a3cd-4aaf2a680626">10,395,473</ix:nonFraction> shares of common stock outstanding.</span></div><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNTI2Mw_ea0ff56d-5474-4ae4-8412-5d505c297235" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation expense was recognized for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5499db67d8414a0fbbfbf13e986ae6dd_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfMi0xLTEtMS00NjMzOA_d5c7d1a6-b107-4cff-a39a-55d4cdc049d2">2,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb0c8219b14e42c7aad0de17683ccf63_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfMi0zLTEtMS00NjMzOA_722c6eea-569f-4faa-ab01-83b251fefcf5">3,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if743a9b99df64882ac59cc7cf3cb3f2b_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfMi01LTEtMS00NjMzOA_97117709-502b-44bd-976e-6f5832e1a3c1">5,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i133be2faddae4492b069093a43dfefae_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfMi03LTEtMS00NjMzOA_b94ff3a0-d5e9-4193-a41a-4e535e62005e">5,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2c0a615ad08480184a8698a62ebdc4b_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfMy0xLTEtMS00NjMzOA_8dc60c1e-7a2b-4a0f-ab92-28e40f83c9b9">2,642</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1253c83d5764ca2869c6ae3052e19ad_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfMy0zLTEtMS00NjMzOA_088bc569-b3b7-4292-bd13-82daee6fe481">3,012</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e41bc1a29374b0f95aa6bf490e51d76_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfMy01LTEtMS00NjMzOA_402aa959-d140-4a0c-a464-fe967f0c302f">5,524</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39128793661549b8bdf32a8a1cc51c91_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfMy03LTEtMS00NjMzOA_48dd5cbb-469c-4d6c-8087-02ac5bbdb3e1">5,571</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfNC0xLTEtMS00NjMzOA_eedbbaf7-ceff-459f-960e-302bb4ca3cc2">5,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfNC0zLTEtMS00NjMzOA_4af2f7c2-e3bc-43bd-9457-a0910ba230f8">6,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfNC01LTEtMS00NjMzOA_d77d4a19-7bcb-436d-8c75-50615ce71f9f">10,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfNC03LTEtMS00NjMzOA_339d2f7f-65f3-466a-9b44-a964a4fa9236">11,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNTI2NA_19a25646-03a6-4993-a21d-5bd8b6908dee" continuedAt="i8c18f27cb00a4ffcbf62a86cb24d761a" escape="true">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="iae81c8ee1a7346e4b380c3514b1da45c"><div style="margin-bottom:9pt;margin-top:15pt"><ix:continuation id="i8c18f27cb00a4ffcbf62a86cb24d761a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfMi0xLTEtMS00NjMzOA_cb810ff9-6a88-4e56-afe4-1caace2ad277">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfMi0zLTEtMS00NjMzOA_cdc95cab-b50d-4c0a-a113-46b4e597cf6c">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic7ffcf2243504d388387524c69d636c3_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfMy0xLTEtMS00NjMzOC90ZXh0cmVnaW9uOjI4N2EyMjhiYzUxZDRlNTQ5YmNmZTU2MDA2MGMyMjE1XzQ_1fdd7296-b6e6-4a76-8e46-4e002b8ca5e1">87.8</ix:nonFraction>% -<ix:nonFraction unitRef="number" contextRef="i424f99869a384d90912972e1c1b09528_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfMy0xLTEtMS00NjMzOC90ZXh0cmVnaW9uOjI4N2EyMjhiYzUxZDRlNTQ5YmNmZTU2MDA2MGMyMjE1Xzg_440543a7-5e70-4452-9765-611847543c4a">89.7</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibd329807983e4f3cb3e69df9ae058545_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfMy0zLTEtMS00NjMzOC90ZXh0cmVnaW9uOmFhYzQzZWRmZjA1ZDRhOTM5MjhmZjU0N2IwMjkyMzNlXzQ_303ccca9-8231-4200-a87a-fb33d9085b3d">86.2</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="id5649fb8ec294f408a306886c4a94ba6_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfMy0zLTEtMS00NjMzOC90ZXh0cmVnaW9uOmFhYzQzZWRmZjA1ZDRhOTM5MjhmZjU0N2IwMjkyMzNlXzk_d1f0cdad-e450-4420-a5df-6b078b6e26f3">86.7</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic7ffcf2243504d388387524c69d636c3_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfNC0xLTEtMS00NjMzOC90ZXh0cmVnaW9uOmMwOWY3OGZhODMyMzQ0MDFhNTc0MjlkODY1MGE4Y2JlXzQ_1ca21082-665c-4ba0-834e-7c4475637650">1.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i424f99869a384d90912972e1c1b09528_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfNC0xLTEtMS00NjMzOC90ZXh0cmVnaW9uOmMwOWY3OGZhODMyMzQ0MDFhNTc0MjlkODY1MGE4Y2JlXzk_631c6318-0594-441d-9f11-e914f3456792">3.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibd329807983e4f3cb3e69df9ae058545_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfNC0zLTEtMS00NjMzOC90ZXh0cmVnaW9uOmQwYWRmMGEzMDdkYjRkMjBhMmI3ZDYyNzNjYjIwMDIwXzQ_8d73f795-e5af-4345-b207-da4f424ef8f7">0.6</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="id5649fb8ec294f408a306886c4a94ba6_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfNC0zLTEtMS00NjMzOC90ZXh0cmVnaW9uOmQwYWRmMGEzMDdkYjRkMjBhMmI3ZDYyNzNjYjIwMDIwXzk_7ae2cfb0-bc28-4fcf-b501-c3da12f520d6">1.4</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfNS0xLTEtMS00NjMzOA_d4b8a82a-9077-4d12-984d-4d4504884ef5">5.95</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfNS0zLTEtMS00NjMzOA_b505cc6b-9b0c-4b91-bce9-6dd42d6b23f6">6.25</ix:nonNumeric> years</span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNTI2Ng_eac2cccb-7a88-409f-ba1d-0146b853803c" escape="true"><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the six months ended June&#160;30, 2022:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfMS0xLTEtMS00NjMzOA_911e8d08-952c-4e89-9b0c-6dd79ab4c8ea">8,373,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfMS0zLTEtMS00NjMzOA_48076a0c-329f-4790-880f-5a08614cd863">21.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iacfa9386b3a3414bbb61ae3690fcdc16_D20210101-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfMS01LTEtMS00NjMzOA_c086019e-fceb-4ceb-aa5a-afc3b3434b1c">6.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfMi0xLTEtMS00NjMzOA_5d0f41aa-3a6e-4447-a11b-eacb62354f7d">2,685,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfMi0zLTEtMS00NjMzOA_be168c78-4c64-45e9-aa64-3274ca3d40de">9.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfMy0xLTEtMS00NjMzOA_47f748c9-506c-4d1b-bd04-3eac82fb6439">80,721</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfMy0zLTEtMS00NjMzOA_be0ac180-61d3-4272-92e2-17099e27d34c">1.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfNC0xLTEtMS00NjMzOA_f11b322c-e8d9-4119-869a-9f1d316d3255">267,563</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfNC0zLTEtMS00NjMzOA_2fdd1d59-8348-4a8b-a501-c1e91a3ebec2">16.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfNS0xLTEtMS00NjMzOA_eb85dbd5-29d2-4468-9a10-8d028b897c2e">210,079</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfNS0zLTEtMS00NjMzOA_e71a9234-8cc1-42f4-ac54-cedee8ae0ce3">23.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfNi0xLTEtMS00NjMzOA_33913b6a-0c98-4714-9cfc-1c1ae8932567">10,500,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfNi0zLTEtMS00NjMzOA_57e9c4b1-cd5a-4666-b7d8-b0b5e8b02c94">18.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfNi01LTEtMS00NjMzOA_d14dcf11-aefd-4cae-91de-3dec91045f3a">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfNi03LTEtMS00NjMzOA_35652972-784d-4dfc-82f8-54268cbbddca">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of June 30, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfOC0xLTEtMS00NjMzOA_8363e41c-c2b7-4a18-8428-90423341c0a7">5,930,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfOC0zLTEtMS00NjMzOA_7450098e-bedb-411f-898a-d4fe5357546b">22.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfOC01LTEtMS00NjMzOA_fe8adfb7-b9eb-488b-ba3f-7f08fd951171">5.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfOC03LTEtMS00NjMzOA_57290eae-baa3-4bfa-886e-0890379de3ce">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfOS0xLTEtMS00NjMzOA_0c322fe4-1bcb-4e55-910d-5b1e4f963705">9,719,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfOS0zLTEtMS00NjMzOA_45bd125a-9c2e-44ed-8ebe-e19e221c5d91">19.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfOS01LTEtMS00NjMzOA_c9f2bd8f-bc75-4b8e-8e5f-2ed3a71aa1fa">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfOS03LTEtMS00NjMzOA_93d528a4-8a54-469e-8877-c4f440a6f4f5">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during the six months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfMzg0Nw_4d38e973-62fb-4c45-869b-001c28084bc0">6.96</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfMzg1NA_f7aedc5d-fd69-4f88-90f9-d7cee32ea4de">15.11</ix:nonFraction>, respectively. The total intrinsic value of options exercised during the six months ended June&#160;30, 2022 and 2021 was approximately $<ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfMzk3NA_fd3d8831-bd70-4370-b6da-80a12b3fd5d9">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfMzk4MQ_b378caba-c1ba-40e4-9788-2dad65ed6968">1.8</ix:nonFraction> million, respectively.  The total cash received for options exercised during the six months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNTQ5NzU1ODE5MjY1_524b4583-8b79-4a80-bc3b-a7e0f27fc26e">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNDA5Ng_74ef6109-073f-45cd-b7b7-d36fee4b0a18">4.6</ix:nonFraction> million, respectively. The total fair value of shares vested in the six months ended June&#160;30, 2022 and 2021 was approximately $<ix:nonFraction unitRef="usd" contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNDIzOQ_341b6f02-1167-4502-bc44-b9357ea52ff4">9.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNDI0Ng_3dfb1ce9-2b9a-4ffc-986f-a1dd2f33e44a">8.1</ix:nonFraction> million, respectively. As of June&#160;30, 2022, the total unrecognized compensation expense related to unvested stock options, net of related forfeiture estimates, was approximately $<ix:nonFraction unitRef="usd" contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNDQwOA_6f00b646-e65f-441f-ae80-6feae0a88a13">33.9</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNDQ5OQ_3809698e-515f-4cce-a3bf-6f79b56a1b96">1.5</ix:nonNumeric> years.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants restricted stock units (RSUs) under the 2013 Plan to employees from time to time as a component of their compensation. During the six months ended June 30, 2022, the Company awarded RSUs to employees in conjunction with the annual performance review process. Each RSU vests over a <ix:nonNumeric contextRef="i1104b4f510e448a6aafaae0d08700a68_D20220101-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNTI2Mg_cc5281f1-b4f5-48f1-87f2-f6b93336fea6">two-year</ix:nonNumeric> period and entitles the holder to receive <ix:nonFraction unitRef="shares" contextRef="i1104b4f510e448a6aafaae0d08700a68_D20220101-20220630" decimals="INF" name="mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNDg1NA_13eec218-a126-4688-933b-4dc0f078af07">one</ix:nonFraction> share of the Company's common stock when the RSU vests. Compensation expense is recognized on a straight-line basis over the vesting period. </span></div><ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNTI2OA_ccf3e73e-bf75-4857-89d9-13bda5726f44" escape="true"><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the six months ended June&#160;30, 2022:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a101c2276a549c7b6f9656b0b6d6551_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjBkMWIxNWEyNTRlZTQ4ZWY5NzNlMzg0YzBkZjRhNTExL3RhYmxlcmFuZ2U6MGQxYjE1YTI1NGVlNDhlZjk3M2UzODRjMGRmNGE1MTFfMS0xLTEtMS00NjMzOA_b98da7ca-8af5-4544-ad92-cef7f5559db9">21,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4a101c2276a549c7b6f9656b0b6d6551_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjBkMWIxNWEyNTRlZTQ4ZWY5NzNlMzg0YzBkZjRhNTExL3RhYmxlcmFuZ2U6MGQxYjE1YTI1NGVlNDhlZjk3M2UzODRjMGRmNGE1MTFfMS0zLTEtMS00NjMzOA_bb5d5728-b2a6-4a40-b1bd-a07135d08296">25.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1104b4f510e448a6aafaae0d08700a68_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjBkMWIxNWEyNTRlZTQ4ZWY5NzNlMzg0YzBkZjRhNTExL3RhYmxlcmFuZ2U6MGQxYjE1YTI1NGVlNDhlZjk3M2UzODRjMGRmNGE1MTFfMi0xLTEtMS00NjMzOA_9c5dccfd-0e0a-4624-9925-ca897eb7919d">314,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1104b4f510e448a6aafaae0d08700a68_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjBkMWIxNWEyNTRlZTQ4ZWY5NzNlMzg0YzBkZjRhNTExL3RhYmxlcmFuZ2U6MGQxYjE1YTI1NGVlNDhlZjk3M2UzODRjMGRmNGE1MTFfMi0zLTEtMS00NjMzOA_7404ffaf-e2e5-469a-8f7f-03681376808c">10.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1104b4f510e448a6aafaae0d08700a68_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjBkMWIxNWEyNTRlZTQ4ZWY5NzNlMzg0YzBkZjRhNTExL3RhYmxlcmFuZ2U6MGQxYjE1YTI1NGVlNDhlZjk3M2UzODRjMGRmNGE1MTFfMy0xLTEtMS00NjMzOA_f647dcba-d652-4dbd-94c7-5562de9cbfd7">8,465</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1104b4f510e448a6aafaae0d08700a68_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjBkMWIxNWEyNTRlZTQ4ZWY5NzNlMzg0YzBkZjRhNTExL3RhYmxlcmFuZ2U6MGQxYjE1YTI1NGVlNDhlZjk3M2UzODRjMGRmNGE1MTFfMy0zLTEtMS00NjMzOA_a27f1546-0a9e-4ce9-983f-2b766e4006d4">26.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1104b4f510e448a6aafaae0d08700a68_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjBkMWIxNWEyNTRlZTQ4ZWY5NzNlMzg0YzBkZjRhNTExL3RhYmxlcmFuZ2U6MGQxYjE1YTI1NGVlNDhlZjk3M2UzODRjMGRmNGE1MTFfNC0xLTEtMS00NjMzOA_d849919f-511f-42f5-9864-a5c5230c8670">20,099</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1104b4f510e448a6aafaae0d08700a68_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjBkMWIxNWEyNTRlZTQ4ZWY5NzNlMzg0YzBkZjRhNTExL3RhYmxlcmFuZ2U6MGQxYjE1YTI1NGVlNDhlZjk3M2UzODRjMGRmNGE1MTFfNC0zLTEtMS00NjMzOA_33bb24d4-b2d0-4c50-bee9-7f72b8a05e7a">10.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0fd134611cfd4590aae18ff1ca79c965_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjBkMWIxNWEyNTRlZTQ4ZWY5NzNlMzg0YzBkZjRhNTExL3RhYmxlcmFuZ2U6MGQxYjE1YTI1NGVlNDhlZjk3M2UzODRjMGRmNGE1MTFfNS0xLTEtMS00NjMzOA_4c0a0aba-8893-4f58-9843-40c37f488f81">307,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0fd134611cfd4590aae18ff1ca79c965_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjBkMWIxNWEyNTRlZTQ4ZWY5NzNlMzg0YzBkZjRhNTExL3RhYmxlcmFuZ2U6MGQxYjE1YTI1NGVlNDhlZjk3M2UzODRjMGRmNGE1MTFfNS0zLTEtMS00NjMzOA_03193949-61bf-4e8c-a7c6-6f261006dd6a">10.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i0fd134611cfd4590aae18ff1ca79c965_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNTA5NA_d5fb7e70-cc84-498f-9991-1a1007229dba">2.4</ix:nonFraction> million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of approximately <ix:nonNumeric contextRef="i1104b4f510e448a6aafaae0d08700a68_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNTI2MA_8fa52f1c-fe9a-46c4-b81a-5f97c940fc85">1.3</ix:nonNumeric> years.</span></div></ix:continuation><div id="i01067eced90d451488548dfbb9077922_58"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 9. <ix:nonNumeric contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81OC9mcmFnOjMwNmRmOTBiY2IwYTQwOGRhNDVhMmIwMmEwYjJlOTU0L3RleHRyZWdpb246MzA2ZGY5MGJjYjBhNDA4ZGE0NWEyYjAyYTBiMmU5NTRfMTI5Mg_87d566d7-944c-4b23-8c9b-895ee9f6f407" continuedAt="ie9244dfbb3b448e2a52070f40d6904d3" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie9244dfbb3b448e2a52070f40d6904d3">On September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland (District Court) by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#8217;s SOPHIA trial. On August 17, 2020, the Employees&#8217; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint. The amended complaint asserts a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020. On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice. On October 28, 2021 the Lead Plaintiff filed a Notice of Appeal.  The appeal is now pending in the Fourth Circuit. The Company intends to vigorously defend against this action. However, the outcome of this legal proceeding is uncertain at this time and the Company cannot reasonably estimate a range of loss, if any. Accordingly, the Company has not accrued any liability associated with this action.</ix:continuation></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i01067eced90d451488548dfbb9077922_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations is based upon our unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q, which have been prepared by us in accordance with U.S. generally accepted accounting principles (GAAP), for interim periods and with Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended. This discussion and analysis should be read in conjunction with these unaudited consolidated financial statements and the notes thereto as well as in conjunction with our audited consolidated financial statements and related notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-indent:45pt"><span><br/></span></div><div id="i01067eced90d451488548dfbb9077922_64"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer.  We have a pipeline of product candidates being evaluated in clinical trials sponsored by us or our collaborators.  These product candidates include multiple immuno-oncology programs, some of which were created primarily using our proprietary, antibody-based technology platforms. We believe our product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.  In March 2021, we and our commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced active operations in 2000, and have since devoted substantially all of our resources to staffing our company, developing our technology platforms, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials, developing collaborations, business planning and raising capital. We only began generating revenues from the sale of products in 2021. We have financed our operations primarily through the public and private offerings of our securities, collaborations with other biopharmaceutical companies, and government grants and contracts.&#160;Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of June&#160;30, 2022, combined with anticipated and potential collaboration payments, product revenues and savings from the execution of our recently announced corporate restructuring plan, should enable us to fund our operations into 2024. Our expected funding requirements reflect anticipated expenditures related to the planned Phase 2 portion of the MGC018 clinical trial in metastatic castration-resistant prostate cancer (TAMARACK study), as well as our other clinical and preclinical studies currently ongoing. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through June&#160;30, 2022, we had an accumulated deficit of $1.1 billion. We expect that over the next several years this deficit will increase as we continue to incur research and development expense in connection with our ongoing preclinical and clinical studies.&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic, including the resulting adverse macroeconomic conditions, has negatively impacted the global economy, created significant financial market volatility, disrupted global supply chains, and resulted in a significant number of infections and deaths worldwide.  In addition, several national, state and local governments have placed restrictions on people from gathering in groups or interacting within a certain physical distance. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, although there has been some negative impact on our business and operations, including, for example, slowed clinical trial enrollment, we have been able to mitigate against more severe impacts of the COVID-19 pandemic on our business and operations.  However, the COVID-19 pandemic could have a more significant negative impact on our business in the future depending on the depth of the effects and the duration of the crisis. In response to the COVID-19 pandemic, we have been focused on keeping our employees safe, continuing patients on trials, and maintaining our manufacturing capabilities and research efforts.  The COVID-19 pandemic and its variants continue to evolve and we continue to monitor our business very closely to try and mitigate any potential impacts. We expect the pandemic to continue to have some near-term impact on the initiation of new studies and on clinical trial enrollment.  Significant delays in the timing of our clinical trials and in regulatory reviews could adversely affect our ability to commercialize the product candidates in our pipeline. We are classified as a government contractor and are required to comply with Executive Order 14042. The contract terms include the requirement that all our employees that may be on site at the same location as any employee supporting the government contract be fully vaccinated against COVID-19, unless legally entitled to an accommodation due to a disability or religious belief, practice or observance. In anticipation of deadlines associated with the contract terms and Executive Order 14042, we implemented a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company-wide vaccination requirement by the end of 2021, with certain exceptions.  To date, we do not believe our vaccination requirement has resulted in workforce attrition nor will it result in material difficulty securing future labor needs. If attrition is significant, our business could be adversely affected.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, we cannot precisely predict the impact that the COVID-19 pandemic will have in the future due to numerous uncertainties, including the severity, duration and resurgences of the disease and new variants, actions that may be taken by governmental authorities, the impact to the business of potential variations or disruptions in our supply chain, and other factors identified in Part I, Item 1A. &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2021. Given these uncertainties, the COVID-19 pandemic could disrupt the business of certain of our collaborators and impact our business operations and our ability to execute on our associated business strategies and initiatives, and adversely impact our consolidated results of operations and/or our financial condition in the future. We will continue to closely monitor and evaluate the nature and extent of the impact of the COVID-19 pandemic to our business, consolidated results of operations, and financial condition. </span></div><div><span><br/></span></div><div id="i01067eced90d451488548dfbb9077922_67"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Our current collaborations include the following:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Incyte. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while we retain the right to develop our pipeline assets in combination with retifanlimab. Incyte paid us an upfront payment of $150.0 million under the terms of the agreement. In July 2021, Incyte announced that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal.  Incyte&#8217;s announcement indicated that the FDA determined that additional data were needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte was reviewing the CRL and would discuss next steps with the FDA. Incyte subsequently withdrew its European application for marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies beyond squamous cell carcinoma of the anal canal, including in patients with MSI-high endometrial cancer, Merkel cell carcinoma and non-small cell lung cancer.  Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline. In April 2022, we and Incyte executed an amendment to the Incyte License Agreement to add a milestone for U.S. approval of retifanlimab in a specific indication and to exclude certain other regulatory and development achievements with retifanlimab in this same indication from the milestone events of the Incyte License Agreement.   </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, as amended, Incyte leads global development of retifanlimab. Assuming successful development and commercialization of retifanlimab by Incyte, we could receive total development and regulatory milestones of up to approximately $435.0 million and up to $330.0 million in commercial milestones. We received $70.0 million of the total development milestones through June&#160;30, 2022. In July 2022, we and Incyte further amended the Incyte License Agreement to reflect changes related to the payment of certain milestones and we received $30.0 million in milestone payments from Incyte. If retifanlimab is approved and commercialized, we would be eligible to receive tiered royalties of 15% to 24% on any global net sales and we have the option to co-promote retifanlimab with Incyte. We retain the right to develop our pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and us commercializing our asset(s), if any such potential combinations are approved. We also have an agreement with Incyte under which we are to perform development and manufacturing services for Incyte's clinical needs of retifanlimab (Incyte Clinical Supply Agreement) and another agreement under which we are entitled to manufacture a portion of Incyte&#8217;s global commercial supply of retifanlimab (Incyte Commercial Supply Agreement). </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we entered into a Manufacturing and Clinical Supply Agreement with Incyte (Incyte Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Incyte bulk drug substance over a three-year period at one of our manufacturing facilities. Under the terms of the Incyte Manufacturing and Clinical Supply Agreement, we received an upfront payment of $10.0&#160;million and are eligible </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to receive annual fixed payments paid quarterly over the term of the contract totaling $14.4&#160;million. We will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Zai Lab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In 2018, we entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development in its territory. Zai Lab has informed us that they have decided to discontinue development of tebotelimab for indications they were enrolling in their territory and is evaluating future development plans in other indications.</span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid us an upfront payment of $25.0 million less foreign withholding tax of $2.5 million. Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, we could receive up to $140.0 million in development and regulatory milestones, of which we have already earned $9.0 million. In addition, Zai Lab would pay us tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances.</span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into two agreements under which we are to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements).  </span></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates our DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by us. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while we receive commercial rights in all other territories. Under the Lead Program, Zai Lab received an option upon reaching a predefined clinical milestone to convert the regional arrangement into a global 50/50 profit share. If Zai Lab elects such option, Zai Lab is to pay us $85.0 million plus any research costs incurred by both parties as of the option election date. Zai Lab also obtained exclusive, global licenses from us to develop, manufacture and commercialize two additional molecules (license-only programs). Zai Lab granted us a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to us.</span></div><div style="padding-left:54pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Zai Lab Agreement, the Lead Program includes joint research and development services by both us and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with us to perform research and development services in the future. </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid us an upfront payment of $25.0 million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, we and Zai Lab entered into a separate stock purchase agreement (Stock Purchase Agreement) whereby Zai Lab paid us approximately $30.0 million to purchase 958,467 newly issued shares of our common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date. </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful development and commercialization of the Programs under the 2021 Zai Lab Agreement, we could receive up to $1.4 billion in development, regulatory and commercial milestones. In addition, Zai Lab would pay us tiered royalties at percentage rates of low double digit teens on annual net sales of certain specified products and of mid-single digits to low double digit teens on annual net sales of other specified products in Zai's territory, subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, we may also receive reimbursements from Zai Lab for certain research and development costs incurred by us. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">I-Mab Biopharma.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2019, we entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates our proprietary Fc Optimization technology platform (I-Mab License Agreement). I-Mab obtained </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by us. <br/> <br/>Under the terms of the agreement, I-Mab paid us an upfront payment of $15.0 million. Assuming successful development and commercialization of enoblituzumab, we could receive up to $135.0 million in development and regulatory milestones of which $5.0 million has been earned from the inception of the I-Mab License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, I-Mab would pay us tiered royalties ranging from mid-teens to 20% on annual net sales in its territories.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       In October 2021, we entered into an agreement under which we are to perform development and manufacturing services for I-Mab&#8217;s clinical needs of enoblituzumab</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Janssen. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we entered into a research collaboration and global license agreement to develop a preclinical bispecific molecule with Janssen Biotech, Inc. (Janssen). The research collaboration will incorporate our proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the agreement, Janssen paid us an upfront payment of $20.0 million and will be responsible for funding all expenses. We will also be eligible to receive up to $312.0 million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i01067eced90d451488548dfbb9077922_70"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="text-indent:39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting estimates are policies which require the most significant judgments and estimates in the preparation of our consolidated financial statements. A summary of our critical accounting estimates is presented in Part II, Item&#160;7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" of our Annual Report on Form 10-K for the year ended December&#160;31, 2021.  There have been no material changes with respect to our critical accounting estimates during the six months ended June 30, 2022. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:39pt"><span><br/></span></div><div id="i01067eced90d451488548dfbb9077922_73"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our revenue for the three and six months ended June&#160;30, 2022 and 2021 (dollars in millions):</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaborative and other agreements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in revenue of $4.8 million for the three months ended June 30, 2022 compared to the three months ended June 30, 2021 was primarily due to:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $5.0 million in development milestones recognized under the</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Incyte License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $2.6 million in revenue recognized under the Incyte Commercial Supply Agreement due to timing of manufacturing activities; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $1.3 million in revenue recognized under the I-Mab License Agreement.</span></div><div style="margin-bottom:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by:  </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$4.0 million recognized under the Incyte Manufacturing and Clinical Supply Agreement; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $1.5 million in net product revenue from sales of MARGENZA. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in revenue of $10.6&#160;million for the six months ended June 30, 2022 compared to the six months ended June 30, 2021 was primarily due to:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $15.0 million in development milestones recognized under the</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Incyte License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $5.7 million in revenue recognized under the Incyte Commercial Supply Agreement due to timing of manufacturing activities; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $1.8 million in revenue recognized under the I-Mab License Agreement.</span></div><div style="margin-bottom:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by:  </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of a $5.0 million milestone under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2018 Zai Lab Agreement during the six months ended June 30, 2022</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $4.2 million in net product revenue from sales of MARGENZA; and</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$4.0 million recognized under the Incyte Manufacturing and Clinical Supply Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from collaborative and other agreements may vary substantially from period to period depending on the progress made by our collaborators with their product candidates and the timing of milestones achieved under current agreements, and whether we enter into additional collaboration agreements. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Sales</span></div><div style="margin-bottom:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales for all periods presented consists primarily of product royalties and fill finish costs. Product sold during these periods consisted of drug product that was previously charged to research and development expense prior to FDA approval of MARGENZA, which favorably impacted our gross margin. We expect cost of product sales to continue to be positively impacted as we sell through this drug product.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Manufacturing Services</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain Incyte bulk drug substance under the Incyte Manufacturing and Clinical Supply Agreement.  We entered into this agreement in January 2022, therefore there are no such costs during the three and six months ended June 30, 2021.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our research and development expense for the three and six months ended June&#160;30, 2022 and 2021 (dollars in millions):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.073%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGC018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margetuximab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lorigerlimab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flotetuzumab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enoblituzumab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tebotelimab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMGC936</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DART molecules under HIV government contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retifanlimab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other programs (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)  Includes research and discovery projects, as well as early preclinical and terminated molecules.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expense for the three months ended June 30, 2022 decreased by $4.1 million compared to the three months ended June 30, 2021 primarily due to:</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased retifanlimab manufacturing costs related to the Incyte Commercial Supply Agreement; </span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development, manufacturing and clinical trial costs related to flotetuzumab (due to discontinuance of our company-sponsored trial);</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased margetuximab manufacturing costs related to the Zai Lab Clinical Supply Agreement; and</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">decreased development, manufacturing and clinical trial costs related to tebotelimab.</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These decreases were partially offset by:</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased development of discovery projects and preclinical molecules;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased clinical trial enrollment costs related to lorigerlimab; and</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased development, manufacturing and clinical trial costs related to MGC018.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our research and development expense for the six months ended June 30, 2022 increased by $4.3 million compared to the six months ended June 30, 2021 primarily due to:</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased development, manufacturing and clinical trial costs related to MGC018;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased development of discovery projects and preclinical molecules; and</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased clinical trial enrollment costs related to lorigerlimab.</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These increases were partially offset by:</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">decreased development, manufacturing and clinical trial costs related to flotetuzumab (due to discontinuance of our company-sponsored trial);</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">decreased retifanlimab manufacturing costs related to the Incyte Commercial Supply Agreement; and </span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">decreased margetuximab manufacturing costs related to the Zai Lab Clinical Supply Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are uncertainties associated with our research and development expenses for future quarters which are impacted by multiple variables, including timing of wind down activities for recently closed studies and current and expected expenditures associated with our Phase 2/3 MGC018 TAMARACK study.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expense</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses decreased by $1.6 million for the three months ended June 30, 2022 compared to the three months ended June 30, 2021 and by $0.3 million for the six months ended June 30, 2022 compared to the six months ended June 30, 2021 primarily due to decreased selling costs for MARGENZA, which launched in March 2021, as well as decreased consulting expenses.</span></div><div><span><br/></span></div><div id="i01067eced90d451488548dfbb9077922_76"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use. Our future success is dependent on our ability to identify and develop our product candidates, and ultimately upon our ability to attain profitable operations. We have devoted substantially all of our financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital, and accordingly, our ability to execute our future operating plans.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, we have primarily funded our operations with proceeds from the sale of our common stock in equity offerings, revenue from our multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews our available liquidity relative to our operating budget and forecast to monitor the sufficiency of our working capital, and anticipates continuing to draw upon available sources </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of capital, including equity and debt instruments, to support our product development activities. There can be no assurances that new sources of capital will be available to us on commercially acceptable terms, if at all. Also, any future collaborations, strategic alliances and marketing, distribution or licensing arrangements may require us to give up some or all rights to a product or technology at less than its full potential value. If we are unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, we will assess our capital resources and may be required to delay, reduce the scope of, or eliminate one or more of our product research and development programs or clinical studies, and/or downsize our organization</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of June&#160;30, 2022, combined with $30.0 million subsequently received from Incyte,  anticipated and potential collaboration payments, product revenues and savings from the execution of our corporate restructuring plan, should enable us to fund our operations into 2024. Our expected funding requirements reflect anticipated expenditures related to the planned Phase 2 portion of the MGC018 TAMARACK study, as well as our other clinical and preclinical studies currently ongoing. </span></div><div style="margin-bottom:6pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, there were no significant changes to our material cash requirements, including contractual and other obligations, as presented in Part II, Item 7, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a summary of our cash flows for the six months ended June&#160;30, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:64.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.494%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(102.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities consists of our net loss adjusted for non-cash items such as depreciation and amortization expense and stock-based compensation and changes in working capital.  Net cash used in operating activities for the six months ended June&#160;30, 2022 benefited from the $12.3 million received from Incyte under the Incyte Manufacturing and Clinical Supply Agreement and a $5.0 million milestone received under the 2018 Zai Lab Agreement. Net cash used in operating activities for the six months ended June 30, 2021 benefited from the $15.0 million milestone payments received under the Incyte License Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investing Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities during the six months ended June 30, 2022 is primarily due to maturities of marketable securities, partially offset by purchases of marketable securities. Net cash used in investing activities during the six months ended June 30, 2021 is primarily due to purchases of marketable securities, partially offset by maturities of marketable securities.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the six months ended June 30, 2021 reflects net cash proceeds from our securities offerings of approximately $98.2 million. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i01067eced90d451488548dfbb9077922_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Under SEC rules and regulations, because we are considered to be a &#8220;smaller reporting company&#8221;, we are not required to provide the information required by this item in this Quarterly Report on Form 10-Q. </span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div id="i01067eced90d451488548dfbb9077922_82"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONTROLS AND PROCEDURES</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of June&#160;30, 2022. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in our periodic reports filed with the SEC (such as this Quarterly Report on Form 10-Q) has been appropriately recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Based on their evaluation of our disclosure controls and procedures as of June&#160;30, 2022, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the three months ended June 30, 2022 that materially affected, or are reasonably likely to materially effect, our internal control over financial reporting.</span></div><div id="i01067eced90d451488548dfbb9077922_85"></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i01067eced90d451488548dfbb9077922_88"></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.  Legal Proceedings</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are or may be involved in various legal or regulatory proceedings, claims or  class actions related to alleged patent infringements and other intellectual property rights, or alleged violation of commercial, corporate, securities, labor and employment, and other matters incidental to our business. We do not currently, however, expect such legal proceedings to have a material adverse effect on our business, financial condition or results of operations. However, depending on the nature and timing of a given dispute, an eventual unfavorable resolution could materially affect our current or future results of operations or cash flows.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 9, Commitments and Contingencies, to the consolidated financial statements of this Quarterly Report on Form 10-Q for more information.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i01067eced90d451488548dfbb9077922_91"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:7.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.008%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk Factors</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in the risk factors described in &#8220;Item 1A. Risk Factors&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2021, aside from the risk factors included below:</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and the Development and Commercialization of Our Products and Product Candidates</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development involves a lengthy and expensive process, with a highly uncertain outcome. We expect to incur significant additional costs related to the development of MGC018 and our other product candidates and may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our other products and product candidates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive regulation by the FDA and non-U.S. regulatory authorities, which regulations differ from country to country. We are not permitted to market our product candidates in the United States or in other countries until we receive approval of a Biologics License Application (BLA) from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to the risks of failure inherent in drug development. For example, in November 2021, we announced the discontinuation of Cohort A of the MAHOGANY trial for margetuximab in gastric cancer, based on a number of factors, including the prioritization of our other product candidates given the competition in this indication, and the FDA&#8217;s approval of competing combination therapy with pembrolizumab. Also in July 2022, we announced the discontinuation of the Phase 2 trial of enoblituzumab in combination with either retifanlimab or tebotelimab in the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and neck (SCCHN), based on an internal review of safety data.  In addition, our collaborator Incyte submitted a BLA for retifanlimab in January 2021 and in July 2021, received a Complete Response Letter (CRL) from the FDA regarding its BLA. Incyte&#8217;s announcement indicated that the FDA determined that additional data are needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte is reviewing the CRL and will discuss next steps with the FDA. Obtaining approval of a BLA can be a lengthy, expensive and uncertain process. Further, in October 2021, Incyte withdrew its European application for marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal. In addition, failure to comply with FDA and non-U.S. regulatory requirements may, either before or after product approval, subject our company or our collaborators to administrative or judicially imposed sanctions, including: </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the products, manufacturers, manufacturing facilities or manufacturing process; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning letters; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">civil and criminal penalties; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of regulatory approvals; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizures, detentions or import bans; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">voluntary or mandatory product recalls and publicity requirements; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">total or partial suspension of production; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of restrictions on operations, including costly new manufacturing requirements; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending BLAs or supplements to approved BLAs or analogous marketing approvals outside the United States. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and foreign regulatory authorities also have substantial discretion in the drug approval process. The number of preclinical studies and clinical trials that will be required for regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular drug candidate. Regulatory agencies can delay, limit or deny approval of a product candidate for many reasons, including:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may not be deemed safe or effective; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results may not confirm the positive results from earlier preclinical studies or clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory agencies may not find the data from preclinical studies and clinical trials sufficient or meaningful; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory agencies might not approve or might require changes to our manufacturing processes or facilities; or </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory agencies may change their approval policies or adopt new regulations. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market the product. These limitations may limit the size of the potential market for a product candidate, if approved.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If clinical trials for our product candidates are prolonged, delayed or stopped, for any reason, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, or our collaborators, are either currently enrolling patients in clinical trials or anticipate initiating, continuing, designing or supporting clinical trials for molecules that include MGC018, lorigerlimab, retifanlimab, tebotelimab, IMGC936 and MGD024 as monotherapies or in combination with other product candidates. In addition, Incyte is currently enrolling patients in clinical trials for retifanlimab, and other collaborators outside the United States are developing our product candidates. We anticipate in the future collaborators will initiate or continue clinical trials of one or more our product candidates. The continuation, modification, or commencement of existing or new clinical trials could be substantially delayed or prevented by several factors, including: </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further discussions with the FDA or other regulatory agencies regarding the scope or design of our clinical trials; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the limited number of, and competition for, suitable sites to conduct our clinical trials, many of which may already be engaged in other clinical trial programs, including some that may be for the same indication as our product candidates; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay or failure in patient recruitment or enrollment in our or our collaborators&#8217; trials for any reason, including as a result of public health crises such as the evolving COVID-19 pandemic; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay or failure to obtain regulatory approval or agreement to commence a clinical trial in any of the countries where enrollment is planned; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to obtain sufficient funds required for a clinical trial; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical holds on, or other regulatory objections to, a new or ongoing clinical trial; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or failure to manufacture sufficient supplies of the product candidate for our clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or failure to reach agreement on acceptable clinical trial terms or clinical trial protocols with prospective sites or CROs the terms of which can be subject to extensive negotiation and may vary significantly among different sites or CROs; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or failure to obtain institutional review board (IRB) approval to conduct a clinical trial at a prospective site; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant competition of product candidates that are expected to be more effective or have a more favorable safety profile; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval of potential combination therapies by competitors.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The progress or completion of our, or our collaborators', clinical trials have been and could also be substantially delayed or prevented by many factors, including: </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen safety issues, including severe or unexpected adverse effects experienced by patients, including actual and possible deaths; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in expected site initiation, patient recruitment and enrollment, for any reason, including as a result of public health crises such as the evolving COVID-19 pandemic; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of patients to complete the clinical trial; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of efficacy during clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of our clinical trials by one or more clinical trial sites; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability or unwillingness of patients or clinical investigators to follow our clinical trial protocols; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic and political instability in countries where our trial sites are located, including terrorist attacks, civil unrest and actual or threatened armed conflict;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to monitor patients adequately during or after treatment by us, our collaboration partners and/or our CROs; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to repeat or terminate clinical trials as a result of inconclusive or negative results or unforeseen complications in testing. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in regulatory requirements and guidance may also occur and we may need to significantly amend clinical trial protocols to reflect these changes with appropriate regulatory authorities. Amendments may require us to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing or successful completion of a clinical trial. Our clinical trials may be suspended or terminated at any time by the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or us, due to a number of factors, including: </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen safety issues or any determination that a clinical trial presents unacceptable health risks; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future collaborators that have responsibility for the clinical development of any of our product candidates. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials of our product candidates are subject to partial or full clinical holds from time to time. For example, the Investigational New Drug (IND) submission for MGD024 announced in November 2021 has not yet been accepted by the FDA </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">while we address their comments on the submission. The trial start is on hold, pending alignment with the FDA. We believe we are able to address the FDA&#8217;s comments and the MGD024 IND submission will be accepted for filing. A clinical hold received in the midst of conducting a trial may delay the progress of a clinical trial, or may require us to modify or discontinue such trial. Any failure or significant delay in completing clinical trials for our product candidates would adversely affect our ability to obtain regulatory approval and our commercial prospects and ability to generate product revenue will be diminished. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of previous clinical trials may not be predictive of future results, and interim or top line data may be subject to change or qualification, based on several factors, including a complete analysis of data, or in the case of interim analysis, the continued or ongoing accrual of data. In addition, the results of our current and planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities for product approval. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any of our current and future collaborators may decide, or regulators may require us, to conduct additional clinical or preclinical testing. Success in early clinical trials does not mean that future larger registration clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and non-U.S. regulatory authorities despite having progressed through initial clinical trials.  A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may publicly disclose top line or interim data from time to time, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial or continued progress of the study or trial. The top line or interim results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top line and interim data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. In addition, the achievement of one primary endpoint for a trial does not guarantee that additional co-primary endpoints or secondary endpoints will be achieved, which may have an adverse effect on our ability to obtain or retain additional regulatory approval of MARGENZA and our product candidates in the U.S. or in other jurisdictions. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8239;Our product candidates may have undesirable side effects which may delay or prevent further clinical development or marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although all of our product candidates have undergone or will undergo safety testing, not all adverse effects of drugs can be predicted or anticipated. Unforeseen side effects from any of our product candidates could arise either during clinical development or after the approved product has been marketed. Ongoing or future trials of our product candidates may not support the conclusion that one or more of these product candidates have acceptable safety profiles. The results of future clinical or preclinical trials may show undesirable or unacceptable side effects, which could interrupt, delay or halt clinical trials, and result in delay of, or failure to obtain, marketing approval from the FDA and other regulatory authorities, or result in marketing approval from the FDA and other regulatory authorities with restrictive label warnings or potential product liability claims. For example, in July 2022 we announced the discontinuation of our Phase 2 trial of enoblituzumab in combination with either retifanlimab or tebotelimab in the treatment of patients with recurrent or metastatic SCCHN, based on an internal review of safety data.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or others later identify undesirable or unacceptable side effects potentially caused by such products: </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require us to take our approved product off the market; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way the product is administered, impose other risk-management measures, conduct additional clinical trials or change the labeling of the product; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to limitations on how we may promote the product; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of the product may decrease significantly; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to litigation or product liability claims; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the prescribing information for MARGENZA include warnings and precautions for infusion-related reactions, as well as a boxed warning related to left ventricular dysfunction and embryo-fetal toxicity. Further, based on the identification of future adverse events, we may be required to further revise the prescribing information, including MARGENZA&#8217;s boxed warning, which could negatively impact sales of MARGENZA or adversely affect MARGENZA&#8217;s acceptance in the market. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our products.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters, public health crises such as the COVID-19 pandemic, political crises, geopolitical events, such as the crisis in Ukraine, or other macroeconomic conditions, which have in the past and may in the future negatively impact our business and financial performance. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things, severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, higher interest rates and uncertainty about economic stability. For example, the COVID-19 pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. The Federal Reserve recently raised interest rates multiple times in response to concerns about inflation and it may raise them again. Higher interest rates, coupled with reduced government spending and volatility in financial markets may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflict between Russia and Ukraine has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility and disruptions may adversely affect our business or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more costly or more dilutive or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Employee Matters and Managing Growth </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our restructuring and the associated workforce reduction announced in August 2022 may not result in anticipated cost savings, could result in total costs and expenses that are greater than expected and could disrupt our business. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we announced a reduction in workforce by approximately 15% in connection with the restructuring of our business to prioritize and focus on our lead assets. We may not realize, in full or in part, the anticipated benefits, savings and improvements in our operating structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from the restructuring, our results of operation and financial condition would be adversely affected. We expect to incur additional costs as we recognize one-time employee termination-related charges.  We also cannot guarantee that we will not have to undertake additional workforce reductions or restructuring activities in the future. Furthermore, our strategic restructuring plan may be disruptive to our operations. For example, our workforce reductions could yield unanticipated consequences, such as attrition beyond planned staff reductions, increased difficulties in our day-to-day operations and reduced employee morale. If employees who were not affected by the reduction in force seek alternate employment, this could result in us seeking contract support at unplanned additional expense or harm our productivity. Our workforce reductions could also harm our ability to attract and retain qualified management, scientific, clinical, and manufacturing personnel who are critical to our business. Any failure to attract or retain qualified personnel could prevent us from successfully developing our product candidates in the future. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i01067eced90d451488548dfbb9077922_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"></td><td style="width:6.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:14.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit101-incyte2ndamend.htm">Amendment No. 2 to the Global Collaboration and License Agreement by and between the Company and Incyte Corporation, dated April 7, 2022 </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31-1q22022.htm">Rule 13a-14(a) Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31-2q22022.htm">Rule 13a-14(a) Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">**</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32-1q22022.htm">Section 1350 Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">**</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32-2q22022.htm">Section 1350 Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Schema Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Calculation Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Definition Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Labels Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Presentation Linkbase Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data (formatted as Inline XBRL and contained in Exhibit 101 filed herewith)</span></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+ &#160;&#160;&#160;&#160;Portions of this document (indicated by &#8220;[***]&#8221; have been omitted because they are not material and are the type that MacroGenics, Inc. treats as private and confidential.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Filed herewith</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** &#160;&#160;&#160;&#160;Furnished herewith</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i01067eced90d451488548dfbb9077922_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURES</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MACROGENICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BY:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Koenig</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BY:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James Karrels</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Karrels</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: August 8, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101-incyte2ndamend.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6e73ab75c0e74f6cb87a5e4f83d6bb02_1"></div><div style="min-height:108pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exhibit 10.1</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY &#91;***&#93;) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL.</font></div></div><div style="margin-top:3.05pt;padding-left:30.9pt;padding-right:30.9pt;text-align:center"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">AMENDMENT NO. 2 TO GLOBAL COLLABORATION AND LICENSE</font></div><div style="margin-top:0.75pt;padding-left:30.9pt;padding-right:30.9pt;text-align:center"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">AGREEMENT</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.55pt;padding-left:8.35pt;padding-right:38.05pt;text-align:justify;text-indent:36.5pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">This Amendment No. 2 to Global Collaboration and License Agreement (this &#34;Amendment No. 2&#34;) is dated as of April 7, 2022, by and between </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">INCYTE CORPORATION, </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">a Delaware corporation, having its principal place of business at 1801 Augustine Cut-Off, Wilmington, DE 19803 (hereinafter </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#34;Incyte&#34;), </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">and </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">MACROGENICS, INC., </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">a Delaware corporation, having its principal place of business at 9704 Medical Center Drive, Rockville, MD 20850 (&#34;MacroGenics&#34;, together with Incyte, the &#34;Parties&#34; and each separately, a &#34;Party&#34;), and is meant to amend that certain Global Collaboration and License Agreement, dated as of October 24, 2017, between Incyte and MacroGenics and amended on March 15, 2018 (&#34;Amendment No. 1&#34;). The Global Collaboration and License Agreement and Amendment No. 1, the &#34;Agreement&#34;. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:7.6pt;padding-right:38.7pt;text-align:justify;text-indent:36.7pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">WHEREAS, the Parties wish to add a Milestone to the Agreement specifically for receipt of a Regulatory Approval in the U.S. in the Indication of &#91;***&#93;but do not wish for such Regulatory Approval and Clinical Studies in and regulatory filings for such Indication to qualify as (i) a Development Milestone for the treatment of &#91;***&#93;  under Section 8.2(b)&#59; (ii) a Regulatory Filing Milestone for the filing of a BLA in the U.S. under Section 8.2(c)&#59; or (iii) an Approval Milestone for the receipt of a Regulatory Approval in the U.S. under Section 8.2(d)&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:7.35pt;padding-right:39.45pt;text-align:justify;text-indent:36.1pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained herein, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:7pt;padding-right:39.05pt;text-indent:0.05pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">1.</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:20.33pt;text-decoration:underline">Addition </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">of </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">new </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2(f)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">. The following text is inserted in the Agreement as new Section 8.2(f)&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:73.6pt;padding-right:41pt;text-indent:-31pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">8.2(f) &#91;***&#93;</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%"> Milestone. </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">A payment of &#91;***&#93;dollars ($&#91;***&#93;) shall be payable for receipt of the Regulatory Approval in the U.S. by Incyte, its Affiliates, or sublicensees (excluding Collaborators) for a Monotherapy Regimen or Incyte Combination Regimen in the Indication of &#91;***&#93; (the &#34;&#91;***&#93; Milestone Payment&#34;). For clarity, the &#91;***&#93; Milestone Payment shall be in addition to the existing Approval Milestones such that the &#91;***&#93;Milestone Payment plus the aggregate of the potential Approval Milestones shall equal a total of &#91;***&#93; dollars ($&#91;***&#93;).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:86.8pt;padding-right:52.65pt;text-indent:-17.8pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:7.43pt">The filing of a BLA in the U.S. by Incyte, its Affiliates, or sublicensees (excluding Collaborators) for a Monotherapy Regimen or Incyte Combination Regimen in the Indication of </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> shall not qualify as a Regulatory Filing Milestone under Section 8.2(c).</font></div><div style="margin-bottom:6pt;padding-left:86.8pt;padding-right:52.65pt;text-indent:-17.8pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:5pt">The receipt of a Regulatory Approval in the U.S. by Incyte, its Affiliates, or sublicensees (excluding Collaborators) for a Monotherapy Regimen or Incyte Combination Regimen in the Indication of </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> shall not qualify as an Approval Milestone under Section 8.2(d).</font></div><div style="padding-left:86.8pt;padding-right:52.65pt;text-indent:-17.8pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:2.09pt">The Development Milestone under Section 8.2(b), &#34;Treatment of </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> cumulative subjects across all Incyte Clinical Studies (including Incyte </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:86.8pt;padding-right:52.65pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Monotherapy Studies and Incyte Combination Studies) in a single Indication for greater than &#91;***&#93; continuously at a recommended Phase II or Phase III defined dose and schedule&#34; shall not apply to Clinical Studies in the Indication of &#91;***&#93;, and no payment for such Development Milestone shall be due with respect to the Indication of &#91;***&#93;, whether by reason of actually treating &#91;***&#93;cumulative subjects in the Indication of &#91;***&#93; or by reason of the occurrence of any of the events set forth in the final sentence in the first paragraph of Section 8.2 stating, &#34;In addition, except with respect to the Breakthrough Designation Milestone, if for any reason any other Development Milestone corresponding to a Milestone payment does not occur prior to the occurrence of Regulatory Approval, then such prior non-occurring Development Milestone shall be deemed to occur concurrently with Regulatory Approval, and the applicable Milestone payments for the applicable Development Milestones shall become due and payable in accordance with this Section 8.2.&#34; For clarity, receipt of Regulatory Approval in the U.S., the EU, or Japan by Incyte, its Affiliates, or sublicensees (excluding Collaborators) for a Monotherapy Regimen or Incyte Combination Regimen in the Indication of &#91;***&#93; shall not trigger any such Milestone payment.</font></div><div style="padding-left:14.8pt;padding-right:52.65pt;text-indent:0.2pt"><font><br></font></div><div style="padding-left:6.6pt;padding-right:38.7pt;text-align:justify;text-indent:0.6pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">2.</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:20.18pt;text-decoration:underline">Entire Agreement.</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">The Agreement (including Amendment No. 1), as supplemented and modified by this Amendment No. 2, together with the exhibits thereto, contains the entire understanding of the parties with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into the Agreement.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:6.65pt;padding-right:38.75pt;text-align:justify;text-indent:-0.15pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">3.</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:20.88pt;text-decoration:underline">Governing Law.</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> This Amendment No. 2 shall be governed by and construed under the laws of the State of New York, without giving effect to any choice of law principles that would require the application of the laws of a different state.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:38.95pt;text-align:justify;text-indent:0.45pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">4.</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:21.03pt;text-decoration:underline">Execution </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">in </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparts.</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">This Amendment No. 2 may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by .pdf or other electronically transmitted signatures and such signatures shall be deemed to bind each Party as if they were the original signatures.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.85pt;padding-right:39.4pt;text-align:justify;text-indent:-0.15pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">5.</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:21.68pt;text-decoration:underline">Remaining Provisions of the Agreement.</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> Except as provided herein, each of the other provisions of the Agreement shall remain in full force and effect.</font></div><div style="padding-right:39.4pt;text-align:justify;text-indent:17.85pt"><font><br></font></div><div style="margin-top:3.55pt;padding-left:4.5pt;padding-right:35.25pt;text-align:justify;text-indent:0.4pt"><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">6.</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:22.48pt;text-decoration:underline">References.</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> Upon the effectiveness of this Amendment No. 2, on and after the date hereof, each reference in the Agreement to &#34;this Agreement,&#34; &#34;hereunder,&#34; &#34;hereof,&#34; &#34;herein&#34; or words of like import shall mean and be a reference to the Agreement, as amended hereby.</font></div><div><font><br></font></div><div style="padding-left:49.92pt;padding-right:49.92pt;text-align:center"><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">&#91;signature page follows&#93;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i6e73ab75c0e74f6cb87a5e4f83d6bb02_10"></div><hr style="page-break-after:always"><div style="min-height:71.28pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.3pt;padding-left:11pt;padding-right:36.1pt;text-align:justify;text-indent:36.3pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 2 to Global Collaboration and License Agreement to be duly executed by their respective authorized signatories effective as of the date first indicated above.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.15pt;padding-left:16.15pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">MACROGENICS, INC.</font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:30.7pt;padding-right:227.45pt;text-indent:-14.8pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">By&#58;</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"> &#47;s&#47; Scott Koenig&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:3pt;padding-left:22.5pt;padding-right:227.45pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Scott Koenig</font></div><div style="margin-bottom:3pt;padding-left:22.5pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; President and Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:15.2pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">INCYTE CORPORATION</font></div><div style="margin-top:0.3pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline"> &#47;s&#47; Vijay Iyengar </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">______________________________</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;  Vijay Iyengar</font></div><div style="margin-top:3pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;  EVP, Global Strategy &#38; Corporate Development</font></div><div><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:33.080%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:65.9pt"><font><br></font></div></div><div style="display:inline-block;max-width:0.379%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:33.080%"></div><div style="display:inline-block;max-width:0.379%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:33.082%"></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exhibit31-1q22022.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8fcc4edd51a2440bb30d49ef0020b10e_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.1</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended June&#160;30, 2022 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott Koenig</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scott Koenig, M.D., Ph.D.</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; August&#160;8, 2022 </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exhibit31-2q22022.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i58e8c57c64c942b7ab080b96ea599731_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended June&#160;30, 2022 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President and Chief Financial Officer</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; August&#160;8, 2022 </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exhibit32-1q22022.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9e8b80a930124a82810e7d17f4139e0f_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to 18 U.S.C. 1350</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Section 906 of the Sarbanes-Oxley Act of 2002</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, President and Chief Executive Officer (principal executive officer) of MacroGenics, Inc. (the Registrant), certify, to the best of my knowledge, based upon a review of the Quarterly Report on Form 10-Q for the period ended&#160;June&#160;30, 2022&#160;of the Registrant (the Report), that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div style="padding-left:22pt;text-indent:-22pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott Koenig</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Scott Koenig, M.D., Ph.D.</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;8, 2022 </font></div><div style="padding-left:252pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>exhibit32-2q22022.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1b6704417ad747898485d1dcf86405f5_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.2</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to 18 U.S.C. 1350</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, Senior Vice President and Chief Financial Officer (principal financial officer) of MacroGenics, Inc. (the Registrant), certify, to the best of my knowledge, based upon a review of the Quarterly Report on Form 10-Q for the period ended&#160;June&#160;30, 2022&#160;of the Registrant (the Report), that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;8, 2022 </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>mgnx-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c76f9653-d31d-4b72-a3cc-7cc008424052,g:58338f7a-a7b2-4bbd-85aa-a2b62be307be-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgnx="http://macrogenics.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://macrogenics.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperations" roleURI="http://macrogenics.com/role/NatureofOperations">
        <link:definition>2101101 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2102102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstruments" roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments">
        <link:definition>2104103 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsTables" roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables">
        <link:definition>2305301 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsDetails" roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails">
        <link:definition>2406401 - Disclosure - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://macrogenics.com/role/MarketableSecurities">
        <link:definition>2107104 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://macrogenics.com/role/MarketableSecuritiesTables">
        <link:definition>2308302 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails">
        <link:definition>2409402 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNet" roleURI="http://macrogenics.com/role/InventoryNet">
        <link:definition>2110105 - Disclosure - Inventory, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNetTables" roleURI="http://macrogenics.com/role/InventoryNetTables">
        <link:definition>2311303 - Disclosure - Inventory, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNetDetails" roleURI="http://macrogenics.com/role/InventoryNetDetails">
        <link:definition>2412403 - Disclosure - Inventory, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://macrogenics.com/role/StockholdersEquity">
        <link:definition>2113106 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://macrogenics.com/role/StockholdersEquityDetails">
        <link:definition>2414404 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://macrogenics.com/role/Revenue">
        <link:definition>2115107 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsIncyteCorporationDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails">
        <link:definition>2416405 - Disclosure - Collaboration and Other Agreements - Incyte Corporation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsZaiLabDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails">
        <link:definition>2417406 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsJanssenDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails">
        <link:definition>2418407 - Disclosure - Collaboration and Other Agreements - Janssen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsIMabBiopharmaDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails">
        <link:definition>2419408 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsNIAIDContractDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails">
        <link:definition>2420409 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://macrogenics.com/role/StockBasedCompensation">
        <link:definition>2121108 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://macrogenics.com/role/StockBasedCompensationTables">
        <link:definition>2322304 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2423410 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOptionPricingAssumptionsDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails">
        <link:definition>2424411 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2425412 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationRestrictedStockUnitActivityDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails">
        <link:definition>2426413 - Disclosure - Stock-based Compensation - Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://macrogenics.com/role/CommitmentsandContingencies">
        <link:definition>2127109 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mgnx_CollaborativeAgreementTransactionPrice" abstract="false" name="CollaborativeAgreementTransactionPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement" abstract="false" name="TwoAdditionalMilestoneIncyteLicenseAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" abstract="false" name="CommonStockMaximumAmountAvailableForIssuanceIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabClinicalSupplyAgreementsMember" abstract="true" name="ZaiLabClinicalSupplyAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" abstract="true" name="RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" abstract="true" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CostOfManufacturingServices" abstract="false" name="CostOfManufacturingServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NumberOfPerformanceObligations" abstract="false" name="NumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" abstract="false" name="CollaborationAndOtherAgreementsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" abstract="false" name="PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_StockIssuedDuringPeriodValueStockPlanActivity" abstract="false" name="StockIssuedDuringPeriodValueStockPlanActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" abstract="false" name="PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenuesFromLicenseAgreementsMember" abstract="true" name="RevenuesFromLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" abstract="false" name="CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" abstract="false" name="EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" abstract="true" name="IMabBiopharmaCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" abstract="false" name="PotentialMilestonePaymentsAndRoyaltiesOnProductSales" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenueFromCollaborativeAgreementsMember" abstract="true" name="RevenueFromCollaborativeAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IMabBiopharmaMember" abstract="true" name="IMabBiopharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandSixteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_PremiumReceivedOnStockPurchase" abstract="false" name="PremiumReceivedOnStockPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" abstract="false" name="RevenueInformationUsedToAssessVariableConsiderationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_A2003StockIncentivePlanMember" abstract="true" name="A2003StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" abstract="false" name="DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenuesFromGrantsMember" abstract="true" name="RevenuesFromGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" abstract="false" name="PotentialCommercialMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" abstract="false" name="NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_StockIncentivePlan2013Member" abstract="true" name="StockIncentivePlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_TotalPotentialValueUnderAgreement" abstract="false" name="TotalPotentialValueUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" abstract="false" name="StockIssuedDuringPeriodSharesStockPlanActivity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_MillstoneRevenueRecognized" abstract="false" name="MillstoneRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_ZaiLabMember" abstract="true" name="ZaiLabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" abstract="true" name="IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_OptInFee" abstract="false" name="OptInFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" abstract="false" name="ProceedsfromStockOptionsExercisedAndESPPPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_A2021ZaiLabAgreementsMember" abstract="true" name="A2021ZaiLabAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_TotalAnnualFixedPayments" abstract="false" name="TotalAnnualFixedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncyteMGA012ClinicalServicesMember" abstract="true" name="IncyteMGA012ClinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CommonStockMaximumAmountAvailableForIssuance" abstract="false" name="CommonStockMaximumAmountAvailableForIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementMember" abstract="true" name="IncyteMGA012AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenueFromGovernmentAgreementsMember" abstract="true" name="RevenueFromGovernmentAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IncyteMGA012SupplyAgreementMember" abstract="true" name="IncyteMGA012SupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementClinicalActivitiesMember" abstract="true" name="IncyteMGA012AgreementClinicalActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_JanssenBiotechIncMember" abstract="true" name="JanssenBiotechIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_NonRefundableUpfrontFees" abstract="false" name="NonRefundableUpfrontFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" abstract="false" name="NonrefundableUpfrontFeesNetOfTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenuesFromCMOAgreementsMemberMember" abstract="true" name="RevenuesFromCMOAgreementsMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_JanssenCollaborationAndLicenseAgreementMember" abstract="true" name="JanssenCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ProceedsfromRoyaltiesPercent" abstract="false" name="ProceedsfromRoyaltiesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" abstract="false" name="RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ContractManufacturingMember" abstract="true" name="ContractManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IncyteCorporationMember" abstract="true" name="IncyteCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_OneTimeMillstoneCredit" abstract="false" name="OneTimeMillstoneCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" abstract="true" name="A2018ZaiLabCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_NonrefundablePaymentTaxWithholding" abstract="false" name="NonrefundablePaymentTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>mgnx-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c76f9653-d31d-4b72-a3cc-7cc008424052,g:58338f7a-a7b2-4bbd-85aa-a2b62be307be-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_545eb7c2-82f2-468a-a63b-72904b466966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_19ba1a5d-eee4-4321-aee8-170d807bdf08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_545eb7c2-82f2-468a-a63b-72904b466966" xlink:to="loc_us-gaap_Liabilities_19ba1a5d-eee4-4321-aee8-170d807bdf08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a220fe97-be0b-4b59-a796-87fa2f4bece2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_545eb7c2-82f2-468a-a63b-72904b466966" xlink:to="loc_us-gaap_StockholdersEquity_a220fe97-be0b-4b59-a796-87fa2f4bece2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_321da9cd-c122-4861-9c18-90f1351a88c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9770dca1-8b0e-49b7-8755-800f8d397ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_321da9cd-c122-4861-9c18-90f1351a88c9" xlink:to="loc_us-gaap_AssetsCurrent_9770dca1-8b0e-49b7-8755-800f8d397ded" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10c5f2fa-1b5a-43a6-b1d6-ee5de13fcc98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_321da9cd-c122-4861-9c18-90f1351a88c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10c5f2fa-1b5a-43a6-b1d6-ee5de13fcc98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e5a17975-d697-4f5d-b2a5-8cc9ec6ae104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_321da9cd-c122-4861-9c18-90f1351a88c9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e5a17975-d697-4f5d-b2a5-8cc9ec6ae104" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5d6fc9c4-dc49-461d-ab12-5296ec78869f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_d9e7792d-6e67-4a91-932a-fdb2dc75214a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5d6fc9c4-dc49-461d-ab12-5296ec78869f" xlink:to="loc_us-gaap_Investments_d9e7792d-6e67-4a91-932a-fdb2dc75214a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8124a004-102f-44db-81f5-be1e9697a742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5d6fc9c4-dc49-461d-ab12-5296ec78869f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8124a004-102f-44db-81f5-be1e9697a742" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_3728efd0-4795-42d4-aafe-a1143963675c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5d6fc9c4-dc49-461d-ab12-5296ec78869f" xlink:to="loc_us-gaap_InventoryNet_3728efd0-4795-42d4-aafe-a1143963675c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5bdccc04-caef-4852-8185-eb445ef0e4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5d6fc9c4-dc49-461d-ab12-5296ec78869f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5bdccc04-caef-4852-8185-eb445ef0e4e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ccdc0ccf-596b-4a6d-ba8e-009d147fc263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5d6fc9c4-dc49-461d-ab12-5296ec78869f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ccdc0ccf-596b-4a6d-ba8e-009d147fc263" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_482842a0-3ea1-49eb-958b-e08cff2ad448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_48daa02a-4639-4330-b4fc-4b7235770ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_482842a0-3ea1-49eb-958b-e08cff2ad448" xlink:to="loc_us-gaap_CommonStockValue_48daa02a-4639-4330-b4fc-4b7235770ab9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_779d1512-5aba-404d-924d-39f601ea7979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_482842a0-3ea1-49eb-958b-e08cff2ad448" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_779d1512-5aba-404d-924d-39f601ea7979" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d300708d-88b1-471b-89b4-e2b6e63b3499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_482842a0-3ea1-49eb-958b-e08cff2ad448" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d300708d-88b1-471b-89b4-e2b6e63b3499" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_23c34908-3b79-406d-81f4-7e3f7d707f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_482842a0-3ea1-49eb-958b-e08cff2ad448" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_23c34908-3b79-406d-81f4-7e3f7d707f1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0c39295a-5950-441a-bf03-aeb8ee32caa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ac8626b4-a617-4be4-8131-66154c45fa5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0c39295a-5950-441a-bf03-aeb8ee32caa0" xlink:to="loc_us-gaap_AccountsPayableCurrent_ac8626b4-a617-4be4-8131-66154c45fa5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3f9fd199-d252-418a-9564-625e57878ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0c39295a-5950-441a-bf03-aeb8ee32caa0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3f9fd199-d252-418a-9564-625e57878ecc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cf144c3c-252f-4f0f-9cb4-b8f2bff89d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0c39295a-5950-441a-bf03-aeb8ee32caa0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cf144c3c-252f-4f0f-9cb4-b8f2bff89d19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_fe55e67f-3bbc-47fc-b241-b974e7ad452d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0c39295a-5950-441a-bf03-aeb8ee32caa0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_fe55e67f-3bbc-47fc-b241-b974e7ad452d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_12541e0e-ab2d-4880-a3f7-a0f5b8c676c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_152fc0bc-d267-43cf-82df-c6b5e6c82a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_12541e0e-ab2d-4880-a3f7-a0f5b8c676c9" xlink:to="loc_us-gaap_LiabilitiesCurrent_152fc0bc-d267-43cf-82df-c6b5e6c82a5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b44d952f-e37b-42b3-9e2d-834934433c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_12541e0e-ab2d-4880-a3f7-a0f5b8c676c9" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b44d952f-e37b-42b3-9e2d-834934433c72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_55431204-a373-48c7-aff3-79e6185b0b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_12541e0e-ab2d-4880-a3f7-a0f5b8c676c9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_55431204-a373-48c7-aff3-79e6185b0b60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_653f72bd-914d-4796-9146-ed2c643f9366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_12541e0e-ab2d-4880-a3f7-a0f5b8c676c9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_653f72bd-914d-4796-9146-ed2c643f9366" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9fb2c02a-b0e1-4819-8ac7-6ebd03329b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_30dab748-16d7-42b3-986f-7efa629dea29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9fb2c02a-b0e1-4819-8ac7-6ebd03329b99" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_30dab748-16d7-42b3-986f-7efa629dea29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_db5d2418-9e51-4a75-abe5-1184db249443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9fb2c02a-b0e1-4819-8ac7-6ebd03329b99" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_db5d2418-9e51-4a75-abe5-1184db249443" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices_bb54fccd-fa75-4cff-bfff-66d4ec7cad0f" xlink:href="mgnx-20220630.xsd#mgnx_CostOfManufacturingServices"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9fb2c02a-b0e1-4819-8ac7-6ebd03329b99" xlink:to="loc_mgnx_CostOfManufacturingServices_bb54fccd-fa75-4cff-bfff-66d4ec7cad0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_b71b8b0d-accf-41cd-abd1-b8fe5ca0af4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9fb2c02a-b0e1-4819-8ac7-6ebd03329b99" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_b71b8b0d-accf-41cd-abd1-b8fe5ca0af4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a24fa830-420b-4297-8760-dc5adac72d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ee6df1df-ad2c-48fc-b9e9-f511386ebd17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a24fa830-420b-4297-8760-dc5adac72d05" xlink:to="loc_us-gaap_Revenues_ee6df1df-ad2c-48fc-b9e9-f511386ebd17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_30bcf5f9-2a14-4195-bed7-7aff4c98d358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a24fa830-420b-4297-8760-dc5adac72d05" xlink:to="loc_us-gaap_CostsAndExpenses_30bcf5f9-2a14-4195-bed7-7aff4c98d358" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_da5885e6-85b3-46c0-89c2-17153a8d6a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_df06443b-f72f-4657-aa66-b9e73355c705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_da5885e6-85b3-46c0-89c2-17153a8d6a24" xlink:to="loc_us-gaap_OperatingIncomeLoss_df06443b-f72f-4657-aa66-b9e73355c705" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a1f1669b-f305-477f-b743-615a0a4554bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_da5885e6-85b3-46c0-89c2-17153a8d6a24" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a1f1669b-f305-477f-b743-615a0a4554bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c63b5ee6-9746-476f-8e03-5ca04c44cf18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9ef24d57-9a21-43c4-a6a1-a2f83a7a99c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c63b5ee6-9746-476f-8e03-5ca04c44cf18" xlink:to="loc_us-gaap_NetIncomeLoss_9ef24d57-9a21-43c4-a6a1-a2f83a7a99c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0305a22e-d319-44fd-be80-2adbfe1d7f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c63b5ee6-9746-476f-8e03-5ca04c44cf18" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0305a22e-d319-44fd-be80-2adbfe1d7f77" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4ac3cf80-7f60-4dd6-a0f9-ef3aaf58636d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f7763b58-5ed8-4605-8b5d-14427b0eb7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4ac3cf80-7f60-4dd6-a0f9-ef3aaf58636d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f7763b58-5ed8-4605-8b5d-14427b0eb7c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_474d2fae-ccb4-4ac0-8cec-df234d78b888" xlink:href="mgnx-20220630.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4ac3cf80-7f60-4dd6-a0f9-ef3aaf58636d" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_474d2fae-ccb4-4ac0-8cec-df234d78b888" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_42072edd-d56d-4e89-b033-d673320d2356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_a2130782-a432-4b77-9613-81b4e750804a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_42072edd-d56d-4e89-b033-d673320d2356" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_a2130782-a432-4b77-9613-81b4e750804a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2040a80f-121d-45e9-a4dd-15dc9f9a5832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_42072edd-d56d-4e89-b033-d673320d2356" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2040a80f-121d-45e9-a4dd-15dc9f9a5832" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_efcf84ae-e46d-4bc6-afbc-e29b6f535496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_42072edd-d56d-4e89-b033-d673320d2356" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_efcf84ae-e46d-4bc6-afbc-e29b6f535496" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7609cfcc-6ec6-453c-8629-42bb39e68654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1b80a7c0-53e0-4ae2-9612-de89dcf43e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7609cfcc-6ec6-453c-8629-42bb39e68654" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1b80a7c0-53e0-4ae2-9612-de89dcf43e1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bc2f53e2-c78d-434c-9763-7cb2a3c4490a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7609cfcc-6ec6-453c-8629-42bb39e68654" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bc2f53e2-c78d-434c-9763-7cb2a3c4490a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0ab33e1b-449a-4d59-bac0-6889a68bfcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7609cfcc-6ec6-453c-8629-42bb39e68654" xlink:to="loc_us-gaap_NetIncomeLoss_0ab33e1b-449a-4d59-bac0-6889a68bfcd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9d3e97cd-d705-43c5-b02e-ab407fdfb68b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7609cfcc-6ec6-453c-8629-42bb39e68654" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9d3e97cd-d705-43c5-b02e-ab407fdfb68b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4848b1f5-f0e5-4866-8848-f98725ba812f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7609cfcc-6ec6-453c-8629-42bb39e68654" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4848b1f5-f0e5-4866-8848-f98725ba812f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_e9189bca-ec61-48fa-a181-76284ec3155f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7609cfcc-6ec6-453c-8629-42bb39e68654" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_e9189bca-ec61-48fa-a181-76284ec3155f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ac3cd9cc-fa73-4ded-9d94-e887c2bb4ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7609cfcc-6ec6-453c-8629-42bb39e68654" xlink:to="loc_us-gaap_ShareBasedCompensation_ac3cd9cc-fa73-4ded-9d94-e887c2bb4ecb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_af5298d3-bdb4-43c8-b7f3-6e01763d598d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7609cfcc-6ec6-453c-8629-42bb39e68654" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_af5298d3-bdb4-43c8-b7f3-6e01763d598d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a7232b58-e7ae-488e-910d-e90708c203b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7609cfcc-6ec6-453c-8629-42bb39e68654" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a7232b58-e7ae-488e-910d-e90708c203b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_38c03a47-159c-4fcc-b85b-ba40ac965a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7609cfcc-6ec6-453c-8629-42bb39e68654" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_38c03a47-159c-4fcc-b85b-ba40ac965a7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_38a14dc1-7b1b-47a2-bc0e-c33b01e0dda5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7609cfcc-6ec6-453c-8629-42bb39e68654" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_38a14dc1-7b1b-47a2-bc0e-c33b01e0dda5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_fdfb14c8-6d6a-403c-900d-83346fe0f925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7609cfcc-6ec6-453c-8629-42bb39e68654" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_fdfb14c8-6d6a-403c-900d-83346fe0f925" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_3ef8e5f5-f37e-4b34-9a94-cd1e60808028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7609cfcc-6ec6-453c-8629-42bb39e68654" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_3ef8e5f5-f37e-4b34-9a94-cd1e60808028" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f602fb6d-6fa9-4fda-8165-26acbdeb7025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fee4f54e-6429-4fe6-b1f5-5931284d3137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f602fb6d-6fa9-4fda-8165-26acbdeb7025" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fee4f54e-6429-4fe6-b1f5-5931284d3137" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f487caa5-cc47-4887-b020-48f65882b473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f602fb6d-6fa9-4fda-8165-26acbdeb7025" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f487caa5-cc47-4887-b020-48f65882b473" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8c822f7-da01-464a-a212-afcc9596c2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f602fb6d-6fa9-4fda-8165-26acbdeb7025" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8c822f7-da01-464a-a212-afcc9596c2d5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1909c006-23b0-4a76-a6ed-44a81a8351c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_705d5eb7-f9c8-4d68-b6f1-d4e645584253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1909c006-23b0-4a76-a6ed-44a81a8351c8" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_705d5eb7-f9c8-4d68-b6f1-d4e645584253" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c4e3614d-d4be-4366-8cfb-b51b8cb20891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1909c006-23b0-4a76-a6ed-44a81a8351c8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c4e3614d-d4be-4366-8cfb-b51b8cb20891" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#MarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f294f2b9-9311-44c5-871b-a8b6141214bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3627c074-b7b7-40a0-b601-ea295a51c348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f294f2b9-9311-44c5-871b-a8b6141214bb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3627c074-b7b7-40a0-b601-ea295a51c348" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c1d654ef-a086-4b61-a5a1-9b98ffdba1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f294f2b9-9311-44c5-871b-a8b6141214bb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c1d654ef-a086-4b61-a5a1-9b98ffdba1e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_58e373d0-f78f-4b0d-a817-5a34912c5509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f294f2b9-9311-44c5-871b-a8b6141214bb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_58e373d0-f78f-4b0d-a817-5a34912c5509" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#InventoryNetDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/InventoryNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bd8f70c8-5755-4728-b879-dadf5e0c69bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_a3e2a0c1-88dd-4988-80c5-0b805a0b8d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_bd8f70c8-5755-4728-b879-dadf5e0c69bc" xlink:to="loc_us-gaap_InventoryWorkInProcess_a3e2a0c1-88dd-4988-80c5-0b805a0b8d9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_c9b034c9-03c1-4428-b684-cf26e46ffcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_bd8f70c8-5755-4728-b879-dadf5e0c69bc" xlink:to="loc_us-gaap_InventoryFinishedGoods_c9b034c9-03c1-4428-b684-cf26e46ffcd8" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>mgnx-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c76f9653-d31d-4b72-a3cc-7cc008424052,g:58338f7a-a7b2-4bbd-85aa-a2b62be307be-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="ie153e7d9690e4e9b87f5785c51157aa3_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_76a4f3ae-5110-4e8d-8b1c-accc2503a51d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_838d3a9b-7c5b-40cf-97b0-b032a5b87dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_76a4f3ae-5110-4e8d-8b1c-accc2503a51d" xlink:to="loc_us-gaap_RevenuesAbstract_838d3a9b-7c5b-40cf-97b0-b032a5b87dde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_58693ba9-1351-40b3-a3b4-95bab112ab70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_838d3a9b-7c5b-40cf-97b0-b032a5b87dde" xlink:to="loc_us-gaap_Revenues_58693ba9-1351-40b3-a3b4-95bab112ab70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_726e8219-8ef7-419a-a9b6-d41a2f2437ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_76a4f3ae-5110-4e8d-8b1c-accc2503a51d" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_726e8219-8ef7-419a-a9b6-d41a2f2437ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0e2a05fd-1ddd-4b4a-b6e4-214b5fd7f63a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_726e8219-8ef7-419a-a9b6-d41a2f2437ac" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0e2a05fd-1ddd-4b4a-b6e4-214b5fd7f63a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices_93fe90be-ab6b-4971-998c-fb8ec4af6f95" xlink:href="mgnx-20220630.xsd#mgnx_CostOfManufacturingServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_726e8219-8ef7-419a-a9b6-d41a2f2437ac" xlink:to="loc_mgnx_CostOfManufacturingServices_93fe90be-ab6b-4971-998c-fb8ec4af6f95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2c9bd8ac-7803-442d-aa12-5247eeaf5676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_726e8219-8ef7-419a-a9b6-d41a2f2437ac" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2c9bd8ac-7803-442d-aa12-5247eeaf5676" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_57e8d2a9-9db7-42b5-b16d-67dbff64c1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_726e8219-8ef7-419a-a9b6-d41a2f2437ac" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_57e8d2a9-9db7-42b5-b16d-67dbff64c1e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9faa2dc3-dce5-4042-abd3-92d8463334b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_726e8219-8ef7-419a-a9b6-d41a2f2437ac" xlink:to="loc_us-gaap_CostsAndExpenses_9faa2dc3-dce5-4042-abd3-92d8463334b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_837ed0d6-46fd-4357-a18d-342069173d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_726e8219-8ef7-419a-a9b6-d41a2f2437ac" xlink:to="loc_us-gaap_OperatingIncomeLoss_837ed0d6-46fd-4357-a18d-342069173d55" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_92a6759f-e1c9-407c-9c74-9011d3e7b7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_726e8219-8ef7-419a-a9b6-d41a2f2437ac" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_92a6759f-e1c9-407c-9c74-9011d3e7b7e2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5e53a119-2398-4c22-8dad-1d3554a8f1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_726e8219-8ef7-419a-a9b6-d41a2f2437ac" xlink:to="loc_us-gaap_NetIncomeLoss_5e53a119-2398-4c22-8dad-1d3554a8f1e5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0e3ba8a4-5639-440c-aca4-58c5e2f8bc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_76a4f3ae-5110-4e8d-8b1c-accc2503a51d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0e3ba8a4-5639-440c-aca4-58c5e2f8bc2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_aeea0a05-429c-4d22-a9d1-f406df61bcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0e3ba8a4-5639-440c-aca4-58c5e2f8bc2e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_aeea0a05-429c-4d22-a9d1-f406df61bcb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7886c116-c53d-4a25-82b8-9b7b219b52c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_76a4f3ae-5110-4e8d-8b1c-accc2503a51d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_7886c116-c53d-4a25-82b8-9b7b219b52c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e5a1a0f3-c26d-4104-8feb-41918a725490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_76a4f3ae-5110-4e8d-8b1c-accc2503a51d" xlink:to="loc_us-gaap_EarningsPerShareBasic_e5a1a0f3-c26d-4104-8feb-41918a725490" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2d66b82d-a6f1-4beb-9f26-1d30c7892051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_76a4f3ae-5110-4e8d-8b1c-accc2503a51d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2d66b82d-a6f1-4beb-9f26-1d30c7892051" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_92851ec3-e86e-46d0-badb-da69e0e5e6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_76a4f3ae-5110-4e8d-8b1c-accc2503a51d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_92851ec3-e86e-46d0-badb-da69e0e5e6e8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a0bcc2be-26f4-42cd-ae56-ba2d04b2d4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_76a4f3ae-5110-4e8d-8b1c-accc2503a51d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a0bcc2be-26f4-42cd-ae56-ba2d04b2d4b4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_912e0124-1a2e-43cf-8122-5ddeecb6b0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_76a4f3ae-5110-4e8d-8b1c-accc2503a51d" xlink:to="loc_us-gaap_StatementTable_912e0124-1a2e-43cf-8122-5ddeecb6b0ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_86e7f9a2-e3fa-4474-a802-af42d8a2866c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_912e0124-1a2e-43cf-8122-5ddeecb6b0ea" xlink:to="loc_srt_ProductOrServiceAxis_86e7f9a2-e3fa-4474-a802-af42d8a2866c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_86e7f9a2-e3fa-4474-a802-af42d8a2866c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_86e7f9a2-e3fa-4474-a802-af42d8a2866c" xlink:to="loc_srt_ProductsAndServicesDomain_86e7f9a2-e3fa-4474-a802-af42d8a2866c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ad46ec89-63b0-4b7b-9e7f-fb2e6469595a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_86e7f9a2-e3fa-4474-a802-af42d8a2866c" xlink:to="loc_srt_ProductsAndServicesDomain_ad46ec89-63b0-4b7b-9e7f-fb2e6469595a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_71a6f451-3a94-4c85-94ec-ff7c8133b423" xlink:href="mgnx-20220630.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ad46ec89-63b0-4b7b-9e7f-fb2e6469595a" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_71a6f451-3a94-4c85-94ec-ff7c8133b423" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4cb40d7e-e97f-470b-9230-3b82d09ffe8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ad46ec89-63b0-4b7b-9e7f-fb2e6469595a" xlink:to="loc_us-gaap_ProductMember_4cb40d7e-e97f-470b-9230-3b82d09ffe8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_d8af98d7-6f33-4d57-8b5e-ce9513a42659" xlink:href="mgnx-20220630.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ad46ec89-63b0-4b7b-9e7f-fb2e6469595a" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_d8af98d7-6f33-4d57-8b5e-ce9513a42659" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ContractManufacturingMember_3c9e8d4f-458e-4b38-806a-60e736bb6070" xlink:href="mgnx-20220630.xsd#mgnx_ContractManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ad46ec89-63b0-4b7b-9e7f-fb2e6469595a" xlink:to="loc_mgnx_ContractManufacturingMember_3c9e8d4f-458e-4b38-806a-60e736bb6070" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i0c9697d6931b461c94d07e44b8ab2db1_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ab0128ec-2138-4081-9893-ff40b566f7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab0128ec-2138-4081-9893-ff40b566f7ae" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_55a3452d-3da8-4fd7-97ca-f2e795418b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_us-gaap_SharesIssued_55a3452d-3da8-4fd7-97ca-f2e795418b29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a92ed1e3-188d-4004-bffb-6c970c156912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a92ed1e3-188d-4004-bffb-6c970c156912" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4636b919-e912-4c96-8caf-9fea52de1c98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4636b919-e912-4c96-8caf-9fea52de1c98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_5ac5febe-8458-4926-a240-5a975f6a2cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_5ac5febe-8458-4926-a240-5a975f6a2cec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_b0b82f8e-3e0c-4a5d-a2a8-429ec3015d24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_b0b82f8e-3e0c-4a5d-a2a8-429ec3015d24" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_a122a4e3-9f34-4de3-a87c-a828d868522f" xlink:href="mgnx-20220630.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_a122a4e3-9f34-4de3-a87c-a828d868522f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_f38244bb-f0b3-4eee-af92-062f0c4b94c9" xlink:href="mgnx-20220630.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_f38244bb-f0b3-4eee-af92-062f0c4b94c9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d8e201b8-5466-4585-a779-ded99c31e70f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d8e201b8-5466-4585-a779-ded99c31e70f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6a160258-6a06-4620-a399-55c4ff1b5ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6a160258-6a06-4620-a399-55c4ff1b5ea0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_742f7534-ad99-490f-8af1-4be52d565bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_742f7534-ad99-490f-8af1-4be52d565bc9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1782e72d-98c3-4ef4-8ad1-26648fbf4516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_us-gaap_NetIncomeLoss_1782e72d-98c3-4ef4-8ad1-26648fbf4516" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_c4b9c49c-76ef-4e32-8178-c7ee435cbf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a83de58d-94a4-43db-a2f6-c676d2481741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_611ca187-0a03-4352-888b-6cf2d9dc0c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ab0128ec-2138-4081-9893-ff40b566f7ae" xlink:to="loc_us-gaap_StatementTable_611ca187-0a03-4352-888b-6cf2d9dc0c5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5906c023-a811-4f48-8cbf-cee61ea6f531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_611ca187-0a03-4352-888b-6cf2d9dc0c5f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5906c023-a811-4f48-8cbf-cee61ea6f531" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5906c023-a811-4f48-8cbf-cee61ea6f531_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5906c023-a811-4f48-8cbf-cee61ea6f531" xlink:to="loc_us-gaap_EquityComponentDomain_5906c023-a811-4f48-8cbf-cee61ea6f531_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d4359c6b-4ca9-49f0-b4e5-38094d9c515a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5906c023-a811-4f48-8cbf-cee61ea6f531" xlink:to="loc_us-gaap_EquityComponentDomain_d4359c6b-4ca9-49f0-b4e5-38094d9c515a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a831bed4-10d2-435c-b065-670a3700d24b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d4359c6b-4ca9-49f0-b4e5-38094d9c515a" xlink:to="loc_us-gaap_CommonStockMember_a831bed4-10d2-435c-b065-670a3700d24b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_bcc37488-2bc5-4859-903a-b066be418ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d4359c6b-4ca9-49f0-b4e5-38094d9c515a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_bcc37488-2bc5-4859-903a-b066be418ed0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_aa05f0f7-a83f-4233-acd7-d7a1a7eb8b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d4359c6b-4ca9-49f0-b4e5-38094d9c515a" xlink:to="loc_us-gaap_RetainedEarningsMember_aa05f0f7-a83f-4233-acd7-d7a1a7eb8b3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_3d7d5c97-424a-4af1-801d-fab0b0d144d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d4359c6b-4ca9-49f0-b4e5-38094d9c515a" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_3d7d5c97-424a-4af1-801d-fab0b0d144d4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended" id="i705301d7e7fc48da80ab762c89d5749e_FairValueofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff77da76-8fb2-4150-bb69-5f69ac5d8f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_7a424178-b2e9-4c3b-9507-bff10dce69da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff77da76-8fb2-4150-bb69-5f69ac5d8f7c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_7a424178-b2e9-4c3b-9507-bff10dce69da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7545c40f-f00d-498b-9e46-843c60dbc438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7a424178-b2e9-4c3b-9507-bff10dce69da" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7545c40f-f00d-498b-9e46-843c60dbc438" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fbbd2bf1-dcee-4087-902e-a5772dc88879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7a424178-b2e9-4c3b-9507-bff10dce69da" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fbbd2bf1-dcee-4087-902e-a5772dc88879" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1c9c9cf8-6567-48d7-9d4b-4ebc62b41b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7a424178-b2e9-4c3b-9507-bff10dce69da" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1c9c9cf8-6567-48d7-9d4b-4ebc62b41b92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_505df7c8-517d-4b3c-8ee9-86c09276edd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff77da76-8fb2-4150-bb69-5f69ac5d8f7c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_505df7c8-517d-4b3c-8ee9-86c09276edd7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7b30a925-846b-4dbd-a3bf-cb96c703ab7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_505df7c8-517d-4b3c-8ee9-86c09276edd7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7b30a925-846b-4dbd-a3bf-cb96c703ab7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7b30a925-846b-4dbd-a3bf-cb96c703ab7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7b30a925-846b-4dbd-a3bf-cb96c703ab7d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7b30a925-846b-4dbd-a3bf-cb96c703ab7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d4629de5-0dc7-4907-b85a-684a8250cfab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7b30a925-846b-4dbd-a3bf-cb96c703ab7d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d4629de5-0dc7-4907-b85a-684a8250cfab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_928349e9-452e-4419-b59b-97fac21590be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d4629de5-0dc7-4907-b85a-684a8250cfab" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_928349e9-452e-4419-b59b-97fac21590be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_389bdd9c-2e18-41b6-abc7-683301f80428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_505df7c8-517d-4b3c-8ee9-86c09276edd7" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_389bdd9c-2e18-41b6-abc7-683301f80428" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_389bdd9c-2e18-41b6-abc7-683301f80428_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_389bdd9c-2e18-41b6-abc7-683301f80428" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_389bdd9c-2e18-41b6-abc7-683301f80428_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51a7bfb5-0abf-4cfb-9d9f-5f7c7a2049bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_389bdd9c-2e18-41b6-abc7-683301f80428" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51a7bfb5-0abf-4cfb-9d9f-5f7c7a2049bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_86a77061-9661-42a3-a762-03dd6bd95342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51a7bfb5-0abf-4cfb-9d9f-5f7c7a2049bb" xlink:to="loc_us-gaap_MoneyMarketFundsMember_86a77061-9661-42a3-a762-03dd6bd95342" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_6c195092-cfeb-46aa-b7c7-3f6aab26386e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51a7bfb5-0abf-4cfb-9d9f-5f7c7a2049bb" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_6c195092-cfeb-46aa-b7c7-3f6aab26386e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_182a6f4b-f083-45ce-b9bb-57cac2640d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51a7bfb5-0abf-4cfb-9d9f-5f7c7a2049bb" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_182a6f4b-f083-45ce-b9bb-57cac2640d00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_962b5ed1-1ea2-4366-a3c6-f9d9d9b4c37f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51a7bfb5-0abf-4cfb-9d9f-5f7c7a2049bb" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_962b5ed1-1ea2-4366-a3c6-f9d9d9b4c37f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae60427a-d139-49e6-aa9b-b0ecdd476197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_505df7c8-517d-4b3c-8ee9-86c09276edd7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae60427a-d139-49e6-aa9b-b0ecdd476197" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae60427a-d139-49e6-aa9b-b0ecdd476197_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae60427a-d139-49e6-aa9b-b0ecdd476197" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae60427a-d139-49e6-aa9b-b0ecdd476197_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32e3b616-9d6f-4528-86fe-4434cca12755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae60427a-d139-49e6-aa9b-b0ecdd476197" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32e3b616-9d6f-4528-86fe-4434cca12755" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_05bcfafa-56f7-43ca-8c2a-a96e91e8416f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32e3b616-9d6f-4528-86fe-4434cca12755" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_05bcfafa-56f7-43ca-8c2a-a96e91e8416f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f9dcf282-1e3b-471d-a391-09c5470dc4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32e3b616-9d6f-4528-86fe-4434cca12755" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f9dcf282-1e3b-471d-a391-09c5470dc4e0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended" id="i47fe765f9293485e90c4d0236017614e_MarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ab264eb7-050a-4b94-9a68-ce4a7e2f2bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_09b7178f-a084-4ce5-83a6-5744e842615c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ab264eb7-050a-4b94-9a68-ce4a7e2f2bc8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_09b7178f-a084-4ce5-83a6-5744e842615c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a02a341a-74d2-4dbe-b1e1-b7608412e7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ab264eb7-050a-4b94-9a68-ce4a7e2f2bc8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a02a341a-74d2-4dbe-b1e1-b7608412e7db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b0e63277-5284-42a5-8b6d-6f8ebfcd0840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ab264eb7-050a-4b94-9a68-ce4a7e2f2bc8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b0e63277-5284-42a5-8b6d-6f8ebfcd0840" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_91aebe60-ad18-495a-89ba-227284b84c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ab264eb7-050a-4b94-9a68-ce4a7e2f2bc8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_91aebe60-ad18-495a-89ba-227284b84c0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_179c90f4-40bd-4939-810b-a7eb88e96f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ab264eb7-050a-4b94-9a68-ce4a7e2f2bc8" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_179c90f4-40bd-4939-810b-a7eb88e96f3f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_db0e2588-1d17-4764-850b-55e93ce513fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_179c90f4-40bd-4939-810b-a7eb88e96f3f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_db0e2588-1d17-4764-850b-55e93ce513fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_db0e2588-1d17-4764-850b-55e93ce513fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_db0e2588-1d17-4764-850b-55e93ce513fc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_db0e2588-1d17-4764-850b-55e93ce513fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_de55b9e6-2a76-4c3d-8ec2-2bad6aeff839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_db0e2588-1d17-4764-850b-55e93ce513fc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_de55b9e6-2a76-4c3d-8ec2-2bad6aeff839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_e184e20a-73ef-433c-bf55-1cd03c9bd563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_de55b9e6-2a76-4c3d-8ec2-2bad6aeff839" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_e184e20a-73ef-433c-bf55-1cd03c9bd563" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_bf7d50df-2e0d-4bc6-810c-cd53525fb232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_de55b9e6-2a76-4c3d-8ec2-2bad6aeff839" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_bf7d50df-2e0d-4bc6-810c-cd53525fb232" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_e08d350e-0ea0-4f75-aeb9-9408659f34b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_de55b9e6-2a76-4c3d-8ec2-2bad6aeff839" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_e08d350e-0ea0-4f75-aeb9-9408659f34b9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended" id="i3341ad974b23484395b642def58933ab_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5afa5801-c27c-4cc8-9f4f-72862ca74dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_3753ca00-aef8-44b2-b67c-27903f5fef04" xlink:href="mgnx-20220630.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5afa5801-c27c-4cc8-9f4f-72862ca74dc3" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_3753ca00-aef8-44b2-b67c-27903f5fef04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2a955944-0707-4978-8f38-981dd469f1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5afa5801-c27c-4cc8-9f4f-72862ca74dc3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2a955944-0707-4978-8f38-981dd469f1c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_e1bd80fe-1834-4832-afb6-2fe23d4ae63d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5afa5801-c27c-4cc8-9f4f-72862ca74dc3" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_e1bd80fe-1834-4832-afb6-2fe23d4ae63d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_961f4611-a120-4f99-9533-7f4b4b33e5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5afa5801-c27c-4cc8-9f4f-72862ca74dc3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_961f4611-a120-4f99-9533-7f4b4b33e5d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_1a65c18c-0462-4e09-a10a-29305a628861" xlink:href="mgnx-20220630.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5afa5801-c27c-4cc8-9f4f-72862ca74dc3" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_1a65c18c-0462-4e09-a10a-29305a628861" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a8b80744-46e4-4a1d-8607-88edcd8783c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5afa5801-c27c-4cc8-9f4f-72862ca74dc3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a8b80744-46e4-4a1d-8607-88edcd8783c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9df1f6c8-9dff-4c5b-923b-e99704173561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5afa5801-c27c-4cc8-9f4f-72862ca74dc3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9df1f6c8-9dff-4c5b-923b-e99704173561" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ce236fe4-a684-4f7e-b2ad-c29ec1b75353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_5afa5801-c27c-4cc8-9f4f-72862ca74dc3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ce236fe4-a684-4f7e-b2ad-c29ec1b75353" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_590e4474-4305-4609-80bd-74bba137484c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ce236fe4-a684-4f7e-b2ad-c29ec1b75353" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_590e4474-4305-4609-80bd-74bba137484c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_590e4474-4305-4609-80bd-74bba137484c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_590e4474-4305-4609-80bd-74bba137484c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_590e4474-4305-4609-80bd-74bba137484c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce7f0c39-1b14-4f4e-b906-b0548856bda6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_590e4474-4305-4609-80bd-74bba137484c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce7f0c39-1b14-4f4e-b906-b0548856bda6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_845ef6b4-4634-4093-97cc-f4d81ebd5c00" xlink:href="mgnx-20220630.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce7f0c39-1b14-4f4e-b906-b0548856bda6" xlink:to="loc_mgnx_AtTheMarketOfferingMember_845ef6b4-4634-4093-97cc-f4d81ebd5c00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4443dc0f-e84e-4dfa-9af0-5a021c0bf128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ce236fe4-a684-4f7e-b2ad-c29ec1b75353" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4443dc0f-e84e-4dfa-9af0-5a021c0bf128" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4443dc0f-e84e-4dfa-9af0-5a021c0bf128_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4443dc0f-e84e-4dfa-9af0-5a021c0bf128" xlink:to="loc_us-gaap_EquityComponentDomain_4443dc0f-e84e-4dfa-9af0-5a021c0bf128_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7d07ee4a-578b-4522-9632-01d8c0efa607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4443dc0f-e84e-4dfa-9af0-5a021c0bf128" xlink:to="loc_us-gaap_EquityComponentDomain_7d07ee4a-578b-4522-9632-01d8c0efa607" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4d89a256-7c63-48f9-91ef-10d8a7a1dc81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7d07ee4a-578b-4522-9632-01d8c0efa607" xlink:to="loc_us-gaap_CommonStockMember_4d89a256-7c63-48f9-91ef-10d8a7a1dc81" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CollaborationandOtherAgreementsIncyteCorporationDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="extended" id="i9942dc6f162949d78bd53ba2f69c222f_CollaborationandOtherAgreementsIncyteCorporationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_c15f637a-29f4-423b-9b57-038bad909c17" xlink:href="mgnx-20220630.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_mgnx_NonRefundableUpfrontFees_c15f637a-29f4-423b-9b57-038bad909c17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_fdf4258a-4ac1-4989-8d60-c112397b22b4" xlink:href="mgnx-20220630.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_fdf4258a-4ac1-4989-8d60-c112397b22b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_7b00e9c9-6073-49c5-89bd-86d9326dd38c" xlink:href="mgnx-20220630.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_7b00e9c9-6073-49c5-89bd-86d9326dd38c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_9a288a9d-25d6-4a9a-9976-fbcdf11ea373" xlink:href="mgnx-20220630.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_9a288a9d-25d6-4a9a-9976-fbcdf11ea373" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_6670cc89-9fa1-4fc7-826b-4d5877b37488" xlink:href="mgnx-20220630.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_6670cc89-9fa1-4fc7-826b-4d5877b37488" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_2d873861-0cf8-44c9-b04e-56002c0029c1" xlink:href="mgnx-20220630.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_mgnx_NumberOfPerformanceObligations_2d873861-0cf8-44c9-b04e-56002c0029c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_bd8d01a7-5927-4fff-afd5-d5f8dd3a3a71" xlink:href="mgnx-20220630.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_bd8d01a7-5927-4fff-afd5-d5f8dd3a3a71" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_be396797-b582-44ac-83a2-67e5d940d4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_us-gaap_Revenues_be396797-b582-44ac-83a2-67e5d940d4f9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_995f503a-6849-4e8c-925e-88e0009c1055" xlink:href="mgnx-20220630.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_995f503a-6849-4e8c-925e-88e0009c1055" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a733a7c0-80e2-458f-8cc4-51633c9872f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a733a7c0-80e2-458f-8cc4-51633c9872f1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_df5bab2e-df9f-4c68-99c3-fea99b0126d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_df5bab2e-df9f-4c68-99c3-fea99b0126d6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8560fa0a-3db8-4533-8329-7cae0f383c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8560fa0a-3db8-4533-8329-7cae0f383c62" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalAnnualFixedPayments_db26a332-6a5f-4fa0-bc88-0424583d5a9f" xlink:href="mgnx-20220630.xsd#mgnx_TotalAnnualFixedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_mgnx_TotalAnnualFixedPayments_db26a332-6a5f-4fa0-bc88-0424583d5a9f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement_cfef0f1d-41b4-4c10-839c-aa9ed118ceb3" xlink:href="mgnx-20220630.xsd#mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement_cfef0f1d-41b4-4c10-839c-aa9ed118ceb3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d35e5b97-a1ef-4962-a4ce-d5aceb277cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d35e5b97-a1ef-4962-a4ce-d5aceb277cea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_83b4200c-d01c-4dd7-b5ec-dba2d548583c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d35e5b97-a1ef-4962-a4ce-d5aceb277cea" xlink:to="loc_srt_ProductOrServiceAxis_83b4200c-d01c-4dd7-b5ec-dba2d548583c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_83b4200c-d01c-4dd7-b5ec-dba2d548583c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_83b4200c-d01c-4dd7-b5ec-dba2d548583c" xlink:to="loc_srt_ProductsAndServicesDomain_83b4200c-d01c-4dd7-b5ec-dba2d548583c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_62eb5d85-01c1-47ff-be95-ab94f9772785" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_83b4200c-d01c-4dd7-b5ec-dba2d548583c" xlink:to="loc_srt_ProductsAndServicesDomain_62eb5d85-01c1-47ff-be95-ab94f9772785" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_c7840999-1b5b-4fd9-82ce-d55cfced31ec" xlink:href="mgnx-20220630.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_62eb5d85-01c1-47ff-be95-ab94f9772785" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_c7840999-1b5b-4fd9-82ce-d55cfced31ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_f79b9539-9a1b-4d6d-aa92-99ff49d8b277" xlink:href="mgnx-20220630.xsd#mgnx_RevenuesFromCMOAgreementsMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_62eb5d85-01c1-47ff-be95-ab94f9772785" xlink:to="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_f79b9539-9a1b-4d6d-aa92-99ff49d8b277" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ef6b29cb-f077-4da6-a48d-6b0493b22626" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d35e5b97-a1ef-4962-a4ce-d5aceb277cea" xlink:to="loc_srt_RangeAxis_ef6b29cb-f077-4da6-a48d-6b0493b22626" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ef6b29cb-f077-4da6-a48d-6b0493b22626_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ef6b29cb-f077-4da6-a48d-6b0493b22626" xlink:to="loc_srt_RangeMember_ef6b29cb-f077-4da6-a48d-6b0493b22626_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ee12a278-fd9f-4c93-a6a5-4e4d715a1823" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ef6b29cb-f077-4da6-a48d-6b0493b22626" xlink:to="loc_srt_RangeMember_ee12a278-fd9f-4c93-a6a5-4e4d715a1823" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1cf934bb-2954-4102-be23-db914e2e78ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ee12a278-fd9f-4c93-a6a5-4e4d715a1823" xlink:to="loc_srt_MinimumMember_1cf934bb-2954-4102-be23-db914e2e78ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a92a206e-15bf-48c4-a2cf-b9b1516fa9ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ee12a278-fd9f-4c93-a6a5-4e4d715a1823" xlink:to="loc_srt_MaximumMember_a92a206e-15bf-48c4-a2cf-b9b1516fa9ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5c9e3b4e-35fc-4dab-9d55-d37d78cb3752" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d35e5b97-a1ef-4962-a4ce-d5aceb277cea" xlink:to="loc_srt_CounterpartyNameAxis_5c9e3b4e-35fc-4dab-9d55-d37d78cb3752" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c9e3b4e-35fc-4dab-9d55-d37d78cb3752_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5c9e3b4e-35fc-4dab-9d55-d37d78cb3752" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c9e3b4e-35fc-4dab-9d55-d37d78cb3752_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e32c3ab7-ac1f-4a4a-8b60-3c4aabd3053f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5c9e3b4e-35fc-4dab-9d55-d37d78cb3752" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e32c3ab7-ac1f-4a4a-8b60-3c4aabd3053f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_6e203376-bf1d-4da4-8e0e-f7fae390812c" xlink:href="mgnx-20220630.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e32c3ab7-ac1f-4a4a-8b60-3c4aabd3053f" xlink:to="loc_mgnx_IncyteCorporationMember_6e203376-bf1d-4da4-8e0e-f7fae390812c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_dc1b6097-4811-4a5e-8544-c5453a2bd9d3" xlink:href="mgnx-20220630.xsd#mgnx_IMabBiopharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e32c3ab7-ac1f-4a4a-8b60-3c4aabd3053f" xlink:to="loc_mgnx_IMabBiopharmaMember_dc1b6097-4811-4a5e-8544-c5453a2bd9d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_405e72e4-f007-402e-9b24-4b0c538ac18e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d35e5b97-a1ef-4962-a4ce-d5aceb277cea" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_405e72e4-f007-402e-9b24-4b0c538ac18e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_405e72e4-f007-402e-9b24-4b0c538ac18e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_405e72e4-f007-402e-9b24-4b0c538ac18e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_405e72e4-f007-402e-9b24-4b0c538ac18e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e59438f5-c2f3-43e4-a51c-85349f160cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_405e72e4-f007-402e-9b24-4b0c538ac18e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e59438f5-c2f3-43e4-a51c-85349f160cf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_3ae45f93-c281-413b-9a79-4b1d2da7780f" xlink:href="mgnx-20220630.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e59438f5-c2f3-43e4-a51c-85349f160cf8" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_3ae45f93-c281-413b-9a79-4b1d2da7780f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_5bfb8248-f123-46a5-b791-fbe105921461" xlink:href="mgnx-20220630.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_3ae45f93-c281-413b-9a79-4b1d2da7780f" xlink:to="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_5bfb8248-f123-46a5-b791-fbe105921461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012ClinicalServicesMember_cf301778-3381-42f7-a327-8015d5e350d2" xlink:href="mgnx-20220630.xsd#mgnx_IncyteMGA012ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e59438f5-c2f3-43e4-a51c-85349f160cf8" xlink:to="loc_mgnx_IncyteMGA012ClinicalServicesMember_cf301778-3381-42f7-a327-8015d5e350d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012SupplyAgreementMember_82f6d66e-afd6-4182-a57e-f631231c075c" xlink:href="mgnx-20220630.xsd#mgnx_IncyteMGA012SupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e59438f5-c2f3-43e4-a51c-85349f160cf8" xlink:to="loc_mgnx_IncyteMGA012SupplyAgreementMember_82f6d66e-afd6-4182-a57e-f631231c075c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_5d084027-7bb1-47e1-8ae1-ebfad6c4e3ff" xlink:href="mgnx-20220630.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e59438f5-c2f3-43e4-a51c-85349f160cf8" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_5d084027-7bb1-47e1-8ae1-ebfad6c4e3ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_497882c5-f0f7-463c-bc5d-37a9c94e70e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d35e5b97-a1ef-4962-a4ce-d5aceb277cea" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_497882c5-f0f7-463c-bc5d-37a9c94e70e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_497882c5-f0f7-463c-bc5d-37a9c94e70e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_497882c5-f0f7-463c-bc5d-37a9c94e70e8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_497882c5-f0f7-463c-bc5d-37a9c94e70e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9595df49-84d9-40dd-afa3-9e09ddd5fa97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_497882c5-f0f7-463c-bc5d-37a9c94e70e8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9595df49-84d9-40dd-afa3-9e09ddd5fa97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5b1d47cc-f8e8-4a41-b4ef-38c7c4e0ab45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9595df49-84d9-40dd-afa3-9e09ddd5fa97" xlink:to="loc_us-gaap_SubsequentEventMember_5b1d47cc-f8e8-4a41-b4ef-38c7c4e0ab45" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended" id="i1f06dc5f2c7343ab800b5e7a5e9cd003_CollaborationandOtherAgreementsZaiLabDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_4690aa4e-846c-4eab-b1bb-d7820240d4cc" xlink:href="mgnx-20220630.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_NonRefundableUpfrontFees_4690aa4e-846c-4eab-b1bb-d7820240d4cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_11dbfaac-92bb-4f97-885a-4ced3426d2d9" xlink:href="mgnx-20220630.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_11dbfaac-92bb-4f97-885a-4ced3426d2d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_67c33975-1cab-45ba-a8f6-e8e7463b4ab0" xlink:href="mgnx-20220630.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_67c33975-1cab-45ba-a8f6-e8e7463b4ab0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_970fa032-05c6-478a-8651-8ea8db8fda1e" xlink:href="mgnx-20220630.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_970fa032-05c6-478a-8651-8ea8db8fda1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_f33d742e-3621-4232-b1b1-23f09b3af352" xlink:href="mgnx-20220630.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_f33d742e-3621-4232-b1b1-23f09b3af352" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_dfc087be-357d-4f99-8274-59d114dc3bf3" xlink:href="mgnx-20220630.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_dfc087be-357d-4f99-8274-59d114dc3bf3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a58715f9-e437-4ff2-846f-342501502efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a58715f9-e437-4ff2-846f-342501502efd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4a37e58a-af7b-45ea-9b74-cdec5ee01ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_us-gaap_Revenues_4a37e58a-af7b-45ea-9b74-cdec5ee01ef0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptInFee_4041451f-031c-4c2c-b535-d34f17eb24c1" xlink:href="mgnx-20220630.xsd#mgnx_OptInFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_OptInFee_4041451f-031c-4c2c-b535-d34f17eb24c1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_65cc633c-1806-49a4-bda8-ec95dc9f6103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_65cc633c-1806-49a4-bda8-ec95dc9f6103" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a2e64f14-2413-4fc4-9481-d3afd7c6a277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a2e64f14-2413-4fc4-9481-d3afd7c6a277" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_0e08e2a8-a811-4a6e-a6a1-971dede23be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_0e08e2a8-a811-4a6e-a6a1-971dede23be3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_9c539c77-7905-4527-971e-86aac3f79582" xlink:href="mgnx-20220630.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_PremiumReceivedOnStockPurchase_9c539c77-7905-4527-971e-86aac3f79582" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_84b62cab-7025-4959-8e25-c9e38f5a5198" xlink:href="mgnx-20220630.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_84b62cab-7025-4959-8e25-c9e38f5a5198" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_a4f9d989-6426-4e1f-a662-a3d6721b888d" xlink:href="mgnx-20220630.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_a4f9d989-6426-4e1f-a662-a3d6721b888d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_334ce63b-f573-43fa-a4ac-0a1bb2c593ae" xlink:href="mgnx-20220630.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_334ce63b-f573-43fa-a4ac-0a1bb2c593ae" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c5f7d22e-24f6-4d40-94f8-f8e37ca5de2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c5f7d22e-24f6-4d40-94f8-f8e37ca5de2b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9568bd78-97b2-4819-ae88-b719a9ce2642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9568bd78-97b2-4819-ae88-b719a9ce2642" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MillstoneRevenueRecognized_6c8adeee-a591-4455-81e7-fa504cd97f82" xlink:href="mgnx-20220630.xsd#mgnx_MillstoneRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_MillstoneRevenueRecognized_6c8adeee-a591-4455-81e7-fa504cd97f82" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47c8ca0f-6f6b-4f6f-aef1-55cbd5804de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47c8ca0f-6f6b-4f6f-aef1-55cbd5804de0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3cf6de35-625c-4ce5-a752-c74c0670ed02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47c8ca0f-6f6b-4f6f-aef1-55cbd5804de0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3cf6de35-625c-4ce5-a752-c74c0670ed02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3cf6de35-625c-4ce5-a752-c74c0670ed02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3cf6de35-625c-4ce5-a752-c74c0670ed02" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3cf6de35-625c-4ce5-a752-c74c0670ed02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ee7e850-b66a-4f67-9e4d-2a64f0d2df0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3cf6de35-625c-4ce5-a752-c74c0670ed02" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ee7e850-b66a-4f67-9e4d-2a64f0d2df0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_4325a54d-d028-49c5-b342-365cc989d0e2" xlink:href="mgnx-20220630.xsd#mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ee7e850-b66a-4f67-9e4d-2a64f0d2df0b" xlink:to="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_4325a54d-d028-49c5-b342-365cc989d0e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_06d4916c-8b97-45ae-9a34-3f801e4af5de" xlink:href="mgnx-20220630.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ee7e850-b66a-4f67-9e4d-2a64f0d2df0b" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_06d4916c-8b97-45ae-9a34-3f801e4af5de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_f9aa1b5f-defe-42f1-8029-8ed8c2e8adc0" xlink:href="mgnx-20220630.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ee7e850-b66a-4f67-9e4d-2a64f0d2df0b" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_f9aa1b5f-defe-42f1-8029-8ed8c2e8adc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_a1e9c990-692a-4fdf-91f3-c3226c334ee3" xlink:href="mgnx-20220630.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ee7e850-b66a-4f67-9e4d-2a64f0d2df0b" xlink:to="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_a1e9c990-692a-4fdf-91f3-c3226c334ee3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_8699a7af-3883-4309-940d-7aa5f3b20a5d" xlink:href="mgnx-20220630.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ee7e850-b66a-4f67-9e4d-2a64f0d2df0b" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_8699a7af-3883-4309-940d-7aa5f3b20a5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_72b36cd3-21c0-4d45-a4cf-0cae5a61e3bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47c8ca0f-6f6b-4f6f-aef1-55cbd5804de0" xlink:to="loc_srt_CounterpartyNameAxis_72b36cd3-21c0-4d45-a4cf-0cae5a61e3bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_72b36cd3-21c0-4d45-a4cf-0cae5a61e3bf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_72b36cd3-21c0-4d45-a4cf-0cae5a61e3bf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_72b36cd3-21c0-4d45-a4cf-0cae5a61e3bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_44909404-0e5b-49c1-b0d7-8a8ebcc528ed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_72b36cd3-21c0-4d45-a4cf-0cae5a61e3bf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_44909404-0e5b-49c1-b0d7-8a8ebcc528ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_6645cbb3-ce1a-4a38-849d-8ec8327c3f81" xlink:href="mgnx-20220630.xsd#mgnx_ZaiLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_44909404-0e5b-49c1-b0d7-8a8ebcc528ed" xlink:to="loc_mgnx_ZaiLabMember_6645cbb3-ce1a-4a38-849d-8ec8327c3f81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dfabbc4f-9aaf-4506-8afc-713e760e47fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47c8ca0f-6f6b-4f6f-aef1-55cbd5804de0" xlink:to="loc_srt_RangeAxis_dfabbc4f-9aaf-4506-8afc-713e760e47fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dfabbc4f-9aaf-4506-8afc-713e760e47fd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_dfabbc4f-9aaf-4506-8afc-713e760e47fd" xlink:to="loc_srt_RangeMember_dfabbc4f-9aaf-4506-8afc-713e760e47fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2d91bd40-0283-4948-b026-48044d5ca94a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_dfabbc4f-9aaf-4506-8afc-713e760e47fd" xlink:to="loc_srt_RangeMember_2d91bd40-0283-4948-b026-48044d5ca94a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40f2e99e-57af-4054-9b09-4af45caa188f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2d91bd40-0283-4948-b026-48044d5ca94a" xlink:to="loc_srt_MaximumMember_40f2e99e-57af-4054-9b09-4af45caa188f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_356a9e7c-3ed6-49b0-a7f8-09aa4ecc775e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47c8ca0f-6f6b-4f6f-aef1-55cbd5804de0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_356a9e7c-3ed6-49b0-a7f8-09aa4ecc775e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_356a9e7c-3ed6-49b0-a7f8-09aa4ecc775e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_356a9e7c-3ed6-49b0-a7f8-09aa4ecc775e" xlink:to="loc_us-gaap_EquityComponentDomain_356a9e7c-3ed6-49b0-a7f8-09aa4ecc775e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e32421f2-5d21-4f98-b350-8cd3c5bc16fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_356a9e7c-3ed6-49b0-a7f8-09aa4ecc775e" xlink:to="loc_us-gaap_EquityComponentDomain_e32421f2-5d21-4f98-b350-8cd3c5bc16fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fbced3a6-a70d-4a18-9f0d-c5ce855e78c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e32421f2-5d21-4f98-b350-8cd3c5bc16fe" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fbced3a6-a70d-4a18-9f0d-c5ce855e78c8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CollaborationandOtherAgreementsJanssenDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="extended" id="ie01f3d4d4cd14dd6b3a5f68f8a112d99_CollaborationandOtherAgreementsJanssenDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78c341ad-9242-45b9-be35-205e6300b93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_b16b9bc5-cc87-4e48-9b15-a080f964d405" xlink:href="mgnx-20220630.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78c341ad-9242-45b9-be35-205e6300b93a" xlink:to="loc_mgnx_NonRefundableUpfrontFees_b16b9bc5-cc87-4e48-9b15-a080f964d405" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_2fbfba97-b0d5-4a54-93dd-190d4cb79c00" xlink:href="mgnx-20220630.xsd#mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78c341ad-9242-45b9-be35-205e6300b93a" xlink:to="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_2fbfba97-b0d5-4a54-93dd-190d4cb79c00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_125f7662-2a34-40f6-b1ef-ae22bba54235" xlink:href="mgnx-20220630.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78c341ad-9242-45b9-be35-205e6300b93a" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_125f7662-2a34-40f6-b1ef-ae22bba54235" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_0c594e05-bf28-4328-80af-e741c1d68cda" xlink:href="mgnx-20220630.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78c341ad-9242-45b9-be35-205e6300b93a" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_0c594e05-bf28-4328-80af-e741c1d68cda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_045a7c85-6fa6-4d6e-bc47-e59ed16216f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78c341ad-9242-45b9-be35-205e6300b93a" xlink:to="loc_us-gaap_Revenues_045a7c85-6fa6-4d6e-bc47-e59ed16216f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_2a458fba-c96c-405f-a779-af4c1f6c6b3e" xlink:href="mgnx-20220630.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78c341ad-9242-45b9-be35-205e6300b93a" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_2a458fba-c96c-405f-a779-af4c1f6c6b3e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e2a6023b-f68e-447a-b9ee-061f98f2eb25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78c341ad-9242-45b9-be35-205e6300b93a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e2a6023b-f68e-447a-b9ee-061f98f2eb25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1410bd8f-98f4-47d0-a633-898dde138622" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e2a6023b-f68e-447a-b9ee-061f98f2eb25" xlink:to="loc_srt_CounterpartyNameAxis_1410bd8f-98f4-47d0-a633-898dde138622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1410bd8f-98f4-47d0-a633-898dde138622_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1410bd8f-98f4-47d0-a633-898dde138622" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1410bd8f-98f4-47d0-a633-898dde138622_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6e1e9cc-7766-4241-b707-60c37484b4ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1410bd8f-98f4-47d0-a633-898dde138622" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6e1e9cc-7766-4241-b707-60c37484b4ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_846facf5-17d8-4159-8428-4851b21d39e5" xlink:href="mgnx-20220630.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6e1e9cc-7766-4241-b707-60c37484b4ae" xlink:to="loc_mgnx_JanssenBiotechIncMember_846facf5-17d8-4159-8428-4851b21d39e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_432dbbf9-2b8a-43ff-81cb-640b2187ff29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e2a6023b-f68e-447a-b9ee-061f98f2eb25" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_432dbbf9-2b8a-43ff-81cb-640b2187ff29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_432dbbf9-2b8a-43ff-81cb-640b2187ff29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_432dbbf9-2b8a-43ff-81cb-640b2187ff29" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_432dbbf9-2b8a-43ff-81cb-640b2187ff29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6e1b162a-8e21-4b16-80ae-87b65b042ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_432dbbf9-2b8a-43ff-81cb-640b2187ff29" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6e1b162a-8e21-4b16-80ae-87b65b042ff2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_49d4dda5-0451-4d7a-909c-e977a9d4914c" xlink:href="mgnx-20220630.xsd#mgnx_JanssenCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6e1b162a-8e21-4b16-80ae-87b65b042ff2" xlink:to="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_49d4dda5-0451-4d7a-909c-e977a9d4914c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4d6634cd-4694-48bb-b092-3998b592d3e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e2a6023b-f68e-447a-b9ee-061f98f2eb25" xlink:to="loc_srt_ProductOrServiceAxis_4d6634cd-4694-48bb-b092-3998b592d3e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4d6634cd-4694-48bb-b092-3998b592d3e7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4d6634cd-4694-48bb-b092-3998b592d3e7" xlink:to="loc_srt_ProductsAndServicesDomain_4d6634cd-4694-48bb-b092-3998b592d3e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_328c6c31-289a-41da-9fb6-557a19946482" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4d6634cd-4694-48bb-b092-3998b592d3e7" xlink:to="loc_srt_ProductsAndServicesDomain_328c6c31-289a-41da-9fb6-557a19946482" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_90b51dee-2f29-45a5-9515-df1f4a3e1012" xlink:href="mgnx-20220630.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_328c6c31-289a-41da-9fb6-557a19946482" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_90b51dee-2f29-45a5-9515-df1f4a3e1012" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_45662845-0cbd-4e4c-a658-77784cc9c6b0" xlink:href="mgnx-20220630.xsd#mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_328c6c31-289a-41da-9fb6-557a19946482" xlink:to="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_45662845-0cbd-4e4c-a658-77784cc9c6b0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CollaborationandOtherAgreementsIMabBiopharmaDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="extended" id="i5cf077f804894ef29086bbe2a6a223e3_CollaborationandOtherAgreementsIMabBiopharmaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_ec12bae0-0faa-4ba6-ace8-3ed65ca8a733" xlink:href="mgnx-20220630.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:to="loc_mgnx_NonRefundableUpfrontFees_ec12bae0-0faa-4ba6-ace8-3ed65ca8a733" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_916b3f26-2a0f-42cb-a4ee-36bdd779ddc5" xlink:href="mgnx-20220630.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_916b3f26-2a0f-42cb-a4ee-36bdd779ddc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_435d5252-417f-4765-a7cb-c1dd7d254480" xlink:href="mgnx-20220630.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_435d5252-417f-4765-a7cb-c1dd7d254480" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_85a1dec0-4c86-43f4-acf6-71bc80587d32" xlink:href="mgnx-20220630.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_85a1dec0-4c86-43f4-acf6-71bc80587d32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_0c4f5004-179f-435c-b340-95289d813449" xlink:href="mgnx-20220630.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:to="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_0c4f5004-179f-435c-b340-95289d813449" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d2ed76a3-977d-4476-b1cd-7c0fbcbbd86e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:to="loc_us-gaap_Revenues_d2ed76a3-977d-4476-b1cd-7c0fbcbbd86e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8e1ee1ff-23fa-49ba-9654-d594920077f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8e1ee1ff-23fa-49ba-9654-d594920077f4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9d8a0d5b-7824-401c-9b29-ddb0683ec483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9d8a0d5b-7824-401c-9b29-ddb0683ec483" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_55c516ce-f7cc-4b22-b4ab-3197c79bb4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_55c516ce-f7cc-4b22-b4ab-3197c79bb4f9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OneTimeMillstoneCredit_afe84e56-3912-449e-bd8a-4e6a9f147bba" xlink:href="mgnx-20220630.xsd#mgnx_OneTimeMillstoneCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:to="loc_mgnx_OneTimeMillstoneCredit_afe84e56-3912-449e-bd8a-4e6a9f147bba" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_03b285e9-add6-4763-890f-518206d91b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_03b285e9-add6-4763-890f-518206d91b04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1838169e-7ab8-4249-8980-ca2f72e7d69f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_03b285e9-add6-4763-890f-518206d91b04" xlink:to="loc_srt_CounterpartyNameAxis_1838169e-7ab8-4249-8980-ca2f72e7d69f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1838169e-7ab8-4249-8980-ca2f72e7d69f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1838169e-7ab8-4249-8980-ca2f72e7d69f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1838169e-7ab8-4249-8980-ca2f72e7d69f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6c195d76-6a24-403f-bf2b-933b15a7df6b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1838169e-7ab8-4249-8980-ca2f72e7d69f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6c195d76-6a24-403f-bf2b-933b15a7df6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_37735959-3d5b-495b-acc4-fcd03d4eebfc" xlink:href="mgnx-20220630.xsd#mgnx_IMabBiopharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6c195d76-6a24-403f-bf2b-933b15a7df6b" xlink:to="loc_mgnx_IMabBiopharmaMember_37735959-3d5b-495b-acc4-fcd03d4eebfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_38607870-3331-4422-8bd5-f84dc8b8e190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_03b285e9-add6-4763-890f-518206d91b04" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_38607870-3331-4422-8bd5-f84dc8b8e190" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_38607870-3331-4422-8bd5-f84dc8b8e190_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_38607870-3331-4422-8bd5-f84dc8b8e190" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_38607870-3331-4422-8bd5-f84dc8b8e190_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_58a74662-106a-473f-9bee-9024c4aca97b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_38607870-3331-4422-8bd5-f84dc8b8e190" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_58a74662-106a-473f-9bee-9024c4aca97b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_926c548e-1bd2-4704-9468-802d613402d5" xlink:href="mgnx-20220630.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_58a74662-106a-473f-9bee-9024c4aca97b" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_926c548e-1bd2-4704-9468-802d613402d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_e6b6deff-c8bf-4e0c-9d17-5c6acff2e035" xlink:href="mgnx-20220630.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_58a74662-106a-473f-9bee-9024c4aca97b" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_e6b6deff-c8bf-4e0c-9d17-5c6acff2e035" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_887c4876-fce6-4c43-8ffc-a453708358c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_03b285e9-add6-4763-890f-518206d91b04" xlink:to="loc_srt_RangeAxis_887c4876-fce6-4c43-8ffc-a453708358c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_887c4876-fce6-4c43-8ffc-a453708358c2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_887c4876-fce6-4c43-8ffc-a453708358c2" xlink:to="loc_srt_RangeMember_887c4876-fce6-4c43-8ffc-a453708358c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e1ce54f0-e7f5-45f9-b1ce-03fbdea13b59" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_887c4876-fce6-4c43-8ffc-a453708358c2" xlink:to="loc_srt_RangeMember_e1ce54f0-e7f5-45f9-b1ce-03fbdea13b59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d8f86fc0-86a9-42e1-aa88-b575df8211b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e1ce54f0-e7f5-45f9-b1ce-03fbdea13b59" xlink:to="loc_srt_MaximumMember_d8f86fc0-86a9-42e1-aa88-b575df8211b3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended" id="i0cd97502cdf943d99cc7290f287a055d_CollaborationandOtherAgreementsNIAIDContractDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d228f63-675f-49ee-91ef-c7de13c68306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_1ff3a011-c2b3-4465-b3bd-0c4ce6bf5a72" xlink:href="mgnx-20220630.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d228f63-675f-49ee-91ef-c7de13c68306" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_1ff3a011-c2b3-4465-b3bd-0c4ce6bf5a72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_a2759cf0-d7d6-4f04-80e7-8460069b171a" xlink:href="mgnx-20220630.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d228f63-675f-49ee-91ef-c7de13c68306" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_a2759cf0-d7d6-4f04-80e7-8460069b171a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3d20dcc7-e65e-4b6b-aefe-47a1ef4bfab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d228f63-675f-49ee-91ef-c7de13c68306" xlink:to="loc_us-gaap_Revenues_3d20dcc7-e65e-4b6b-aefe-47a1ef4bfab4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_316a996b-e051-4569-bde0-88b5e187425d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d228f63-675f-49ee-91ef-c7de13c68306" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_316a996b-e051-4569-bde0-88b5e187425d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9830476a-a0ee-4462-a857-ebe920c7a935" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_316a996b-e051-4569-bde0-88b5e187425d" xlink:to="loc_srt_ProductOrServiceAxis_9830476a-a0ee-4462-a857-ebe920c7a935" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9830476a-a0ee-4462-a857-ebe920c7a935_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9830476a-a0ee-4462-a857-ebe920c7a935" xlink:to="loc_srt_ProductsAndServicesDomain_9830476a-a0ee-4462-a857-ebe920c7a935_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1f86555b-85bd-4275-b21d-e7bdcb7bb51d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9830476a-a0ee-4462-a857-ebe920c7a935" xlink:to="loc_srt_ProductsAndServicesDomain_1f86555b-85bd-4275-b21d-e7bdcb7bb51d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_ce864dd4-ef33-4948-a1db-599bf8255d39" xlink:href="mgnx-20220630.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1f86555b-85bd-4275-b21d-e7bdcb7bb51d" xlink:to="loc_mgnx_RevenuesFromGrantsMember_ce864dd4-ef33-4948-a1db-599bf8255d39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_92be48c2-bb1e-4178-8f7d-474b0ca03aeb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_316a996b-e051-4569-bde0-88b5e187425d" xlink:to="loc_srt_CounterpartyNameAxis_92be48c2-bb1e-4178-8f7d-474b0ca03aeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92be48c2-bb1e-4178-8f7d-474b0ca03aeb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_92be48c2-bb1e-4178-8f7d-474b0ca03aeb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92be48c2-bb1e-4178-8f7d-474b0ca03aeb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c852843-253c-4baa-893e-37583c87a40a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_92be48c2-bb1e-4178-8f7d-474b0ca03aeb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c852843-253c-4baa-893e-37583c87a40a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_c9848a73-229e-46a1-a216-752b315196df" xlink:href="mgnx-20220630.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c852843-253c-4baa-893e-37583c87a40a" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_c9848a73-229e-46a1-a216-752b315196df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4434ce72-4d12-48cd-a15e-c971246da984" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_316a996b-e051-4569-bde0-88b5e187425d" xlink:to="loc_srt_RangeAxis_4434ce72-4d12-48cd-a15e-c971246da984" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4434ce72-4d12-48cd-a15e-c971246da984_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4434ce72-4d12-48cd-a15e-c971246da984" xlink:to="loc_srt_RangeMember_4434ce72-4d12-48cd-a15e-c971246da984_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5708fd92-5b25-4822-afc4-44ad4dd0f385" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4434ce72-4d12-48cd-a15e-c971246da984" xlink:to="loc_srt_RangeMember_5708fd92-5b25-4822-afc4-44ad4dd0f385" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8d2a9dba-97bb-48db-97be-16d05dd1840a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5708fd92-5b25-4822-afc4-44ad4dd0f385" xlink:to="loc_srt_MaximumMember_8d2a9dba-97bb-48db-97be-16d05dd1840a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="i5fa221fffda54850a75246049ddc4e58_StockBasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ea27370b-74d1-4cb9-91ba-f9bf78d82381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ea27370b-74d1-4cb9-91ba-f9bf78d82381" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_03b33b11-1106-4249-98b9-75d056c55edc" xlink:href="mgnx-20220630.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_03b33b11-1106-4249-98b9-75d056c55edc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_0d482031-3d21-4644-81f0-939d8f8df1d8" xlink:href="mgnx-20220630.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_0d482031-3d21-4644-81f0-939d8f8df1d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7247c14d-1ffa-4f41-b344-a94cc10ff18a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7247c14d-1ffa-4f41-b344-a94cc10ff18a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_7160b2a8-7810-42e4-b244-4af9f86be7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_7160b2a8-7810-42e4-b244-4af9f86be7db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3e0e85d6-2a64-409f-bea8-350afc17d0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3e0e85d6-2a64-409f-bea8-350afc17d0bf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4b9f0073-8093-4a5b-b464-643ef6fcf029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4b9f0073-8093-4a5b-b464-643ef6fcf029" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_ab51198c-6015-4c20-bf15-61d11ca393b3" xlink:href="mgnx-20220630.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_ab51198c-6015-4c20-bf15-61d11ca393b3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_88e01434-b441-45bf-907b-6d75fabc4fb5" xlink:href="mgnx-20220630.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_88e01434-b441-45bf-907b-6d75fabc4fb5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bc75b21-ca0a-45d3-9a8f-9384f5999bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bc75b21-ca0a-45d3-9a8f-9384f5999bed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d91b5a78-2957-4986-96a1-2e269a785513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bc75b21-ca0a-45d3-9a8f-9384f5999bed" xlink:to="loc_us-gaap_PlanNameAxis_d91b5a78-2957-4986-96a1-2e269a785513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d91b5a78-2957-4986-96a1-2e269a785513_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d91b5a78-2957-4986-96a1-2e269a785513" xlink:to="loc_us-gaap_PlanNameDomain_d91b5a78-2957-4986-96a1-2e269a785513_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_33737ef6-a06b-49ec-8da2-55891fb12287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d91b5a78-2957-4986-96a1-2e269a785513" xlink:to="loc_us-gaap_PlanNameDomain_33737ef6-a06b-49ec-8da2-55891fb12287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_e6b443b7-31aa-4eae-a6e2-ba52b3e058e1" xlink:href="mgnx-20220630.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_33737ef6-a06b-49ec-8da2-55891fb12287" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_e6b443b7-31aa-4eae-a6e2-ba52b3e058e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember_28365033-d5e4-42fe-a220-a5c52c8548d7" xlink:href="mgnx-20220630.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_33737ef6-a06b-49ec-8da2-55891fb12287" xlink:to="loc_mgnx_A2003StockIncentivePlanMember_28365033-d5e4-42fe-a220-a5c52c8548d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_0d66fae8-f122-455b-8cdc-c090b5ef406f" xlink:href="mgnx-20220630.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_33737ef6-a06b-49ec-8da2-55891fb12287" xlink:to="loc_mgnx_StockIncentivePlan2013Member_0d66fae8-f122-455b-8cdc-c090b5ef406f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0cc38a46-8de4-4555-9bc8-7b44b4ba029c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_caf31006-c27a-4564-88ef-0dde96a6a5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0cc38a46-8de4-4555-9bc8-7b44b4ba029c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_caf31006-c27a-4564-88ef-0dde96a6a5f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f1dfd300-781a-46e6-9ddb-4ed688e3385b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0cc38a46-8de4-4555-9bc8-7b44b4ba029c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f1dfd300-781a-46e6-9ddb-4ed688e3385b" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0fb2699f-b4d1-4533-9847-c60e29df3ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f1dfd300-781a-46e6-9ddb-4ed688e3385b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0fb2699f-b4d1-4533-9847-c60e29df3ae9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0fb2699f-b4d1-4533-9847-c60e29df3ae9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0fb2699f-b4d1-4533-9847-c60e29df3ae9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0fb2699f-b4d1-4533-9847-c60e29df3ae9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cd005f8b-5995-40a4-bc3d-27645c3e64b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0fb2699f-b4d1-4533-9847-c60e29df3ae9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cd005f8b-5995-40a4-bc3d-27645c3e64b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_353ff91a-a655-40f1-a2c5-fb5f53e9b29f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cd005f8b-5995-40a4-bc3d-27645c3e64b5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_353ff91a-a655-40f1-a2c5-fb5f53e9b29f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4a7f4b3b-e833-4e4f-ab5e-4e52e3810d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cd005f8b-5995-40a4-bc3d-27645c3e64b5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4a7f4b3b-e833-4e4f-ab5e-4e52e3810d48" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#StockBasedCompensationOptionPricingAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended" id="i99b086797e2f4c7aab47215c5da9c46a_StockBasedCompensationOptionPricingAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03d557c5-08a4-49d8-8347-32dfd2e4d987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_427db450-18a8-4d58-8d69-57d0597b0c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03d557c5-08a4-49d8-8347-32dfd2e4d987" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_427db450-18a8-4d58-8d69-57d0597b0c05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b358001c-e75c-4c07-87c8-c022438ba8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03d557c5-08a4-49d8-8347-32dfd2e4d987" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b358001c-e75c-4c07-87c8-c022438ba8b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8e9e59a2-7cee-46c0-b849-f6cb7e727960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03d557c5-08a4-49d8-8347-32dfd2e4d987" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8e9e59a2-7cee-46c0-b849-f6cb7e727960" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ccc696d6-77e4-4214-af22-0b9e20865742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03d557c5-08a4-49d8-8347-32dfd2e4d987" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ccc696d6-77e4-4214-af22-0b9e20865742" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_187524ea-fa31-4ff1-936e-f0ab8ce686a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03d557c5-08a4-49d8-8347-32dfd2e4d987" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_187524ea-fa31-4ff1-936e-f0ab8ce686a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a613367-4905-45c2-885a-dc6941812cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03d557c5-08a4-49d8-8347-32dfd2e4d987" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a613367-4905-45c2-885a-dc6941812cca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_92ffcfe2-52a0-42c9-a558-99975bba66a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a613367-4905-45c2-885a-dc6941812cca" xlink:to="loc_srt_RangeAxis_92ffcfe2-52a0-42c9-a558-99975bba66a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_92ffcfe2-52a0-42c9-a558-99975bba66a6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_92ffcfe2-52a0-42c9-a558-99975bba66a6" xlink:to="loc_srt_RangeMember_92ffcfe2-52a0-42c9-a558-99975bba66a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1b512e81-2dba-4003-aae5-9bbcf5304361" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_92ffcfe2-52a0-42c9-a558-99975bba66a6" xlink:to="loc_srt_RangeMember_1b512e81-2dba-4003-aae5-9bbcf5304361" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3f40732d-86e3-4f9e-82b5-356472b9b767" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1b512e81-2dba-4003-aae5-9bbcf5304361" xlink:to="loc_srt_MinimumMember_3f40732d-86e3-4f9e-82b5-356472b9b767" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_70057a9f-968c-4dd9-89ca-25abccac592c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1b512e81-2dba-4003-aae5-9bbcf5304361" xlink:to="loc_srt_MaximumMember_70057a9f-968c-4dd9-89ca-25abccac592c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#StockbasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended" id="i6b4d06fbe59542c58e5f04c8893f95c7_StockbasedCompensationRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87da916e-da62-4f78-aa8f-aca8b9a38e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3deebef7-1ffd-485e-9e64-899eb3d4ae8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87da916e-da62-4f78-aa8f-aca8b9a38e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3deebef7-1ffd-485e-9e64-899eb3d4ae8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f549eb8b-0b26-4755-b3e6-6a164730c585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3deebef7-1ffd-485e-9e64-899eb3d4ae8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f549eb8b-0b26-4755-b3e6-6a164730c585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8eb703f8-e04d-4f18-8580-12053d861bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3deebef7-1ffd-485e-9e64-899eb3d4ae8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8eb703f8-e04d-4f18-8580-12053d861bf1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_acc6dd6a-6698-4e14-a352-cb8111389a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3deebef7-1ffd-485e-9e64-899eb3d4ae8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_acc6dd6a-6698-4e14-a352-cb8111389a9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_bcb36520-870f-4856-9848-e44b180ffe8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3deebef7-1ffd-485e-9e64-899eb3d4ae8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_bcb36520-870f-4856-9848-e44b180ffe8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3c360ad4-91cc-463e-b24e-08a220f5ce24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3deebef7-1ffd-485e-9e64-899eb3d4ae8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3c360ad4-91cc-463e-b24e-08a220f5ce24" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8fa82e97-3be1-4be7-a2c2-091fd62ddc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0a3509da-ad45-4a68-b213-55a7b089b683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87da916e-da62-4f78-aa8f-aca8b9a38e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0a3509da-ad45-4a68-b213-55a7b089b683" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cc5d9e43-a76c-4f73-ac58-6cf3381940b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0a3509da-ad45-4a68-b213-55a7b089b683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cc5d9e43-a76c-4f73-ac58-6cf3381940b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_90599a69-56f6-4eea-beef-f90956d0e704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0a3509da-ad45-4a68-b213-55a7b089b683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_90599a69-56f6-4eea-beef-f90956d0e704" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_71b16296-09af-4628-a7e5-01fd3c652005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0a3509da-ad45-4a68-b213-55a7b089b683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_71b16296-09af-4628-a7e5-01fd3c652005" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b24b9438-3389-4999-8923-afe96fa19fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ae6d0b47-7ad3-4d99-b70a-00cbe8ed272b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87da916e-da62-4f78-aa8f-aca8b9a38e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ae6d0b47-7ad3-4d99-b70a-00cbe8ed272b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward_9e657160-4af8-4ebd-baa0-c26059a41912" xlink:href="mgnx-20220630.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87da916e-da62-4f78-aa8f-aca8b9a38e30" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward_9e657160-4af8-4ebd-baa0-c26059a41912" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_159043ed-1313-440c-a5ad-608d5f1bc43c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87da916e-da62-4f78-aa8f-aca8b9a38e30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_159043ed-1313-440c-a5ad-608d5f1bc43c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_addb151d-bbff-46ec-9cd2-837ce7dd2f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87da916e-da62-4f78-aa8f-aca8b9a38e30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_addb151d-bbff-46ec-9cd2-837ce7dd2f8b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8adbf58f-88e6-48d5-b171-864e71cdc1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87da916e-da62-4f78-aa8f-aca8b9a38e30" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8adbf58f-88e6-48d5-b171-864e71cdc1f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_56eba306-29b8-4797-a562-97a3b725e607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8adbf58f-88e6-48d5-b171-864e71cdc1f5" xlink:to="loc_us-gaap_AwardTypeAxis_56eba306-29b8-4797-a562-97a3b725e607" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56eba306-29b8-4797-a562-97a3b725e607_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_56eba306-29b8-4797-a562-97a3b725e607" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56eba306-29b8-4797-a562-97a3b725e607_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2edf89b-4411-4f76-ac7c-891bd591aad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_56eba306-29b8-4797-a562-97a3b725e607" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2edf89b-4411-4f76-ac7c-891bd591aad3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_661169c4-1d0b-479d-bda4-f88c23e8d773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2edf89b-4411-4f76-ac7c-891bd591aad3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_661169c4-1d0b-479d-bda4-f88c23e8d773" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>mgnx-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c76f9653-d31d-4b72-a3cc-7cc008424052,g:58338f7a-a7b2-4bbd-85aa-a2b62be307be-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_df3bc0ac-aac8-473f-8449-0776bc3488fb_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62ab1150-01e4-40cc-802b-4ac0a8c89282_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9c1181c5-caa8-4a24-8fb8-98677d22333a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_cf223420-03e4-4f1d-8a63-468042b513e7_terseLabel_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential commercial milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialCommercialMilestonePaymentsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:href="mgnx-20220630.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6bfacc9d-ebae-4422-b06c-8b07923ab848_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_ed9afdae-051e-40fd-872f-86c9f105a4ea_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_15924d92-267b-4780-a71d-abc074ab0e9e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4e52c2cc-d0b7-4a1c-ba56-e4ea8a05b10d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_32b4897a-e153-4d83-8348-f424abcdac65_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a0519e4a-1d8e-4210-8e92-b12f360887c5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0c1017e0-4b87-4712-a467-40ff43f80c19_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e90b44a3-e455-4f38-99a0-77a97e9cf13d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_e5dc6f04-aab2-47af-92ee-60feb30f5318_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential proceeds from royalties (percent)</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_label_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProceedsfromRoyaltiesPercent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:href="mgnx-20220630.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:to="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3d44f135-556c-4e90-8672-b612f6ccd4cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_c08b0115-9fa7-4e18-b001-25c667dadd80_terseLabel_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIAID</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_label_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NationalInstituteOfAllergyAndInfectiousDiseasesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:href="mgnx-20220630.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_7b073e3a-dcbb-40ee-a370-b74dc9ce7a92_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_dc441fd9-e73f-4478-bf87-b77205fad51a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f9c8ffed-08a1-4d95-b183-6073d2a2cda8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value -- 125,000,000 shares authorized, 61,458,790 and 61,307,428 shares outstanding at June&#160;30, 2022 and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_0a9c820b-d250-444f-a616-8cc89fb692ec_terseLabel_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment, net of tax withholding</link:label>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_label_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Upfront Fees, Net Of Tax Withholding</link:label>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Upfront Fees, Net Of Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:href="mgnx-20220630.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:to="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5849d36e-a6e8-4148-8ff7-8e28e062bb36_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_791cc405-7cc8-42ee-a214-d2a14b1e2427_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_557003a1-0f46-4575-bf0f-5c8f2ce5321b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_45e71be5-911f-4ec5-9a58-8a918a21454b_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_aeccbe45-e24d-4d2b-afda-3ef20295964f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_399a2c9d-fcfc-443e-b527-8b0683626ce6_terseLabel_en-US" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan related activity</link:label>
    <link:label id="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_e9ddd98c-0b02-4c26-98ef-73bd06a64684_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ec9dfecb-0973-4bee-91df-749d8c7c797c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ebba10d7-fe32-40d9-b4a7-c676bf3ef58f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012SupplyAgreementMember_69b78fed-9eb9-4cf4-995f-9aa116479119_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012SupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Supply Agreement</link:label>
    <link:label id="lab_mgnx_IncyteMGA012SupplyAgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012SupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Supply Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IncyteMGA012SupplyAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IncyteMGA012SupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012SupplyAgreementMember" xlink:href="mgnx-20220630.xsd#mgnx_IncyteMGA012SupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012SupplyAgreementMember" xlink:to="lab_mgnx_IncyteMGA012SupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_742b3147-755c-4bdf-a4b6-151eb4d9d855_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash items</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7fb3fa31-3624-4994-a371-bf2693642d71_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_687e094d-b92e-47a2-8f50-a57c6d16c483_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteMGA012AgreementMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember" xlink:href="mgnx-20220630.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementMember" xlink:to="lab_mgnx_IncyteMGA012AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_3d538870-7ba6-4f4c-a23c-adb2c3b3d61c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_ed2e2fda-7152-40ac-808a-8b4347ae787e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_14274041-3fba-45d9-806e-0f1ab269c971_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Vested and expected to vest (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_23f7888d-01a5-4dc6-8d12-1cd335b384e5_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c2a4113a-d20a-4eac-b2f1-539253895d2e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ac7f6e75-d38d-4c5a-8074-b3861bb516d0_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_b75a1579-9d4f-4f19-8d37-79fdd94e5d74_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_6d91e62e-c6cc-422d-ae7b-65ba61669c49_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c6e51c32-f334-47cd-8bde-e1c1813f901d_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software included in accounts payable or accruals</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_3ae9cc8d-eb68-48e3-a755-21175f52b262_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3af16326-0f33-4034-9417-e8895b321f21_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ad61b8cf-beb0-42d7-b124-a47f5ba8cb38_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_fba09a75-d593-4dd4-a7b0-6423ad5bebeb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_29eaab62-56a1-49f6-b921-aea0a431f49e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c2d96d78-d31c-442c-8298-ece853d1c92f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_94589c17-ba03-4cbc-b6af-a3da0e6a2489_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_dc79ac55-d113-4741-b4e1-78890d1f6ce6_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_ff43bcf3-9824-441e-9f3b-76c262d9deb2_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9b530bf2-a4d5-4ec7-88e3-f36642ba981b_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromCMOAgreementsMemberMember_78aded80-9251-4f45-812c-133632ddfd9c_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromCMOAgreementsMember</link:label>
    <link:label id="lab_mgnx_RevenuesFromCMOAgreementsMemberMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromCMOAgreementsMember [Member]</link:label>
    <link:label id="lab_mgnx_RevenuesFromCMOAgreementsMemberMember_documentation_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromCMOAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:href="mgnx-20220630.xsd#mgnx_RevenuesFromCMOAgreementsMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:to="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_8aac694c-fd39-40e9-a5f9-a250f2f4539c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_42fb957e-820d-4e08-bc00-4d7ad9a36351_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_ea76d7d7-78f1-4a33-a8b6-e7ed0a9166c4_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6ffd9ac8-39ee-4ed3-911b-ce65a1405262_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d638c89a-ec48-46c8-9c7e-d5f65bf28fce_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f87f044e-0ce7-4bd5-94ca-2b31045e56b2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_6460fc7a-b242-40d0-a23a-4d9de1f7435f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_62febc95-545c-4ae7-96f6-0705b2826d81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_5ab663eb-01d6-41e2-ad46-51d158621a76_terseLabel_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_label_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonRefundableUpfrontFees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees" xlink:href="mgnx-20220630.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonRefundableUpfrontFees" xlink:to="lab_mgnx_NonRefundableUpfrontFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_e942fe73-1026-4e5a-b924-0d0a9961ce8f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_015dcbc9-3a37-4b01-8d9e-55bc9e17e28d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_746efa23-de0c-40cd-a51b-31bd7c3377ef_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7c217342-97f0-49f0-9367-5a899d1ff88b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock percent of the fair market value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d6c08231-a5ab-4778-b67f-ed89bdc4c8d9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_59474183-cfcd-468f-aac4-a6c3eb7b1ae7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d2137a70-780d-4084-b480-4d7346455b93_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d699e682-b7fc-43ed-bb49-feff1722efde_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_99408a6e-1a9c-43ea-bcbf-764055de02b2_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_06452580-2331-4f3f-bcbd-7f634de58d5d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8e550085-c2a3-4301-a390-0334f23d6b86_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a66dc277-706e-459a-b9ce-571f33522ecf_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b586d99b-96db-4481-9b60-714309fc62ad_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_8fb62559-5e45-4e90-b519-613df5dc47f5_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_8ae82269-c729-4f60-9796-688f040eba11_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_989c20e6-1bfc-4988-b278-8d340f2a7eb2_verboseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises and ESPP Purchases</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_label_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProceedsfromStockOptionsExercisedAndESPPPurchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:href="mgnx-20220630.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:to="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_34de5cce-78e7-42f9-bc84-bc6928a8a6ce_terseLabel_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc</link:label>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_label_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc [Member]</link:label>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_documentation_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember" xlink:href="mgnx-20220630.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenBiotechIncMember" xlink:to="lab_mgnx_JanssenBiotechIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_abfab06b-7c8b-4bda-b147-478304d3dca5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_de461be8-8ec1-4df1-afef-397da29efa4e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_81bc04db-cf56-4a74-9673-36bc557208a7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fb21ad3-b3b9-4b93-8df8-1f0ab1af2016_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Other Agreements [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c130088b-927e-4b31-aaa5-654ff92c2dcc_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_791328aa-12c1-4b3f-ac96-9eee701796da_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_e242ec68-7a45-4596-b060-61a84a28906d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dc6454a6-5782-4787-9d02-7921e329fb26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1d4ace08-4cd6-47d4-8fd1-46980d77a567_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_0061fa19-1ce8-415e-ae6b-5872673bfa5f_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement - Clinical activities</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteMGA012AgreementClinicalActivitiesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:href="mgnx-20220630.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:to="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_cfd42a36-e159-4536-a247-665eab8c9c3a_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount available for issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_documentation_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:href="mgnx-20220630.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_2779d00f-a721-49a0-8341-b71163597fb1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012ClinicalServicesMember_a494f7ad-707f-41ab-960f-6d1ec8997521_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services</link:label>
    <link:label id="lab_mgnx_IncyteMGA012ClinicalServicesMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services [Member]</link:label>
    <link:label id="lab_mgnx_IncyteMGA012ClinicalServicesMember_documentation_en-US" xlink:label="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012ClinicalServicesMember" xlink:href="mgnx-20220630.xsd#mgnx_IncyteMGA012ClinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012ClinicalServicesMember" xlink:to="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_8e832a8e-bace-45d3-ac92-1671bbbf4588_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_89a97ebc-f309-4b73-bee7-3a0c0e239066_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_19c6f95a-fa65-4b42-b298-5e90d5ae3acc_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3b2c5754-7ca5-4702-a3a2-18fea3076271_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_b791e19d-8a1e-4219-ae85-e44158474b6c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_dc666f96-f70a-487a-8cff-0d01297cf26c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_82065532-48b9-46f7-8050-6fdb3b3e3f0c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of stock purchase price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_6042426f-58a0-4ca9-b8ef-df46cbc5ac67_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan activity (in shares)</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:href="mgnx-20220630.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:to="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_75932b76-e451-47cc-b43f-d88deb167ed1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_2544b8b1-cbd4-4f89-98eb-070f1bf7f68c_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a6f5d11-a55b-4c6f-8639-5346a6077a52_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_921e7322-71af-4d19-8104-b29cd5dbaa64_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a4b46c6a-de34-4195-945d-9274ffce68fe_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_b8fa1b7c-2fdb-4606-b48c-e516234e8f37_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_fa973135-8a7c-48c5-828b-2129664d53b3_terseLabel_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:href="mgnx-20220630.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ccebf572-1dd7-4434-a5e5-ad7ff49fa847_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fd0a1854-3d65-4090-9698-76403da7f003_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ContractManufacturingMember_a4d11683-bfee-4877-b132-dbe0a219cc9b_terseLabel_en-US" xlink:label="lab_mgnx_ContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Manufacturing</link:label>
    <link:label id="lab_mgnx_ContractManufacturingMember_label_en-US" xlink:label="lab_mgnx_ContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Manufacturing [Member]</link:label>
    <link:label id="lab_mgnx_ContractManufacturingMember_documentation_en-US" xlink:label="lab_mgnx_ContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ContractManufacturingMember" xlink:href="mgnx-20220630.xsd#mgnx_ContractManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ContractManufacturingMember" xlink:to="lab_mgnx_ContractManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7c5319bf-8a45-48e7-8a61-5d2bdda3f88c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_5a6be712-ffc8-41a8-80be-8405fec6dd24_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_2348e864-d18c-444c-b668-1b5f7163b9b2_terseLabel_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the Market Offering</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember" xlink:href="mgnx-20220630.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AtTheMarketOfferingMember" xlink:to="lab_mgnx_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0c326b9b-4edc-4fe8-81f0-70214c94fb5a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_97b71095-7b75-4dec-b5a4-bc69cf09cd3e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_94f4f75e-4b83-439c-93e6-a7e301dfe2d6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_41d1b550-9d0f-4523-8786-72fc844ffed4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0319505c-0c39-4767-96fd-dd1d13281bdf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_b37448b6-b567-439e-8376-7e009e957d0d_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_69e4b9a8-1632-4f34-a079-adfa98cba2ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_371b8b8b-60ff-43cd-a1e4-b4587cc7aa8b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_750d2142-503a-4871-ab30-804ac94c9511_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_36552962-4748-40d4-b387-4c16c465bb2d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_7de72509-8f5c-44ae-9239-0e7236995b71_terseLabel_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium received on stock purchase</link:label>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_label_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PremiumReceivedOnStockPurchase</link:label>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_documentation_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PremiumReceivedOnStockPurchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase" xlink:href="mgnx-20220630.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PremiumReceivedOnStockPurchase" xlink:to="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_6a3398e9-bc1b-4d12-9503-c4380cc048c9_terseLabel_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable payment tax withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_label_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Payment Tax Withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Payment Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:href="mgnx-20220630.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:to="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_f352044a-b710-42fe-b74b-b215491de809_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_d31675cd-2529-4106-966d-a1da562f7cdb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_706a8791-d15c-4a81-aa17-aebf515a8442_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3f01e9f1-43f8-45c4-a4bd-b053c2b41104_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_3c117fbc-61c9-49d1-8412-6df02aabcf28_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_6495065e-e714-4639-9471-b85a1afe9fda_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9fc6608c-bba3-4b35-9c9e-b327b0bf0b1b_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b450438e-0fe0-4e50-9994-11e97b87a71a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_e3d933d8-90d9-4525-b690-9cea3b39a279_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84f37923-b656-4fb1-8aab-ee6f46071c3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_c5c39d06-5b4b-45b5-b87f-69a7fa33c991_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_9bd7916b-8daf-4e9d-b19c-78e0f3168ee6_terseLabel_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_label_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_documentation_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:href="mgnx-20220630.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0634e7d3-e021-4f8b-a243-61ea744db2ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Ending Balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_6ea33b13-9532-45b7-ad8c-579b025dfc6a_terseLabel_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated variable consideration</link:label>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_label_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Assess Variable Consideration, Amount</link:label>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_documentation_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Assess Variable Consideration, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:href="mgnx-20220630.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:to="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_cd0d3f62-eb01-40cb-837e-47f7e79f57b6_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_f02d1fe8-d638-40af-bb4f-8d95bf97a75b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_183d40fe-a2d2-47b0-bf00-779fbbc49540_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_d77c1120-fe12-4d3a-8c7c-2e1e0e2ead79_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_e9d84698-efb2-4e9f-b293-94b2ecfe1273_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and other agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueFromCollaborativeAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:href="mgnx-20220630.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:to="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_eb1db0a5-df70-4381-9115-f2bd2f1379fe_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements</link:label>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_label_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:href="mgnx-20220630.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:to="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_dcadbe64-38a9-4835-8d6f-49ab611d1e14_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_92aa8e73-7f29-462c-a0de-d419d311a9fa_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_7d7c20ce-730a-4d61-9458-c4ff15d19547_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement, TRIDENT molecule</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, TRIDENT molecule</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:href="mgnx-20220630.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_34fed273-a815-4c2c-8fbb-cf79625fd148_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_c64409c6-829f-4c23-b396-743e8811aa03_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_3899ca4f-a1cc-45b1-88f9-8b4fb3ee0873_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CostOfManufacturingServices_55963827-b0b1-4abe-897b-c4f75b7984a1_terseLabel_en-US" xlink:label="lab_mgnx_CostOfManufacturingServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of manufacturing services</link:label>
    <link:label id="lab_mgnx_CostOfManufacturingServices_label_en-US" xlink:label="lab_mgnx_CostOfManufacturingServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of manufacturing services</link:label>
    <link:label id="lab_mgnx_CostOfManufacturingServices_documentation_en-US" xlink:label="lab_mgnx_CostOfManufacturingServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of manufacturing services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices" xlink:href="mgnx-20220630.xsd#mgnx_CostOfManufacturingServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CostOfManufacturingServices" xlink:to="lab_mgnx_CostOfManufacturingServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4fb8d531-46c5-47fe-81ad-8165feb5d6a2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums and discounts on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_139cff13-9554-4545-8500-4b31b4a4e43f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_e74a028a-3c9e-42a0-aa20-58ce5bff82b2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_edf1d715-2a63-4bea-9058-ff6557b28dd0_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_label_en-US" xlink:label="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Other Agreements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:href="mgnx-20220630.xsd#mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:to="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fca0696d-6ea6-4919-a8d5-fd6dc2173d50_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_8c166547-1816-4ebb-9c11-73f688653c35_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_d4f14e3f-7142-4e29-9e29-c728b0ba3d87_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_40f95fe1-b47d-4d30-9f8b-c69ac0f709e7_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_652a63ab-729d-433c-a62a-cb0fedb2e491_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6e8e41ac-ce79-4e79-bf0a-0d4cfaa9f923_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_256c57a3-675a-4627-bc3b-90359e593cdb_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2fe3bd46-ac67-4dc7-86cd-01b8e739e316_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ff154114-10df-480b-84a7-9af623e1e51b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_e1bb0956-5a8b-477d-bb80-d28ad2925a77_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_c54e0dc2-fd55-48c4-bb6e-2da504847dd0_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement Clinical Supply</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement Clinical Supply [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement Clinical Supply</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:href="mgnx-20220630.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:to="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_556168ec-a069-47b8-a825-fac9de05be7f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of stock sale</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_86f3183f-06fa-4153-9623-4e61e5cd8299_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_fb248929-43cb-4a22-a873-4a3cc1d4ae90_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_254d7428-8698-4cc8-b9f1-fd072e7e6c09_terseLabel_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and regulatory milestones recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_label_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_documentation_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:href="mgnx-20220630.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:to="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_04719a98-0973-4f90-b13c-19e1391c9dbc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_a9e70f74-a5d3-436e-be97-3b8726ede11a_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments and royalties on product sales</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments and Royalties On Product Sales</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_documentation_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments and Royalties On Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:href="mgnx-20220630.xsd#mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:to="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_fcaba4db-3c40-4310-b0ed-456db87df522_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_aeca6c99-8bdb-423b-8194-bdb970394604_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8460d010-9f9b-4b44-81aa-338868c521ac_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f4e5ce1b-b2b5-480b-9343-1732e06ed895_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_73c6c3de-1167-490e-ab75-6f0d17fce269_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement, Margetuximab</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, Margetuximab [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, Margetuximab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:href="mgnx-20220630.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c9182fbd-41c9-4196-bd48-4c721ec22f78_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Assumptions Using the Black-Scholes Option-Pricing Model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_09e05f72-1250-44ca-aade-8c3288b0c10e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_640a625d-3831-49cc-92dd-3ecef566fa93_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ba5a51ae-ee54-45c4-8fbd-01e5495a84e6_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_MillstoneRevenueRecognized_52aa7e58-ee38-4ce6-821e-7a17541407b7_terseLabel_en-US" xlink:label="lab_mgnx_MillstoneRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Millstone Revenue Recognized</link:label>
    <link:label id="lab_mgnx_MillstoneRevenueRecognized_label_en-US" xlink:label="lab_mgnx_MillstoneRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Millstone Revenue Recognized</link:label>
    <link:label id="lab_mgnx_MillstoneRevenueRecognized_documentation_en-US" xlink:label="lab_mgnx_MillstoneRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Millstone Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MillstoneRevenueRecognized" xlink:href="mgnx-20220630.xsd#mgnx_MillstoneRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_MillstoneRevenueRecognized" xlink:to="lab_mgnx_MillstoneRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_addc10ae-0f08-47df-8574-07960dbe005b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b963f570-b578-4c29-b6ff-a9d775ba2afb_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e568c588-4f9f-4c97-bac8-2ef1c7e46a79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_4360ce5e-ca3c-466b-a06a-ad7aadb2d7b1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_8a7ac894-2298-4c38-9d07-5844c1dbd33a_terseLabel_en-US" xlink:label="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Zai Lab Agreement</link:label>
    <link:label id="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Zai Lab Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Zai Lab Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20220630.xsd#mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4f780604-86a5-446f-8712-b49bef2a1102_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense recognition period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_fba47ec3-403a-4059-ba89-9179739fc8c2_terseLabel_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TwoThousandSixteenEmployeeStockPurchasePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:href="mgnx-20220630.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:to="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_387e1d04-1fff-457f-bb81-81073529f744_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_06d54112-4e45-4c74-92c4-6294314327c4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_75b42fb3-72b9-425c-a84f-c9fe7f561f44_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward_e6dad136-e602-4aa9-a98e-9155b06a1f11_terseLabel_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares per employee</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward_label_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number Of Shares Received For Each Vested Award</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward_documentation_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number Of Shares Received For Each Vested Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" xlink:href="mgnx-20220630.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" xlink:to="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_11a0d14d-4244-4bd6-a9e9-031f6f9cb056_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d4552d2c-ec62-440c-80b5-549d281b7b3d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5f43eb21-5bc2-4e3d-90c0-814a98f4a75f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price of stock options outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d17b484d-16ed-488f-9310-73aeff48db97_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3e5d2052-2ff3-4e0f-a294-a774e85022b0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3540e97d-1e82-47c6-bf4f-0be56af38f3b_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1e60d22a-b1b0-4a7f-abd3-0915c8705bfb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued or sold (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OneTimeMillstoneCredit_a305e729-814a-4840-99bc-1cfeb4dcfa0f_terseLabel_en-US" xlink:label="lab_mgnx_OneTimeMillstoneCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Millstone Credit</link:label>
    <link:label id="lab_mgnx_OneTimeMillstoneCredit_label_en-US" xlink:label="lab_mgnx_OneTimeMillstoneCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Millstone Credit</link:label>
    <link:label id="lab_mgnx_OneTimeMillstoneCredit_documentation_en-US" xlink:label="lab_mgnx_OneTimeMillstoneCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Millstone Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OneTimeMillstoneCredit" xlink:href="mgnx-20220630.xsd#mgnx_OneTimeMillstoneCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OneTimeMillstoneCredit" xlink:to="lab_mgnx_OneTimeMillstoneCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3a4600c7-d590-432c-8720-417ce7cc0936_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteCorporationMember_54e553a3-217b-4354-8c69-0ae5d20936f1_terseLabel_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Corporation</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_label_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteCorporationMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember" xlink:href="mgnx-20220630.xsd#mgnx_IncyteCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteCorporationMember" xlink:to="lab_mgnx_IncyteCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_2215ee6f-70f1-4c86-a3c3-39342d1fe183_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fe65e25f-12a3-4b45-8937-9cc181ff0371_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c66e9085-902a-4ae7-a5f8-dd4237045ae8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1ac5f271-9d42-4627-b835-402143dcd6fe_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0ad39626-157c-44d7-806f-891947f17e66_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_79b4949e-46d0-4292-a184-23be0917d3fe_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From Grants</link:label>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromGrantsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember" xlink:href="mgnx-20220630.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromGrantsMember" xlink:to="lab_mgnx_RevenuesFromGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d2746fee-646e-4044-b4eb-ce411e15c43f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_bd81345e-8d47-455d-8592-229419036650_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_551bb5e9-df81-4f5d-a25b-7bbd1f430319_terseLabel_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential annual increase in shares reserved for future issuance as percentage of outstanding share</link:label>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_label_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:href="mgnx-20220630.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:to="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_2951a99f-d90f-43eb-97ab-42fe680fad51_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_aca09bb7-7c84-4bfb-a108-62b0054aa0a4_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_b2fc41ab-b37b-43a6-86c5-7d19d75454eb_terseLabel_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll deduction percentage</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="mgnx-20220630.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_3a29c6e6-6a8d-4c98-9258-d1c77ca7bafa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f9c60c85-52b4-4afc-b6b7-b87e5b3775b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember_093ec41b-d290-4613-bcdb-cded2db6f4da_terseLabel_en-US" xlink:label="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration and License Agreement</link:label>
    <link:label id="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20220630.xsd#mgnx_JanssenCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_879fa221-4324-4f05-b598-3ef50e43af80_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_3722da3b-7615-4c7d-be87-0acb5ce200be_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_670f3413-429e-408a-ba5d-86cf36724880_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_89f32505-4335-4f9d-966e-f8b201f6a5aa_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_c2cb5928-e4f4-4738-b3c0-0b6a4f167060_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a0c779d8-0139-4aa1-a6c1-a7d3b48292b2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TotalAnnualFixedPayments_e6b2a666-1e21-4e9d-a64a-33976235846d_terseLabel_en-US" xlink:label="lab_mgnx_TotalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Fixed Payments</link:label>
    <link:label id="lab_mgnx_TotalAnnualFixedPayments_label_en-US" xlink:label="lab_mgnx_TotalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Annual Fixed Payments</link:label>
    <link:label id="lab_mgnx_TotalAnnualFixedPayments_documentation_en-US" xlink:label="lab_mgnx_TotalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Annual Fixed Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalAnnualFixedPayments" xlink:href="mgnx-20220630.xsd#mgnx_TotalAnnualFixedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalAnnualFixedPayments" xlink:to="lab_mgnx_TotalAnnualFixedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e063f60b-5c69-48a5-a31d-1825d6c70ecc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_dc417bb5-5739-4a30-baf8-fa539d818243_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b8420b0f-d2c8-454d-9eb9-5be00d2c9c8d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_6bcc6e0f-9d72-4a6d-9c49-17c36b096472_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6a8f9312-d6d5-46ed-9831-bdb105b6f78c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_5e5c7fc4-d642-437f-a987-81ab6a0e77ae_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_a880b71f-a1c9-4788-9fa2-b314da4fdc12_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_729827de-721e-4fee-9309-977ef2661c20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_7a79c3a8-71eb-441d-94f2-d65c1d00c475_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4f09d5b8-927e-415e-86d5-b5a62eab8d0b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c34d8a05-b903-4fc1-b1ec-0a616f939db4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1ace50e7-eb9f-49fd-8e05-b6506f46b8df_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaMember_6c8d8e80-775f-4e2a-a3be-0a316d57ac9f_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember" xlink:href="mgnx-20220630.xsd#mgnx_IMabBiopharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaMember" xlink:to="lab_mgnx_IMabBiopharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_cc88b3bb-4b18-40e3-a4e0-49b66618dafc_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7e23a32c-6da6-4ae9-9329-c59a3685206e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_5a949834-a826-4ed8-9c3e-2c74ab9c2603_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of commercialized molecules</link:label>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_label_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:href="mgnx-20220630.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:to="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_e6117963-6b63-4006-87aa-f0af699d1472_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_2e653f63-9824-437d-99a1-6fdaa8e6b3aa_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_9c1185ae-40b3-4f34-a275-fae487adb20f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1a251368-a0f1-43b3-a4ed-2102909cc98a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_a5306914-5d49-44e8-a2b6-add46a941737_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_609d6d1c-e000-4604-889c-44ec81c305c3_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_766e4650-305c-4177-b6b3-618585166bd0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_cbae8127-f130-4982-b825-e9bfe43c5e94_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_5d744e90-0df5-48e8-b29d-993b3a2b532b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_605181be-fc46-41c4-82d5-caa8a655ebca_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_0440df85-0212-46cf-8edc-e693ef6bb274_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration and License Agreement</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20220630.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_d82e8e39-5432-4736-9862-782f3ed503ff_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_1f04bf31-1cde-46d6-80e6-3afbecc73bd9_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c6cfca64-73e3-4daa-8cec-406c94bcbebc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_5ab94cfd-405b-4b4e-9240-4b00af58a346_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss related to available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_e603eb11-63e2-4398-9e3a-8f5afb2c91a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_07648c23-95e1-4b0f-84ad-94a5cdeba429_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_990c210a-81b3-4679-b383-34d7d0be5171_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4480576b-a983-47a2-b7a1-e520f62e3550_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement_bd9dacd8-b820-4c54-8a5d-48cb37c924e5_terseLabel_en-US" xlink:label="lab_mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Additional Incyte License Agreement Milestone</link:label>
    <link:label id="lab_mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement_label_en-US" xlink:label="lab_mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Additional Milestone Incyte License Agreement</link:label>
    <link:label id="lab_mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement_documentation_en-US" xlink:label="lab_mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Additional Milestone Incyte License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement" xlink:href="mgnx-20220630.xsd#mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement" xlink:to="lab_mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_4ecf235e-120e-48fc-bb52-8985de7d9166_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5106bfc0-bedb-46ea-9301-1e9ea1a73f27_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_7605057f-f382-4e01-9146-e498f8480111_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory valuation reserves</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_204ad601-e5c5-45b4-af1d-c86b0a57eb28_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_c9b80f37-65fb-4003-8a73-a2c65f1901bd_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_f33a771a-5bac-4957-aa4e-b95ed75e29d9_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Performance of the Research and Development Activities</link:label>
    <link:label id="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_label_en-US" xlink:label="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Performance Of The Research And Development Activities [Member]</link:label>
    <link:label id="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_documentation_en-US" xlink:label="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Performance Of The Research And Development Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:href="mgnx-20220630.xsd#mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:to="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_8ca073f2-929b-4f65-9e54-f9ed5f4f57e9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_cce3057a-4c38-46a5-9635-1ee25e72752f_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_82479c65-be7e-4f9d-a9cc-b6c34472cac7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_1f6eaf06-f039-45e9-a323-dd24832a8732_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement transaction price</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CollaborativeAgreementTransactionPrice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:href="mgnx-20220630.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:to="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_7dd8f2db-1f2a-4b98-a69c-35a12c3ce8bd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4ca73840-5ae4-4dde-abab-0c8e6b30259e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_f2642d37-f3e4-473d-9aed-a56b0a883211_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan related activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:href="mgnx-20220630.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:to="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_c777a622-b356-416a-8903-0b3de9fb4483_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabMember_da64bb54-850b-4b21-94f4-cb016574f4f4_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_label_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember" xlink:href="mgnx-20220630.xsd#mgnx_ZaiLabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabMember" xlink:to="lab_mgnx_ZaiLabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b4e67141-ec01-4801-8c26-cb8eb363dc61_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_ca25bb32-3594-4214-ac5f-b50310ce4ad7_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_516092c9-db46-4856-9ce5-06c735d03075_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_d6a186a3-11ee-4c2d-81ce-9bbf60cecacc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_bbbbf59c-380c-495f-8ff1-5cf0514677e9_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_f648e793-b085-4d91-9b5b-4a3c8f61193f_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From License Agreements</link:label>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromLicenseAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:href="mgnx-20220630.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:to="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_491c47e8-ddf1-4d65-a256-a4d9aefc9904_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueFromGovernmentAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:href="mgnx-20220630.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:to="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_45f16f5c-fe7d-46ca-892c-22f319454832_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_bb446e61-c03d-46dd-971f-a34282c27674_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_10439096-e5a9-4e61-bbf3-bd3ede2bae1f_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2003StockIncentivePlanMember_70dd7b35-2625-4ff9-82e3-9c69f33c7ca2_terseLabel_en-US" xlink:label="lab_mgnx_A2003StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2003 Stock Incentive Plan</link:label>
    <link:label id="lab_mgnx_A2003StockIncentivePlanMember_label_en-US" xlink:label="lab_mgnx_A2003StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2003StockIncentivePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember" xlink:href="mgnx-20220630.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2003StockIncentivePlanMember" xlink:to="lab_mgnx_A2003StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c0da02a7-899d-463f-96ad-87d9f384e3ca_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_cfb241bc-26f1-4692-a8b5-d77bf34431c3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d26a23e7-2c95-4965-88f5-443634546733_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_5d509ab2-5f36-46ba-89e6-0a79cded559a_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_label_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations" xlink:href="mgnx-20220630.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfPerformanceObligations" xlink:to="lab_mgnx_NumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OptInFee_70da5192-6b2f-4fc7-946b-fef7f63957d6_terseLabel_en-US" xlink:label="lab_mgnx_OptInFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt-in fee</link:label>
    <link:label id="lab_mgnx_OptInFee_label_en-US" xlink:label="lab_mgnx_OptInFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt-in Fee</link:label>
    <link:label id="lab_mgnx_OptInFee_documentation_en-US" xlink:label="lab_mgnx_OptInFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt-in Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptInFee" xlink:href="mgnx-20220630.xsd#mgnx_OptInFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OptInFee" xlink:to="lab_mgnx_OptInFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_1c906456-beea-44c9-8224-a74fe3b17bb0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5a3e8f5b-956b-4dca-b6b4-f1870cc30414_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_588f08a4-91cf-493b-a2b4-60cba37bfd64_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e2e38311-28e7-423f-88d3-3133a3ac14bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea27ac13-7cea-4665-bd25-53edec0a8342_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_17636cec-d69c-4c88-9b9a-111e786d7816_terseLabel_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable consideration recognized</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_f058f030-80d0-447b-8e21-44abe15435ae_verboseLabel_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial activities selling price amount</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_label_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_documentation_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:href="mgnx-20220630.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:to="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_8c4102f8-bfdd-4aac-a084-149fa53ec9ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_dbc35eb0-e435-4cd2-af21-826f9d9aef24_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_601de226-aa38-4af5-a25e-46c31f9b44ef_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_09d01653-3751-48d8-9721-3fb219f7c558_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_f89851b0-83de-4d41-8ea2-9063a15db1d2_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_2c948d40-cbd5-46bb-bbeb-6b35f8dc3d8a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c0674906-50bf-428f-b7e1-b1b1eba8b17c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ee18e8ad-0b68-4e92-bec6-a7b6abe37ae7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dea21a6b-39a7-48bf-870c-27486f2a0b4a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_02e40e82-ec15-458f-8e3c-09135ff74191_terseLabel_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential value</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_label_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TotalPotentialValueUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:href="mgnx-20220630.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:to="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_7b02c6c8-c191-447b-a8c6-d4485fac145d_terseLabel_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Zai Lab Agreements</link:label>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_label_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Zai Lab Agreements [Member]</link:label>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Zai Lab Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember" xlink:href="mgnx-20220630.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2021ZaiLabAgreementsMember" xlink:to="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_96510518-6e02-4dfd-874e-f7519dc74079_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_674a1254-b126-4fff-b378-b7b7e67f0862_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_944c55d2-d49a-4864-a419-9cd041fb5ce1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_53e064a4-8a8d-4bae-9c4b-4d6b84228364_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_0b890de4-856b-4dd7-86e2-966081034b9e_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_5941062d-1a6a-4aff-a6cb-2771ccd5b86f_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount available for issuance, increase</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance, Increase</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_documentation_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:href="mgnx-20220630.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_bd85e297-e69a-4bfd-858a-911d14d91565_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential annual increase in shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:href="mgnx-20220630.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:to="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_58bf44af-5cc8-490d-b1f3-befccb7984b4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_af010260-9a0e-4b37-bbb6-23a490bee7d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_66ab296a-9324-4597-92d0-869a1db43a1e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_2b7a1daf-3f0b-4af6-8c51-406f1dbada21_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_cb51f1df-7784-4297-91e8-eaf94931ffed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_47d00d3c-fecd-4817-8691-8564086e358f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_51d81124-b9b4-4850-a190-e20ac0bf4241_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_fc8a330e-a111-48d6-bff1-2150a20ea9a9_terseLabel_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2013</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_label_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">StockIncentivePlan2013Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member" xlink:href="mgnx-20220630.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIncentivePlan2013Member" xlink:to="lab_mgnx_StockIncentivePlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9fe8325d-575b-4e4e-a1c8-41012635fe3c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and software</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_056e9f0a-75e9-4a57-be3b-17ede4964bc9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_d9abe040-9506-4e3a-8cb6-a48e8b7e2a84_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_c3b1b4f0-a5b6-4602-86d1-edffc4590e8a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_001aebe8-d164-443e-93da-15a3a0dbc117_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_9991439d-dd87-4c2c-9dff-9816f99111f5_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:href="mgnx-20220630.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2eecae8f-3d98-4462-ba16-9fb1c39dbdd3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_92c39cab-df73-440c-aa6a-7f89fe069e08_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>mgnx-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c76f9653-d31d-4b72-a3cc-7cc008424052,g:58338f7a-a7b2-4bbd-85aa-a2b62be307be-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CoverPage" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9b9bedf6-26b9-4e9c-a26f-a561bb2323c9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_DocumentType_9b9bedf6-26b9-4e9c-a26f-a561bb2323c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_d9254dce-4924-4dc3-9655-e563e5447dae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_DocumentQuarterlyReport_d9254dce-4924-4dc3-9655-e563e5447dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_087447fe-05c5-4c14-a41f-f46bd7254938" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_DocumentPeriodEndDate_087447fe-05c5-4c14-a41f-f46bd7254938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_cbac0632-02d2-4db4-bdf0-c724354859e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_DocumentTransitionReport_cbac0632-02d2-4db4-bdf0-c724354859e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_388355c4-f81d-4ba7-bb82-b3c60f5ef724" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_EntityFileNumber_388355c4-f81d-4ba7-bb82-b3c60f5ef724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d2453cc9-b38a-4f94-a6a2-48519d8a8505" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_EntityRegistrantName_d2453cc9-b38a-4f94-a6a2-48519d8a8505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4672ef4f-0176-4f9e-b38e-9d6ddd930959" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4672ef4f-0176-4f9e-b38e-9d6ddd930959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_acca7878-22c1-452b-a946-a4765e8edc37" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_EntityTaxIdentificationNumber_acca7878-22c1-452b-a946-a4765e8edc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3a330726-09b4-4874-9e78-2716b27a8a10" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_EntityAddressAddressLine1_3a330726-09b4-4874-9e78-2716b27a8a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e37c5467-1ca5-4bad-8f06-25304860dfb4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_EntityAddressCityOrTown_e37c5467-1ca5-4bad-8f06-25304860dfb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6798c9e2-2c8d-434e-9653-4d01220d2bdb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_EntityAddressStateOrProvince_6798c9e2-2c8d-434e-9653-4d01220d2bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ce50f547-460d-4452-a3c5-444a24d24b6a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_EntityAddressPostalZipCode_ce50f547-460d-4452-a3c5-444a24d24b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a71996ec-598b-4f36-9363-0d0a650c0074" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_CityAreaCode_a71996ec-598b-4f36-9363-0d0a650c0074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d4c1817f-17d3-4b12-a7b4-325bd89ed6ba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_LocalPhoneNumber_d4c1817f-17d3-4b12-a7b4-325bd89ed6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ec4acaf3-9c2c-4085-8b6e-ef7296266edc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_Security12bTitle_ec4acaf3-9c2c-4085-8b6e-ef7296266edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c0b5e091-34a8-4116-9381-4bb0e5607555" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_TradingSymbol_c0b5e091-34a8-4116-9381-4bb0e5607555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_65857290-7c50-4e7d-b7b6-a164dba7a46a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_SecurityExchangeName_65857290-7c50-4e7d-b7b6-a164dba7a46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_5968b471-f3df-4f1c-aeb0-c7abf5ca6e46" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_EntityCurrentReportingStatus_5968b471-f3df-4f1c-aeb0-c7abf5ca6e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_8cbfb013-7096-484d-975a-14ef5df8698f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_EntityInteractiveDataCurrent_8cbfb013-7096-484d-975a-14ef5df8698f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_98c5b23d-3016-4123-be5f-44b08485ef44" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_EntityFilerCategory_98c5b23d-3016-4123-be5f-44b08485ef44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_93d31af8-153e-4ddc-b0b8-a4a37157ab36" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_EntitySmallBusiness_93d31af8-153e-4ddc-b0b8-a4a37157ab36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e87d6b90-e589-4290-a9bd-fc1561d60e48" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_EntityEmergingGrowthCompany_e87d6b90-e589-4290-a9bd-fc1561d60e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e4ef8b0e-7693-4aa7-a86d-370391fba1b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_EntityShellCompany_e4ef8b0e-7693-4aa7-a86d-370391fba1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a52ffc1b-34d2-415a-bf1c-45f51069f828" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a52ffc1b-34d2-415a-bf1c-45f51069f828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ee622036-496e-4f67-948b-9af778bd7bea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_AmendmentFlag_ee622036-496e-4f67-948b-9af778bd7bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_dea0ee12-253f-499e-ac1d-ade4cdeb7c9c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_DocumentFiscalYearFocus_dea0ee12-253f-499e-ac1d-ade4cdeb7c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5f617b17-08f5-411f-80c5-640a1dd5b508" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5f617b17-08f5-411f-80c5-640a1dd5b508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3939aaa8-219e-45c5-908e-575f93d7366c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_EntityCentralIndexKey_3939aaa8-219e-45c5-908e-575f93d7366c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_2459fc7e-d22c-474f-8769-d30936127529" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3656f282-252d-4eab-9794-2140118da089" xlink:to="loc_dei_CurrentFiscalYearEndDate_2459fc7e-d22c-474f-8769-d30936127529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_454d8a72-e04d-4c46-8648-1293a7b5adbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a6f1c378-d203-4cb1-9113-85281eb4bc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_454d8a72-e04d-4c46-8648-1293a7b5adbf" xlink:to="loc_us-gaap_AssetsAbstract_a6f1c378-d203-4cb1-9113-85281eb4bc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_012d51ad-7913-4c68-b483-163262c18472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a6f1c378-d203-4cb1-9113-85281eb4bc4d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_012d51ad-7913-4c68-b483-163262c18472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cef32808-9064-404a-b82f-d392ace6862e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_012d51ad-7913-4c68-b483-163262c18472" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cef32808-9064-404a-b82f-d392ace6862e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_531e6b46-bb8a-402c-96cc-03fad4509bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_012d51ad-7913-4c68-b483-163262c18472" xlink:to="loc_us-gaap_Investments_531e6b46-bb8a-402c-96cc-03fad4509bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_efd7454f-d289-486c-8e37-cb34ad90b30e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_012d51ad-7913-4c68-b483-163262c18472" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_efd7454f-d289-486c-8e37-cb34ad90b30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_223396b9-0947-468d-9344-d725f6ef9283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_012d51ad-7913-4c68-b483-163262c18472" xlink:to="loc_us-gaap_InventoryNet_223396b9-0947-468d-9344-d725f6ef9283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6de4b5c3-5fe8-4c7e-9506-fc0f991765cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_012d51ad-7913-4c68-b483-163262c18472" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6de4b5c3-5fe8-4c7e-9506-fc0f991765cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9584421e-81f4-496f-b310-c6362728a33f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_012d51ad-7913-4c68-b483-163262c18472" xlink:to="loc_us-gaap_AssetsCurrent_9584421e-81f4-496f-b310-c6362728a33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d3a0ce65-a99f-4102-b2e7-0c1f479aed70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a6f1c378-d203-4cb1-9113-85281eb4bc4d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d3a0ce65-a99f-4102-b2e7-0c1f479aed70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a21809ac-de82-4ee9-8c23-d76aef51fdf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a6f1c378-d203-4cb1-9113-85281eb4bc4d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a21809ac-de82-4ee9-8c23-d76aef51fdf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f69f1976-f33f-4531-8c11-b82d591efe2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a6f1c378-d203-4cb1-9113-85281eb4bc4d" xlink:to="loc_us-gaap_Assets_f69f1976-f33f-4531-8c11-b82d591efe2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fb1e477c-54a6-4e39-884c-f1e0240e0662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_454d8a72-e04d-4c46-8648-1293a7b5adbf" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fb1e477c-54a6-4e39-884c-f1e0240e0662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_42487eda-dd00-4594-8b77-f1e411c8a4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fb1e477c-54a6-4e39-884c-f1e0240e0662" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_42487eda-dd00-4594-8b77-f1e411c8a4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_50e8a713-97e3-4d60-8a62-a594fab18258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_42487eda-dd00-4594-8b77-f1e411c8a4d8" xlink:to="loc_us-gaap_AccountsPayableCurrent_50e8a713-97e3-4d60-8a62-a594fab18258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3669741d-031d-4d59-b53b-79b2f64f997a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_42487eda-dd00-4594-8b77-f1e411c8a4d8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3669741d-031d-4d59-b53b-79b2f64f997a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_dfb4c03c-f455-49dd-8b90-40adf4705c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_42487eda-dd00-4594-8b77-f1e411c8a4d8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_dfb4c03c-f455-49dd-8b90-40adf4705c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_073777d3-9361-4e16-b56e-ab1f0d1313c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_42487eda-dd00-4594-8b77-f1e411c8a4d8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_073777d3-9361-4e16-b56e-ab1f0d1313c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_de99d355-2591-4952-92c1-5d56be2b5850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_42487eda-dd00-4594-8b77-f1e411c8a4d8" xlink:to="loc_us-gaap_LiabilitiesCurrent_de99d355-2591-4952-92c1-5d56be2b5850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ed8a2250-d193-4281-903f-6f937083dcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fb1e477c-54a6-4e39-884c-f1e0240e0662" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ed8a2250-d193-4281-903f-6f937083dcdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d0f68094-05fc-4169-8a7b-fb544eebe352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fb1e477c-54a6-4e39-884c-f1e0240e0662" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d0f68094-05fc-4169-8a7b-fb544eebe352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_68c89887-3d18-4f7e-ac68-832a5fac32b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fb1e477c-54a6-4e39-884c-f1e0240e0662" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_68c89887-3d18-4f7e-ac68-832a5fac32b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_868e8380-52d9-4a32-a0f3-754d4542adc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fb1e477c-54a6-4e39-884c-f1e0240e0662" xlink:to="loc_us-gaap_Liabilities_868e8380-52d9-4a32-a0f3-754d4542adc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4d3222b8-57f3-4938-b454-6de3ccfcba24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fb1e477c-54a6-4e39-884c-f1e0240e0662" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4d3222b8-57f3-4938-b454-6de3ccfcba24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_020593bf-5ec1-4283-a491-a281e302a796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4d3222b8-57f3-4938-b454-6de3ccfcba24" xlink:to="loc_us-gaap_CommonStockValue_020593bf-5ec1-4283-a491-a281e302a796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f7f70707-bb9b-4ae4-ad8d-e1e1faa43369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4d3222b8-57f3-4938-b454-6de3ccfcba24" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f7f70707-bb9b-4ae4-ad8d-e1e1faa43369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0eef9875-449e-4224-bdd2-34cc4fb449df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4d3222b8-57f3-4938-b454-6de3ccfcba24" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0eef9875-449e-4224-bdd2-34cc4fb449df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6467d2cd-8b66-4546-ae47-69045f71d8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4d3222b8-57f3-4938-b454-6de3ccfcba24" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6467d2cd-8b66-4546-ae47-69045f71d8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_61560115-0ce8-4f33-b7e5-89c93f95b76d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4d3222b8-57f3-4938-b454-6de3ccfcba24" xlink:to="loc_us-gaap_StockholdersEquity_61560115-0ce8-4f33-b7e5-89c93f95b76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9102c99-c8d3-4935-bca8-f2bb86b05448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fb1e477c-54a6-4e39-884c-f1e0240e0662" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9102c99-c8d3-4935-bca8-f2bb86b05448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9e92b7fd-558b-42c1-bb3f-a339e7d1e85a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_290eb25c-f5ba-4d29-b729-f7e984cd7f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9e92b7fd-558b-42c1-bb3f-a339e7d1e85a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_290eb25c-f5ba-4d29-b729-f7e984cd7f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_789bb933-7c65-49bc-ab01-96aeda4ba456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_290eb25c-f5ba-4d29-b729-f7e984cd7f3e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_789bb933-7c65-49bc-ab01-96aeda4ba456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5989e2b7-f067-4197-80c1-bcaab2833df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_789bb933-7c65-49bc-ab01-96aeda4ba456" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5989e2b7-f067-4197-80c1-bcaab2833df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_d31d627b-26e7-450d-b265-0aae863f4414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_789bb933-7c65-49bc-ab01-96aeda4ba456" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_d31d627b-26e7-450d-b265-0aae863f4414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_758f353f-1de6-4c4e-b9b8-796d8ad60066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_789bb933-7c65-49bc-ab01-96aeda4ba456" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_758f353f-1de6-4c4e-b9b8-796d8ad60066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c64d0e8c-8e3a-4bc3-be3e-1079e766c273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_912e0124-1a2e-43cf-8122-5ddeecb6b0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c64d0e8c-8e3a-4bc3-be3e-1079e766c273" xlink:to="loc_us-gaap_StatementTable_912e0124-1a2e-43cf-8122-5ddeecb6b0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_86e7f9a2-e3fa-4474-a802-af42d8a2866c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_912e0124-1a2e-43cf-8122-5ddeecb6b0ea" xlink:to="loc_srt_ProductOrServiceAxis_86e7f9a2-e3fa-4474-a802-af42d8a2866c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ad46ec89-63b0-4b7b-9e7f-fb2e6469595a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_86e7f9a2-e3fa-4474-a802-af42d8a2866c" xlink:to="loc_srt_ProductsAndServicesDomain_ad46ec89-63b0-4b7b-9e7f-fb2e6469595a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_71a6f451-3a94-4c85-94ec-ff7c8133b423" xlink:href="mgnx-20220630.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ad46ec89-63b0-4b7b-9e7f-fb2e6469595a" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_71a6f451-3a94-4c85-94ec-ff7c8133b423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4cb40d7e-e97f-470b-9230-3b82d09ffe8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ad46ec89-63b0-4b7b-9e7f-fb2e6469595a" xlink:to="loc_us-gaap_ProductMember_4cb40d7e-e97f-470b-9230-3b82d09ffe8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_d8af98d7-6f33-4d57-8b5e-ce9513a42659" xlink:href="mgnx-20220630.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ad46ec89-63b0-4b7b-9e7f-fb2e6469595a" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_d8af98d7-6f33-4d57-8b5e-ce9513a42659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ContractManufacturingMember_3c9e8d4f-458e-4b38-806a-60e736bb6070" xlink:href="mgnx-20220630.xsd#mgnx_ContractManufacturingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ad46ec89-63b0-4b7b-9e7f-fb2e6469595a" xlink:to="loc_mgnx_ContractManufacturingMember_3c9e8d4f-458e-4b38-806a-60e736bb6070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_76a4f3ae-5110-4e8d-8b1c-accc2503a51d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_912e0124-1a2e-43cf-8122-5ddeecb6b0ea" xlink:to="loc_us-gaap_StatementLineItems_76a4f3ae-5110-4e8d-8b1c-accc2503a51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_838d3a9b-7c5b-40cf-97b0-b032a5b87dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_76a4f3ae-5110-4e8d-8b1c-accc2503a51d" xlink:to="loc_us-gaap_RevenuesAbstract_838d3a9b-7c5b-40cf-97b0-b032a5b87dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_58693ba9-1351-40b3-a3b4-95bab112ab70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_838d3a9b-7c5b-40cf-97b0-b032a5b87dde" xlink:to="loc_us-gaap_Revenues_58693ba9-1351-40b3-a3b4-95bab112ab70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_726e8219-8ef7-419a-a9b6-d41a2f2437ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_76a4f3ae-5110-4e8d-8b1c-accc2503a51d" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_726e8219-8ef7-419a-a9b6-d41a2f2437ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0e2a05fd-1ddd-4b4a-b6e4-214b5fd7f63a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_726e8219-8ef7-419a-a9b6-d41a2f2437ac" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0e2a05fd-1ddd-4b4a-b6e4-214b5fd7f63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices_93fe90be-ab6b-4971-998c-fb8ec4af6f95" xlink:href="mgnx-20220630.xsd#mgnx_CostOfManufacturingServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_726e8219-8ef7-419a-a9b6-d41a2f2437ac" xlink:to="loc_mgnx_CostOfManufacturingServices_93fe90be-ab6b-4971-998c-fb8ec4af6f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2c9bd8ac-7803-442d-aa12-5247eeaf5676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_726e8219-8ef7-419a-a9b6-d41a2f2437ac" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2c9bd8ac-7803-442d-aa12-5247eeaf5676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_57e8d2a9-9db7-42b5-b16d-67dbff64c1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_726e8219-8ef7-419a-a9b6-d41a2f2437ac" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_57e8d2a9-9db7-42b5-b16d-67dbff64c1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9faa2dc3-dce5-4042-abd3-92d8463334b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_726e8219-8ef7-419a-a9b6-d41a2f2437ac" xlink:to="loc_us-gaap_CostsAndExpenses_9faa2dc3-dce5-4042-abd3-92d8463334b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_837ed0d6-46fd-4357-a18d-342069173d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_726e8219-8ef7-419a-a9b6-d41a2f2437ac" xlink:to="loc_us-gaap_OperatingIncomeLoss_837ed0d6-46fd-4357-a18d-342069173d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_92a6759f-e1c9-407c-9c74-9011d3e7b7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_726e8219-8ef7-419a-a9b6-d41a2f2437ac" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_92a6759f-e1c9-407c-9c74-9011d3e7b7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5e53a119-2398-4c22-8dad-1d3554a8f1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_726e8219-8ef7-419a-a9b6-d41a2f2437ac" xlink:to="loc_us-gaap_NetIncomeLoss_5e53a119-2398-4c22-8dad-1d3554a8f1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0e3ba8a4-5639-440c-aca4-58c5e2f8bc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_76a4f3ae-5110-4e8d-8b1c-accc2503a51d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0e3ba8a4-5639-440c-aca4-58c5e2f8bc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_aeea0a05-429c-4d22-a9d1-f406df61bcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0e3ba8a4-5639-440c-aca4-58c5e2f8bc2e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_aeea0a05-429c-4d22-a9d1-f406df61bcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7886c116-c53d-4a25-82b8-9b7b219b52c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_76a4f3ae-5110-4e8d-8b1c-accc2503a51d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_7886c116-c53d-4a25-82b8-9b7b219b52c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e5a1a0f3-c26d-4104-8feb-41918a725490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_76a4f3ae-5110-4e8d-8b1c-accc2503a51d" xlink:to="loc_us-gaap_EarningsPerShareBasic_e5a1a0f3-c26d-4104-8feb-41918a725490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2d66b82d-a6f1-4beb-9f26-1d30c7892051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_76a4f3ae-5110-4e8d-8b1c-accc2503a51d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2d66b82d-a6f1-4beb-9f26-1d30c7892051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_92851ec3-e86e-46d0-badb-da69e0e5e6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_76a4f3ae-5110-4e8d-8b1c-accc2503a51d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_92851ec3-e86e-46d0-badb-da69e0e5e6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a0bcc2be-26f4-42cd-ae56-ba2d04b2d4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_76a4f3ae-5110-4e8d-8b1c-accc2503a51d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a0bcc2be-26f4-42cd-ae56-ba2d04b2d4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3293d130-ad39-4a57-8d52-878daa7eadf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_611ca187-0a03-4352-888b-6cf2d9dc0c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3293d130-ad39-4a57-8d52-878daa7eadf9" xlink:to="loc_us-gaap_StatementTable_611ca187-0a03-4352-888b-6cf2d9dc0c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5906c023-a811-4f48-8cbf-cee61ea6f531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_611ca187-0a03-4352-888b-6cf2d9dc0c5f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5906c023-a811-4f48-8cbf-cee61ea6f531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d4359c6b-4ca9-49f0-b4e5-38094d9c515a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5906c023-a811-4f48-8cbf-cee61ea6f531" xlink:to="loc_us-gaap_EquityComponentDomain_d4359c6b-4ca9-49f0-b4e5-38094d9c515a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a831bed4-10d2-435c-b065-670a3700d24b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d4359c6b-4ca9-49f0-b4e5-38094d9c515a" xlink:to="loc_us-gaap_CommonStockMember_a831bed4-10d2-435c-b065-670a3700d24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_bcc37488-2bc5-4859-903a-b066be418ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d4359c6b-4ca9-49f0-b4e5-38094d9c515a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_bcc37488-2bc5-4859-903a-b066be418ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_aa05f0f7-a83f-4233-acd7-d7a1a7eb8b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d4359c6b-4ca9-49f0-b4e5-38094d9c515a" xlink:to="loc_us-gaap_RetainedEarningsMember_aa05f0f7-a83f-4233-acd7-d7a1a7eb8b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_3d7d5c97-424a-4af1-801d-fab0b0d144d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d4359c6b-4ca9-49f0-b4e5-38094d9c515a" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_3d7d5c97-424a-4af1-801d-fab0b0d144d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ab0128ec-2138-4081-9893-ff40b566f7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_611ca187-0a03-4352-888b-6cf2d9dc0c5f" xlink:to="loc_us-gaap_StatementLineItems_ab0128ec-2138-4081-9893-ff40b566f7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab0128ec-2138-4081-9893-ff40b566f7ae" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_55a3452d-3da8-4fd7-97ca-f2e795418b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_us-gaap_SharesIssued_55a3452d-3da8-4fd7-97ca-f2e795418b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a92ed1e3-188d-4004-bffb-6c970c156912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a92ed1e3-188d-4004-bffb-6c970c156912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4636b919-e912-4c96-8caf-9fea52de1c98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4636b919-e912-4c96-8caf-9fea52de1c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_5ac5febe-8458-4926-a240-5a975f6a2cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_5ac5febe-8458-4926-a240-5a975f6a2cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_b0b82f8e-3e0c-4a5d-a2a8-429ec3015d24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_b0b82f8e-3e0c-4a5d-a2a8-429ec3015d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_a122a4e3-9f34-4de3-a87c-a828d868522f" xlink:href="mgnx-20220630.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_a122a4e3-9f34-4de3-a87c-a828d868522f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_f38244bb-f0b3-4eee-af92-062f0c4b94c9" xlink:href="mgnx-20220630.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_f38244bb-f0b3-4eee-af92-062f0c4b94c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d8e201b8-5466-4585-a779-ded99c31e70f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d8e201b8-5466-4585-a779-ded99c31e70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6a160258-6a06-4620-a399-55c4ff1b5ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6a160258-6a06-4620-a399-55c4ff1b5ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_742f7534-ad99-490f-8af1-4be52d565bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_742f7534-ad99-490f-8af1-4be52d565bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1782e72d-98c3-4ef4-8ad1-26648fbf4516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_us-gaap_NetIncomeLoss_1782e72d-98c3-4ef4-8ad1-26648fbf4516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_c4b9c49c-76ef-4e32-8178-c7ee435cbf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_us-gaap_SharesIssued_c4b9c49c-76ef-4e32-8178-c7ee435cbf7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a83de58d-94a4-43db-a2f6-c676d2481741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d8d6100-1c20-4ad9-9c31-0e0030a93b43" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a83de58d-94a4-43db-a2f6-c676d2481741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b96552b9-551e-4968-b74e-71c2498c1ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6a66b414-0cf0-4a82-b38a-c17f27efa468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b96552b9-551e-4968-b74e-71c2498c1ba3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6a66b414-0cf0-4a82-b38a-c17f27efa468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1277ba8a-ae09-439c-bf24-967e5c8092cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6a66b414-0cf0-4a82-b38a-c17f27efa468" xlink:to="loc_us-gaap_NetIncomeLoss_1277ba8a-ae09-439c-bf24-967e5c8092cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5e5561b6-a954-4f37-be8e-b62f5da55426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6a66b414-0cf0-4a82-b38a-c17f27efa468" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5e5561b6-a954-4f37-be8e-b62f5da55426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_afe70b38-84f6-41e7-9fce-0c12b4a73fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5e5561b6-a954-4f37-be8e-b62f5da55426" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_afe70b38-84f6-41e7-9fce-0c12b4a73fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_e9c6f271-a9ce-439e-815e-8995c2c98518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5e5561b6-a954-4f37-be8e-b62f5da55426" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_e9c6f271-a9ce-439e-815e-8995c2c98518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_caab9fa9-d416-46c4-a102-610f6e034fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5e5561b6-a954-4f37-be8e-b62f5da55426" xlink:to="loc_us-gaap_ShareBasedCompensation_caab9fa9-d416-46c4-a102-610f6e034fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1e417c24-161f-4df4-b3c0-42b1f3041db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5e5561b6-a954-4f37-be8e-b62f5da55426" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1e417c24-161f-4df4-b3c0-42b1f3041db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fd32043f-01c4-44e4-b079-39d4777a556a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1e417c24-161f-4df4-b3c0-42b1f3041db7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fd32043f-01c4-44e4-b079-39d4777a556a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_54b98d07-a431-4332-bc47-79c98e4ed86e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1e417c24-161f-4df4-b3c0-42b1f3041db7" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_54b98d07-a431-4332-bc47-79c98e4ed86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ba59707a-eeb1-4b9a-86f9-5cb5e3e3c8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1e417c24-161f-4df4-b3c0-42b1f3041db7" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ba59707a-eeb1-4b9a-86f9-5cb5e3e3c8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e3699e59-cd5a-4cfd-9702-e102e9e5d649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1e417c24-161f-4df4-b3c0-42b1f3041db7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e3699e59-cd5a-4cfd-9702-e102e9e5d649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_73b2558b-5dc2-48d2-94b5-f1fad9d884ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1e417c24-161f-4df4-b3c0-42b1f3041db7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_73b2558b-5dc2-48d2-94b5-f1fad9d884ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_25cea8e2-ad93-4a1a-99f0-26d152f6053a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1e417c24-161f-4df4-b3c0-42b1f3041db7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_25cea8e2-ad93-4a1a-99f0-26d152f6053a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_eb390778-cc87-4c8a-88ec-c09d81ebf4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1e417c24-161f-4df4-b3c0-42b1f3041db7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_eb390778-cc87-4c8a-88ec-c09d81ebf4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4f9b4170-f441-45d9-a335-bf458b87674a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1e417c24-161f-4df4-b3c0-42b1f3041db7" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4f9b4170-f441-45d9-a335-bf458b87674a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_964d1232-1647-44ef-956b-35bc01d5f69f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6a66b414-0cf0-4a82-b38a-c17f27efa468" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_964d1232-1647-44ef-956b-35bc01d5f69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_eb392b7a-25de-4ec8-8500-a7277745a26f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b96552b9-551e-4968-b74e-71c2498c1ba3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_eb392b7a-25de-4ec8-8500-a7277745a26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7200bfd8-a524-4553-82ad-779ee544bf28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_eb392b7a-25de-4ec8-8500-a7277745a26f" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7200bfd8-a524-4553-82ad-779ee544bf28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_90611e38-4300-446f-9ead-9896498f0d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_eb392b7a-25de-4ec8-8500-a7277745a26f" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_90611e38-4300-446f-9ead-9896498f0d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_646b6d01-7e4d-4c9f-bda6-44d35bda1445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_eb392b7a-25de-4ec8-8500-a7277745a26f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_646b6d01-7e4d-4c9f-bda6-44d35bda1445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4cd26707-4aef-41ef-b08b-e7542d330816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_eb392b7a-25de-4ec8-8500-a7277745a26f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4cd26707-4aef-41ef-b08b-e7542d330816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29cb3546-f47c-43b7-80b1-56eeb13b6f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b96552b9-551e-4968-b74e-71c2498c1ba3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29cb3546-f47c-43b7-80b1-56eeb13b6f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_57f14f39-06b8-4354-9834-d17d1c6ec918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29cb3546-f47c-43b7-80b1-56eeb13b6f7e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_57f14f39-06b8-4354-9834-d17d1c6ec918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_e54e31db-e7d0-42d3-8245-3b4859420f68" xlink:href="mgnx-20220630.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29cb3546-f47c-43b7-80b1-56eeb13b6f7e" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_e54e31db-e7d0-42d3-8245-3b4859420f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0ac891d9-dc04-430c-9658-4ca861810bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29cb3546-f47c-43b7-80b1-56eeb13b6f7e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0ac891d9-dc04-430c-9658-4ca861810bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_81173c3f-734b-48b0-bdb3-d8e52da75318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b96552b9-551e-4968-b74e-71c2498c1ba3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_81173c3f-734b-48b0-bdb3-d8e52da75318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bd9a248f-6cb2-47f2-a94b-03b159875eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b96552b9-551e-4968-b74e-71c2498c1ba3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bd9a248f-6cb2-47f2-a94b-03b159875eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c511a1ce-058f-4a5b-9cd1-67d2fe2463fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b96552b9-551e-4968-b74e-71c2498c1ba3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c511a1ce-058f-4a5b-9cd1-67d2fe2463fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_e8500ba0-69a9-4247-ae18-b6d82c0c743f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b96552b9-551e-4968-b74e-71c2498c1ba3" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_e8500ba0-69a9-4247-ae18-b6d82c0c743f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_80371807-d1a8-40a5-86d5-5cf0a944252e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e8500ba0-69a9-4247-ae18-b6d82c0c743f" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_80371807-d1a8-40a5-86d5-5cf0a944252e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_e8237045-1496-4677-9504-c9e26a7efca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b96552b9-551e-4968-b74e-71c2498c1ba3" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_e8237045-1496-4677-9504-c9e26a7efca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/NatureofOperations" xlink:type="simple" xlink:href="mgnx-20220630.xsd#NatureofOperations"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/NatureofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dba71233-0bfa-402b-81ee-9d68eb89d8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_060dc0cc-005d-41a3-bb68-a2f893ac3a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dba71233-0bfa-402b-81ee-9d68eb89d8aa" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_060dc0cc-005d-41a3-bb68-a2f893ac3a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20220630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a75b97f4-8356-4980-897e-cca5b4a9229f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_79a21ae1-777d-429e-92fe-29b22fff3a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a75b97f4-8356-4980-897e-cca5b4a9229f" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_79a21ae1-777d-429e-92fe-29b22fff3a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20220630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ec56b594-41c0-4af9-837c-6ad302742d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_bf710e13-10a3-4c89-a243-9c6483e0e90d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ec56b594-41c0-4af9-837c-6ad302742d16" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_bf710e13-10a3-4c89-a243-9c6483e0e90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2b2100f2-eed1-4297-917c-51b256506d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ec56b594-41c0-4af9-837c-6ad302742d16" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2b2100f2-eed1-4297-917c-51b256506d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_a8eca211-f716-4283-a9ad-b2bd58d2a7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ec56b594-41c0-4af9-837c-6ad302742d16" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_a8eca211-f716-4283-a9ad-b2bd58d2a7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="mgnx-20220630.xsd#FairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_81d15ca4-59c9-4f17-93bb-0fe93febe647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_0b20c159-2b37-4142-b32c-12cf6e9b586d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_81d15ca4-59c9-4f17-93bb-0fe93febe647" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_0b20c159-2b37-4142-b32c-12cf6e9b586d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="mgnx-20220630.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ec9f55ab-3fd6-4495-9125-bcc19cd209b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_72686e5b-e94c-428e-8e58-46c3abc26e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ec9f55ab-3fd6-4495-9125-bcc19cd209b2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_72686e5b-e94c-428e-8e58-46c3abc26e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5347e44f-e3ce-4e43-9ccd-f1d8a7acd7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_505df7c8-517d-4b3c-8ee9-86c09276edd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5347e44f-e3ce-4e43-9ccd-f1d8a7acd7d4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_505df7c8-517d-4b3c-8ee9-86c09276edd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7b30a925-846b-4dbd-a3bf-cb96c703ab7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_505df7c8-517d-4b3c-8ee9-86c09276edd7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7b30a925-846b-4dbd-a3bf-cb96c703ab7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d4629de5-0dc7-4907-b85a-684a8250cfab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7b30a925-846b-4dbd-a3bf-cb96c703ab7d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d4629de5-0dc7-4907-b85a-684a8250cfab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_928349e9-452e-4419-b59b-97fac21590be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d4629de5-0dc7-4907-b85a-684a8250cfab" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_928349e9-452e-4419-b59b-97fac21590be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_389bdd9c-2e18-41b6-abc7-683301f80428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_505df7c8-517d-4b3c-8ee9-86c09276edd7" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_389bdd9c-2e18-41b6-abc7-683301f80428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51a7bfb5-0abf-4cfb-9d9f-5f7c7a2049bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_389bdd9c-2e18-41b6-abc7-683301f80428" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51a7bfb5-0abf-4cfb-9d9f-5f7c7a2049bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_86a77061-9661-42a3-a762-03dd6bd95342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51a7bfb5-0abf-4cfb-9d9f-5f7c7a2049bb" xlink:to="loc_us-gaap_MoneyMarketFundsMember_86a77061-9661-42a3-a762-03dd6bd95342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_6c195092-cfeb-46aa-b7c7-3f6aab26386e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51a7bfb5-0abf-4cfb-9d9f-5f7c7a2049bb" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_6c195092-cfeb-46aa-b7c7-3f6aab26386e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_182a6f4b-f083-45ce-b9bb-57cac2640d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51a7bfb5-0abf-4cfb-9d9f-5f7c7a2049bb" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_182a6f4b-f083-45ce-b9bb-57cac2640d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_962b5ed1-1ea2-4366-a3c6-f9d9d9b4c37f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51a7bfb5-0abf-4cfb-9d9f-5f7c7a2049bb" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_962b5ed1-1ea2-4366-a3c6-f9d9d9b4c37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae60427a-d139-49e6-aa9b-b0ecdd476197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_505df7c8-517d-4b3c-8ee9-86c09276edd7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae60427a-d139-49e6-aa9b-b0ecdd476197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32e3b616-9d6f-4528-86fe-4434cca12755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae60427a-d139-49e6-aa9b-b0ecdd476197" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32e3b616-9d6f-4528-86fe-4434cca12755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_05bcfafa-56f7-43ca-8c2a-a96e91e8416f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32e3b616-9d6f-4528-86fe-4434cca12755" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_05bcfafa-56f7-43ca-8c2a-a96e91e8416f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f9dcf282-1e3b-471d-a391-09c5470dc4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32e3b616-9d6f-4528-86fe-4434cca12755" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f9dcf282-1e3b-471d-a391-09c5470dc4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff77da76-8fb2-4150-bb69-5f69ac5d8f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_505df7c8-517d-4b3c-8ee9-86c09276edd7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff77da76-8fb2-4150-bb69-5f69ac5d8f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_7a424178-b2e9-4c3b-9507-bff10dce69da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff77da76-8fb2-4150-bb69-5f69ac5d8f7c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_7a424178-b2e9-4c3b-9507-bff10dce69da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7545c40f-f00d-498b-9e46-843c60dbc438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7a424178-b2e9-4c3b-9507-bff10dce69da" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7545c40f-f00d-498b-9e46-843c60dbc438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fbbd2bf1-dcee-4087-902e-a5772dc88879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7a424178-b2e9-4c3b-9507-bff10dce69da" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fbbd2bf1-dcee-4087-902e-a5772dc88879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1c9c9cf8-6567-48d7-9d4b-4ebc62b41b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7a424178-b2e9-4c3b-9507-bff10dce69da" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1c9c9cf8-6567-48d7-9d4b-4ebc62b41b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20220630.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5fc2b99a-8c3f-4cf9-a306-4889f1ffa4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1ee218e1-c1e1-47b1-b083-5458a56ed9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5fc2b99a-8c3f-4cf9-a306-4889f1ffa4a8" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1ee218e1-c1e1-47b1-b083-5458a56ed9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20220630.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_91ce37fb-9f2e-41c7-9a95-1d761927a7de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_be040a93-cdbd-4574-bfdb-31584df2335d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_91ce37fb-9f2e-41c7-9a95-1d761927a7de" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_be040a93-cdbd-4574-bfdb-31584df2335d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f666cf1d-2378-4622-b2ca-9ae479472b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_179c90f4-40bd-4939-810b-a7eb88e96f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f666cf1d-2378-4622-b2ca-9ae479472b5d" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_179c90f4-40bd-4939-810b-a7eb88e96f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_db0e2588-1d17-4764-850b-55e93ce513fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_179c90f4-40bd-4939-810b-a7eb88e96f3f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_db0e2588-1d17-4764-850b-55e93ce513fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_de55b9e6-2a76-4c3d-8ec2-2bad6aeff839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_db0e2588-1d17-4764-850b-55e93ce513fc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_de55b9e6-2a76-4c3d-8ec2-2bad6aeff839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_e184e20a-73ef-433c-bf55-1cd03c9bd563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_de55b9e6-2a76-4c3d-8ec2-2bad6aeff839" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_e184e20a-73ef-433c-bf55-1cd03c9bd563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_bf7d50df-2e0d-4bc6-810c-cd53525fb232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_de55b9e6-2a76-4c3d-8ec2-2bad6aeff839" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_bf7d50df-2e0d-4bc6-810c-cd53525fb232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_e08d350e-0ea0-4f75-aeb9-9408659f34b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_de55b9e6-2a76-4c3d-8ec2-2bad6aeff839" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_e08d350e-0ea0-4f75-aeb9-9408659f34b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ab264eb7-050a-4b94-9a68-ce4a7e2f2bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_179c90f4-40bd-4939-810b-a7eb88e96f3f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ab264eb7-050a-4b94-9a68-ce4a7e2f2bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_09b7178f-a084-4ce5-83a6-5744e842615c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ab264eb7-050a-4b94-9a68-ce4a7e2f2bc8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_09b7178f-a084-4ce5-83a6-5744e842615c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a02a341a-74d2-4dbe-b1e1-b7608412e7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ab264eb7-050a-4b94-9a68-ce4a7e2f2bc8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a02a341a-74d2-4dbe-b1e1-b7608412e7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b0e63277-5284-42a5-8b6d-6f8ebfcd0840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ab264eb7-050a-4b94-9a68-ce4a7e2f2bc8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b0e63277-5284-42a5-8b6d-6f8ebfcd0840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_91aebe60-ad18-495a-89ba-227284b84c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ab264eb7-050a-4b94-9a68-ce4a7e2f2bc8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_91aebe60-ad18-495a-89ba-227284b84c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_3d3f74f6-abf9-41f8-b93c-536d1b45bd57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f666cf1d-2378-4622-b2ca-9ae479472b5d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_3d3f74f6-abf9-41f8-b93c-536d1b45bd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNet" xlink:type="simple" xlink:href="mgnx-20220630.xsd#InventoryNet"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a0d48bde-cc84-45b1-be95-8a8edcb7c45f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_9909629d-ad11-40d0-8904-33cf2f4e6782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a0d48bde-cc84-45b1-be95-8a8edcb7c45f" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_9909629d-ad11-40d0-8904-33cf2f4e6782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetTables" xlink:type="simple" xlink:href="mgnx-20220630.xsd#InventoryNetTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e357847e-0bc9-4a48-88d3-e7068b02963b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d7928c35-a522-47db-834b-628bfabf8802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e357847e-0bc9-4a48-88d3-e7068b02963b" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d7928c35-a522-47db-834b-628bfabf8802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#InventoryNetDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5b47ca3a-da73-4288-9d29-0ef81c588fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_fbb0f239-1b7f-4660-aecb-0eb67a8cbf37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5b47ca3a-da73-4288-9d29-0ef81c588fd7" xlink:to="loc_us-gaap_InventoryWorkInProcess_fbb0f239-1b7f-4660-aecb-0eb67a8cbf37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_d8a0087e-e985-4c6c-bc45-c5d7cff06169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5b47ca3a-da73-4288-9d29-0ef81c588fd7" xlink:to="loc_us-gaap_InventoryFinishedGoods_d8a0087e-e985-4c6c-bc45-c5d7cff06169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_014a254f-5732-4b0e-bdd2-cc67c4873256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5b47ca3a-da73-4288-9d29-0ef81c588fd7" xlink:to="loc_us-gaap_InventoryNet_014a254f-5732-4b0e-bdd2-cc67c4873256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_333c8c00-4c3d-4eae-9448-43765fcf8bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5b47ca3a-da73-4288-9d29-0ef81c588fd7" xlink:to="loc_us-gaap_InventoryValuationReserves_333c8c00-4c3d-4eae-9448-43765fcf8bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20220630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b0ba822f-f17a-442a-a5b0-96645df6cd31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1d2fce91-01db-476e-9806-0e5f0df9354e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b0ba822f-f17a-442a-a5b0-96645df6cd31" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1d2fce91-01db-476e-9806-0e5f0df9354e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_43a7b3c0-bf17-44f0-beb0-eeb82f004859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ce236fe4-a684-4f7e-b2ad-c29ec1b75353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_43a7b3c0-bf17-44f0-beb0-eeb82f004859" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ce236fe4-a684-4f7e-b2ad-c29ec1b75353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_590e4474-4305-4609-80bd-74bba137484c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ce236fe4-a684-4f7e-b2ad-c29ec1b75353" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_590e4474-4305-4609-80bd-74bba137484c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce7f0c39-1b14-4f4e-b906-b0548856bda6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_590e4474-4305-4609-80bd-74bba137484c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce7f0c39-1b14-4f4e-b906-b0548856bda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_845ef6b4-4634-4093-97cc-f4d81ebd5c00" xlink:href="mgnx-20220630.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce7f0c39-1b14-4f4e-b906-b0548856bda6" xlink:to="loc_mgnx_AtTheMarketOfferingMember_845ef6b4-4634-4093-97cc-f4d81ebd5c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4443dc0f-e84e-4dfa-9af0-5a021c0bf128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ce236fe4-a684-4f7e-b2ad-c29ec1b75353" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4443dc0f-e84e-4dfa-9af0-5a021c0bf128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7d07ee4a-578b-4522-9632-01d8c0efa607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4443dc0f-e84e-4dfa-9af0-5a021c0bf128" xlink:to="loc_us-gaap_EquityComponentDomain_7d07ee4a-578b-4522-9632-01d8c0efa607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4d89a256-7c63-48f9-91ef-10d8a7a1dc81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7d07ee4a-578b-4522-9632-01d8c0efa607" xlink:to="loc_us-gaap_CommonStockMember_4d89a256-7c63-48f9-91ef-10d8a7a1dc81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5afa5801-c27c-4cc8-9f4f-72862ca74dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ce236fe4-a684-4f7e-b2ad-c29ec1b75353" xlink:to="loc_us-gaap_ClassOfStockLineItems_5afa5801-c27c-4cc8-9f4f-72862ca74dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_3753ca00-aef8-44b2-b67c-27903f5fef04" xlink:href="mgnx-20220630.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5afa5801-c27c-4cc8-9f4f-72862ca74dc3" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_3753ca00-aef8-44b2-b67c-27903f5fef04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2a955944-0707-4978-8f38-981dd469f1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5afa5801-c27c-4cc8-9f4f-72862ca74dc3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2a955944-0707-4978-8f38-981dd469f1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_e1bd80fe-1834-4832-afb6-2fe23d4ae63d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5afa5801-c27c-4cc8-9f4f-72862ca74dc3" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_e1bd80fe-1834-4832-afb6-2fe23d4ae63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_961f4611-a120-4f99-9533-7f4b4b33e5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5afa5801-c27c-4cc8-9f4f-72862ca74dc3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_961f4611-a120-4f99-9533-7f4b4b33e5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_1a65c18c-0462-4e09-a10a-29305a628861" xlink:href="mgnx-20220630.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5afa5801-c27c-4cc8-9f4f-72862ca74dc3" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_1a65c18c-0462-4e09-a10a-29305a628861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a8b80744-46e4-4a1d-8607-88edcd8783c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5afa5801-c27c-4cc8-9f4f-72862ca74dc3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a8b80744-46e4-4a1d-8607-88edcd8783c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9df1f6c8-9dff-4c5b-923b-e99704173561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5afa5801-c27c-4cc8-9f4f-72862ca74dc3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9df1f6c8-9dff-4c5b-923b-e99704173561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/Revenue" xlink:type="simple" xlink:href="mgnx-20220630.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_36939802-0e36-4f90-a1a0-5877f33bdb07" xlink:href="mgnx-20220630.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_8835bf3e-f7d1-436a-a69e-0bb914400971" xlink:href="mgnx-20220630.xsd#mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_36939802-0e36-4f90-a1a0-5877f33bdb07" xlink:to="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_8835bf3e-f7d1-436a-a69e-0bb914400971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CollaborationandOtherAgreementsIncyteCorporationDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_daa66035-5e7b-400a-a4a1-8bcd5db20efb" xlink:href="mgnx-20220630.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d35e5b97-a1ef-4962-a4ce-d5aceb277cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_daa66035-5e7b-400a-a4a1-8bcd5db20efb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d35e5b97-a1ef-4962-a4ce-d5aceb277cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_83b4200c-d01c-4dd7-b5ec-dba2d548583c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d35e5b97-a1ef-4962-a4ce-d5aceb277cea" xlink:to="loc_srt_ProductOrServiceAxis_83b4200c-d01c-4dd7-b5ec-dba2d548583c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_62eb5d85-01c1-47ff-be95-ab94f9772785" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_83b4200c-d01c-4dd7-b5ec-dba2d548583c" xlink:to="loc_srt_ProductsAndServicesDomain_62eb5d85-01c1-47ff-be95-ab94f9772785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_c7840999-1b5b-4fd9-82ce-d55cfced31ec" xlink:href="mgnx-20220630.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_62eb5d85-01c1-47ff-be95-ab94f9772785" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_c7840999-1b5b-4fd9-82ce-d55cfced31ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_f79b9539-9a1b-4d6d-aa92-99ff49d8b277" xlink:href="mgnx-20220630.xsd#mgnx_RevenuesFromCMOAgreementsMemberMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_62eb5d85-01c1-47ff-be95-ab94f9772785" xlink:to="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_f79b9539-9a1b-4d6d-aa92-99ff49d8b277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ef6b29cb-f077-4da6-a48d-6b0493b22626" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d35e5b97-a1ef-4962-a4ce-d5aceb277cea" xlink:to="loc_srt_RangeAxis_ef6b29cb-f077-4da6-a48d-6b0493b22626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ee12a278-fd9f-4c93-a6a5-4e4d715a1823" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ef6b29cb-f077-4da6-a48d-6b0493b22626" xlink:to="loc_srt_RangeMember_ee12a278-fd9f-4c93-a6a5-4e4d715a1823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1cf934bb-2954-4102-be23-db914e2e78ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ee12a278-fd9f-4c93-a6a5-4e4d715a1823" xlink:to="loc_srt_MinimumMember_1cf934bb-2954-4102-be23-db914e2e78ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a92a206e-15bf-48c4-a2cf-b9b1516fa9ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ee12a278-fd9f-4c93-a6a5-4e4d715a1823" xlink:to="loc_srt_MaximumMember_a92a206e-15bf-48c4-a2cf-b9b1516fa9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5c9e3b4e-35fc-4dab-9d55-d37d78cb3752" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d35e5b97-a1ef-4962-a4ce-d5aceb277cea" xlink:to="loc_srt_CounterpartyNameAxis_5c9e3b4e-35fc-4dab-9d55-d37d78cb3752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e32c3ab7-ac1f-4a4a-8b60-3c4aabd3053f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5c9e3b4e-35fc-4dab-9d55-d37d78cb3752" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e32c3ab7-ac1f-4a4a-8b60-3c4aabd3053f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_6e203376-bf1d-4da4-8e0e-f7fae390812c" xlink:href="mgnx-20220630.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e32c3ab7-ac1f-4a4a-8b60-3c4aabd3053f" xlink:to="loc_mgnx_IncyteCorporationMember_6e203376-bf1d-4da4-8e0e-f7fae390812c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_dc1b6097-4811-4a5e-8544-c5453a2bd9d3" xlink:href="mgnx-20220630.xsd#mgnx_IMabBiopharmaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e32c3ab7-ac1f-4a4a-8b60-3c4aabd3053f" xlink:to="loc_mgnx_IMabBiopharmaMember_dc1b6097-4811-4a5e-8544-c5453a2bd9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_405e72e4-f007-402e-9b24-4b0c538ac18e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d35e5b97-a1ef-4962-a4ce-d5aceb277cea" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_405e72e4-f007-402e-9b24-4b0c538ac18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e59438f5-c2f3-43e4-a51c-85349f160cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_405e72e4-f007-402e-9b24-4b0c538ac18e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e59438f5-c2f3-43e4-a51c-85349f160cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_3ae45f93-c281-413b-9a79-4b1d2da7780f" xlink:href="mgnx-20220630.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e59438f5-c2f3-43e4-a51c-85349f160cf8" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_3ae45f93-c281-413b-9a79-4b1d2da7780f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_5bfb8248-f123-46a5-b791-fbe105921461" xlink:href="mgnx-20220630.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_3ae45f93-c281-413b-9a79-4b1d2da7780f" xlink:to="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_5bfb8248-f123-46a5-b791-fbe105921461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012ClinicalServicesMember_cf301778-3381-42f7-a327-8015d5e350d2" xlink:href="mgnx-20220630.xsd#mgnx_IncyteMGA012ClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e59438f5-c2f3-43e4-a51c-85349f160cf8" xlink:to="loc_mgnx_IncyteMGA012ClinicalServicesMember_cf301778-3381-42f7-a327-8015d5e350d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012SupplyAgreementMember_82f6d66e-afd6-4182-a57e-f631231c075c" xlink:href="mgnx-20220630.xsd#mgnx_IncyteMGA012SupplyAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e59438f5-c2f3-43e4-a51c-85349f160cf8" xlink:to="loc_mgnx_IncyteMGA012SupplyAgreementMember_82f6d66e-afd6-4182-a57e-f631231c075c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_5d084027-7bb1-47e1-8ae1-ebfad6c4e3ff" xlink:href="mgnx-20220630.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e59438f5-c2f3-43e4-a51c-85349f160cf8" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_5d084027-7bb1-47e1-8ae1-ebfad6c4e3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_497882c5-f0f7-463c-bc5d-37a9c94e70e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d35e5b97-a1ef-4962-a4ce-d5aceb277cea" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_497882c5-f0f7-463c-bc5d-37a9c94e70e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9595df49-84d9-40dd-afa3-9e09ddd5fa97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_497882c5-f0f7-463c-bc5d-37a9c94e70e8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9595df49-84d9-40dd-afa3-9e09ddd5fa97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5b1d47cc-f8e8-4a41-b4ef-38c7c4e0ab45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9595df49-84d9-40dd-afa3-9e09ddd5fa97" xlink:to="loc_us-gaap_SubsequentEventMember_5b1d47cc-f8e8-4a41-b4ef-38c7c4e0ab45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d35e5b97-a1ef-4962-a4ce-d5aceb277cea" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_c15f637a-29f4-423b-9b57-038bad909c17" xlink:href="mgnx-20220630.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_mgnx_NonRefundableUpfrontFees_c15f637a-29f4-423b-9b57-038bad909c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_fdf4258a-4ac1-4989-8d60-c112397b22b4" xlink:href="mgnx-20220630.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_fdf4258a-4ac1-4989-8d60-c112397b22b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_7b00e9c9-6073-49c5-89bd-86d9326dd38c" xlink:href="mgnx-20220630.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_7b00e9c9-6073-49c5-89bd-86d9326dd38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_9a288a9d-25d6-4a9a-9976-fbcdf11ea373" xlink:href="mgnx-20220630.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_9a288a9d-25d6-4a9a-9976-fbcdf11ea373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_6670cc89-9fa1-4fc7-826b-4d5877b37488" xlink:href="mgnx-20220630.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_6670cc89-9fa1-4fc7-826b-4d5877b37488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_2d873861-0cf8-44c9-b04e-56002c0029c1" xlink:href="mgnx-20220630.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_mgnx_NumberOfPerformanceObligations_2d873861-0cf8-44c9-b04e-56002c0029c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_bd8d01a7-5927-4fff-afd5-d5f8dd3a3a71" xlink:href="mgnx-20220630.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_bd8d01a7-5927-4fff-afd5-d5f8dd3a3a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_be396797-b582-44ac-83a2-67e5d940d4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_us-gaap_Revenues_be396797-b582-44ac-83a2-67e5d940d4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_995f503a-6849-4e8c-925e-88e0009c1055" xlink:href="mgnx-20220630.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_995f503a-6849-4e8c-925e-88e0009c1055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a733a7c0-80e2-458f-8cc4-51633c9872f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a733a7c0-80e2-458f-8cc4-51633c9872f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_df5bab2e-df9f-4c68-99c3-fea99b0126d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_df5bab2e-df9f-4c68-99c3-fea99b0126d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8560fa0a-3db8-4533-8329-7cae0f383c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8560fa0a-3db8-4533-8329-7cae0f383c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalAnnualFixedPayments_db26a332-6a5f-4fa0-bc88-0424583d5a9f" xlink:href="mgnx-20220630.xsd#mgnx_TotalAnnualFixedPayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_mgnx_TotalAnnualFixedPayments_db26a332-6a5f-4fa0-bc88-0424583d5a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement_cfef0f1d-41b4-4c10-839c-aa9ed118ceb3" xlink:href="mgnx-20220630.xsd#mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4b3eeaf-ab58-4e26-8ba4-c9c9d8bcbf76" xlink:to="loc_mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement_cfef0f1d-41b4-4c10-839c-aa9ed118ceb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_f6f79982-3d61-4bf4-bf3c-2dc26dc5315d" xlink:href="mgnx-20220630.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47c8ca0f-6f6b-4f6f-aef1-55cbd5804de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_f6f79982-3d61-4bf4-bf3c-2dc26dc5315d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47c8ca0f-6f6b-4f6f-aef1-55cbd5804de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3cf6de35-625c-4ce5-a752-c74c0670ed02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47c8ca0f-6f6b-4f6f-aef1-55cbd5804de0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3cf6de35-625c-4ce5-a752-c74c0670ed02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ee7e850-b66a-4f67-9e4d-2a64f0d2df0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3cf6de35-625c-4ce5-a752-c74c0670ed02" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ee7e850-b66a-4f67-9e4d-2a64f0d2df0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_4325a54d-d028-49c5-b342-365cc989d0e2" xlink:href="mgnx-20220630.xsd#mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ee7e850-b66a-4f67-9e4d-2a64f0d2df0b" xlink:to="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_4325a54d-d028-49c5-b342-365cc989d0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_06d4916c-8b97-45ae-9a34-3f801e4af5de" xlink:href="mgnx-20220630.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ee7e850-b66a-4f67-9e4d-2a64f0d2df0b" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_06d4916c-8b97-45ae-9a34-3f801e4af5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_f9aa1b5f-defe-42f1-8029-8ed8c2e8adc0" xlink:href="mgnx-20220630.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ee7e850-b66a-4f67-9e4d-2a64f0d2df0b" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_f9aa1b5f-defe-42f1-8029-8ed8c2e8adc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_a1e9c990-692a-4fdf-91f3-c3226c334ee3" xlink:href="mgnx-20220630.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ee7e850-b66a-4f67-9e4d-2a64f0d2df0b" xlink:to="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_a1e9c990-692a-4fdf-91f3-c3226c334ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_8699a7af-3883-4309-940d-7aa5f3b20a5d" xlink:href="mgnx-20220630.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ee7e850-b66a-4f67-9e4d-2a64f0d2df0b" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_8699a7af-3883-4309-940d-7aa5f3b20a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_72b36cd3-21c0-4d45-a4cf-0cae5a61e3bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47c8ca0f-6f6b-4f6f-aef1-55cbd5804de0" xlink:to="loc_srt_CounterpartyNameAxis_72b36cd3-21c0-4d45-a4cf-0cae5a61e3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_44909404-0e5b-49c1-b0d7-8a8ebcc528ed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_72b36cd3-21c0-4d45-a4cf-0cae5a61e3bf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_44909404-0e5b-49c1-b0d7-8a8ebcc528ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_6645cbb3-ce1a-4a38-849d-8ec8327c3f81" xlink:href="mgnx-20220630.xsd#mgnx_ZaiLabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_44909404-0e5b-49c1-b0d7-8a8ebcc528ed" xlink:to="loc_mgnx_ZaiLabMember_6645cbb3-ce1a-4a38-849d-8ec8327c3f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dfabbc4f-9aaf-4506-8afc-713e760e47fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47c8ca0f-6f6b-4f6f-aef1-55cbd5804de0" xlink:to="loc_srt_RangeAxis_dfabbc4f-9aaf-4506-8afc-713e760e47fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2d91bd40-0283-4948-b026-48044d5ca94a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_dfabbc4f-9aaf-4506-8afc-713e760e47fd" xlink:to="loc_srt_RangeMember_2d91bd40-0283-4948-b026-48044d5ca94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40f2e99e-57af-4054-9b09-4af45caa188f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2d91bd40-0283-4948-b026-48044d5ca94a" xlink:to="loc_srt_MaximumMember_40f2e99e-57af-4054-9b09-4af45caa188f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_356a9e7c-3ed6-49b0-a7f8-09aa4ecc775e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47c8ca0f-6f6b-4f6f-aef1-55cbd5804de0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_356a9e7c-3ed6-49b0-a7f8-09aa4ecc775e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e32421f2-5d21-4f98-b350-8cd3c5bc16fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_356a9e7c-3ed6-49b0-a7f8-09aa4ecc775e" xlink:to="loc_us-gaap_EquityComponentDomain_e32421f2-5d21-4f98-b350-8cd3c5bc16fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fbced3a6-a70d-4a18-9f0d-c5ce855e78c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e32421f2-5d21-4f98-b350-8cd3c5bc16fe" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fbced3a6-a70d-4a18-9f0d-c5ce855e78c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47c8ca0f-6f6b-4f6f-aef1-55cbd5804de0" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_4690aa4e-846c-4eab-b1bb-d7820240d4cc" xlink:href="mgnx-20220630.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_NonRefundableUpfrontFees_4690aa4e-846c-4eab-b1bb-d7820240d4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_11dbfaac-92bb-4f97-885a-4ced3426d2d9" xlink:href="mgnx-20220630.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_11dbfaac-92bb-4f97-885a-4ced3426d2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_67c33975-1cab-45ba-a8f6-e8e7463b4ab0" xlink:href="mgnx-20220630.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_67c33975-1cab-45ba-a8f6-e8e7463b4ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_970fa032-05c6-478a-8651-8ea8db8fda1e" xlink:href="mgnx-20220630.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_970fa032-05c6-478a-8651-8ea8db8fda1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_f33d742e-3621-4232-b1b1-23f09b3af352" xlink:href="mgnx-20220630.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_f33d742e-3621-4232-b1b1-23f09b3af352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_dfc087be-357d-4f99-8274-59d114dc3bf3" xlink:href="mgnx-20220630.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_dfc087be-357d-4f99-8274-59d114dc3bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a58715f9-e437-4ff2-846f-342501502efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a58715f9-e437-4ff2-846f-342501502efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4a37e58a-af7b-45ea-9b74-cdec5ee01ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_us-gaap_Revenues_4a37e58a-af7b-45ea-9b74-cdec5ee01ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptInFee_4041451f-031c-4c2c-b535-d34f17eb24c1" xlink:href="mgnx-20220630.xsd#mgnx_OptInFee"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_OptInFee_4041451f-031c-4c2c-b535-d34f17eb24c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_65cc633c-1806-49a4-bda8-ec95dc9f6103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_65cc633c-1806-49a4-bda8-ec95dc9f6103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a2e64f14-2413-4fc4-9481-d3afd7c6a277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a2e64f14-2413-4fc4-9481-d3afd7c6a277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_0e08e2a8-a811-4a6e-a6a1-971dede23be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_0e08e2a8-a811-4a6e-a6a1-971dede23be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_9c539c77-7905-4527-971e-86aac3f79582" xlink:href="mgnx-20220630.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_PremiumReceivedOnStockPurchase_9c539c77-7905-4527-971e-86aac3f79582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_84b62cab-7025-4959-8e25-c9e38f5a5198" xlink:href="mgnx-20220630.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_84b62cab-7025-4959-8e25-c9e38f5a5198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_a4f9d989-6426-4e1f-a662-a3d6721b888d" xlink:href="mgnx-20220630.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_a4f9d989-6426-4e1f-a662-a3d6721b888d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_334ce63b-f573-43fa-a4ac-0a1bb2c593ae" xlink:href="mgnx-20220630.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_334ce63b-f573-43fa-a4ac-0a1bb2c593ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c5f7d22e-24f6-4d40-94f8-f8e37ca5de2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c5f7d22e-24f6-4d40-94f8-f8e37ca5de2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9568bd78-97b2-4819-ae88-b719a9ce2642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9568bd78-97b2-4819-ae88-b719a9ce2642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MillstoneRevenueRecognized_6c8adeee-a591-4455-81e7-fa504cd97f82" xlink:href="mgnx-20220630.xsd#mgnx_MillstoneRevenueRecognized"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eefaa03f-a532-449a-a9a9-7d9c5ee08d14" xlink:to="loc_mgnx_MillstoneRevenueRecognized_6c8adeee-a591-4455-81e7-fa504cd97f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CollaborationandOtherAgreementsJanssenDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_26e303cd-fdb3-40a2-894b-d5ad0bdb40ad" xlink:href="mgnx-20220630.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e2a6023b-f68e-447a-b9ee-061f98f2eb25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_26e303cd-fdb3-40a2-894b-d5ad0bdb40ad" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e2a6023b-f68e-447a-b9ee-061f98f2eb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1410bd8f-98f4-47d0-a633-898dde138622" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e2a6023b-f68e-447a-b9ee-061f98f2eb25" xlink:to="loc_srt_CounterpartyNameAxis_1410bd8f-98f4-47d0-a633-898dde138622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6e1e9cc-7766-4241-b707-60c37484b4ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1410bd8f-98f4-47d0-a633-898dde138622" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6e1e9cc-7766-4241-b707-60c37484b4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_846facf5-17d8-4159-8428-4851b21d39e5" xlink:href="mgnx-20220630.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6e1e9cc-7766-4241-b707-60c37484b4ae" xlink:to="loc_mgnx_JanssenBiotechIncMember_846facf5-17d8-4159-8428-4851b21d39e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_432dbbf9-2b8a-43ff-81cb-640b2187ff29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e2a6023b-f68e-447a-b9ee-061f98f2eb25" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_432dbbf9-2b8a-43ff-81cb-640b2187ff29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6e1b162a-8e21-4b16-80ae-87b65b042ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_432dbbf9-2b8a-43ff-81cb-640b2187ff29" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6e1b162a-8e21-4b16-80ae-87b65b042ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_49d4dda5-0451-4d7a-909c-e977a9d4914c" xlink:href="mgnx-20220630.xsd#mgnx_JanssenCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6e1b162a-8e21-4b16-80ae-87b65b042ff2" xlink:to="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_49d4dda5-0451-4d7a-909c-e977a9d4914c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4d6634cd-4694-48bb-b092-3998b592d3e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e2a6023b-f68e-447a-b9ee-061f98f2eb25" xlink:to="loc_srt_ProductOrServiceAxis_4d6634cd-4694-48bb-b092-3998b592d3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_328c6c31-289a-41da-9fb6-557a19946482" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4d6634cd-4694-48bb-b092-3998b592d3e7" xlink:to="loc_srt_ProductsAndServicesDomain_328c6c31-289a-41da-9fb6-557a19946482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_90b51dee-2f29-45a5-9515-df1f4a3e1012" xlink:href="mgnx-20220630.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_328c6c31-289a-41da-9fb6-557a19946482" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_90b51dee-2f29-45a5-9515-df1f4a3e1012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_45662845-0cbd-4e4c-a658-77784cc9c6b0" xlink:href="mgnx-20220630.xsd#mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_328c6c31-289a-41da-9fb6-557a19946482" xlink:to="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_45662845-0cbd-4e4c-a658-77784cc9c6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78c341ad-9242-45b9-be35-205e6300b93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e2a6023b-f68e-447a-b9ee-061f98f2eb25" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78c341ad-9242-45b9-be35-205e6300b93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_b16b9bc5-cc87-4e48-9b15-a080f964d405" xlink:href="mgnx-20220630.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78c341ad-9242-45b9-be35-205e6300b93a" xlink:to="loc_mgnx_NonRefundableUpfrontFees_b16b9bc5-cc87-4e48-9b15-a080f964d405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_2fbfba97-b0d5-4a54-93dd-190d4cb79c00" xlink:href="mgnx-20220630.xsd#mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78c341ad-9242-45b9-be35-205e6300b93a" xlink:to="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_2fbfba97-b0d5-4a54-93dd-190d4cb79c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_125f7662-2a34-40f6-b1ef-ae22bba54235" xlink:href="mgnx-20220630.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78c341ad-9242-45b9-be35-205e6300b93a" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_125f7662-2a34-40f6-b1ef-ae22bba54235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_0c594e05-bf28-4328-80af-e741c1d68cda" xlink:href="mgnx-20220630.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78c341ad-9242-45b9-be35-205e6300b93a" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_0c594e05-bf28-4328-80af-e741c1d68cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_045a7c85-6fa6-4d6e-bc47-e59ed16216f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78c341ad-9242-45b9-be35-205e6300b93a" xlink:to="loc_us-gaap_Revenues_045a7c85-6fa6-4d6e-bc47-e59ed16216f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_2a458fba-c96c-405f-a779-af4c1f6c6b3e" xlink:href="mgnx-20220630.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_78c341ad-9242-45b9-be35-205e6300b93a" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_2a458fba-c96c-405f-a779-af4c1f6c6b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CollaborationandOtherAgreementsIMabBiopharmaDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_76251ea8-2ecc-4264-b114-c9d516b0cc3d" xlink:href="mgnx-20220630.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_03b285e9-add6-4763-890f-518206d91b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_76251ea8-2ecc-4264-b114-c9d516b0cc3d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_03b285e9-add6-4763-890f-518206d91b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1838169e-7ab8-4249-8980-ca2f72e7d69f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_03b285e9-add6-4763-890f-518206d91b04" xlink:to="loc_srt_CounterpartyNameAxis_1838169e-7ab8-4249-8980-ca2f72e7d69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6c195d76-6a24-403f-bf2b-933b15a7df6b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1838169e-7ab8-4249-8980-ca2f72e7d69f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6c195d76-6a24-403f-bf2b-933b15a7df6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_37735959-3d5b-495b-acc4-fcd03d4eebfc" xlink:href="mgnx-20220630.xsd#mgnx_IMabBiopharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6c195d76-6a24-403f-bf2b-933b15a7df6b" xlink:to="loc_mgnx_IMabBiopharmaMember_37735959-3d5b-495b-acc4-fcd03d4eebfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_38607870-3331-4422-8bd5-f84dc8b8e190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_03b285e9-add6-4763-890f-518206d91b04" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_38607870-3331-4422-8bd5-f84dc8b8e190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_58a74662-106a-473f-9bee-9024c4aca97b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_38607870-3331-4422-8bd5-f84dc8b8e190" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_58a74662-106a-473f-9bee-9024c4aca97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_926c548e-1bd2-4704-9468-802d613402d5" xlink:href="mgnx-20220630.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_58a74662-106a-473f-9bee-9024c4aca97b" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_926c548e-1bd2-4704-9468-802d613402d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_e6b6deff-c8bf-4e0c-9d17-5c6acff2e035" xlink:href="mgnx-20220630.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_58a74662-106a-473f-9bee-9024c4aca97b" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_e6b6deff-c8bf-4e0c-9d17-5c6acff2e035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_887c4876-fce6-4c43-8ffc-a453708358c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_03b285e9-add6-4763-890f-518206d91b04" xlink:to="loc_srt_RangeAxis_887c4876-fce6-4c43-8ffc-a453708358c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e1ce54f0-e7f5-45f9-b1ce-03fbdea13b59" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_887c4876-fce6-4c43-8ffc-a453708358c2" xlink:to="loc_srt_RangeMember_e1ce54f0-e7f5-45f9-b1ce-03fbdea13b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d8f86fc0-86a9-42e1-aa88-b575df8211b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e1ce54f0-e7f5-45f9-b1ce-03fbdea13b59" xlink:to="loc_srt_MaximumMember_d8f86fc0-86a9-42e1-aa88-b575df8211b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_03b285e9-add6-4763-890f-518206d91b04" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_ec12bae0-0faa-4ba6-ace8-3ed65ca8a733" xlink:href="mgnx-20220630.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:to="loc_mgnx_NonRefundableUpfrontFees_ec12bae0-0faa-4ba6-ace8-3ed65ca8a733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_916b3f26-2a0f-42cb-a4ee-36bdd779ddc5" xlink:href="mgnx-20220630.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_916b3f26-2a0f-42cb-a4ee-36bdd779ddc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_435d5252-417f-4765-a7cb-c1dd7d254480" xlink:href="mgnx-20220630.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_435d5252-417f-4765-a7cb-c1dd7d254480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_85a1dec0-4c86-43f4-acf6-71bc80587d32" xlink:href="mgnx-20220630.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_85a1dec0-4c86-43f4-acf6-71bc80587d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_0c4f5004-179f-435c-b340-95289d813449" xlink:href="mgnx-20220630.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:to="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_0c4f5004-179f-435c-b340-95289d813449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d2ed76a3-977d-4476-b1cd-7c0fbcbbd86e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:to="loc_us-gaap_Revenues_d2ed76a3-977d-4476-b1cd-7c0fbcbbd86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8e1ee1ff-23fa-49ba-9654-d594920077f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8e1ee1ff-23fa-49ba-9654-d594920077f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9d8a0d5b-7824-401c-9b29-ddb0683ec483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9d8a0d5b-7824-401c-9b29-ddb0683ec483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_55c516ce-f7cc-4b22-b4ab-3197c79bb4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_55c516ce-f7cc-4b22-b4ab-3197c79bb4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OneTimeMillstoneCredit_afe84e56-3912-449e-bd8a-4e6a9f147bba" xlink:href="mgnx-20220630.xsd#mgnx_OneTimeMillstoneCredit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_81a9b725-04ae-4bf9-a9c9-0b8e2999a1b9" xlink:to="loc_mgnx_OneTimeMillstoneCredit_afe84e56-3912-449e-bd8a-4e6a9f147bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_e4d6b2f8-47f1-4309-895c-867d184fc1a3" xlink:href="mgnx-20220630.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_316a996b-e051-4569-bde0-88b5e187425d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_e4d6b2f8-47f1-4309-895c-867d184fc1a3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_316a996b-e051-4569-bde0-88b5e187425d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9830476a-a0ee-4462-a857-ebe920c7a935" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_316a996b-e051-4569-bde0-88b5e187425d" xlink:to="loc_srt_ProductOrServiceAxis_9830476a-a0ee-4462-a857-ebe920c7a935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1f86555b-85bd-4275-b21d-e7bdcb7bb51d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9830476a-a0ee-4462-a857-ebe920c7a935" xlink:to="loc_srt_ProductsAndServicesDomain_1f86555b-85bd-4275-b21d-e7bdcb7bb51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_ce864dd4-ef33-4948-a1db-599bf8255d39" xlink:href="mgnx-20220630.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1f86555b-85bd-4275-b21d-e7bdcb7bb51d" xlink:to="loc_mgnx_RevenuesFromGrantsMember_ce864dd4-ef33-4948-a1db-599bf8255d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_92be48c2-bb1e-4178-8f7d-474b0ca03aeb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_316a996b-e051-4569-bde0-88b5e187425d" xlink:to="loc_srt_CounterpartyNameAxis_92be48c2-bb1e-4178-8f7d-474b0ca03aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c852843-253c-4baa-893e-37583c87a40a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_92be48c2-bb1e-4178-8f7d-474b0ca03aeb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c852843-253c-4baa-893e-37583c87a40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_c9848a73-229e-46a1-a216-752b315196df" xlink:href="mgnx-20220630.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c852843-253c-4baa-893e-37583c87a40a" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_c9848a73-229e-46a1-a216-752b315196df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4434ce72-4d12-48cd-a15e-c971246da984" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_316a996b-e051-4569-bde0-88b5e187425d" xlink:to="loc_srt_RangeAxis_4434ce72-4d12-48cd-a15e-c971246da984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5708fd92-5b25-4822-afc4-44ad4dd0f385" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4434ce72-4d12-48cd-a15e-c971246da984" xlink:to="loc_srt_RangeMember_5708fd92-5b25-4822-afc4-44ad4dd0f385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8d2a9dba-97bb-48db-97be-16d05dd1840a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5708fd92-5b25-4822-afc4-44ad4dd0f385" xlink:to="loc_srt_MaximumMember_8d2a9dba-97bb-48db-97be-16d05dd1840a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d228f63-675f-49ee-91ef-c7de13c68306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_316a996b-e051-4569-bde0-88b5e187425d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d228f63-675f-49ee-91ef-c7de13c68306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_1ff3a011-c2b3-4465-b3bd-0c4ce6bf5a72" xlink:href="mgnx-20220630.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d228f63-675f-49ee-91ef-c7de13c68306" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_1ff3a011-c2b3-4465-b3bd-0c4ce6bf5a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_a2759cf0-d7d6-4f04-80e7-8460069b171a" xlink:href="mgnx-20220630.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d228f63-675f-49ee-91ef-c7de13c68306" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_a2759cf0-d7d6-4f04-80e7-8460069b171a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3d20dcc7-e65e-4b6b-aefe-47a1ef4bfab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d228f63-675f-49ee-91ef-c7de13c68306" xlink:to="loc_us-gaap_Revenues_3d20dcc7-e65e-4b6b-aefe-47a1ef4bfab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mgnx-20220630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5f5233c2-f468-415e-8a09-8b74759b808d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1a66334b-826b-4cb9-8fd0-17e8d4b98470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5f5233c2-f468-415e-8a09-8b74759b808d" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1a66334b-826b-4cb9-8fd0-17e8d4b98470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20220630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cba2a292-2c24-48af-8e4a-10dfe27199d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5a36c1c7-68ab-42eb-8256-7195b788eea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cba2a292-2c24-48af-8e4a-10dfe27199d7" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5a36c1c7-68ab-42eb-8256-7195b788eea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_199ce346-55e9-4c7b-b44f-25df17d10cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cba2a292-2c24-48af-8e4a-10dfe27199d7" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_199ce346-55e9-4c7b-b44f-25df17d10cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_9f1cbbda-56a4-4658-b33f-d5a83dedc9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cba2a292-2c24-48af-8e4a-10dfe27199d7" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_9f1cbbda-56a4-4658-b33f-d5a83dedc9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_9ee58e21-719a-4b94-b1e7-9664786b57cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cba2a292-2c24-48af-8e4a-10dfe27199d7" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_9ee58e21-719a-4b94-b1e7-9664786b57cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d41aade7-95bb-43fd-ae1f-f1193d92b10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bc75b21-ca0a-45d3-9a8f-9384f5999bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d41aade7-95bb-43fd-ae1f-f1193d92b10c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bc75b21-ca0a-45d3-9a8f-9384f5999bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d91b5a78-2957-4986-96a1-2e269a785513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bc75b21-ca0a-45d3-9a8f-9384f5999bed" xlink:to="loc_us-gaap_PlanNameAxis_d91b5a78-2957-4986-96a1-2e269a785513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_33737ef6-a06b-49ec-8da2-55891fb12287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d91b5a78-2957-4986-96a1-2e269a785513" xlink:to="loc_us-gaap_PlanNameDomain_33737ef6-a06b-49ec-8da2-55891fb12287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_e6b443b7-31aa-4eae-a6e2-ba52b3e058e1" xlink:href="mgnx-20220630.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_33737ef6-a06b-49ec-8da2-55891fb12287" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_e6b443b7-31aa-4eae-a6e2-ba52b3e058e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember_28365033-d5e4-42fe-a220-a5c52c8548d7" xlink:href="mgnx-20220630.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_33737ef6-a06b-49ec-8da2-55891fb12287" xlink:to="loc_mgnx_A2003StockIncentivePlanMember_28365033-d5e4-42fe-a220-a5c52c8548d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_0d66fae8-f122-455b-8cdc-c090b5ef406f" xlink:href="mgnx-20220630.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_33737ef6-a06b-49ec-8da2-55891fb12287" xlink:to="loc_mgnx_StockIncentivePlan2013Member_0d66fae8-f122-455b-8cdc-c090b5ef406f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bc75b21-ca0a-45d3-9a8f-9384f5999bed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ea27370b-74d1-4cb9-91ba-f9bf78d82381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ea27370b-74d1-4cb9-91ba-f9bf78d82381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_03b33b11-1106-4249-98b9-75d056c55edc" xlink:href="mgnx-20220630.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_03b33b11-1106-4249-98b9-75d056c55edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_0d482031-3d21-4644-81f0-939d8f8df1d8" xlink:href="mgnx-20220630.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_0d482031-3d21-4644-81f0-939d8f8df1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7247c14d-1ffa-4f41-b344-a94cc10ff18a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7247c14d-1ffa-4f41-b344-a94cc10ff18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_7160b2a8-7810-42e4-b244-4af9f86be7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_7160b2a8-7810-42e4-b244-4af9f86be7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3e0e85d6-2a64-409f-bea8-350afc17d0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3e0e85d6-2a64-409f-bea8-350afc17d0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4b9f0073-8093-4a5b-b464-643ef6fcf029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4b9f0073-8093-4a5b-b464-643ef6fcf029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_ab51198c-6015-4c20-bf15-61d11ca393b3" xlink:href="mgnx-20220630.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_ab51198c-6015-4c20-bf15-61d11ca393b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_88e01434-b441-45bf-907b-6d75fabc4fb5" xlink:href="mgnx-20220630.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6a4c74-78fd-4df1-94cf-545e33098e74" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_88e01434-b441-45bf-907b-6d75fabc4fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f1dfd300-781a-46e6-9ddb-4ed688e3385b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d41aade7-95bb-43fd-ae1f-f1193d92b10c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f1dfd300-781a-46e6-9ddb-4ed688e3385b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0fb2699f-b4d1-4533-9847-c60e29df3ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f1dfd300-781a-46e6-9ddb-4ed688e3385b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0fb2699f-b4d1-4533-9847-c60e29df3ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cd005f8b-5995-40a4-bc3d-27645c3e64b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0fb2699f-b4d1-4533-9847-c60e29df3ae9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cd005f8b-5995-40a4-bc3d-27645c3e64b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_353ff91a-a655-40f1-a2c5-fb5f53e9b29f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cd005f8b-5995-40a4-bc3d-27645c3e64b5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_353ff91a-a655-40f1-a2c5-fb5f53e9b29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4a7f4b3b-e833-4e4f-ab5e-4e52e3810d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cd005f8b-5995-40a4-bc3d-27645c3e64b5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4a7f4b3b-e833-4e4f-ab5e-4e52e3810d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0cc38a46-8de4-4555-9bc8-7b44b4ba029c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f1dfd300-781a-46e6-9ddb-4ed688e3385b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0cc38a46-8de4-4555-9bc8-7b44b4ba029c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_caf31006-c27a-4564-88ef-0dde96a6a5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0cc38a46-8de4-4555-9bc8-7b44b4ba029c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_caf31006-c27a-4564-88ef-0dde96a6a5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#StockBasedCompensationOptionPricingAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_243990fa-1f49-484f-8f6d-581421f6a361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a613367-4905-45c2-885a-dc6941812cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_243990fa-1f49-484f-8f6d-581421f6a361" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a613367-4905-45c2-885a-dc6941812cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_92ffcfe2-52a0-42c9-a558-99975bba66a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a613367-4905-45c2-885a-dc6941812cca" xlink:to="loc_srt_RangeAxis_92ffcfe2-52a0-42c9-a558-99975bba66a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1b512e81-2dba-4003-aae5-9bbcf5304361" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_92ffcfe2-52a0-42c9-a558-99975bba66a6" xlink:to="loc_srt_RangeMember_1b512e81-2dba-4003-aae5-9bbcf5304361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3f40732d-86e3-4f9e-82b5-356472b9b767" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1b512e81-2dba-4003-aae5-9bbcf5304361" xlink:to="loc_srt_MinimumMember_3f40732d-86e3-4f9e-82b5-356472b9b767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_70057a9f-968c-4dd9-89ca-25abccac592c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1b512e81-2dba-4003-aae5-9bbcf5304361" xlink:to="loc_srt_MaximumMember_70057a9f-968c-4dd9-89ca-25abccac592c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03d557c5-08a4-49d8-8347-32dfd2e4d987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a613367-4905-45c2-885a-dc6941812cca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03d557c5-08a4-49d8-8347-32dfd2e4d987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_427db450-18a8-4d58-8d69-57d0597b0c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03d557c5-08a4-49d8-8347-32dfd2e4d987" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_427db450-18a8-4d58-8d69-57d0597b0c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b358001c-e75c-4c07-87c8-c022438ba8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03d557c5-08a4-49d8-8347-32dfd2e4d987" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b358001c-e75c-4c07-87c8-c022438ba8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8e9e59a2-7cee-46c0-b849-f6cb7e727960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03d557c5-08a4-49d8-8347-32dfd2e4d987" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8e9e59a2-7cee-46c0-b849-f6cb7e727960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ccc696d6-77e4-4214-af22-0b9e20865742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03d557c5-08a4-49d8-8347-32dfd2e4d987" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ccc696d6-77e4-4214-af22-0b9e20865742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_187524ea-fa31-4ff1-936e-f0ab8ce686a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03d557c5-08a4-49d8-8347-32dfd2e4d987" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_187524ea-fa31-4ff1-936e-f0ab8ce686a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5cc1c200-36fb-4aec-b760-5ade8bb10f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_49eae75d-ee13-48ee-bcbd-69a90524cff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5cc1c200-36fb-4aec-b760-5ade8bb10f52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_49eae75d-ee13-48ee-bcbd-69a90524cff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_03a31ba2-418d-4412-9a6d-fc0e44025235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_49eae75d-ee13-48ee-bcbd-69a90524cff5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_03a31ba2-418d-4412-9a6d-fc0e44025235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_12455e72-7684-461a-8e7c-e905a3ad2ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_49eae75d-ee13-48ee-bcbd-69a90524cff5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_12455e72-7684-461a-8e7c-e905a3ad2ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2623ee18-2cea-4961-b552-4007c0e983b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_49eae75d-ee13-48ee-bcbd-69a90524cff5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2623ee18-2cea-4961-b552-4007c0e983b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ea421c99-e68d-4099-9e8e-678ebb682933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_49eae75d-ee13-48ee-bcbd-69a90524cff5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ea421c99-e68d-4099-9e8e-678ebb682933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4d33018b-2afe-45f7-a07a-6c630ab75f81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_49eae75d-ee13-48ee-bcbd-69a90524cff5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4d33018b-2afe-45f7-a07a-6c630ab75f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cd554ac4-8bbd-46e6-8a00-fed2024f61b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_49eae75d-ee13-48ee-bcbd-69a90524cff5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cd554ac4-8bbd-46e6-8a00-fed2024f61b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c1ab0bf4-99c4-4b31-bd35-9bd2bf8bf91e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_49eae75d-ee13-48ee-bcbd-69a90524cff5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c1ab0bf4-99c4-4b31-bd35-9bd2bf8bf91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_26ba09ab-5369-4d50-b4ef-079db93f025d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_49eae75d-ee13-48ee-bcbd-69a90524cff5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_26ba09ab-5369-4d50-b4ef-079db93f025d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_336726c5-ece4-4788-a4ee-bec3d6af98f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5cc1c200-36fb-4aec-b760-5ade8bb10f52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_336726c5-ece4-4788-a4ee-bec3d6af98f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_323d9278-92c1-4b60-a8a6-8086755bde73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_336726c5-ece4-4788-a4ee-bec3d6af98f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_323d9278-92c1-4b60-a8a6-8086755bde73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_aa70c683-af68-4906-99c8-9e4e79c1e4da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_336726c5-ece4-4788-a4ee-bec3d6af98f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_aa70c683-af68-4906-99c8-9e4e79c1e4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c6efb730-406e-49b4-9d04-57b41f463468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_336726c5-ece4-4788-a4ee-bec3d6af98f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c6efb730-406e-49b4-9d04-57b41f463468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_10bc3fe0-af59-4b71-9d80-1876352afb46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_336726c5-ece4-4788-a4ee-bec3d6af98f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_10bc3fe0-af59-4b71-9d80-1876352afb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1dccf6fa-e630-4df4-932a-1e67379281bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_336726c5-ece4-4788-a4ee-bec3d6af98f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1dccf6fa-e630-4df4-932a-1e67379281bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2a4e23a3-c56a-43dc-ac7c-028b2ac024af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_336726c5-ece4-4788-a4ee-bec3d6af98f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2a4e23a3-c56a-43dc-ac7c-028b2ac024af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9a34d9bc-c578-4dab-91ad-556d896973ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_336726c5-ece4-4788-a4ee-bec3d6af98f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9a34d9bc-c578-4dab-91ad-556d896973ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_66825319-ff46-42af-b716-15ef58b058fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_336726c5-ece4-4788-a4ee-bec3d6af98f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_66825319-ff46-42af-b716-15ef58b058fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_233f3c59-6805-46b1-8ee8-715e52a41715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5cc1c200-36fb-4aec-b760-5ade8bb10f52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_233f3c59-6805-46b1-8ee8-715e52a41715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d7150842-eca4-42cf-8f26-9741976d89cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_233f3c59-6805-46b1-8ee8-715e52a41715" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d7150842-eca4-42cf-8f26-9741976d89cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_63b0f0d6-1e1f-46bc-bfd8-a46c5cfbab47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_233f3c59-6805-46b1-8ee8-715e52a41715" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_63b0f0d6-1e1f-46bc-bfd8-a46c5cfbab47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_702f899a-875e-4623-aa3d-e4597e708214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_233f3c59-6805-46b1-8ee8-715e52a41715" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_702f899a-875e-4623-aa3d-e4597e708214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a6a4c4cf-720c-4cec-8d82-c863c947ecb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_233f3c59-6805-46b1-8ee8-715e52a41715" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a6a4c4cf-720c-4cec-8d82-c863c947ecb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_e2e652b7-8afb-4d26-860a-c4f7929e24f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_233f3c59-6805-46b1-8ee8-715e52a41715" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_e2e652b7-8afb-4d26-860a-c4f7929e24f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ddf85777-4d41-4e0f-841d-ae4f32cb330a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_233f3c59-6805-46b1-8ee8-715e52a41715" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ddf85777-4d41-4e0f-841d-ae4f32cb330a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f7b32f65-7960-4d6a-8af2-df7c5b4c6149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5cc1c200-36fb-4aec-b760-5ade8bb10f52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f7b32f65-7960-4d6a-8af2-df7c5b4c6149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_387f4b27-1fef-40ab-9b09-50d512255beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5cc1c200-36fb-4aec-b760-5ade8bb10f52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_387f4b27-1fef-40ab-9b09-50d512255beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_a9d54abc-d409-41da-9eb3-4b42f1fc5d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5cc1c200-36fb-4aec-b760-5ade8bb10f52" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_a9d54abc-d409-41da-9eb3-4b42f1fc5d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_76e477e0-d7ba-457a-a446-7849d7907269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5cc1c200-36fb-4aec-b760-5ade8bb10f52" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_76e477e0-d7ba-457a-a446-7849d7907269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_cc076ad3-5511-4ffb-9646-396d712dae0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5cc1c200-36fb-4aec-b760-5ade8bb10f52" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_cc076ad3-5511-4ffb-9646-396d712dae0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_eaf96d69-5faa-4dc1-8194-541c9ad7404f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5cc1c200-36fb-4aec-b760-5ade8bb10f52" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_eaf96d69-5faa-4dc1-8194-541c9ad7404f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20220630.xsd#StockbasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e8f35802-3095-49ef-86d4-924d0ea873b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8adbf58f-88e6-48d5-b171-864e71cdc1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e8f35802-3095-49ef-86d4-924d0ea873b7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8adbf58f-88e6-48d5-b171-864e71cdc1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_56eba306-29b8-4797-a562-97a3b725e607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8adbf58f-88e6-48d5-b171-864e71cdc1f5" xlink:to="loc_us-gaap_AwardTypeAxis_56eba306-29b8-4797-a562-97a3b725e607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2edf89b-4411-4f76-ac7c-891bd591aad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_56eba306-29b8-4797-a562-97a3b725e607" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2edf89b-4411-4f76-ac7c-891bd591aad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_661169c4-1d0b-479d-bda4-f88c23e8d773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2edf89b-4411-4f76-ac7c-891bd591aad3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_661169c4-1d0b-479d-bda4-f88c23e8d773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87da916e-da62-4f78-aa8f-aca8b9a38e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8adbf58f-88e6-48d5-b171-864e71cdc1f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87da916e-da62-4f78-aa8f-aca8b9a38e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3deebef7-1ffd-485e-9e64-899eb3d4ae8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87da916e-da62-4f78-aa8f-aca8b9a38e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3deebef7-1ffd-485e-9e64-899eb3d4ae8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f549eb8b-0b26-4755-b3e6-6a164730c585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3deebef7-1ffd-485e-9e64-899eb3d4ae8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f549eb8b-0b26-4755-b3e6-6a164730c585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8eb703f8-e04d-4f18-8580-12053d861bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3deebef7-1ffd-485e-9e64-899eb3d4ae8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8eb703f8-e04d-4f18-8580-12053d861bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_acc6dd6a-6698-4e14-a352-cb8111389a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3deebef7-1ffd-485e-9e64-899eb3d4ae8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_acc6dd6a-6698-4e14-a352-cb8111389a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_bcb36520-870f-4856-9848-e44b180ffe8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3deebef7-1ffd-485e-9e64-899eb3d4ae8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_bcb36520-870f-4856-9848-e44b180ffe8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3c360ad4-91cc-463e-b24e-08a220f5ce24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3deebef7-1ffd-485e-9e64-899eb3d4ae8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3c360ad4-91cc-463e-b24e-08a220f5ce24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8fa82e97-3be1-4be7-a2c2-091fd62ddc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3deebef7-1ffd-485e-9e64-899eb3d4ae8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8fa82e97-3be1-4be7-a2c2-091fd62ddc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0a3509da-ad45-4a68-b213-55a7b089b683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87da916e-da62-4f78-aa8f-aca8b9a38e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0a3509da-ad45-4a68-b213-55a7b089b683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cc5d9e43-a76c-4f73-ac58-6cf3381940b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0a3509da-ad45-4a68-b213-55a7b089b683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cc5d9e43-a76c-4f73-ac58-6cf3381940b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_90599a69-56f6-4eea-beef-f90956d0e704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0a3509da-ad45-4a68-b213-55a7b089b683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_90599a69-56f6-4eea-beef-f90956d0e704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_71b16296-09af-4628-a7e5-01fd3c652005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0a3509da-ad45-4a68-b213-55a7b089b683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_71b16296-09af-4628-a7e5-01fd3c652005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b24b9438-3389-4999-8923-afe96fa19fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0a3509da-ad45-4a68-b213-55a7b089b683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b24b9438-3389-4999-8923-afe96fa19fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ae6d0b47-7ad3-4d99-b70a-00cbe8ed272b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87da916e-da62-4f78-aa8f-aca8b9a38e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ae6d0b47-7ad3-4d99-b70a-00cbe8ed272b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward_9e657160-4af8-4ebd-baa0-c26059a41912" xlink:href="mgnx-20220630.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87da916e-da62-4f78-aa8f-aca8b9a38e30" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward_9e657160-4af8-4ebd-baa0-c26059a41912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_159043ed-1313-440c-a5ad-608d5f1bc43c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87da916e-da62-4f78-aa8f-aca8b9a38e30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_159043ed-1313-440c-a5ad-608d5f1bc43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_addb151d-bbff-46ec-9cd2-837ce7dd2f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87da916e-da62-4f78-aa8f-aca8b9a38e30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_addb151d-bbff-46ec-9cd2-837ce7dd2f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mgnx-20220630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5d42e93e-6bd3-4d97-8389-18de0fa2edf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d25267a2-5132-4bbf-a4b9-64eb51e88e52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5d42e93e-6bd3-4d97-8389-18de0fa2edf6" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d25267a2-5132-4bbf-a4b9-64eb51e88e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372127024464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1591613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9704 Medical Center Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">251-5172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGNX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,458,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372128804944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 21,469<span></span>
</td>
<td class="nump">$ 123,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Marketable securities</a></td>
<td class="nump">112,271<span></span>
</td>
<td class="nump">120,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">18,385<span></span>
</td>
<td class="nump">10,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">2,949<span></span>
</td>
<td class="nump">4,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">12,559<span></span>
</td>
<td class="nump">21,170<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">167,633<span></span>
</td>
<td class="nump">279,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">34,022<span></span>
</td>
<td class="nump">37,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non current assets</a></td>
<td class="nump">16,388<span></span>
</td>
<td class="nump">18,009<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">218,043<span></span>
</td>
<td class="nump">335,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,609<span></span>
</td>
<td class="nump">15,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">31,763<span></span>
</td>
<td class="nump">33,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">11,565<span></span>
</td>
<td class="nump">20,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">4,940<span></span>
</td>
<td class="nump">4,677<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">50,877<span></span>
</td>
<td class="nump">74,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">6,163<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">18,264<span></span>
</td>
<td class="nump">20,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non current liabilities</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">75,562<span></span>
</td>
<td class="nump">95,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value -- 125,000,000 shares authorized, 61,458,790 and 61,307,428 shares outstanding at June&#160;30, 2022 and December&#160;31, 2021, respectively</a></td>
<td class="nump">615<span></span>
</td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,223,875<span></span>
</td>
<td class="nump">1,213,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(326)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,081,683)<span></span>
</td>
<td class="num">(973,936)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">142,481<span></span>
</td>
<td class="nump">239,618<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 218,043<span></span>
</td>
<td class="nump">$ 335,245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372128294368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">61,458,790<span></span>
</td>
<td class="nump">61,307,428<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372122628576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 26,007<span></span>
</td>
<td class="nump">$ 30,757<span></span>
</td>
<td class="nump">$ 37,108<span></span>
</td>
<td class="nump">$ 47,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CostOfManufacturingServices', window );">Cost of manufacturing services</a></td>
<td class="nump">2,222<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,222<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">51,744<span></span>
</td>
<td class="nump">55,780<span></span>
</td>
<td class="nump">113,182<span></span>
</td>
<td class="nump">108,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">13,669<span></span>
</td>
<td class="nump">15,234<span></span>
</td>
<td class="nump">29,922<span></span>
</td>
<td class="nump">30,270<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">67,815<span></span>
</td>
<td class="nump">71,036<span></span>
</td>
<td class="nump">145,554<span></span>
</td>
<td class="nump">139,210<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(41,808)<span></span>
</td>
<td class="num">(40,279)<span></span>
</td>
<td class="num">(108,446)<span></span>
</td>
<td class="num">(91,572)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">504<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="nump">699<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(41,304)<span></span>
</td>
<td class="num">(39,935)<span></span>
</td>
<td class="num">(107,747)<span></span>
</td>
<td class="num">(91,207)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(265)<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (41,347)<span></span>
</td>
<td class="num">$ (39,945)<span></span>
</td>
<td class="num">$ (108,012)<span></span>
</td>
<td class="num">$ (91,199)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in usd per share)</a></td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="num">$ (1.76)<span></span>
</td>
<td class="num">$ (1.56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in usd per share)</a></td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="num">$ (1.76)<span></span>
</td>
<td class="num">$ (1.56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (in shares)</a></td>
<td class="nump">61,384,943<span></span>
</td>
<td class="nump">60,068,315<span></span>
</td>
<td class="nump">61,354,721<span></span>
</td>
<td class="nump">58,643,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (in shares)</a></td>
<td class="nump">61,384,943<span></span>
</td>
<td class="nump">60,068,315<span></span>
</td>
<td class="nump">61,354,721<span></span>
</td>
<td class="nump">58,643,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember', window );">Collaborative and other agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 16,863<span></span>
</td>
<td class="nump">$ 27,168<span></span>
</td>
<td class="nump">$ 23,956<span></span>
</td>
<td class="nump">$ 42,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">4,672<span></span>
</td>
<td class="nump">3,203<span></span>
</td>
<td class="nump">8,252<span></span>
</td>
<td class="nump">4,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember', window );">Government agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">480<span></span>
</td>
<td class="nump">386<span></span>
</td>
<td class="nump">908<span></span>
</td>
<td class="nump">1,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_ContractManufacturingMember', window );">Contract Manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 3,992<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,992<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CostOfManufacturingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of manufacturing services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CostOfManufacturingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_ContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_ContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372122459312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,244,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 295,884<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">$ 1,067,150<span></span>
</td>
<td class="num">$ (771,821)<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">5,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">2,458<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,622,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">98,200<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">98,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(51,272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,011,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">350,531<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">1,173,013<span></span>
</td>
<td class="num">(823,093)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,244,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">295,884<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">1,067,150<span></span>
</td>
<td class="num">(771,821)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(91,207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,133,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">319,045<span></span>
</td>
<td class="nump">$ 601<span></span>
</td>
<td class="nump">1,181,471<span></span>
</td>
<td class="num">(863,028)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,011,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">350,531<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">1,173,013<span></span>
</td>
<td class="num">(823,093)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">6,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares, Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">2,346<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(39,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,133,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">319,045<span></span>
</td>
<td class="nump">$ 601<span></span>
</td>
<td class="nump">1,181,471<span></span>
</td>
<td class="num">(863,028)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,307,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">239,618<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">1,213,002<span></span>
</td>
<td class="num">(973,936)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">5,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(66,443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,333,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">178,214<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">1,218,263<span></span>
</td>
<td class="num">(1,040,379)<span></span>
</td>
<td class="num">(283)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,307,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 239,618<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">1,213,002<span></span>
</td>
<td class="num">(973,936)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares, Granted (in shares)</a></td>
<td class="nump">2,685,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (107,747)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,458,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">142,481<span></span>
</td>
<td class="nump">$ 615<span></span>
</td>
<td class="nump">1,223,875<span></span>
</td>
<td class="num">(1,081,683)<span></span>
</td>
<td class="num">(326)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,333,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">178,214<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">1,218,263<span></span>
</td>
<td class="num">(1,040,379)<span></span>
</td>
<td class="num">(283)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">5,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares, Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(41,304)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,304)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,458,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 142,481<span></span>
</td>
<td class="nump">$ 615<span></span>
</td>
<td class="nump">$ 1,223,875<span></span>
</td>
<td class="num">$ (1,081,683)<span></span>
</td>
<td class="num">$ (326)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodSharesStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodValueStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=128088960&amp;loc=d3e3913-113898<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126965701&amp;loc=d3e15009-113911<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372122571056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (107,747)<span></span>
</td>
<td class="num">$ (91,207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">5,790<span></span>
</td>
<td class="nump">5,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on marketable securities</a></td>
<td class="nump">628<span></span>
</td>
<td class="nump">808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">10,574<span></span>
</td>
<td class="nump">11,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(7,999)<span></span>
</td>
<td class="num">(22,166)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">362<span></span>
</td>
<td class="num">(6,476)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,611<span></span>
</td>
<td class="num">(974)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other non current assets</a></td>
<td class="nump">1,622<span></span>
</td>
<td class="nump">4,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable</a></td>
<td class="num">(12,896)<span></span>
</td>
<td class="nump">1,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(1,697)<span></span>
</td>
<td class="nump">5,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(2,264)<span></span>
</td>
<td class="num">(1,673)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(2,918)<span></span>
</td>
<td class="nump">18,659<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(106,857)<span></span>
</td>
<td class="num">(74,726)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(75,457)<span></span>
</td>
<td class="num">(117,546)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sale and maturities of marketable securities</a></td>
<td class="nump">82,440<span></span>
</td>
<td class="nump">99,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and software</a></td>
<td class="num">(2,426)<span></span>
</td>
<td class="num">(2,693)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">4,557<span></span>
</td>
<td class="num">(20,439)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">98,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases', window );">Proceeds from stock option exercises and ESPP Purchases</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">4,804<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">103,004<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(102,000)<span></span>
</td>
<td class="nump">7,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">123,469<span></span>
</td>
<td class="nump">181,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">21,469<span></span>
</td>
<td class="nump">188,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property, equipment and software included in accounts payable or accruals</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="nump">$ 1,077<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372128778704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Nature of Operations</a></td>
<td class="text">Nature of Operations<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of the business</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company has a pipeline of product candidates being evaluated in clinical trials sponsored by the Company or its collaborators.  These product candidates include multiple immuno-oncology programs, some of which were created primarily using the Company&#8217;s proprietary, antibody-based technology platforms. The Company believes its product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.  In March 2021, the Company and its commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.  </span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future success of the Company is dependent on its ability to identify and develop its product candidates, and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company&#8217;s stockholders&#8217; equity and working capital, and accordingly, its ability to execute its future operating plans.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings, revenue from its multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases (NIAID).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews the Company&#8217;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#8217;s working capital.   The Company plans to meet its future operating requirements by generating revenue from current and future strategic collaborations or other arrangements, and product sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities.  If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, reduce other operating expenses, and/or downsize its organization. It is considered probable that the Company can successfully implement efforts to manage uncommitted spending and carry out necessary cost saving measures, including from our recently announced corporate restructuring plan. Therefore, based on the Company&#8217;s most recent cash flow forecast, the Company believes its current resources are sufficient to fund its operating plans for a minimum of twelve months from the date that this Quarterly Report on Form 10-Q was filed.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to the Company's business, the COVID-19 pandemic and geopolitical tensions, including the ongoing military conflict between Russia and Ukraine and the related sanctions imposed against Russia, and related global slowdown of economic activity, decades-high inflation, rising interest rates and a potential recession in the United States might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to these uncertainties, the Company will continue to evaluate the nature and extent of the impact of these uncertainties on its business and financial position.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div>The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2021 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 24, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372129377440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, there have been no material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements that were issued or became effective since the issuance of the Company&#8217;s 2021 Annual Report on Form 10-K that had, or are expected to have, a material impact on its consolidated financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372131322080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial Instruments<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between levels during the periods presented. </span></div><div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:15pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,433&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,999&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,348&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,014&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at June&#160;30, 2022 includes approximately $8.2 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2021 includes approximately $23.2 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372131336224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's marketable debt securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,596&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,271&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,208&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All available-for-sale marketable debt securities held as of June&#160;30, 2022 and December&#160;31, 2021 had contractual maturities of less than one year.  All of the Company's available-for-sale marketable debt securities in an unrealized loss position as of June&#160;30, 2022 and December&#160;31, 2021 were in a loss position for less than twelve months.&#160; Unrealized losses on available-for-sale debt securities as of June&#160;30, 2022 and December&#160;31, 2021 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded </span></div>for any periods presented. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372127488464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory, Net</a></td>
<td class="text">Inventory, Net<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's net inventory (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,949&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,388&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>Prior to U.S. Food and Drug Administration (FDA) approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of June&#160;30, 2022 and December&#160;31, 2021 is net of a reserve of  $3.1&#160;million and $2.0&#160;million, respectively, for unsaleable inventory.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372127523808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0 million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. The shares that were sold under the Sales Agreement were issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 4, 2020.  During the six months ended June 30, 2021, the Company sold 3,622,186 shares of common stock at a weighted average price per share of $27.60, resulting in net proceeds of approximately $98.2 million, net of underwriting discounts and commissions and other offering expenses. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increases the amount of the Company&#8217;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $100.0&#160;million to an aggregate offering price of up to $300.0&#160;million.  The Company has not sold any shares of common stock related to Amendment No. 1 to the Sales Agreement as of June&#160;30, 2022.  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the consideration for the rights granted to Zai Lab US LLC under the collaboration and license agreement described more fully in Note 7, Revenue, the Company and Zai Lab US LLC entered into a separate stock purchase agreement (Stock Purchase Agreement) in June 2021.  Under this Stock Purchase Agreement, Zai Lab US LLC paid the Company approximately $30.0 million to purchase 958,467 newly issued shares of the Company's common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372131137072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock', window );">Revenue</a></td>
<td class="text">Revenue <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborative and Other Agreements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte Corporation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte License Agreement</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab.  Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017. In July 2021, Incyte announced that the FDA had issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal. Incyte&#8217;s announcement indicated that the FDA determined that additional data are needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte was reviewing the CRL and would discuss next steps with the FDA. Incyte subsequently withdrew its European application for marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal. Incyte has stated it is pursuing development of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">retifanlimab in potentially registration-enabling studies beyond squamous cell carcinoma of the anal canal, including in patients with MSI-high endometrial cancer, Merkel cell carcinoma and non-small cell lung cancer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline. In April 2022, the Company and Incyte executed an amendment to the Incyte License Agreement to add a milestone for U.S. approval of retifanlimab in a specific indication and to exclude certain other regulatory and development achievements with retifanlimab in this same indication from the milestone events of the Incyte License Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, as amended, Incyte will lead global development of retifanlimab.  Assuming successful development and commercialization by Incyte, the Company could receive up to $435.0 million in development and regulatory milestones and up to $330.0 million in commercial milestones. From the inception of the Incyte License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has recognized $70.0 million in development milestones under the Incyte License Agreement. In July 2022, the Company and Incyte further amended the Incyte License Agreement to reflect changes related to the payment of certain milestones and the Company received $30.0 million in milestone payments from Incyte.  If retifanlimab is approved and commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales.  The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte License Agreement under the provisions of Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606) and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte License Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. From 2018 through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, it became probable that a significant reversal of cumulative revenue would not occur for development milestones totaling $70.0 million related to </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical and regulatory activities related to the further advancement of retifanlimab, including Incyte&#8217;s initiation of a Phase 3 clinical trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Therefore, the associated consideration was added to the estimated transaction price and was recognized as revenue</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $150.0 million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $4.0 million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018. No revenue was recognized under the Incyte License Agreement during the three and  six months ended June 30, 2022.  $5.0&#160;million and $15.0 million in milestone revenue was recognized under the Incyte License Agreement during the three and six months ended June 30, 2021, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Clinical Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into an agreement with Incyte, under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement).  The Company evaluated the Incyte Clinical Supply Agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the manufacturing services.  During the three months ended June 30, 2022 and 2021, the Company recognized revenue of $0.2 million and $0.7 million, respectively, for services performed under the Incyte Clinical Supply Agreement.   During the six months ended June 30, 2022 and 2021, the Company recognized revenue of $0.5 million and $0.8 million, respectively, for services performed under the Incyte Clinical Supply Agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Commercial Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#8217;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated the Incyte Commercial Supply Agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor costs incurred) related to the manufacturing services.  During the three months ended June 30, 2022 and 2021,  the Company recognized $0.3&#160;million and $2.8&#160;million, respectively, for services performed under the Incyte Commercial Supply Agreement.  During the six months ended June 30, 2022 and 2021, the Company recognized $0.3&#160;million and $5.9&#160;million, respectively, for services performed under the Incyte Commercial Supply Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab Limited</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Zai Lab Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab)  under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab, a bispecific DART&#174; molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development of these molecules in its territory.  Zai Lab has informed the Company that they have decided to discontinue development of tebotelimab for indications they were enrolling in their territory and is evaluating future development plans in other indications.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0 million ($22.5 million after netting value-added tax withholdings of $2.5 million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones, of which the Company has earned $9.0 million through June&#160;30, 2022. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2018 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $22.5 million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales </span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.  From 2020 through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, it became probable that a significant reversal of cumulative revenue would not occur for development and regulatory milestones totaling $9.0 million.  Therefore, the associated consideration was added to the estimated transaction price and was recognized as revenue</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Of this </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.0 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.0 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was recognized as revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the six months ended June 30, 2022. During the three and six months ended June 30, 2022, the Company recognized $0.4&#160;million and $5.4&#160;million, respectively, under the 2018 Zai Lab Agreement.  No revenue was recognized during the three and six months ended June 30, 2021 under the 2018 Zai Lab Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zai Lab Clinical Supply Agreements</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements). The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab.  The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing service. During the three months ended June 30, 2022 and 2021, the Company recognized revenue of $0.1 million and $0.5 million, respectively, related to the Zai Lab Clinical Supply Agreements. During the six months ended June 30, 2022 and 2021, the Company recognized revenue of $0.3 million and $1.6 million, respectively, related to the Zai Lab Clinical Supply Agreements. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Zai Lab Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates the Company&#8217;s DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by the Company. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while the Company receives commercial rights in all other territories. Under the Lead Program, Zai Lab received an option upon reaching a predefined clinical milestone to convert the regional arrangement into a global 50/50 profit share. If Zai Lab elects such option, Zai Lab is to pay the Company $85.0&#160;million plus any research costs incurred by both parties as of the option election date. Zai Lab also obtained exclusive, global licenses from the Company to develop, manufacture and commercialize two additional molecules. Zai Lab granted the Company a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to the Company.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Zai Lab Agreement, the Lead Program includes joint research and development services by both the Company and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with the Company to perform research and development services in the future. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0&#160;million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into the Stock Purchase Agreement whereby Zai Lab paid the Company approximately $30.0 million to purchase shares of the Company&#8217;s common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful development and commercialization of the Programs, the Company could receive up to approximately $800.0&#160;million in development and regulatory milestones and $600.0&#160;million in commercial milestones. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of low double digit teens on annual net sales of certain specified products and of mid-single digits to low double digit teens on annual net sales of other specified products in Zai Lab&#8217;s territory, which may be subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, the Company may also receive reimbursements from Zai Lab for certain research and development costs incurred by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#8217;s territory for each Program and (ii) certain research and development activities for the Lead Program. The Company determined that for the Lead Program, the license is not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#8217;s significant expertise in this area and as such, the research and development services are expected to significantly modify and customize the license. Therefore, for the Lead Program, the license and the services were combined into a single performance obligation. Since the other programs each represent distinct intellectual property and there are no other services included in the 2021 Zai Lab Agreement related to these licenses, each license is considered to be a distinct performance obligation. As such, there are four performance obligations included in the 2021 Zai Lab Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the estimated transaction price is $40.4 million, consisting of the $25.0 million upfront payment, the $10.4 million premium related to the purchase of the Company&#8217;s common stock, and the $5.0 million estimated reimbursement by Zai Lab for research and development activities for the Lead Program. The potential milestone payments were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company will re-assess the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $40.4 million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believes a market participant is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#8217;s estimate of the probability of success for each Program. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to the Lead Program license and related research and development services performance obligation is being recognized over time as the research and development activities are performed. The Company will utilize a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in June 2021.  During the three months ended June 30, 2022 and 2021, the Company recognized revenue of $14.7 million and $14.4 million, respectively, under the 2021 Zai Lab Agreement. During the six months ended June 30, 2022 and 2021, the Company recognized revenue of $15.0 million and $14.4 million, respectively, under the 2021 Zai Lab Agreement. As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022, $1.8 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenue was deferred under the agreement, all of which was current. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December&#160;31, 2021, $16.1 million in revenue was deferred, all of which was current.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Biotech, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a research collaboration and license agreement with Janssen Biotech, Inc. (Janssen) to develop a novel DART molecule (Janssen Agreement).  The research collaboration will incorporate the Company&#8217;s proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the Janssen Agreement, Janssen paid the Company an upfront payment of $20.0&#160;million and will be responsible for funding all research and development expenses. The Company will also be eligible to receive up to $312.0&#160;million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales. </span><span style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Janssen an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term. The Company evaluated the Janssen Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i)  a license to develop the preclinical bispecific molecule and (ii) performing certain research and development activities during the research term. The Company determined that the license and research and development activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as Janssen could benefit from the license on its own without the Company&#8217;s involvement during the research term.  The Company determined that the transaction price of the Janssen Agreement at inception was $22.2&#160;million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for research and development activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">considering similar collaboration and license agreements as well as current market conditions. The standalone selling price for agreed-upon research and development activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. This variable consideration is fully constrained until the Company begins its work under the performance obligation.  The potential milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Janssen and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $20.0&#160;million allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Janssen in December 2020. The $2.2&#160;million allocated to the research and development activities is being recognized over the Company&#8217;s involvement in the research term, which is estimated to be less than two years. During the three months ended June 30, 2022 and 2021, the Company recognized revenue of  $0.2 million and $0.6&#160;million, respectively, for research and development activities performed under the Janssen Agreement.  During the six months ended June 30, 2022, and 2021 the Company recognized revenue of $0.6 million and $0.9&#160;million, respectively, for research and development activities performed under the Janssen Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I-Mab Biopharma</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I-Mab License Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab License Agreement).  I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the I-Mab License Agreement, I-Mab paid the Company an upfront payment of $15.0 million.  Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $135.0 million in development and regulatory milestones, of which $5.0&#160;million has been earned from the inception of the I-Mab License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, I-Mab would pay the Company tiered royalties ranging from mid-teens to 20% on annual net sales in I-Mab's territory.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the I-Mab License Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i) an exclusive license to develop and commercialize enoblituzumab in I-Mab&#8217;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $15.0 million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $1.0 million. I-Mab paid the Company for the cost of this study as the costs were incurred and I-Mab received a one-time credit of eighty percent of the total amount of such costs against the milestone achieved during 2021. The Company reassessed the transaction price as it became probable that a significant reversal of cumulative revenue would not occur for a $5.0&#160;million milestone ($4.5&#160;million after netting a one-time credit as described above) related to development progress of enoblituzumab, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue during 2021. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Revenue under the I-Mab License Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations.  During the three months ended June </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30, 2022 and 2021, the Company recognized revenue of $0.6 million and $1.9 million, respectively, under the I-Mab License Agreement. During the six months ended June 30, 2022 and 2021, the Company recognized revenue of $0.7 million and $2.5 million, respectively, under the I-Mab License Agreement. As of June&#160;30, 2022, $3.8 million in revenue was deferred under the I-Mab License Agreement, all of which was current. As of December&#160;31, 2021, $4.5 million in revenue was deferred under the I-Mab License Agreement, all of which was current.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I-Mab Clinical Supply Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into an agreement under which the Company is to perform development and manufacturing services for I-Mab&#8217;s clinical needs of enoblituzumab (I-Mab Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of enoblituzumab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the three and six months ended June 30, 2022, the Company recognized revenue of $0.3&#160;million and $1.1 million, respectively, for research and development activities performed under the I-Mab Clinical Supply Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing Services Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Incyte (Incyte Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Incyte bulk drug substance over a three-year period at one of the Company&#8217;s manufacturing facilities. Under the terms of the Incyte Manufacturing and Clinical Supply Agreement, the Company received an upfront payment of $10.0&#160;million and is eligible to receive annual fixed payments paid quarterly over the term of the contract totaling $14.4&#160;million. The Company will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte Manufacturing and Clinical Supply Agreement under the provisions of ASC 606 and identified one performance obligation to provide manufacturing runs to Incyte, as and when requested by Incyte, over the term of the contract that is part of a series of goods and services. The Company determined that the transaction price at inception consists of the upfront payment received of $10.0&#160;million and the annual fixed payments totaling $14.4&#160;million.   The Company will recognize revenue over time on a straight-line basis as the manufacturing services are provided to Incyte, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Incyte will be allocated to the related manufacturing activities and will be recognized as revenue as those activities occur.  Materials purchased by the Company to manufacture the product for Incyte are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue of $4.0&#160;million under the Incyte Manufacturing and Clinical Supply Agreement during each of the three and six month periods ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.5&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.3&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.2&#160;million </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of which was non-current.  </span></div><div style="margin-bottom:6pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, MGD014 and MGD020 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.</span></div>Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of June&#160;30, 2022 is $25.1&#160;million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in July 2023. During the three months ended June 30, 2022 and 2021, the Company recognized revenue under the NIAID Contract of $0.5 million and $0.4 million, respectively.   During the six months ended June 30, 2022 and 2021, the Company recognized revenue under the NIAID Contract of $0.9 million and $1.2 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372127431968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#8217;s common stock on the last day of the offering period.  During the six months ended June&#160;30, 2022, 65,125 shares of common stock were purchased under the 2016 ESPP.   </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Option Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of June&#160;30, 2022, under the 2003 Plan, there were options to purchase an aggregate of 105,282 shares of common stock outstanding.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&#160;&#160;The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Company's Board of Directors. During the six months ended June&#160;30, 2022, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 15,816,949.&#160;&#160; If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards.  As of June&#160;30, 2022, there were options to purchase an aggregate of 10,395,473 shares of common stock outstanding.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation expense was recognized for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,012&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,571&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,300&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,574&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</span></div><div style="margin-bottom:9pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.8% -89.7%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.2% - 86.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4% - 3.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6% - 1.4%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the six months ended June&#160;30, 2022:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.010%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,373,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,721)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(267,563)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210,079)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,500,755&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of June 30, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,930,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,719,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during the six months ended June&#160;30, 2022 and 2021 was $6.96 and $15.11, respectively. The total intrinsic value of options exercised during the six months ended June&#160;30, 2022 and 2021 was approximately $0.5 million and $1.8 million, respectively.  The total cash received for options exercised during the six months ended June&#160;30, 2022 and 2021 was $0.3 million and $4.6 million, respectively. The total fair value of shares vested in the six months ended June&#160;30, 2022 and 2021 was approximately $9.4 million and $8.1 million, respectively. As of June&#160;30, 2022, the total unrecognized compensation expense related to unvested stock options, net of related forfeiture estimates, was approximately $33.9 million, which the Company expects to recognize over a weighted-average period of approximately 1.5 years.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants restricted stock units (RSUs) under the 2013 Plan to employees from time to time as a component of their compensation. During the six months ended June 30, 2022, the Company awarded RSUs to employees in conjunction with the annual performance review process. Each RSU vests over a two-year period and entitles the holder to receive one share of the Company's common stock when the RSU vests. Compensation expense is recognized on a straight-line basis over the vesting period. </span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the six months ended June&#160;30, 2022:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,465)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,099)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,308&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2022, there was $2.4 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of approximately 1.3 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372127460784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and ContingenciesOn September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland (District Court) by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#8217;s SOPHIA trial. On August 17, 2020, the Employees&#8217; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint. The amended complaint asserts a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020. On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice. On October 28, 2021 the Lead Plaintiff filed a Notice of Appeal.  The appeal is now pending in the Fourth Circuit. The Company intends to vigorously defend against this action. However, the outcome of this legal proceeding is uncertain at this time and the Company cannot reasonably estimate a range of loss, if any. Accordingly, the Company has not accrued any liability associated with this action.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372128185984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div>The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2021 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 24, 2022.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements that were issued or became effective since the issuance of the Company&#8217;s 2021 Annual Report on Form 10-K that had, or are expected to have, a material impact on its consolidated financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div>The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. There were no transfers between levels during the periods presented.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372127606576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Financial Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:15pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,433&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,999&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,348&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,014&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at June&#160;30, 2022 includes approximately $8.2 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2021 includes approximately $23.2 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372127447088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Available-for-sale Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's marketable debt securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,596&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,271&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,208&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372127455760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's net inventory (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,949&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,388&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372129380000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation expense was recognized for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,012&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,571&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,300&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,574&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Valuation Assumptions Using the Black-Scholes Option-Pricing Model</a></td>
<td class="text">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.8% -89.7%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.2% - 86.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4% - 3.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6% - 1.4%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of Stock Options Roll Forward</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the six months ended June&#160;30, 2022:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.010%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,373,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,721)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(267,563)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210,079)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,500,755&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of June 30, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,930,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,719,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text"><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the six months ended June&#160;30, 2022:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,465)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,099)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,308&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372121141680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">$ 112,271<span></span>
</td>
<td class="nump">$ 120,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">8,200<span></span>
</td>
<td class="nump">23,200<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">120,433<span></span>
</td>
<td class="nump">143,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">113,999<span></span>
</td>
<td class="nump">98,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">6,434<span></span>
</td>
<td class="nump">45,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">8,162<span></span>
</td>
<td class="nump">17,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">8,162<span></span>
</td>
<td class="nump">17,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">105,837<span></span>
</td>
<td class="nump">81,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">105,837<span></span>
</td>
<td class="nump">81,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">6,434<span></span>
</td>
<td class="nump">37,280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">$ 6,434<span></span>
</td>
<td class="nump">$ 37,280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372128772576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 112,596,000<span></span>
</td>
<td class="nump">$ 120,208,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(325,000)<span></span>
</td>
<td class="num">(61,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">112,271,000<span></span>
</td>
<td class="nump">120,147,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit loss related to available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">106,147,000<span></span>
</td>
<td class="nump">81,184,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(310,000)<span></span>
</td>
<td class="num">(52,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">105,837,000<span></span>
</td>
<td class="nump">81,132,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,739,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,734,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">6,449,000<span></span>
</td>
<td class="nump">31,285,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 6,434,000<span></span>
</td>
<td class="nump">$ 31,281,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372126998576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">$ 2,231<span></span>
</td>
<td class="nump">$ 3,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">718<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory, net</a></td>
<td class="nump">2,949<span></span>
</td>
<td class="nump">4,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory valuation reserves</a></td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372122479184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold (in shares)</a></td>
<td class="nump">958,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,622,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember', window );">At the Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuance', window );">Maximum amount available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,622,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sales of stock purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease', window );">Maximum amount available for issuance, increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Maximum Amount Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Maximum Amount Available For Issuance, Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372120263744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Incyte Corporation (Details)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1">54 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>performanceObligation</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 26,007,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,757,000<span></span>
</td>
<td class="nump">$ 37,108,000<span></span>
</td>
<td class="nump">$ 47,638,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">11,565,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,565,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,565,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,646,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">6,163,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,163,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,163,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfPerformanceObligations', window );">Number of performance obligations | performanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Variable consideration recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation | Incyte MGA012 Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement', window );">Two Additional Incyte License Agreement Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember', window );">I-Mab | I-Mab Biopharma Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | I-Mab | I-Mab Biopharma Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Clinical activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAgreementsMemberMember', window );">RevenuesFromCMOAgreementsMember | Incyte Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_TotalAnnualFixedPayments', window );">Annual Fixed Payments</a></td>
<td class="nump">$ 14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAgreementsMemberMember', window );">RevenuesFromCMOAgreementsMember | Incyte Corporation | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalAnnualFixedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Annual Fixed Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalAnnualFixedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two Additional Milestone Incyte License Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementClinicalActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementClinicalActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012SupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012SupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAgreementsMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAgreementsMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372125616496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Zai Lab (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 15, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,007<span></span>
</td>
<td class="nump">$ 30,757<span></span>
</td>
<td class="nump">$ 37,108<span></span>
</td>
<td class="nump">$ 47,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,565<span></span>
</td>
<td class="nump">$ 20,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,163<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember', window );">2018 Zai Lab Agreement | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding', window );">Non-refundable upfront payment, net of tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonrefundablePaymentTaxWithholding', window );">Nonrefundable payment tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_MillstoneRevenueRecognized', window );">Millstone Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember', window );">Zai Lab Agreement, Margetuximab | Zai Labs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember', window );">Zai Lab Agreement, TRIDENT molecule | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember', window );">Zai Lab Clinical Supply Agreements | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember', window );">2021 Zai Lab Agreements | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 16,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="nump">$ 14,400<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 14,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OptInFee', window );">Opt-in fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sales of stock purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Variable consideration recognized</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember', window );">2021 Zai Lab Agreements | Zai Labs | Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PremiumReceivedOnStockPurchase', window );">Premium received on stock purchase</a></td>
<td class="nump">$ 10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_MillstoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Millstone Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_MillstoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonrefundablePaymentTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable Payment Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonrefundablePaymentTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable Upfront Fees, Net Of Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OptInFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Opt-in Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OptInFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PremiumReceivedOnStockPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PremiumReceivedOnStockPurchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PremiumReceivedOnStockPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372126772464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Janssen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,007<span></span>
</td>
<td class="nump">$ 30,757<span></span>
</td>
<td class="nump">$ 37,108<span></span>
</td>
<td class="nump">$ 47,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc | Janssen Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales', window );">Potential milestone payments and royalties on product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 312,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Clinical trial activities selling price amount</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc | Janssen Collaboration and License Agreement | Revenues From License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc | Janssen Collaboration and License Agreement | Revenue From Performance of the Research and Development Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payments and Royalties On Product Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372120239280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - I-Mab Biopharma (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 26,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,757<span></span>
</td>
<td class="nump">$ 37,108<span></span>
</td>
<td class="nump">$ 47,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">11,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">6,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember', window );">I-Mab | I-Mab Biopharma Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount', window );">Estimated variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OneTimeMillstoneCredit', window );">One Time Millstone Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember', window );">I-Mab | I-Mab Biopharma Collaboration and License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember', window );">I-Mab | I-Mab Biopharma Collaboration And License Agreement Clinical Supply</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OneTimeMillstoneCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>One Time Millstone Credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OneTimeMillstoneCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Information Used To Assess Variable Consideration, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372125322976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - NIAID Contract (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 15, 2015 </div>
<div>Molecule</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,007<span></span>
</td>
<td class="nump">$ 30,757<span></span>
</td>
<td class="nump">$ 37,108<span></span>
</td>
<td class="nump">$ 47,638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement', window );">Number of commercialized molecules | Molecule</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_TotalPotentialValueUnderAgreement', window );">Total potential value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember', window );">Revenues From Grants | NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalPotentialValueUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalPotentialValueUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372129257216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,373,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price of stock options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="nump">$ 6,070<span></span>
</td>
<td class="nump">$ 10,574<span></span>
</td>
<td class="nump">$ 11,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent', window );">Payroll deduction percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock percent of the fair market value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember', window );">2003 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,816,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,816,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,395,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,395,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance', window );">Potential annual increase in shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan', window );">Potential annual increase in shares reserved for future issuance as percentage of outstanding share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,658<span></span>
</td>
<td class="nump">3,058<span></span>
</td>
<td class="nump">$ 5,050<span></span>
</td>
<td class="nump">5,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,642<span></span>
</td>
<td class="nump">$ 3,012<span></span>
</td>
<td class="nump">$ 5,524<span></span>
</td>
<td class="nump">$ 5,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372126149232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Option Pricing Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 11 months 12 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Expired (in dollars per share)</a></td>
<td class="nump">$ 23.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">87.80%<span></span>
</td>
<td class="nump">86.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">89.70%<span></span>
</td>
<td class="nump">86.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372128954688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Beginning Balance (in shares)</a></td>
<td class="nump">8,373,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares, Granted (in shares)</a></td>
<td class="nump">2,685,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised (in shares)</a></td>
<td class="num">(80,721)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Forfeited or expired (in shares)</a></td>
<td class="num">(267,563)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</a></td>
<td class="num">(210,079)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Ending Balance (in shares)</a></td>
<td class="nump">10,500,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable (in shares)</a></td>
<td class="nump">5,930,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares, Vested and expected to vest (in shares)</a></td>
<td class="nump">9,719,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 21.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Granted (in dollars per share)</a></td>
<td class="nump">9.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercised (in dollars per share)</a></td>
<td class="nump">1.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Forfeited (in dollars per share)</a></td>
<td class="nump">16.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Expired (in dollars per share)</a></td>
<td class="nump">23.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)</a></td>
<td class="nump">18.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercisable (in dollars per share)</a></td>
<td class="nump">22.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term, Outstanding (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Exercisable (in years)</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Vested and expected to vest (in years)</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding, Ending Balance</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">$ 79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 6.96<span></span>
</td>
<td class="nump">$ 15.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received for options exercised</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">9,400<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates</a></td>
<td class="nump">$ 33,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period (in years)</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140372126981120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Restricted Stock Unit Activity (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period (in years)</a></td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">21,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">314,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</a></td>
<td class="num">(8,465)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 26.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="num">(20,099)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">307,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 25.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">10.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited or expired (in dollars per share) | $ / shares</a></td>
<td class="nump">10.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward', window );">Number of shares per employee</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total unrecognized compensation cost | $</a></td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period (in years)</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number Of Shares Received For Each Vested Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>mgnx-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mgnx="http://macrogenics.com/20220630"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgnx-20220630.xsd" xlink:type="simple"/>
    <context id="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic86da2ca86ec48249282e0c8b9afcedb_I20220803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2022-08-03</instant>
        </period>
    </context>
    <context id="i19ba873ecda04a69b9b0b78f7944a57b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i111ca364d8d9452c98412cfc77554d5c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1aa36d71f2554ec7ac421732f1d56211_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1474e19bd49641ca95f1df5b97ffda84_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7c5b5f80fcf64edf9a7ce9cdd569016c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5520922931f84525b041ec1a665396db_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i70f2b39b029e4400ab336e9eb752d124_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if6157a5193cc4e70a8fa23f4827f2dbb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if15ff1812c10442899e2cf54325cbfe9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1b3615a23c9c49bc81b71aa860b0c3fa_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5ca289337e7c4ed690151a7e54c4fc70_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ide2e659901eb4ab195007de738bac04a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7335a3b467a240e1858fea3db99d4a4d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3d787d37774e49e1915ebd2702c26bdb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8d736da8f18d4111a5767bccb6535145_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idebaf5ecdd6c4fea8b83671370499c05_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4d4bdfd68712460f823d1bf125c86b3f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i03eb5525f9b94ed7873d9f8250b3cca6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6975b1f7488c45198ae9150fbe3b8c7b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0c69bb719c3497d90be7f759811e800_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaff1f4fb6ef74e32a52bbd7c4bb14937_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5305ed22a6544700a6decb559d43709a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9409a0811aab41deb09d84f3c21fdd0f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i02e4e511353d4dd8adc8ee7f27200377_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib9193ad0c43c49adb87caf0bb8cc1a6a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia01bbab25f694758af9fdb20e188c211_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id6af280d8c83413794a1f147acb2c7b5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i84633159b9d94cbaba6793f1e6477f84_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i09ff33671d854a77b9d0d807ec309f96_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6c6e7b24f80040eab49e7800603cd599_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1eb8f9dc25b944a7aafb7dd67b63c8eb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id238f32381334840b79f44311e1018c2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i421f9269a5cb42afa04a5399caed4fd6_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia1913ba16a654f48bcf967f37f5fb82a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie08c6695ec9b444685aa4d16e4738d38_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4eccd5582ce54a15822ae39c44fefe89_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2528ec96deee48b9987b5e9d12b2014b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic7860cbece44418a8ff3040d49e386e3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i15f04b0e26d44b449fc94c3e591045a1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7a41dc55370a496293ef975cede85db1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie4e23f5d9b7e42e6af2e22c7b835b9ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i315ea40550944380a8a795ffaf599935_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7d1da529eb6147c8bcc77a537372ae17_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i28c3d485a47347b8a63e5c0279d3d948_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib2bddaadb46348c0b4ffff238bc156b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7f8510121d6c43aa911e2ac76934ed91_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id01dffdb96844c10acb64f346aef127a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4d5a5adb662d4445b57b4f674696d537_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib2ba53e0fd1a4ee8bf3144621333cc43_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idc5b069d236c47748328d17bca6c1d10_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id3b3a5a72fdd4b3da840a570e5af718b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5451c73989d1424e9f9e8846cbf00e5c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4ebb9cbc861e4a39b4be17cc2b7ea234_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i33615ead81b149f3b55531f86d45463c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i705e1bd323d14eb592155589c5b08fec_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5296297226cf40d094b2d74708621179_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4c0b210150ec456fa3744f3cc68cea51_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8484507c9a614dbabce63ba8e51bfce5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idbfc2b733cfd4233983a58b4045191a4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7d08ce914c5c47fd8befe84917164ba8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie06048008ce14472b49e66e78b382b06_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i71939f0c66ac4a5da0b6b7b12b9d9d10_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i88719d0849ae41bd9b947552c67ca2c2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6ef21de7a8c14c07a9a31936ea4dcc72_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4f2cf382a17b4e04bc62223c9662497b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iaee5df7c6fd24644b6271803fce2aae2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3209e333ef1b4efc9f643a26585398bb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7cacffd890924583aaf540298dbf7a8c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i74bfe05c99f446cba0ad613ef542784b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic926423ab3114b2784c30e3020c5be6e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2edf905318ec4cc88d408a7710dfea8b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i412eca49d41d47de87d3a53713b8e50e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia9708b71437741bc98bf41f57791fef6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7c140531ab074f03aea8d010a367b9b3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i232d1bddbda24a9786d7b4e89ec55bfc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if7d4f9b1948e4f9c8fc832ab374f303c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2e22930bedfe4f48b55574f1491fe4b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5c4c855042e4bc586a5317d9125cfe4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1dfffc601f2c44cf829806a11359034d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie88ae8b3089f4d8bbd25cc1cecc99d47_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie8d60276ffc34955ab0ae2df036b1032_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64bbb463b56f459e848a5399c786db9b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad0c041aa4bc458e8e7d118fe4c9e08f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied25e1f92b644194804e5004a17b2d7d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id44b34a1bd494162bed536c9eb0de155_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75ac06ceb7484bb8bd34e4033c4faf19_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19535bf1b5074b99b2df151eb4bc4d31_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5bf3535880a4ceb822d925ba094e608_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib610d63458364b959341d2c275fc3966_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i79d5f7405cf1437c9d2766b6093531d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i250e6d1dd1d14d73a9e40891670e7259_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19fed250b414468dbaf9d90c31a31e26_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iae8184b5fd91450ea18de2dae673882c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifa546adbe93e4c63a396fe25106b66ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i31aa193c0dfc4403bbdb295edc147c6e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia56c7c0c5dd64063ade2d2b387b7f6c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ae83217782a49f581625143e7d04f9d_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="ia6b440df4f4e426d8d698f7cb5f42342_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i99f0316ba50d4c39a9c3d29ef8473c34_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5d0a69ad66bb4c0b8b17295ffe63c014_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i6417b05cf7d64d0bb5cc9aa0b049314b_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia1adbba07b474f27be0bcec58c6f439a_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8862965ac7c74eaa91fbf299dcefad53_I20210615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-15</instant>
        </period>
    </context>
    <context id="ibbbb27e355214928b77e2fc758f95088_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id672cb9284434e3a9202e6f51f077bac_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i00c0c8a5e81842d6ad36655e19d61684_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8b2a073d3c794192a595450d0028cae4_D20180101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i96f7ff3791204451aedc226872ae5fcb_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i5d06233b12574a07a62e6512ccf7e4fb_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i61b3c4379d88468da27af3737a110d8c_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i5c253e1b8d354889a4ce47f6161201e6_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="idf96f2f2d3bb4019aab8b83995fbefb6_D20170101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id33701a0fbcb45c99cf26d0167b17df9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i76d65ceb505a48e1acdee1cd35c24fd7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8427f430b14a43c5a0c839c84cd2fac8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3d2a0a32c3bf4466ba347ecd77c315eb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i252d416a130b4aef83acef014a242473_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i868d68accdbb4b1baea1ef30a6c728af_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie30a746971b840fa954d23a4bd59f89e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6171432917614920af3bc0adaae45923_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib69d294a237f46dbb406c9df90ddc345_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012SupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1434bddbeff34ada94d5f3a35035e034_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012SupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib07fdf3f2fc0440ca7f2e21164cc1d94_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012SupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if65110ca3e22439a98fecb99c1d702d2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012SupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1b2807234912469ba06c538de023e4f5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i27227311568a45f2b51cd61543ae9030_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic8e1dffc03b44a83ab8e292584fd3d5b_D20200701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id5b94f0e0eeb4a01aea4900a9c756dd1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icb889204b9fb4dcc80d0bb9f95f21240_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic6983323f60e4a67818ce6a331b74360_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3fbf626084c549ea9aa5a07ec92ed81d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7c76ddf33fdb445c8361740c1a5a1d36_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i20167305bd354a7886c63d0edbe908a2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icba2317be6d9465d9e494fbbc525bc2c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i55649e5833464f0ca12e4ad111b17c07_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0ca75e3ff4904b2a89f832e75c1ca3da_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iea8d6ea8007a4fedb1d035394ed7db3f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3c3f1cf70f6e49f2a38e855d5b0e46c2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i66ee9789245a4404aaebbe85e877994a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i94bc3a3ceb5941fb8aa911e2ffb733eb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i70ebe69ee2214b73974336b7a5727cc9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iaa61f3996c3c405984b11d51d65bf3ae_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i05e7befa8e9d45b6893dabb2ea11e658_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iae3a758cac9b4c67ac48b3d949bb81ab_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i98ee39cd1bfe4c6fadfe480718e3ef13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8f16bac8141c4383a00685b230199498_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i613268f3651e4fae832a1050b7bc8c75_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i702fa2d64613432cba42480b770b9427_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i460b9af7b2724b7e931ef3fcbb896107_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8c06d5991f5342a9bc4118c142fb5a68_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie6784addc67c4bffab8c458f3a96daaf_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i118a870a47a847ab9a59d307cf7a8dec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ief27732f4ac54730a699b2393bb54497_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibcd59b18a37243bfb09019e459954829_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8c7222aea8cc4fe58941ee0a062a32d5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia7f623bc792547a1a41b06a0787a398e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20c8da099331485ba579926bf66c0d17_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2497d88ae95c4519b39b87d1ba7cdeb7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic969da273e7b44dba3060478dc9568ab_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9e4dca55397644a2849eaef94593433c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i63be51e66fd743578dd0ea8c55b930fc_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9537b5eb6ae949c28d9293e9e3ce85f9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i427113310e024f5eb793d1e86f25cad4_D20220101-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="ic55bd316cd91463e82b7d37fc8a0975a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7ee85754d5014401ad61235f662351ae_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i096d5137725d40148157656180087db8_D20150915-20150915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-15</startDate>
            <endDate>2015-09-15</endDate>
        </period>
    </context>
    <context id="i772a42253ce1405785340b3edb6899da_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib4a0eb4c0fe649c482ed64bbcf0d0b11_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3f9782aefce248e491b1017c418c61ad_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i655cea49e809491ba22491fc3a7a1477_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7d1bdfd0b85f4ac79e062c9afd027395_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5806f140f2fb4121a04208d77d725e5d_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="i0bb8e7382f584403b0bd73897bfafdc4_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="id5c46189a60a4d9e98d6758e10e520b4_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i164a86dfd80c4e50a7e23e302c1c0bf0_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i43fa69d5c22045ddbb94dd1e3a59d966_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:A2003StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i978da7f614aa4ea690dbff8c9356eb6d_I20131031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-10-31</instant>
        </period>
    </context>
    <context id="idf3d70a2fb43424cb1591bef0c3534e4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3d1a4774b1f345f19d161adf566fb6fd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5499db67d8414a0fbbfbf13e986ae6dd_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibb0c8219b14e42c7aad0de17683ccf63_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if743a9b99df64882ac59cc7cf3cb3f2b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i133be2faddae4492b069093a43dfefae_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id2c0a615ad08480184a8698a62ebdc4b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia1253c83d5764ca2869c6ae3052e19ad_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6e41bc1a29374b0f95aa6bf490e51d76_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i39128793661549b8bdf32a8a1cc51c91_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic7ffcf2243504d388387524c69d636c3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i424f99869a384d90912972e1c1b09528_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibd329807983e4f3cb3e69df9ae058545_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id5649fb8ec294f408a306886c4a94ba6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iacfa9386b3a3414bbb61ae3690fcdc16_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1104b4f510e448a6aafaae0d08700a68_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4a101c2276a549c7b6f9656b0b6d6551_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0fd134611cfd4590aae18ff1ca79c965_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="performanceobligation">
        <measure>mgnx:performanceObligation</measure>
    </unit>
    <unit id="molecule">
        <measure>mgnx:Molecule</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80L2ZyYWc6NWI1NzFlNDBjZDE5NDNiYjkxNmMxZjFmYmExN2VlYjYvdGFibGU6YThiZTQ1YzIzMGNjNDkxMTgwMjQyYmUzMThjOWVlNzkvdGFibGVyYW5nZTphOGJlNDVjMjMwY2M0OTExODAyNDJiZTMxOGM5ZWU3OV8yLTEtMS0xLTQ2MzM4_468d7ef4-50b9-49c1-a2bc-15656b57b7ff">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80L2ZyYWc6NWI1NzFlNDBjZDE5NDNiYjkxNmMxZjFmYmExN2VlYjYvdGFibGU6YThiZTQ1YzIzMGNjNDkxMTgwMjQyYmUzMThjOWVlNzkvdGFibGVyYW5nZTphOGJlNDVjMjMwY2M0OTExODAyNDJiZTMxOGM5ZWU3OV80LTEtMS0xLTQ2MzM4_f048a2b3-3031-456f-bd94-dcc17050f18f">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80L2ZyYWc6NWI1NzFlNDBjZDE5NDNiYjkxNmMxZjFmYmExN2VlYjYvdGFibGU6YThiZTQ1YzIzMGNjNDkxMTgwMjQyYmUzMThjOWVlNzkvdGFibGVyYW5nZTphOGJlNDVjMjMwY2M0OTExODAyNDJiZTMxOGM5ZWU3OV81LTEtMS0xLTQ2MzM4_b82b2222-8717-4d3c-a8ba-0c4d7f7a1972">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80L2ZyYWc6NWI1NzFlNDBjZDE5NDNiYjkxNmMxZjFmYmExN2VlYjYvdGV4dHJlZ2lvbjo1YjU3MWU0MGNkMTk0M2JiOTE2YzFmMWZiYTE3ZWViNl8xMzA_dda1eef6-9d56-481f-875b-112ed6a31123">0001125345</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80L2ZyYWc6NWI1NzFlNDBjZDE5NDNiYjkxNmMxZjFmYmExN2VlYjYvdGV4dHJlZ2lvbjo1YjU3MWU0MGNkMTk0M2JiOTE2YzFmMWZiYTE3ZWViNl8xMzI_f362e2bb-45dd-45e1-b11c-a6f2ce89ae3a">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGV4dHJlZ2lvbjphN2VmYTY2ZDMzYzA0NGM0YTUzNDM1NjM4YTY2NzkyNl84Mg_1310d4d9-2340-4362-9c91-cd2096cbe633">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6ZmRkOWMzY2U1NzU2NGYyN2EwMTU5ZjNmYzNjNzliNzIvdGFibGVyYW5nZTpmZGQ5YzNjZTU3NTY0ZjI3YTAxNTlmM2ZjM2M3OWI3Ml8wLTAtMS0xLTQ2MzM4_8f2dccd2-7adb-4958-a3ab-7cff28027a1b">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGV4dHJlZ2lvbjphN2VmYTY2ZDMzYzA0NGM0YTUzNDM1NjM4YTY2NzkyNl8xMTc_c8822f59-1890-4e34-af85-ddc249310c98">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6NzFhN2E0YmJmNDMxNDAyMjgwMzBkNTgwOWRmYWE5YmUvdGFibGVyYW5nZTo3MWE3YTRiYmY0MzE0MDIyODAzMGQ1ODA5ZGZhYTliZV8wLTAtMS0xLTQ2MzM4_3fdcf9ce-9c40-49ac-9cd3-38b30789cbe4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGV4dHJlZ2lvbjphN2VmYTY2ZDMzYzA0NGM0YTUzNDM1NjM4YTY2NzkyNl8yMDg_a404f032-c559-441d-ae1f-aa1037c877ea">001-36112</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGV4dHJlZ2lvbjphN2VmYTY2ZDMzYzA0NGM0YTUzNDM1NjM4YTY2NzkyNl8yMTE_103320ad-fa36-4537-ab22-45c0e53fc11d">MACROGENICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6Y2YyZjM4NjAxZmYxNDc0OGE0MjAzMTYwZmI1ZThkMTUvdGFibGVyYW5nZTpjZjJmMzg2MDFmZjE0NzQ4YTQyMDMxNjBmYjVlOGQxNV8wLTAtMS0xLTQ2MzM4_ad9799d9-39f2-4508-9044-ee4b303e0d8c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6Y2YyZjM4NjAxZmYxNDc0OGE0MjAzMTYwZmI1ZThkMTUvdGFibGVyYW5nZTpjZjJmMzg2MDFmZjE0NzQ4YTQyMDMxNjBmYjVlOGQxNV8wLTEtMS0xLTQ2MzM4_96517f0f-bdd8-4ce9-9915-fac6240ab2c2">06-1591613</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6Y2YyZjM4NjAxZmYxNDc0OGE0MjAzMTYwZmI1ZThkMTUvdGFibGVyYW5nZTpjZjJmMzg2MDFmZjE0NzQ4YTQyMDMxNjBmYjVlOGQxNV8zLTAtMS0xLTQ2MzM4L3RleHRyZWdpb246NGI3M2FmMWQ2NzU5NDNlZWIzZTBmOTczZDQ3ZmE0Y2ZfNQ_36636e0d-6904-4828-8fa8-a7b4701c21be">9704 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6Y2YyZjM4NjAxZmYxNDc0OGE0MjAzMTYwZmI1ZThkMTUvdGFibGVyYW5nZTpjZjJmMzg2MDFmZjE0NzQ4YTQyMDMxNjBmYjVlOGQxNV8zLTAtMS0xLTQ2MzM4L3RleHRyZWdpb246NGI3M2FmMWQ2NzU5NDNlZWIzZTBmOTczZDQ3ZmE0Y2ZfOA_26e02701-8f7d-4c50-ab15-3e16661acbfe">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6Y2YyZjM4NjAxZmYxNDc0OGE0MjAzMTYwZmI1ZThkMTUvdGFibGVyYW5nZTpjZjJmMzg2MDFmZjE0NzQ4YTQyMDMxNjBmYjVlOGQxNV8zLTAtMS0xLTQ2MzM4L3RleHRyZWdpb246NGI3M2FmMWQ2NzU5NDNlZWIzZTBmOTczZDQ3ZmE0Y2ZfMTI_4301dde7-d345-440e-8a45-bced3fc0c839">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6Y2YyZjM4NjAxZmYxNDc0OGE0MjAzMTYwZmI1ZThkMTUvdGFibGVyYW5nZTpjZjJmMzg2MDFmZjE0NzQ4YTQyMDMxNjBmYjVlOGQxNV8zLTEtMS0xLTQ2MzM4_9758677b-8a41-4fc9-a839-1901cc711e87">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGV4dHJlZ2lvbjphN2VmYTY2ZDMzYzA0NGM0YTUzNDM1NjM4YTY2NzkyNl8yNzA_ce00e72c-1d49-4834-bc46-aabbab472816">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGV4dHJlZ2lvbjphN2VmYTY2ZDMzYzA0NGM0YTUzNDM1NjM4YTY2NzkyNl8yNzM_e3948d22-65d1-433f-b7ba-15720c8305fe">251-5172</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6MjBiMDFlYzExMWY3NDdkMWEyY2MwNjY1OWJhNWRlOTkvdGFibGVyYW5nZToyMGIwMWVjMTExZjc0N2QxYTJjYzA2NjU5YmE1ZGU5OV8xLTAtMS0xLTQ2MzM4_840ac799-ee87-425c-af4f-857a41238d76">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6MjBiMDFlYzExMWY3NDdkMWEyY2MwNjY1OWJhNWRlOTkvdGFibGVyYW5nZToyMGIwMWVjMTExZjc0N2QxYTJjYzA2NjU5YmE1ZGU5OV8xLTEtMS0xLTQ2MzM4_496ddbf6-f680-44d0-8a7e-228d079c157c">MGNX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6MjBiMDFlYzExMWY3NDdkMWEyY2MwNjY1OWJhNWRlOTkvdGFibGVyYW5nZToyMGIwMWVjMTExZjc0N2QxYTJjYzA2NjU5YmE1ZGU5OV8xLTItMS0xLTQ2MzM4_ee52d341-e802-4323-8a21-7c2a313c2b3e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGV4dHJlZ2lvbjphN2VmYTY2ZDMzYzA0NGM0YTUzNDM1NjM4YTY2NzkyNl8xOTE3_5309a683-6290-40e4-a47d-aa17d4df3a9f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGV4dHJlZ2lvbjphN2VmYTY2ZDMzYzA0NGM0YTUzNDM1NjM4YTY2NzkyNl8xOTE1_b8c85808-13de-479d-adf6-5d302040ce7a">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6NzM5YjAyNzUwMjI2NDdjNzlhMDc5ZGM3NDhmZWZjYWYvdGFibGVyYW5nZTo3MzliMDI3NTAyMjY0N2M3OWEwNzlkYzc0OGZlZmNhZl8wLTAtMS0xLTQ2MzM4_3f80b6fe-cc9d-4f4f-a84e-42259f78d498">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6NzM5YjAyNzUwMjI2NDdjNzlhMDc5ZGM3NDhmZWZjYWYvdGFibGVyYW5nZTo3MzliMDI3NTAyMjY0N2M3OWEwNzlkYzc0OGZlZmNhZl8yLTMtMS0xLTQ2MzM4_a17ca926-7690-4ecf-b15a-66e5dcb1ffa6">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGFibGU6NzM5YjAyNzUwMjI2NDdjNzlhMDc5ZGM3NDhmZWZjYWYvdGFibGVyYW5nZTo3MzliMDI3NTAyMjY0N2M3OWEwNzlkYzc0OGZlZmNhZl80LTEtMS0xLTQ2MzM4_3106c86d-7047-486f-b262-77dc85597840">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGV4dHJlZ2lvbjphN2VmYTY2ZDMzYzA0NGM0YTUzNDM1NjM4YTY2NzkyNl8xOTE2_a47a48de-03f3-4ff9-b831-4d337c113bd0">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ic86da2ca86ec48249282e0c8b9afcedb_I20220803"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xL2ZyYWc6YTdlZmE2NmQzM2MwNDRjNGE1MzQzNTYzOGE2Njc5MjYvdGV4dHJlZ2lvbjphN2VmYTY2ZDMzYzA0NGM0YTUzNDM1NjM4YTY2NzkyNl8xODI4_e2d7041a-424d-4a96-8c5b-5abe61c59d67"
      unitRef="shares">61458790</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfNC0xLTEtMS00NjMzOA_65b04186-e803-4372-b126-a718ea3c9677"
      unitRef="usd">21469000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfNC0zLTEtMS00NjMzOA_34e9748f-464b-46f1-9c7d-1f47d6e7d436"
      unitRef="usd">123469000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Investments
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfNS0xLTEtMS00NjMzOA_e3558d0d-b695-400e-8954-f998ee818a10"
      unitRef="usd">112271000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfNS0zLTEtMS00NjMzOA_7e4979ac-016a-4fb8-8216-9e6c3ac78d58"
      unitRef="usd">120147000</us-gaap:Investments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfNi0xLTEtMS00NjMzOA_88821d5e-e8a7-4d0c-96e9-dc5da56e0359"
      unitRef="usd">18385000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfNi0zLTEtMS00NjMzOA_5ae277bc-0487-416f-9517-2c1a4c9bd7a3"
      unitRef="usd">10386000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfNy0xLTEtMS00NjMzOA_35d96bba-23aa-466e-84c3-bd1041e516b6"
      unitRef="usd">2949000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfNy0zLTEtMS00NjMzOA_1b12d84d-b966-4904-9f6f-130b875d688a"
      unitRef="usd">4388000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfOC0xLTEtMS00NjMzOA_6a287449-c1aa-4771-9e85-02446eaa731b"
      unitRef="usd">12559000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfOC0zLTEtMS00NjMzOA_e36d706b-f615-435f-afaf-47bc564e8112"
      unitRef="usd">21170000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTAtMS0xLTEtNDYzMzg_a6524dc4-16bc-4357-acab-ce5978d8b7b0"
      unitRef="usd">167633000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTAtMy0xLTEtNDYzMzg_e5261b62-5fdd-44bd-bb14-d1ab13136ee0"
      unitRef="usd">279560000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTEtMS0xLTEtNDYzMzg_9c126235-ab8d-476c-ba52-a6cf24e61fe1"
      unitRef="usd">34022000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTEtMy0xLTEtNDYzMzg_fb506c84-a25e-42f7-b7c9-d76a2d798cfa"
      unitRef="usd">37676000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTMtMS0xLTEtNDYzMzg_a020a7b5-a68d-4010-b93f-8762d3398351"
      unitRef="usd">16388000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTMtMy0xLTEtNDYzMzg_b93f78f9-659c-482d-b4e9-5c6997d25992"
      unitRef="usd">18009000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTQtMS0xLTEtNDYzMzg_951d132f-e925-4d4f-9c79-b05007c576cd"
      unitRef="usd">218043000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTQtMy0xLTEtNDYzMzg_21f604c6-13e3-412d-bdc8-17617601bc74"
      unitRef="usd">335245000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTgtMS0xLTEtNDYzMzg_2f91c9c6-f85c-4943-b83a-c2053ed785dd"
      unitRef="usd">2609000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTgtMy0xLTEtNDYzMzg_03b5d3a3-05c5-48e2-940d-a8a42b513e1d"
      unitRef="usd">15500000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTktMS0xLTEtNDYzMzg_1f71d94b-c626-4a66-98a0-2f63c6fc4730"
      unitRef="usd">31763000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMTktMy0xLTEtNDYzMzg_90b8cdee-5459-411a-a0d7-38c53e0bf482"
      unitRef="usd">33755000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjAtMS0xLTEtNDYzMzg_7268d3e5-e150-4888-a51d-3b2ccae200c8"
      unitRef="usd">11565000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjAtMy0xLTEtNDYzMzg_6c1291e3-99bd-4d24-8e88-ee331cc66cf2"
      unitRef="usd">20646000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjEtMS0xLTEtNDYzMzg_45b57871-7ca8-4630-8042-bc5e988a72ab"
      unitRef="usd">4940000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjEtMy0xLTEtNDYzMzg_dbb489a2-e435-4165-acec-63d0db7e0a96"
      unitRef="usd">4677000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjMtMS0xLTEtNDYzMzg_4a5ef22e-ce69-464f-8444-aa84a7ae38f1"
      unitRef="usd">50877000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjMtMy0xLTEtNDYzMzg_3b239871-5309-41df-962b-d1d481512546"
      unitRef="usd">74578000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjQtMS0xLTEtNDYzMzg_be11d5c5-29dc-47f8-b586-beba9ff51c05"
      unitRef="usd">6163000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjQtMy0xLTEtNDYzMzg_d890e641-807e-43f6-9c7c-8a066d19bee4"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjUtMS0xLTEtNDYzMzg_183305dc-58fe-47d8-913f-377af2a769db"
      unitRef="usd">18264000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjUtMy0xLTEtNDYzMzg_d6bbf29b-e4d4-4830-b8d9-710cbbb0e0c8"
      unitRef="usd">20791000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjYtMS0xLTEtNDYzMzg_1e3aa09c-d70a-4a74-a660-89b33abcc477"
      unitRef="usd">258000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjYtMy0xLTEtNDYzMzg_8f541a53-4eaf-41c0-b9a9-c3fa045d17f6"
      unitRef="usd">258000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjctMS0xLTEtNDYzMzg_96bb88a8-6141-4a08-81ab-966c408329aa"
      unitRef="usd">75562000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjctMy0xLTEtNDYzMzg_66963f2a-e941-4373-bd19-e095feeca133"
      unitRef="usd">95627000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjktMC0xLTEtNDYzMzgvdGV4dHJlZ2lvbjpjYmU3Y2EzZWNiNDA0ZmFiYjJiOWYxMmMwNTk5ZDAzZF8xOA_277b6099-cb74-4a7c-8f3b-0a3e7e1aaad3"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjktMC0xLTEtNDYzMzgvdGV4dHJlZ2lvbjpjYmU3Y2EzZWNiNDA0ZmFiYjJiOWYxMmMwNTk5ZDAzZF8xOA_9396ead0-5846-46cb-a5dc-532c57c81f64"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjktMC0xLTEtNDYzMzgvdGV4dHJlZ2lvbjpjYmU3Y2EzZWNiNDA0ZmFiYjJiOWYxMmMwNTk5ZDAzZF8zNA_d9151642-c4aa-407d-8672-781322b0c1ec"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjktMC0xLTEtNDYzMzgvdGV4dHJlZ2lvbjpjYmU3Y2EzZWNiNDA0ZmFiYjJiOWYxMmMwNTk5ZDAzZF8zNA_fcfe45e1-e4c5-44cc-abed-bc476f98f087"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjktMC0xLTEtNDYzMzgvdGV4dHJlZ2lvbjpjYmU3Y2EzZWNiNDA0ZmFiYjJiOWYxMmMwNTk5ZDAzZF81Ng_99074007-bb9d-4ead-977e-82ef0280ef6f"
      unitRef="shares">61458790</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjktMC0xLTEtNDYzMzgvdGV4dHJlZ2lvbjpjYmU3Y2EzZWNiNDA0ZmFiYjJiOWYxMmMwNTk5ZDAzZF82Mw_a5e49d7d-daa1-4265-971d-661e4e753453"
      unitRef="shares">61307428</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjktMS0xLTEtNDYzMzg_afe67535-82b3-4fdc-98ea-4eb846dbc9b8"
      unitRef="usd">615000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMjktMy0xLTEtNDYzMzg_7b53442f-09aa-44d3-931d-2faa07b91c9c"
      unitRef="usd">613000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMzAtMS0xLTEtNDYzMzg_10e2365f-e6c5-492c-8aa3-be6a65e03b11"
      unitRef="usd">1223875000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMzAtMy0xLTEtNDYzMzg_07c0e3f3-2909-44ee-96f5-75a0ea96a9d4"
      unitRef="usd">1213002000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMzEtMS0xLTEtNDYzMzg_d37e1372-0569-49dd-8319-02a7ae0f7a13"
      unitRef="usd">-326000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMzEtMy0xLTEtNDYzMzg_8b44290c-1a6c-4b69-8a06-8098229a203d"
      unitRef="usd">-61000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMzItMS0xLTEtNDYzMzg_231d5b18-857b-4d27-b5ec-41b38a3b8f95"
      unitRef="usd">-1081683000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMzItMy0xLTEtNDYzMzg_d16b849c-0bce-4de9-9454-0c2ad052c76c"
      unitRef="usd">-973936000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMzMtMS0xLTEtNDYzMzg_cbfe408b-c2e0-442d-8596-78cf68ceae00"
      unitRef="usd">142481000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMzMtMy0xLTEtNDYzMzg_96e856ef-fcfc-41de-b31d-f12e4294267f"
      unitRef="usd">239618000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMzQtMS0xLTEtNDYzMzg_e8c79946-3e40-483a-8243-a8cd8bc61e7d"
      unitRef="usd">218043000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8xOS9mcmFnOjdjZGUxNTEwZWY0ZDRhMmFiYzMxOThkYzI4NGY4ZmI0L3RhYmxlOjI4OWZiMjU5YmE2ZDRjYmJiYjFkM2RjZGM3OWYzNTY4L3RhYmxlcmFuZ2U6Mjg5ZmIyNTliYTZkNGNiYmJiMWQzZGNkYzc5ZjM1NjhfMzQtMy0xLTEtNDYzMzg_a7382893-c3f6-4808-9ca1-06a55c52e152"
      unitRef="usd">335245000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i1aa36d71f2554ec7ac421732f1d56211_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMy0xLTEtMS00NjMzOA_3c6b7c68-f4ce-467b-af96-4e4c62257b3b"
      unitRef="usd">16863000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1474e19bd49641ca95f1df5b97ffda84_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMy0zLTEtMS00NjMzOA_faf0a04b-0298-446a-92d6-4450ef5944ab"
      unitRef="usd">27168000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7c5b5f80fcf64edf9a7ce9cdd569016c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMy01LTEtMS00NjMzOA_f3d87405-f1a5-4bfa-ae7e-57c97018c56c"
      unitRef="usd">23956000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5520922931f84525b041ec1a665396db_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMy03LTEtMS00NjMzOA_0a96bf69-454f-48ef-ac5f-0d8c9d6c009e"
      unitRef="usd">42352000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i70f2b39b029e4400ab336e9eb752d124_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNC0xLTEtMS00NjMzOA_94401956-be3e-46ef-bb2e-ba2345c07d8c"
      unitRef="usd">4672000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if6157a5193cc4e70a8fa23f4827f2dbb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNC0zLTEtMS00NjMzOA_4d043f07-5903-424f-81a3-f4bdc92b5043"
      unitRef="usd">3203000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if15ff1812c10442899e2cf54325cbfe9_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNC01LTEtMS00NjMzOA_55e5050b-a8d3-4c2c-9f28-e412746c01c2"
      unitRef="usd">8252000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1b3615a23c9c49bc81b71aa860b0c3fa_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNC03LTEtMS00NjMzOA_5bd8fec9-7be5-4c44-b1b7-5223f1aff821"
      unitRef="usd">4090000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5ca289337e7c4ed690151a7e54c4fc70_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNS0xLTEtMS00NzY3MA_6a457ccd-38d9-42ce-a06d-57e5c8dfbf31"
      unitRef="usd">3992000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide2e659901eb4ab195007de738bac04a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNS0zLTEtMS00NzY3Nw_67b24d5d-758d-4408-b22e-a59173028b04"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7335a3b467a240e1858fea3db99d4a4d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNS01LTEtMS00NzY4NA_33fa4f66-8d7b-4344-bb34-f95536df869f"
      unitRef="usd">3992000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d787d37774e49e1915ebd2702c26bdb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNS03LTEtMS00NzY5MQ_29097958-9d33-4594-ae7c-b6a206ddfb56"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8d736da8f18d4111a5767bccb6535145_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNS0xLTEtMS00NjMzOA_86bebe78-f53c-4459-b02e-bc66e0923568"
      unitRef="usd">480000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idebaf5ecdd6c4fea8b83671370499c05_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNS0zLTEtMS00NjMzOA_50a35b06-6005-4ab8-9671-4328b0e1177c"
      unitRef="usd">386000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4d4bdfd68712460f823d1bf125c86b3f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNS01LTEtMS00NjMzOA_6bbb0bd3-9405-426b-a46d-1ce04908e7c0"
      unitRef="usd">908000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03eb5525f9b94ed7873d9f8250b3cca6_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNS03LTEtMS00NjMzOA_b3641e14-1c1e-491d-939c-447f98c7470a"
      unitRef="usd">1196000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNi0xLTEtMS00NjMzOA_b198e8ec-2fee-4a75-a799-47df3e66b049"
      unitRef="usd">26007000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNi0zLTEtMS00NjMzOA_bbbb8bcd-691c-4ad2-a6a2-fcf7d9be00a2"
      unitRef="usd">30757000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNi01LTEtMS00NjMzOA_414d4af0-322f-438f-8fe4-8a91929ca505"
      unitRef="usd">37108000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfNi03LTEtMS00NjMzOA_1c9d8a9f-ac6b-43dd-a89b-1a62be7fc64f"
      unitRef="usd">47638000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfOC0xLTEtMS00NjMzOA_26bbc01b-1a75-4c10-8a38-243f927b2510"
      unitRef="usd">180000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfOC0zLTEtMS00NjMzOA_ebfe5ca1-6959-41f3-944c-4bed82ee7de5"
      unitRef="usd">22000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfOC01LTEtMS00NjMzOA_73829530-84f0-48f2-acee-192becc8b087"
      unitRef="usd">228000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfOC03LTEtMS00NjMzOA_08c8d1a7-b4e1-4f79-b6b0-4843322149a7"
      unitRef="usd">39000</us-gaap:CostOfGoodsAndServicesSold>
    <mgnx:CostOfManufacturingServices
      contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTAtMS0xLTEtNDg5MTk_2321441d-a7cc-460c-912d-05cb66a6850e"
      unitRef="usd">2222000</mgnx:CostOfManufacturingServices>
    <mgnx:CostOfManufacturingServices
      contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTAtMy0xLTEtNDg4NjE_7d2a3d0b-5db5-4da2-ab6c-7db58281ce75"
      unitRef="usd">0</mgnx:CostOfManufacturingServices>
    <mgnx:CostOfManufacturingServices
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTAtNS0xLTEtNDg5MjY_301f7ba9-9438-48bb-9587-d91d4da6e26e"
      unitRef="usd">2222000</mgnx:CostOfManufacturingServices>
    <mgnx:CostOfManufacturingServices
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTAtNy0xLTEtNDg4Njg_21caaeee-3ef5-4703-9c8d-d5755c7530dc"
      unitRef="usd">0</mgnx:CostOfManufacturingServices>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfOS0xLTEtMS00NjMzOA_e12bf92f-033b-4eb7-bd12-a924565f46cc"
      unitRef="usd">51744000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfOS0zLTEtMS00NjMzOA_2ca593d2-9dae-4afe-909f-011ff21e0c96"
      unitRef="usd">55780000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfOS01LTEtMS00NjMzOA_001aeb49-7acb-41cd-9861-5225e9bda07a"
      unitRef="usd">113182000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfOS03LTEtMS00NjMzOA_1073845a-4eda-4b64-b0b0-862dd16a9438"
      unitRef="usd">108901000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTAtMS0xLTEtNDYzMzg_5dd235d6-fda9-45be-bdac-2a65a8abb4dc"
      unitRef="usd">13669000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTAtMy0xLTEtNDYzMzg_eddb83e2-8dc5-46be-9992-9f8fd73f53f9"
      unitRef="usd">15234000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTAtNS0xLTEtNDYzMzg_fde2ab81-b08a-44af-b973-e91d7b7c519b"
      unitRef="usd">29922000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTAtNy0xLTEtNDYzMzg_4adaeb34-0391-4346-8d5f-b10f9dccc232"
      unitRef="usd">30270000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTEtMS0xLTEtNDYzMzg_80ce15cd-7f7d-4f23-a161-17266fbad26c"
      unitRef="usd">67815000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTEtMy0xLTEtNDYzMzg_a700a42d-af91-4f0f-be6d-8014caf818b3"
      unitRef="usd">71036000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTEtNS0xLTEtNDYzMzg_21f1a69b-40b0-45bb-b963-0a7fbe68e004"
      unitRef="usd">145554000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTEtNy0xLTEtNDYzMzg_35e5fabe-8893-40fc-9e9b-04a9fbdacbe4"
      unitRef="usd">139210000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTItMS0xLTEtNDYzMzg_63ec869a-650d-4688-83df-cd5f837fac97"
      unitRef="usd">-41808000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTItMy0xLTEtNDYzMzg_d966b3de-ea80-478f-9fad-cc33b89c32c3"
      unitRef="usd">-40279000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTItNS0xLTEtNDYzMzg_29bae111-bf5c-4075-86bb-4c2950640bce"
      unitRef="usd">-108446000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTItNy0xLTEtNDYzMzg_684b6f56-4f76-4d93-b226-5e53c008f8dd"
      unitRef="usd">-91572000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTMtMS0xLTEtNDYzMzg_b52fa179-7591-44a7-938b-8fd615b1e68e"
      unitRef="usd">504000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTMtMy0xLTEtNDYzMzg_da44ca30-4988-4cd5-8647-c0de4269eb65"
      unitRef="usd">344000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTMtNS0xLTEtNDYzMzg_aa728027-6fd5-4099-8350-f7ac4ea84247"
      unitRef="usd">699000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTMtNy0xLTEtNDYzMzg_cb751312-13bf-4876-aa1d-949ea745e61c"
      unitRef="usd">365000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTQtMS0xLTEtNDYzMzg_6455e493-4243-4bed-8148-20a9d24abf89"
      unitRef="usd">-41304000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTQtMy0xLTEtNDYzMzg_72b0f0c3-9b4c-4913-8acd-d32590bbf537"
      unitRef="usd">-39935000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTQtNS0xLTEtNDYzMzg_e4df569d-ced5-450e-be4a-685382ae1f74"
      unitRef="usd">-107747000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTQtNy0xLTEtNDYzMzg_ebe5022a-ccff-4201-af34-9ab2a7234b28"
      unitRef="usd">-91207000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTYtMS0xLTEtNDYzMzg_4662572e-3511-4bbe-be82-d8d0288cd494"
      unitRef="usd">-43000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTYtMy0xLTEtNDYzMzg_a20203aa-b929-4591-8da5-b6077d0ccb4b"
      unitRef="usd">-10000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTYtNS0xLTEtNDYzMzg_ebf18ff9-be1a-4501-b3fa-a63a9ba24ebf"
      unitRef="usd">-265000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTYtNy0xLTEtNDYzMzg_d9ca0614-7324-4c40-878b-a09eaab27fd6"
      unitRef="usd">8000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTctMS0xLTEtNDYzMzg_5e0aca22-e9db-4080-ab0d-882e29442d1f"
      unitRef="usd">-41347000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTctMy0xLTEtNDYzMzg_b22599c1-8d61-404e-859a-536270f3c88b"
      unitRef="usd">-39945000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTctNS0xLTEtNDYzMzg_c98c431e-f137-4169-ac4a-34f36e22e21d"
      unitRef="usd">-108012000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTctNy0xLTEtNDYzMzg_7eb6c9c8-a11d-4a2c-8204-e3f0c4497bab"
      unitRef="usd">-91199000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTktMS0xLTEtNDYzMzg_0999c159-2dc5-45fc-882e-ce10876c4f5a"
      unitRef="usdPerShare">-0.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTktMS0xLTEtNDYzMzg_c0f11a93-a1f9-4eeb-a7e7-96a976c584f0"
      unitRef="usdPerShare">-0.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTktMy0xLTEtNDYzMzg_6f93673a-dcb1-43f2-ac11-6d6b3e8424b7"
      unitRef="usdPerShare">-0.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTktMy0xLTEtNDYzMzg_a596322c-4e0b-485b-8ae5-445f40db5c68"
      unitRef="usdPerShare">-0.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTktNS0xLTEtNDYzMzg_a038e543-375b-4d5c-be13-a389074eae30"
      unitRef="usdPerShare">-1.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTktNS0xLTEtNDYzMzg_e4e96c58-43dc-48f5-b820-6276ef40b117"
      unitRef="usdPerShare">-1.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTktNy0xLTEtNDYzMzg_4acf468c-249e-40d7-ba04-2b0e0dc0626a"
      unitRef="usdPerShare">-1.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMTktNy0xLTEtNDYzMzg_ac63542d-352c-42de-9fce-f3f8e7b2ffa7"
      unitRef="usdPerShare">-1.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMjAtMS0xLTEtNDYzMzg_6c819133-30b6-468d-b7c6-5900a861aa36"
      unitRef="shares">61384943</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMjAtMS0xLTEtNDYzMzg_9c44e4a4-fd2d-4791-bd24-e1b423775ba2"
      unitRef="shares">61384943</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMjAtMy0xLTEtNDYzMzg_46479fff-02d5-4a87-824b-aec52e2ad78d"
      unitRef="shares">60068315</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMjAtMy0xLTEtNDYzMzg_9e9ad83e-78f5-472d-8dce-c9ec8ff25ae4"
      unitRef="shares">60068315</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMjAtNS0xLTEtNDYzMzg_0528b377-01fe-4413-9232-47b8fbaaeb73"
      unitRef="shares">61354721</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMjAtNS0xLTEtNDYzMzg_b0b6b442-50c2-4e9a-bbb2-4e293d5169eb"
      unitRef="shares">61354721</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMjAtNy0xLTEtNDYzMzg_a3407051-af21-4573-baa5-5f1d4212ec84"
      unitRef="shares">58643496</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yMi9mcmFnOjUyNjZiMTAxYmVmYjQ5OTI5MzM5MDU3MTkzZjk4M2JmL3RhYmxlOjI3ZTUzYWM4YmM2NDRmM2I4MmFmMzBlMzIxOWUzNWU4L3RhYmxlcmFuZ2U6MjdlNTNhYzhiYzY0NGYzYjgyYWYzMGUzMjE5ZTM1ZThfMjAtNy0xLTEtNDYzMzg_c87ef2f1-82ef-440f-8ace-239c2d0607df"
      unitRef="shares">58643496</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesIssued
      contextRef="i6975b1f7488c45198ae9150fbe3b8c7b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMi0xLTEtMS00NjMzOA_e1cba271-f88a-41c3-96a4-68f66c08cff8"
      unitRef="shares">61307428</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6975b1f7488c45198ae9150fbe3b8c7b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMi0zLTEtMS00NjMzOA_54834788-ce19-427f-b7f8-26233f789e16"
      unitRef="usd">613000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic0c69bb719c3497d90be7f759811e800_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMi05LTEtMS00NjMzOA_6d491f36-7d38-4052-98b0-7ee779d40db7"
      unitRef="usd">1213002000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaff1f4fb6ef74e32a52bbd7c4bb14937_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMi0xMS0xLTEtNDYzMzg_c2e12ba6-0fe8-475c-95fc-e248cc677520"
      unitRef="usd">-973936000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5305ed22a6544700a6decb559d43709a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMi0xMy0xLTEtNDYzMzg_3e0f843c-50e7-4bf6-b9d1-42b40cb9710c"
      unitRef="usd">-61000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMi0xNS0xLTEtNDYzMzg_9f8cf8b7-0738-4c4c-aaee-64009d07b867"
      unitRef="usd">239618000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9409a0811aab41deb09d84f3c21fdd0f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMy05LTEtMS00NjMzOA_d6e8c439-2859-4043-aa2e-276537b68e77"
      unitRef="usd">5224000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i02e4e511353d4dd8adc8ee7f27200377_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMy0xNS0xLTEtNDYzMzg_bd267a44-6a59-43f9-b552-c48d1825a314"
      unitRef="usd">5224000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="ib9193ad0c43c49adb87caf0bb8cc1a6a_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfNS0xLTEtMS00NjMzOA_db1b9826-f818-4dff-ab55-8ef5215f26b7"
      unitRef="shares">25646</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i9409a0811aab41deb09d84f3c21fdd0f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfNS05LTEtMS00NjMzOA_a245b256-3dea-44e0-9f98-2d7ebcaa5549"
      unitRef="usd">37000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i02e4e511353d4dd8adc8ee7f27200377_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfNS0xNS0xLTEtNDYzMzg_d5aa40d7-99f5-4300-af02-5c3f0b41917e"
      unitRef="usd">37000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ia01bbab25f694758af9fdb20e188c211_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfNi0xMy0xLTEtNDYzMzg_a59337ba-260d-478b-9b8d-ad7f1ebbabfe"
      unitRef="usd">-222000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i02e4e511353d4dd8adc8ee7f27200377_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfNi0xNS0xLTEtNDYzMzg_2b9d1e79-bce5-4f6d-9576-69c5e781c31f"
      unitRef="usd">-222000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="id6af280d8c83413794a1f147acb2c7b5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfNy0xMS0xLTEtNDYzMzg_516c4cd3-3277-4a6e-9219-d4ab909a1a28"
      unitRef="usd">-66443000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i02e4e511353d4dd8adc8ee7f27200377_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfNy0xNS0xLTEtNDYzMzg_5699ef13-71da-4666-ac8e-07dc0d187a10"
      unitRef="usd">-66443000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i84633159b9d94cbaba6793f1e6477f84_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfOC0xLTEtMS00NjMzOA_d34c75a2-4f77-49b9-92c2-e46dabf997f1"
      unitRef="shares">61333074</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i84633159b9d94cbaba6793f1e6477f84_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfOC0zLTEtMS00NjMzOA_9ca469e8-337a-4d60-9ac9-bbc8d4ab0150"
      unitRef="usd">613000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i09ff33671d854a77b9d0d807ec309f96_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfOC05LTEtMS00NjMzOA_d937f7b7-69bf-42c0-a6d6-9d1aa2973da2"
      unitRef="usd">1218263000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6c6e7b24f80040eab49e7800603cd599_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfOC0xMS0xLTEtNDYzMzg_2c1774e1-f0d0-4002-874e-56f5ddd5ebe0"
      unitRef="usd">-1040379000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1eb8f9dc25b944a7aafb7dd67b63c8eb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfOC0xMy0xLTEtNDYzMzg_72f82d4f-950c-4135-8a7f-1f42d53823fe"
      unitRef="usd">-283000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id238f32381334840b79f44311e1018c2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfOC0xNS0xLTEtNDYzMzg_050e93b4-0dde-42fc-988e-56e003833f20"
      unitRef="usd">178214000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i421f9269a5cb42afa04a5399caed4fd6_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfOS05LTEtMS00NjMzOA_3f1ffd3e-0449-44e4-a74e-0ee421ce14f1"
      unitRef="usd">5350000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfOS0xNS0xLTEtNDYzMzg_4a3fa00f-8732-49f4-9eff-93b54ff2f1d3"
      unitRef="usd">5350000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ia1913ba16a654f48bcf967f37f5fb82a_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTAtMS0xLTEtNDYzMzg_ce49b1c6-02e5-48e9-bce6-806a2a04f883"
      unitRef="shares">125716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="ia1913ba16a654f48bcf967f37f5fb82a_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTAtMy0xLTEtNDYzMzg_c121a679-d6da-455e-8118-4d1709b4a2df"
      unitRef="usd">2000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i421f9269a5cb42afa04a5399caed4fd6_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTAtOS0xLTEtNDYzMzg_104e2705-d810-4bb4-ba94-7f7263456bde"
      unitRef="usd">262000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTAtMTUtMS0xLTQ2MzM4_04648101-c7cb-45bd-921d-a044a6805941"
      unitRef="usd">264000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ie08c6695ec9b444685aa4d16e4738d38_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTEtMTMtMS0xLTQ2MzM4_39b26de3-291e-407a-b43c-6f43505aa32e"
      unitRef="usd">-43000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTEtMTUtMS0xLTQ2MzM4_6b74218b-8839-4728-a80a-6f93a3b155cf"
      unitRef="usd">-43000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i4eccd5582ce54a15822ae39c44fefe89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTItMTEtMS0xLTQ2MzM4_1fb7c134-a726-462d-b941-30d0539b72e2"
      unitRef="usd">-41304000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTItMTUtMS0xLTQ2MzM4_7c86aa44-517c-46ec-afdd-caf70e2c5e44"
      unitRef="usd">-41304000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i2528ec96deee48b9987b5e9d12b2014b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTMtMS0xLTEtNDYzMzg_0af9feb8-354a-40c0-a33d-f715743d87af"
      unitRef="shares">61458790</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2528ec96deee48b9987b5e9d12b2014b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTMtMy0xLTEtNDYzMzg_38fff79d-6fa0-4574-9a9c-39ffeaad2a57"
      unitRef="usd">615000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic7860cbece44418a8ff3040d49e386e3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTMtOS0xLTEtNDYzMzg_a803006b-73f5-4bbc-8faa-ee68c7d3bf35"
      unitRef="usd">1223875000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i15f04b0e26d44b449fc94c3e591045a1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTMtMTEtMS0xLTQ2MzM4_e2b35fa7-f9b5-42bc-b423-79ff909f46d7"
      unitRef="usd">-1081683000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7a41dc55370a496293ef975cede85db1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTMtMTMtMS0xLTQ2MzM4_e4df4d67-7f55-4740-b238-06fed943e6ef"
      unitRef="usd">-326000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOjc0NDFjYTk3OTdjZTRkYzM5M2IxZTZhMWRkN2MyYzY4L3RhYmxlcmFuZ2U6NzQ0MWNhOTc5N2NlNGRjMzkzYjFlNmExZGQ3YzJjNjhfMTMtMTUtMS0xLTQ2MzM4_b94f598e-48ed-49e9-b3f8-27aea3107354"
      unitRef="usd">142481000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ie4e23f5d9b7e42e6af2e22c7b835b9ef_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMi0xLTEtMS00NjMzOA_bac1ac86-1464-4dc8-88db-adcaf25b8f6c"
      unitRef="shares">56244771</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie4e23f5d9b7e42e6af2e22c7b835b9ef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMi0zLTEtMS00NjMzOA_8c6bba0d-93ed-4092-9d82-f7d57f322e1b"
      unitRef="usd">562000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i315ea40550944380a8a795ffaf599935_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMi05LTEtMS00NjMzOA_777e2415-ba51-4c13-bf0e-ad2a8ed08a2b"
      unitRef="usd">1067150000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7d1da529eb6147c8bcc77a537372ae17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMi0xMS0xLTEtNDYzMzg_3f4d52a2-7343-45ce-8ac8-ed67e75ae918"
      unitRef="usd">-771821000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i28c3d485a47347b8a63e5c0279d3d948_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMi0xMy0xLTEtNDYzMzg_23b51ab3-5291-415b-b1d0-7aa3c916dbee"
      unitRef="usd">-7000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib2bddaadb46348c0b4ffff238bc156b4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMi0xNS0xLTEtNDYzMzg_9abe92c1-700f-400a-b371-bf739fae0a1f"
      unitRef="usd">295884000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7f8510121d6c43aa911e2ac76934ed91_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMy05LTEtMS00NjMzOA_7083759e-5d7b-49cf-b4a5-a0e900f8d134"
      unitRef="usd">5243000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id01dffdb96844c10acb64f346aef127a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMy0xNS0xLTEtNDYzMzg_c7f7187a-85dc-4561-9838-045e88ac5288"
      unitRef="usd">5243000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i4d5a5adb662d4445b57b4f674696d537_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNC0xLTEtMS00NjMzOA_1df0b446-013c-4749-b61c-f822fda7f8c7"
      unitRef="shares">3622186</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4d5a5adb662d4445b57b4f674696d537_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNC0zLTEtMS00NjMzOA_863a83f4-bb24-4c55-b71b-94cc7c70d95e"
      unitRef="usd">36000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7f8510121d6c43aa911e2ac76934ed91_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNC05LTEtMS00NjMzOA_2c7e9896-a522-4d2e-a254-4b997e0db422"
      unitRef="usd">98164000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id01dffdb96844c10acb64f346aef127a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNC0xNS0xLTEtNDYzMzg_e9d21300-d1d7-41b3-bf73-8a20f94651c0"
      unitRef="usd">98200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="i4d5a5adb662d4445b57b4f674696d537_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNS0xLTEtMS00NjMzOA_e7f1dca7-6319-4e09-930a-0f0a0eff2bd7"
      unitRef="shares">144249</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i4d5a5adb662d4445b57b4f674696d537_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNS0zLTEtMS00NjMzOA_333f86fe-2187-4bc4-9806-8d0a0c6eb9ff"
      unitRef="usd">2000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i7f8510121d6c43aa911e2ac76934ed91_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNS05LTEtMS00NjMzOA_0c66b768-69e5-4d1c-b90e-cae8cb06529a"
      unitRef="usd">2456000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="id01dffdb96844c10acb64f346aef127a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNS0xNS0xLTEtNDYzMzg_0eddb424-7f38-4ecf-bf0c-6c5a2674bfdb"
      unitRef="usd">2458000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ib2ba53e0fd1a4ee8bf3144621333cc43_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNi0xMy0xLTEtNDYzMzg_5f52ed42-51a8-4ed8-9ba5-cfb38c2aef1f"
      unitRef="usd">18000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="id01dffdb96844c10acb64f346aef127a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNi0xNS0xLTEtNDYzMzg_84bfcabb-e38c-4d15-bb97-1e241ef93947"
      unitRef="usd">18000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="idc5b069d236c47748328d17bca6c1d10_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNy0xMS0xLTEtNDYzMzg_2bde6926-c29b-4a2e-8a75-75101a677f04"
      unitRef="usd">-51272000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id01dffdb96844c10acb64f346aef127a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfNy0xNS0xLTEtNDYzMzg_2d91f96a-8d96-42d0-908b-4e71514062c7"
      unitRef="usd">-51272000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="id3b3a5a72fdd4b3da840a570e5af718b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfOC0xLTEtMS00NjMzOA_584b1938-460b-4382-b00d-77409e00a4a2"
      unitRef="shares">60011206</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id3b3a5a72fdd4b3da840a570e5af718b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfOC0zLTEtMS00NjMzOA_f2f74a71-b00f-4a6b-9cf2-96da2ac344a2"
      unitRef="usd">600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5451c73989d1424e9f9e8846cbf00e5c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfOC05LTEtMS00NjMzOA_58fd71b8-48cc-4931-bc1f-19e2a24d0722"
      unitRef="usd">1173013000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4ebb9cbc861e4a39b4be17cc2b7ea234_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfOC0xMS0xLTEtNDYzMzg_ef3c6ebd-1277-4f2e-94ae-88693c4fe002"
      unitRef="usd">-823093000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i33615ead81b149f3b55531f86d45463c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfOC0xMy0xLTEtNDYzMzg_e7e66a92-8cef-4f85-8dd9-eb231b1d8c05"
      unitRef="usd">11000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i705e1bd323d14eb592155589c5b08fec_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfOC0xNS0xLTEtNDYzMzg_cbb66890-7c89-4ba1-a149-1fe912b81cb1"
      unitRef="usd">350531000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5296297226cf40d094b2d74708621179_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfOS05LTEtMS00NjMzOA_26ef0176-52d4-4f32-a0bf-e21aab90da16"
      unitRef="usd">6113000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfOS0xNS0xLTEtNDYzMzg_a0f9c07f-9c3e-4781-9929-3d9744bf1ba3"
      unitRef="usd">6113000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i4c0b210150ec456fa3744f3cc68cea51_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTEtMS0xLTEtNDYzMzg_273d509b-dcb2-42be-ae3e-e6783c7b314a"
      unitRef="shares">122241</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i4c0b210150ec456fa3744f3cc68cea51_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTEtMy0xLTEtNDYzMzg_b3391e70-71e8-45ac-8eb2-2ea88b15800c"
      unitRef="usd">1000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i5296297226cf40d094b2d74708621179_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTEtOS0xLTEtNDYzMzg_a0d3129b-942b-4b84-85d2-4c23ae9a32ee"
      unitRef="usd">2345000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTEtMTUtMS0xLTQ2MzM4_1c7d4a8c-d62f-48d4-b59e-c55cc4639eb2"
      unitRef="usd">2346000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i8484507c9a614dbabce63ba8e51bfce5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTItMTMtMS0xLTQ2MzM4_9e0f85c0-85c6-4624-a3fe-a4a94c57d7e4"
      unitRef="usd">-10000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTItMTUtMS0xLTQ2MzM4_c24c86ea-4ac9-4776-8db1-edb57356cdff"
      unitRef="usd">-10000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="idbfc2b733cfd4233983a58b4045191a4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTMtMTEtMS0xLTQ2MzM4_c1445376-b0f6-42d8-b7a0-e384990577b9"
      unitRef="usd">-39935000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTMtMTUtMS0xLTQ2MzM4_6d2131b5-44a0-40e4-a2b4-9bdfe23cfdc4"
      unitRef="usd">-39935000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i7d08ce914c5c47fd8befe84917164ba8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTQtMS0xLTEtNDYzMzg_d9b2e37c-1f9f-4d00-8308-a577df3ec57f"
      unitRef="shares">60133447</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7d08ce914c5c47fd8befe84917164ba8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTQtMy0xLTEtNDYzMzg_1bb910d1-4421-42f2-9796-01adda63cf13"
      unitRef="usd">601000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie06048008ce14472b49e66e78b382b06_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTQtOS0xLTEtNDYzMzg_2295cbaa-6e2b-474a-a6e3-be96c77ad5cf"
      unitRef="usd">1181471000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i71939f0c66ac4a5da0b6b7b12b9d9d10_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTQtMTEtMS0xLTQ2MzM4_8d9893b2-1561-4070-992a-2e53429e4310"
      unitRef="usd">-863028000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i88719d0849ae41bd9b947552c67ca2c2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTQtMTMtMS0xLTQ2MzM4_9a1dd26f-bcd6-4582-8889-f52ac96aaf46"
      unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6ef21de7a8c14c07a9a31936ea4dcc72_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yNS9mcmFnOjQ1ZjU3OGEzYzMwNjQyYjY4Y2FjNjQwOTVmNTczYzQ0L3RhYmxlOmM2NGNmNTA5NDRjYzQ2NjJiMDZiM2IxZjc5YWVjOTc5L3RhYmxlcmFuZ2U6YzY0Y2Y1MDk0NGNjNDY2MmIwNmIzYjFmNzlhZWM5NzlfMTQtMTUtMS0xLTQ2MzM4_3e565114-9d11-4004-a239-893e6661932f"
      unitRef="usd">319045000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMy0xLTEtMS00NjMzOA_fa27f00b-ac9a-4a9a-a8ff-42aa46c4f2d6"
      unitRef="usd">-107747000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMy0zLTEtMS00NjMzOA_2c21cf79-409f-4b4c-8f0d-5c063752887f"
      unitRef="usd">-91207000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfNS0xLTEtMS00NjMzOA_a4c567b5-34da-404b-9cb7-2c076c8374dc"
      unitRef="usd">5790000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfNS0zLTEtMS00NjMzOA_b4390d9e-074f-4955-8e6f-0d96c4d381f2"
      unitRef="usd">5510000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfNi0xLTEtMS00NjMzOA_4d9e3948-925f-4290-84fa-cd51f1fd9323"
      unitRef="usd">-628000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfNi0zLTEtMS00NjMzOA_1be72ba7-3af2-441a-ab29-e7118de1210a"
      unitRef="usd">-808000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfNy0xLTEtMS00NjMzOA_416f9860-47a8-41a0-b721-518709414bde"
      unitRef="usd">10574000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfNy0zLTEtMS00NjMzOA_bc9e301d-3ee2-4ecf-ac18-34db32034f9b"
      unitRef="usd">11356000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfOS0xLTEtMS00ODk1OQ_54b75062-1c41-42cc-a861-0e9975b38726"
      unitRef="usd">-1077000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfOS0zLTEtMS00ODk2Mw_fcb58b34-441e-4ac4-a782-70ee9cc85c4b"
      unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTAtMS0xLTEtNDYzMzg_e7f74467-0633-4666-a8e3-eaa9a3a0ea82"
      unitRef="usd">7999000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTAtMy0xLTEtNDYzMzg_8decb833-5808-4030-be7d-cdd5948ded7b"
      unitRef="usd">22166000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTEtMS0xLTEtNDYzMzg_9acbb54a-c3fb-4787-be35-1915b3639939"
      unitRef="usd">-362000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTEtMy0xLTEtNDYzMzg_f20f98b1-c687-466d-8722-6469890bf1e9"
      unitRef="usd">6476000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTItMS0xLTEtNDYzMzg_8ca9afe5-8365-4d55-96df-a628185ef8d4"
      unitRef="usd">-8611000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTItMy0xLTEtNDYzMzg_ecf20fa5-3ad6-471e-8e74-3fa3bdacf709"
      unitRef="usd">974000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTMtMS0xLTEtNDYzMzg_f17ce1bc-4029-4091-9815-003252aa6008"
      unitRef="usd">-1622000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTMtMy0xLTEtNDYzMzg_2114a806-1662-4cbc-9733-69dc1ba24937"
      unitRef="usd">-4404000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTQtMS0xLTEtNDYzMzg_0d429979-6439-4ea8-8651-95fc684af0f7"
      unitRef="usd">-12896000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTQtMy0xLTEtNDYzMzg_1fb3bbd1-6d8a-4aff-b7f0-54f99c5f0bbc"
      unitRef="usd">1668000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTUtMS0xLTEtNDYzMzg_baeddc22-98d2-4515-b212-213bfe7072e4"
      unitRef="usd">-1697000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTUtMy0xLTEtNDYzMzg_4cb1b6de-1f07-4d50-80d0-06c931b67a54"
      unitRef="usd">5365000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTYtMS0xLTEtNDYzMzg_81087d9d-814f-4190-820a-75fdc17c1219"
      unitRef="usd">-2264000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTYtMy0xLTEtNDYzMzg_887a59ed-27dd-4117-8d06-30e223dd7039"
      unitRef="usd">-1673000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTctMS0xLTEtNDYzMzg_f6ec885c-8154-474f-9900-6789021f5a76"
      unitRef="usd">-2918000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTctMy0xLTEtNDYzMzg_1c671772-75d9-449a-8dd4-06eb03722088"
      unitRef="usd">18659000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTktMS0xLTEtNDYzMzg_f9ddf948-89bc-4287-a391-65709452d39e"
      unitRef="usd">-106857000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMTktMy0xLTEtNDYzMzg_bf006fb2-473c-4a0a-ae3f-872d637cdbf6"
      unitRef="usd">-74726000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjEtMS0xLTEtNDYzMzg_ee2f16df-6382-4f26-bf0c-b210d1a88a8f"
      unitRef="usd">75457000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjEtMy0xLTEtNDYzMzg_6d500778-3b08-4713-80e3-a45cf68be1ed"
      unitRef="usd">117546000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjItMS0xLTEtNDYzMzg_e3a156a7-7ce0-415c-a87d-bd7be5e18053"
      unitRef="usd">82440000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjItMy0xLTEtNDYzMzg_20492185-ac09-4e2a-a14e-97d26d1084f3"
      unitRef="usd">99800000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjMtMS0xLTEtNDYzMzg_64b957e8-2387-4849-bb9e-c87ec4ed444e"
      unitRef="usd">2426000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjMtMy0xLTEtNDYzMzg_dfda879e-f31f-456d-9631-3621f2e42b27"
      unitRef="usd">2693000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjQtMS0xLTEtNDYzMzg_17a84a3b-817d-4e4d-a40d-bfcfd585643d"
      unitRef="usd">4557000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjQtMy0xLTEtNDYzMzg_703e5100-0d58-48dd-ae4a-2172b7dcb809"
      unitRef="usd">-20439000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjYtMS0xLTEtNDYzMzg_e04e559c-a1d2-4c71-b5a9-ced7d2ef316d"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjYtMy0xLTEtNDYzMzg_3bb419a5-69df-4cd4-bf5e-f3d4d6eab88f"
      unitRef="usd">98200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjctMS0xLTEtNDYzMzg_293914da-6252-438a-b8ec-e41559979e78"
      unitRef="usd">300000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjctMy0xLTEtNDYzMzg_f0bd9d80-59ff-41b3-ab0a-ff8f52a3a9be"
      unitRef="usd">4804000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjktMS0xLTEtNDYzMzg_eb8e84a3-87c0-4699-ba59-f707352a8976"
      unitRef="usd">300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMjktMy0xLTEtNDYzMzg_29524fe5-65a2-4d27-8682-3c63982216f2"
      unitRef="usd">103004000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMzAtMS0xLTEtNDYzMzg_a2149d1b-4c4a-405d-b997-cbd975644a76"
      unitRef="usd">-102000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMzAtMy0xLTEtNDYzMzg_2f485143-9717-4175-a6f6-5b375aa563fd"
      unitRef="usd">7839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMzEtMS0xLTEtNDYzMzg_c9412291-2859-4b68-9e19-dd24f9ef1013"
      unitRef="usd">123469000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib2bddaadb46348c0b4ffff238bc156b4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMzEtMy0xLTEtNDYzMzg_d1d6c83c-6dca-4e3a-add8-5c1fb1b25b9c"
      unitRef="usd">181131000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMzItMS0xLTEtNDYzMzg_6786cb00-fba7-453d-b6f8-006665ed259f"
      unitRef="usd">21469000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6ef21de7a8c14c07a9a31936ea4dcc72_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMzItMy0xLTEtNDYzMzg_e02cbb32-f440-4740-a89f-96868ae8fb22"
      unitRef="usd">188970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMzUtMS0xLTEtNDYzMzg_96afb170-1199-4d3e-a495-9e99314a6df2"
      unitRef="usd">295000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8yOC9mcmFnOjQ0MWY3YTQwYjMxYjQ2Y2FhNWYyY2MzZDM1MzYyNjkzL3RhYmxlOjA3NjZmOGVmMGRhOTQxNjNhOTEwZGNhNjE5MTFjZDRjL3RhYmxlcmFuZ2U6MDc2NmY4ZWYwZGE5NDE2M2E5MTBkY2E2MTkxMWNkNGNfMzUtMy0xLTEtNDYzMzg_c73a089e-833c-4cb2-84bc-cdb1de795def"
      unitRef="usd">118000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8zNC9mcmFnOmUzOGJkZWM2MTkyYjRkOWY4NGNhYmFiNzEyOTlhNmFkL3RleHRyZWdpb246ZTM4YmRlYzYxOTJiNGQ5Zjg0Y2FiYWI3MTI5OWE2YWRfNDc0OA_5f32166f-f12e-44d2-a765-7b38519a5f39">Nature of Operations&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of the business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company has a pipeline of product candidates being evaluated in clinical trials sponsored by the Company or its collaborators.  These product candidates include multiple immuno-oncology programs, some of which were created primarily using the Company&#x2019;s proprietary, antibody-based technology platforms. The Company believes its product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.  In March 2021, the Company and its commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future success of the Company is dependent on its ability to identify and develop its product candidates, and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company&#x2019;s stockholders&#x2019; equity and working capital, and accordingly, its ability to execute its future operating plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings, revenue from its multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases (NIAID).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management regularly reviews the Company&#x2019;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#x2019;s working capital.   The Company plans to meet its future operating requirements by generating revenue from current and future strategic collaborations or other arrangements, and product sales.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities.  If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, reduce other operating expenses, and/or downsize its organization. It is considered probable that the Company can successfully implement efforts to manage uncommitted spending and carry out necessary cost saving measures, including from our recently announced corporate restructuring plan. Therefore, based on the Company&#x2019;s most recent cash flow forecast, the Company believes its current resources are sufficient to fund its operating plans for a minimum of twelve months from the date that this Quarterly Report on Form 10-Q was filed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Similar to the other risk factors pertinent to the Company's business, the COVID-19 pandemic and geopolitical tensions, including the ongoing military conflict between Russia and Ukraine and the related sanctions imposed against Russia, and related global slowdown of economic activity, decades-high inflation, rising interest rates and a potential recession in the United States might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to these uncertainties, the Company will continue to evaluate the nature and extent of the impact of these uncertainties on its business and financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2021 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 24, 2022.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8zNC9mcmFnOmUzOGJkZWM2MTkyYjRkOWY4NGNhYmFiNzEyOTlhNmFkL3RleHRyZWdpb246ZTM4YmRlYzYxOTJiNGQ5Zjg0Y2FiYWI3MTI5OWE2YWRfNDc0Nw_14c11a22-fd72-4a89-ae15-425b87d00d29">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2021 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 24, 2022.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8zNy9mcmFnOmEwNGM0ZWU0ODVhZDRlNTM4NGY0NDIzYjhmMDEwMGJhL3RleHRyZWdpb246YTA0YzRlZTQ4NWFkNGU1Mzg0ZjQ0MjNiOGYwMTAwYmFfNTQy_7de62a48-f43a-47af-b4a9-d5de6e1d77bc">Summary of Significant Accounting Policies&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June 30, 2022, there have been no material changes to the significant accounting policies previously disclosed in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements that were issued or became effective since the issuance of the Company&#x2019;s 2021 Annual Report on Form 10-K that had, or are expected to have, a material impact on its consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl8zNy9mcmFnOmEwNGM0ZWU0ODVhZDRlNTM4NGY0NDIzYjhmMDEwMGJhL3RleHRyZWdpb246YTA0YzRlZTQ4NWFkNGU1Mzg0ZjQ0MjNiOGYwMTAwYmFfNTQz_f7b07221-615e-4900-984b-fd84fd0bd29f">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements that were issued or became effective since the issuance of the Company&#x2019;s 2021 Annual Report on Form 10-K that had, or are expected to have, a material impact on its consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RleHRyZWdpb246NGRjYzBmODQwOTJiNDRjNjlmODQ0Yzc2YWNhYjc4OThfMjgzNQ_d7195371-75c9-4d79-a474-c8ec1545a97a">Fair Value of Financial Instruments&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between levels during the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at June&#160;30, 2022 includes approximately $8.2 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2021 includes approximately $23.2 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RleHRyZWdpb246NGRjYzBmODQwOTJiNDRjNjlmODQ0Yzc2YWNhYjc4OThfMjgzNw_a2807062-75b1-4b1f-902a-b563d8cafb28">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. There were no transfers between levels during the periods presented.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RleHRyZWdpb246NGRjYzBmODQwOTJiNDRjNjlmODQ0Yzc2YWNhYjc4OThfMjgzOA_f3c2b9a5-50a3-4d89-ab18-b23d304144ac">&lt;div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at June&#160;30, 2022 includes approximately $8.2 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2021 includes approximately $23.2 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4f2cf382a17b4e04bc62223c9662497b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfMy0xLTEtMS00NjMzOA_42c57048-f72d-4e72-a30f-b53f09c07922"
      unitRef="usd">8162000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaee5df7c6fd24644b6271803fce2aae2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfMy0zLTEtMS00NjMzOA_1b98da6f-9404-4eac-9c92-d3cb4aacf517"
      unitRef="usd">8162000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3209e333ef1b4efc9f643a26585398bb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfMy01LTEtMS00NjMzOA_189e9aed-48e1-4bbf-8494-6aedd14f3618"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7cacffd890924583aaf540298dbf7a8c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfNC0xLTEtMS00NjMzOA_df16fad1-af9a-46cf-9d79-dc606d67726f"
      unitRef="usd">105837000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i74bfe05c99f446cba0ad613ef542784b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfNC0zLTEtMS00NjMzOA_1d2e92f1-7fe5-4ec5-b0ae-8e26565bfcce"
      unitRef="usd">105837000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic926423ab3114b2784c30e3020c5be6e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfNC01LTEtMS00NjMzOA_4178096e-fe73-492c-9c5a-1af6428a397f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2edf905318ec4cc88d408a7710dfea8b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfNi0xLTEtMS00NjMzOA_8d58f5bb-593c-4f52-8e25-17d35ff46949"
      unitRef="usd">6434000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i412eca49d41d47de87d3a53713b8e50e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfNi0zLTEtMS00NjMzOA_af22fcaf-4b6f-42d9-95f5-a74349376fc7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia9708b71437741bc98bf41f57791fef6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfNi01LTEtMS00NjMzOA_49228d56-bed4-479c-b198-69bef53391e3"
      unitRef="usd">6434000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7c140531ab074f03aea8d010a367b9b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfOC0xLTEtMS00NjMzOA_4d3811e0-6874-443a-99b2-d4c3a87710a8"
      unitRef="usd">120433000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i232d1bddbda24a9786d7b4e89ec55bfc_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfOC0zLTEtMS00NjMzOA_1d703f98-533f-4926-b510-660360ba23a4"
      unitRef="usd">113999000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if7d4f9b1948e4f9c8fc832ab374f303c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOmZhNDU3MTIyMmY1NTRiZDM5YjkzZWEyYTFlNTVmYTk1L3RhYmxlcmFuZ2U6ZmE0NTcxMjIyZjU1NGJkMzliOTNlYTJhMWU1NWZhOTVfOC01LTEtMS00NjMzOA_8c1857e8-0a4a-42e5-9995-65f0fd42083a"
      unitRef="usd">6434000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2e22930bedfe4f48b55574f1491fe4b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfMy0xLTEtMS00NjMzOA_c567eff5-89d3-4930-a18e-78b9c510c579"
      unitRef="usd">17202000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie5c4c855042e4bc586a5317d9125cfe4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfMy0zLTEtMS00NjMzOA_a4ae6fe7-b6a3-49dd-8c29-253eb1ca9703"
      unitRef="usd">17202000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1dfffc601f2c44cf829806a11359034d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfMy01LTEtMS00NjMzOA_4e7c282d-c098-4c52-9f4f-770965ca7d61"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie88ae8b3089f4d8bbd25cc1cecc99d47_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfNC0xLTEtMS00NjMzOA_887fda57-5b88-44f8-8f75-4b23e2bd2555"
      unitRef="usd">81132000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie8d60276ffc34955ab0ae2df036b1032_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfNC0zLTEtMS00NjMzOA_2a61449d-181a-4ac4-b577-21f734f03126"
      unitRef="usd">81132000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i64bbb463b56f459e848a5399c786db9b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfNC01LTEtMS00NjMzOA_5fcfb166-fad3-4920-a29a-a52deae5a81a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iad0c041aa4bc458e8e7d118fe4c9e08f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfNS0xLTEtMS00NjMzOA_f8c9a62a-ac02-4b90-889f-fce82ecee5f9"
      unitRef="usd">7734000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ied25e1f92b644194804e5004a17b2d7d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfNS0zLTEtMS00NjMzOA_645d7fb0-9dbe-4586-a25d-396e83465d28"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id44b34a1bd494162bed536c9eb0de155_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfNS01LTEtMS00NjMzOA_0a7164e9-bce9-4397-ab1e-e36d0420200f"
      unitRef="usd">7734000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i75ac06ceb7484bb8bd34e4033c4faf19_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfNi0xLTEtMS00NjMzOA_61052d84-6dfc-4834-b7b4-5f0166d3ce65"
      unitRef="usd">37280000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i19535bf1b5074b99b2df151eb4bc4d31_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfNi0zLTEtMS00NjMzOA_00e4ad52-219c-4afe-b1d5-7778ed2f924b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib5bf3535880a4ceb822d925ba094e608_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfNi01LTEtMS00NjMzOA_9fbcc2cc-6db5-4cb9-8e8b-89e984d5dc60"
      unitRef="usd">37280000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib610d63458364b959341d2c275fc3966_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfOC0xLTEtMS00NjMzOA_b3fe431e-6857-46f5-8508-fae66ff674c8"
      unitRef="usd">143348000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i79d5f7405cf1437c9d2766b6093531d1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfOC0zLTEtMS00NjMzOA_517302f9-b7de-40cb-b7e3-5b1a9606209b"
      unitRef="usd">98334000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i250e6d1dd1d14d73a9e40891670e7259_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RhYmxlOjJlMDgxM2UyM2ExMjQ2YTQ4ZWZlMjY4YmI0YzM4YWVjL3RhYmxlcmFuZ2U6MmUwODEzZTIzYTEyNDZhNDhlZmUyNjhiYjRjMzhhZWNfOC01LTEtMS00NjMzOA_1bdd9dea-d2a2-4b32-9a4d-0d7a57eb2c2c"
      unitRef="usd">45014000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7c140531ab074f03aea8d010a367b9b3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RleHRyZWdpb246NGRjYzBmODQwOTJiNDRjNjlmODQ0Yzc2YWNhYjc4OThfMjYxNg_fb401f12-12e9-4ae3-a998-994551636d8d"
      unitRef="usd">8200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib610d63458364b959341d2c275fc3966_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80MC9mcmFnOjRkY2MwZjg0MDkyYjQ0YzY5Zjg0NGM3NmFjYWI3ODk4L3RleHRyZWdpb246NGRjYzBmODQwOTJiNDRjNjlmODQ0Yzc2YWNhYjc4OThfMjc2MQ_22d28a00-6d0b-488a-87f6-dd737a98dd8d"
      unitRef="usd">23200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RleHRyZWdpb246MDBhNDFkYzQ4MDdmNDJjNjk1ZDhmZTI1ODg2OTBjZDNfMTAzMQ_59b7cf79-1e06-4c6f-86c2-b54986776754">Marketable Securities&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's marketable debt securities (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All available-for-sale marketable debt securities held as of June&#160;30, 2022 and December&#160;31, 2021 had contractual maturities of less than one year.  All of the Company's available-for-sale marketable debt securities in an unrealized loss position as of June&#160;30, 2022 and December&#160;31, 2021 were in a loss position for less than twelve months.&#160; Unrealized losses on available-for-sale debt securities as of June&#160;30, 2022 and December&#160;31, 2021 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded &lt;/span&gt;&lt;/div&gt;for any periods presented. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RleHRyZWdpb246MDBhNDFkYzQ4MDdmNDJjNjk1ZDhmZTI1ODg2OTBjZDNfMTAzMg_a9edcc7a-a9b2-4b63-939a-f2c1050bcbed">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's marketable debt securities (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i19fed250b414468dbaf9d90c31a31e26_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfMi0xLTEtMS00NjMzOA_a2a51e58-0f10-49d4-8b44-164b694db821"
      unitRef="usd">106147000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i19fed250b414468dbaf9d90c31a31e26_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfMi0zLTEtMS00NjMzOA_40f624db-336a-48fb-aa1c-08ccde76f84c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i19fed250b414468dbaf9d90c31a31e26_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfMi01LTEtMS00NjMzOA_daa8ea74-828e-4927-96ed-49fc2639f8ed"
      unitRef="usd">310000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i19fed250b414468dbaf9d90c31a31e26_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfMi03LTEtMS00NjMzOA_a3201264-d270-4cc4-a3ac-88286801d2fd"
      unitRef="usd">105837000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iae8184b5fd91450ea18de2dae673882c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfNC0xLTEtMS00NjMzOA_93601b40-0bb6-46b2-b802-261f5a7f82d3"
      unitRef="usd">6449000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iae8184b5fd91450ea18de2dae673882c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfNC0zLTEtMS00NjMzOA_318b452b-22e6-401f-8722-88e5b47f9b6e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iae8184b5fd91450ea18de2dae673882c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfNC01LTEtMS00NjMzOA_8df716b7-8193-4eb2-b871-ce941f34c169"
      unitRef="usd">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iae8184b5fd91450ea18de2dae673882c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfNC03LTEtMS00NjMzOA_75d39dc4-43bc-45a8-8e72-2ced8068e7ad"
      unitRef="usd">6434000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfNS0xLTEtMS00NjMzOA_dd6d3af1-2979-426e-8a8b-fd214ac82a66"
      unitRef="usd">112596000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfNS0zLTEtMS00NjMzOA_c283abd5-f0a6-4dca-9bd4-77b754ff8462"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfNS01LTEtMS00NjMzOA_494fd5f8-f217-45b7-bb58-e3a80bd1d787"
      unitRef="usd">325000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjI3MDNjYTk0Y2U3MDRkZjY4NDNjZmQ3OGIzYTk2NGJlL3RhYmxlcmFuZ2U6MjcwM2NhOTRjZTcwNGRmNjg0M2NmZDc4YjNhOTY0YmVfNS03LTEtMS00NjMzOA_69a97c9f-3eb6-42a9-9ed0-f3d7f2c3c7e5"
      unitRef="usd">112271000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifa546adbe93e4c63a396fe25106b66ae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfMi0xLTEtMS00NjMzOA_5a25d741-9aca-407f-a298-e5f3c41c5c18"
      unitRef="usd">81184000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifa546adbe93e4c63a396fe25106b66ae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfMi0zLTEtMS00NjMzOA_7bba65b4-bc75-4c22-a377-d56894d7efe4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifa546adbe93e4c63a396fe25106b66ae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfMi01LTEtMS00NjMzOA_53f6427f-b876-4fca-840a-a0d5f0388256"
      unitRef="usd">52000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifa546adbe93e4c63a396fe25106b66ae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfMi03LTEtMS00NjMzOA_3d150ac7-a952-45d7-8d6c-bc29ecbf98be"
      unitRef="usd">81132000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i31aa193c0dfc4403bbdb295edc147c6e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfMy0xLTEtMS00NjMzOA_7ea17476-5a6b-4bab-9690-0ce567f794eb"
      unitRef="usd">7739000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i31aa193c0dfc4403bbdb295edc147c6e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfMy0zLTEtMS00NjMzOA_2d4c7634-c4bf-4a12-9ffe-d3f82247e7e1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i31aa193c0dfc4403bbdb295edc147c6e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfMy01LTEtMS00NjMzOA_3b863339-1f73-4508-aacb-16bfcce543ef"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i31aa193c0dfc4403bbdb295edc147c6e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfMy03LTEtMS00NjMzOA_b57c2832-df2a-4e18-acbb-650cb20cd4e2"
      unitRef="usd">7734000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia56c7c0c5dd64063ade2d2b387b7f6c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfNC0xLTEtMS00NjMzOA_0983feae-d097-4dfc-95e3-06d0047b7e38"
      unitRef="usd">31285000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia56c7c0c5dd64063ade2d2b387b7f6c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfNC0zLTEtMS00NjMzOA_0911f48c-702f-4274-ae97-ba8f7fe1ee49"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia56c7c0c5dd64063ade2d2b387b7f6c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfNC01LTEtMS00NjMzOA_8ed7f4f2-dd83-4ed5-81c2-a3f2ea477eb3"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia56c7c0c5dd64063ade2d2b387b7f6c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfNC03LTEtMS00NjMzOA_91e0dbc5-0772-4f48-aed4-7e7543ac8610"
      unitRef="usd">31281000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfNS0xLTEtMS00NjMzOA_c42a49f0-fe4e-4463-a67e-d1f24ddcb53a"
      unitRef="usd">120208000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfNS0zLTEtMS00NjMzOA_c26186fc-d848-4e56-b138-ce0146852b90"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfNS01LTEtMS00NjMzOA_3bfe6cc8-c6fb-45aa-8e09-c35af95daa75"
      unitRef="usd">61000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RhYmxlOjExYjIwNDY0NDU0YzQxZWNhM2ZjZTM4YjUyYWUzM2M5L3RhYmxlcmFuZ2U6MTFiMjA0NjQ0NTRjNDFlY2EzZmNlMzhiNTJhZTMzYzlfNS03LTEtMS00NjMzOA_7737bdbc-a5e3-437d-9ef5-791e375ef2a1"
      unitRef="usd">120147000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RleHRyZWdpb246MDBhNDFkYzQ4MDdmNDJjNjk1ZDhmZTI1ODg2OTBjZDNfNjgw_6465684a-e58e-4368-8c1e-b8d512d9deca"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80My9mcmFnOjAwYTQxZGM0ODA3ZjQyYzY5NWQ4ZmUyNTg4NjkwY2QzL3RleHRyZWdpb246MDBhNDFkYzQ4MDdmNDJjNjk1ZDhmZTI1ODg2OTBjZDNfNjgw_ac03c959-efd2-4f4d-ba67-d4d6c690063f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80Ni9mcmFnOjFlNmJlNTgyMGFmZjRmZWM4ODdmMTA0YzU0NzRjMGI1L3RleHRyZWdpb246MWU2YmU1ODIwYWZmNGZlYzg4N2YxMDRjNTQ3NGMwYjVfNTc3_82fe0337-f198-4dce-8554-f91b26273368">Inventory, Net&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's net inventory (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Prior to U.S. Food and Drug Administration (FDA) approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of June&#160;30, 2022 and December&#160;31, 2021 is net of a reserve of  $3.1&#160;million and $2.0&#160;million, respectively, for unsaleable inventory.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80Ni9mcmFnOjFlNmJlNTgyMGFmZjRmZWM4ODdmMTA0YzU0NzRjMGI1L3RleHRyZWdpb246MWU2YmU1ODIwYWZmNGZlYzg4N2YxMDRjNTQ3NGMwYjVfNTc4_5bab22af-84c7-43d3-b9e8-25a3d8624c4a">&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's net inventory (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryWorkInProcess
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80Ni9mcmFnOjFlNmJlNTgyMGFmZjRmZWM4ODdmMTA0YzU0NzRjMGI1L3RhYmxlOjQ5MDIwMmQ5ZTViMTRjNzA5YWMwOTUxMDI1N2VkODY0L3RhYmxlcmFuZ2U6NDkwMjAyZDllNWIxNGM3MDlhYzA5NTEwMjU3ZWQ4NjRfMi0xLTEtMS00NjMzOA_fdf3741e-d8ee-419b-97eb-64f466298412"
      unitRef="usd">2231000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80Ni9mcmFnOjFlNmJlNTgyMGFmZjRmZWM4ODdmMTA0YzU0NzRjMGI1L3RhYmxlOjQ5MDIwMmQ5ZTViMTRjNzA5YWMwOTUxMDI1N2VkODY0L3RhYmxlcmFuZ2U6NDkwMjAyZDllNWIxNGM3MDlhYzA5NTEwMjU3ZWQ4NjRfMi0zLTEtMS00NjMzOA_e8dc7d1e-817b-4300-bf7c-ce5116e9cb48"
      unitRef="usd">3929000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80Ni9mcmFnOjFlNmJlNTgyMGFmZjRmZWM4ODdmMTA0YzU0NzRjMGI1L3RhYmxlOjQ5MDIwMmQ5ZTViMTRjNzA5YWMwOTUxMDI1N2VkODY0L3RhYmxlcmFuZ2U6NDkwMjAyZDllNWIxNGM3MDlhYzA5NTEwMjU3ZWQ4NjRfMy0xLTEtMS00NjMzOA_cf0360b2-dcbc-4d4a-beb2-a12c1793f6f9"
      unitRef="usd">718000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80Ni9mcmFnOjFlNmJlNTgyMGFmZjRmZWM4ODdmMTA0YzU0NzRjMGI1L3RhYmxlOjQ5MDIwMmQ5ZTViMTRjNzA5YWMwOTUxMDI1N2VkODY0L3RhYmxlcmFuZ2U6NDkwMjAyZDllNWIxNGM3MDlhYzA5NTEwMjU3ZWQ4NjRfMy0zLTEtMS00NjMzOA_c71894a4-fcc2-4787-8456-4b005b613f4b"
      unitRef="usd">459000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80Ni9mcmFnOjFlNmJlNTgyMGFmZjRmZWM4ODdmMTA0YzU0NzRjMGI1L3RhYmxlOjQ5MDIwMmQ5ZTViMTRjNzA5YWMwOTUxMDI1N2VkODY0L3RhYmxlcmFuZ2U6NDkwMjAyZDllNWIxNGM3MDlhYzA5NTEwMjU3ZWQ4NjRfNC0xLTEtMS00NjMzOA_579abe10-f061-49f8-a203-3111b0794538"
      unitRef="usd">2949000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80Ni9mcmFnOjFlNmJlNTgyMGFmZjRmZWM4ODdmMTA0YzU0NzRjMGI1L3RhYmxlOjQ5MDIwMmQ5ZTViMTRjNzA5YWMwOTUxMDI1N2VkODY0L3RhYmxlcmFuZ2U6NDkwMjAyZDllNWIxNGM3MDlhYzA5NTEwMjU3ZWQ4NjRfNC0zLTEtMS00NjMzOA_fcd5f3d4-eee5-49c0-8349-3944d150ac89"
      unitRef="usd">4388000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80Ni9mcmFnOjFlNmJlNTgyMGFmZjRmZWM4ODdmMTA0YzU0NzRjMGI1L3RleHRyZWdpb246MWU2YmU1ODIwYWZmNGZlYzg4N2YxMDRjNTQ3NGMwYjVfNTQ5NzU1ODE0NDY5_4b64848a-6ec3-4a0d-9a1f-1e7ed3c911f6"
      unitRef="usd">3100000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80Ni9mcmFnOjFlNmJlNTgyMGFmZjRmZWM4ODdmMTA0YzU0NzRjMGI1L3RleHRyZWdpb246MWU2YmU1ODIwYWZmNGZlYzg4N2YxMDRjNTQ3NGMwYjVfNTQ5NzU1ODE0NDg4_071f2d9a-80b2-4c6e-ac77-bcbe511083a4"
      unitRef="usd">2000000</us-gaap:InventoryValuationReserves>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfMTc2MQ_328772ea-040e-4fd2-bc59-2870b7e2dd4d">Stockholders' Equity&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0 million through an &#x201c;at the market offering&#x201d; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. The shares that were sold under the Sales Agreement were issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 4, 2020.  During the six months ended June 30, 2021, the Company sold 3,622,186 shares of common stock at a weighted average price per share of $27.60, resulting in net proceeds of approximately $98.2 million, net of underwriting discounts and commissions and other offering expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increases the amount of the Company&#x2019;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $100.0&#160;million to an aggregate offering price of up to $300.0&#160;million.  The Company has not sold any shares of common stock related to Amendment No. 1 to the Sales Agreement as of June&#160;30, 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the consideration for the rights granted to Zai Lab US LLC under the collaboration and license agreement described more fully in Note 7, Revenue, the Company and Zai Lab US LLC entered into a separate stock purchase agreement (Stock Purchase Agreement) in June 2021.  Under this Stock Purchase Agreement, Zai Lab US LLC paid the Company approximately $30.0 million to purchase 958,467 newly issued shares of the Company's common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="i0ae83217782a49f581625143e7d04f9d_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfMjE4_641eb9f1-b935-45a4-a415-3c1a14335214"
      unitRef="usd">100000000</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia6b440df4f4e426d8d698f7cb5f42342_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfNTk0_029b17cf-eb77-43ab-b978-2e1fb20992af"
      unitRef="shares">3622186</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i99f0316ba50d4c39a9c3d29ef8473c34_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfNjYx_3350ec51-9f1b-4d47-9333-379c5408cce4"
      unitRef="usdPerShare">27.6</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ia6b440df4f4e426d8d698f7cb5f42342_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfNzA4_09385fad-56ac-4b08-a03e-bc134b8d209c"
      unitRef="usd">98200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="i0ae83217782a49f581625143e7d04f9d_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfMTA0MA_6f6b7c56-93b7-49da-9181-270437f4a3ca"
      unitRef="usd">100000000</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease
      contextRef="i5d0a69ad66bb4c0b8b17295ffe63c014_D20210401-20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfMTA4Mw_93a7e7f9-dd99-43e7-bb88-488b27d66b8f"
      unitRef="usd">300000000</mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i6417b05cf7d64d0bb5cc9aa0b049314b_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfMTU2NA_1654a8e2-386d-4e81-8aef-bfdb45e97215"
      unitRef="usd">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia1adbba07b474f27be0bcec58c6f439a_D20210601-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfMTU3OQ_3648aea6-91ca-448e-b952-aa1ddb406952"
      unitRef="shares">958467</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfMTY0Mw_8c22cd83-d639-4902-87d3-328ab0983266"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i8862965ac7c74eaa91fbf299dcefad53_I20210615"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfMTY2Nw_972312f8-bb52-4500-967a-6a5c6158dca1"
      unitRef="usdPerShare">31.3</us-gaap:SaleOfStockPricePerShare>
    <mgnx:PremiumReceivedOnStockPurchase
      contextRef="ibbbb27e355214928b77e2fc758f95088_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl80OS9mcmFnOjgzMDFjNDQ5MDU0MjQ1MDY5NTQ4MzhkYWExYTJhMDlhL3RleHRyZWdpb246ODMwMWM0NDkwNTQyNDUwNjk1NDgzOGRhYTFhMmEwOWFfMTY5MA_c0781a70-2663-47df-a039-9ccb7ebe5ad7"
      unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzMzMTM_a4dbddba-ffe2-4224-bfe9-707d7fe775f3">Revenue &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaborative and Other Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incyte Corporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Incyte License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab.  Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017. In July 2021, Incyte announced that the FDA had issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal. Incyte&#x2019;s announcement indicated that the FDA determined that additional data are needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte was reviewing the CRL and would discuss next steps with the FDA. Incyte subsequently withdrew its European application for marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal. Incyte has stated it is pursuing development of &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;retifanlimab in potentially registration-enabling studies beyond squamous cell carcinoma of the anal canal, including in patients with MSI-high endometrial cancer, Merkel cell carcinoma and non-small cell lung cancer.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline. In April 2022, the Company and Incyte executed an amendment to the Incyte License Agreement to add a milestone for U.S. approval of retifanlimab in a specific indication and to exclude certain other regulatory and development achievements with retifanlimab in this same indication from the milestone events of the Incyte License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Incyte License Agreement, as amended, Incyte will lead global development of retifanlimab.  Assuming successful development and commercialization by Incyte, the Company could receive up to $435.0 million in development and regulatory milestones and up to $330.0 million in commercial milestones. From the inception of the Incyte License Agreement through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company has recognized $70.0 million in development milestones under the Incyte License Agreement. In July 2022, the Company and Incyte further amended the Incyte License Agreement to reflect changes related to the payment of certain milestones and the Company received $30.0 million in milestone payments from Incyte.  If retifanlimab is approved and commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales.  The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Incyte License Agreement under the provisions of Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 606) and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte License Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. From 2018 through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, it became probable that a significant reversal of cumulative revenue would not occur for development milestones totaling $70.0 million related to &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;clinical and regulatory activities related to the further advancement of retifanlimab, including Incyte&#x2019;s initiation of a Phase 3 clinical trial&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  Therefore, the associated consideration was added to the estimated transaction price and was recognized as revenue&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized the $150.0 million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $4.0 million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018. No revenue was recognized under the Incyte License Agreement during the three and  six months ended June 30, 2022.  $5.0&#160;million and $15.0 million in milestone revenue was recognized under the Incyte License Agreement during the three and six months ended June 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Incyte Clinical Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company entered into an agreement with Incyte, under which the Company is to perform development and manufacturing services for Incyte&#x2019;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement).  The Company evaluated the Incyte Clinical Supply Agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;related to the manufacturing services.  During the three months ended June 30, 2022 and 2021, the Company recognized revenue of $0.2 million and $0.7 million, respectively, for services performed under the Incyte Clinical Supply Agreement.   During the six months ended June 30, 2022 and 2021, the Company recognized revenue of $0.5 million and $0.8 million, respectively, for services performed under the Incyte Clinical Supply Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Incyte Commercial Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#x2019;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated the Incyte Commercial Supply Agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor costs incurred) related to the manufacturing services.  During the three months ended June 30, 2022 and 2021,  the Company recognized $0.3&#160;million and $2.8&#160;million, respectively, for services performed under the Incyte Commercial Supply Agreement.  During the six months ended June 30, 2022 and 2021, the Company recognized $0.3&#160;million and $5.9&#160;million, respectively, for services performed under the Incyte Commercial Supply Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Zai Lab Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2018 Zai Lab Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab)  under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#x2019;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab, a bispecific DART&#xae; molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development of these molecules in its territory.  Zai Lab has informed the Company that they have decided to discontinue development of tebotelimab for indications they were enrolling in their territory and is evaluating future development plans in other indications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0 million ($22.5 million after netting value-added tax withholdings of $2.5 million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones, of which the Company has earned $9.0 million through June&#160;30, 2022. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#x2019;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#x2019;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#x2019;s territory, which may be subject to adjustment in specified circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the 2018 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#x2019;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $22.5 million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.  From 2020 through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, it became probable that a significant reversal of cumulative revenue would not occur for development and regulatory milestones totaling $9.0 million.  Therefore, the associated consideration was added to the estimated transaction price and was recognized as revenue&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Of this &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$9.0 million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$5.0 million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was recognized as revenue &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during the six months ended June 30, 2022. During the three and six months ended June 30, 2022, the Company recognized $0.4&#160;million and $5.4&#160;million, respectively, under the 2018 Zai Lab Agreement.  No revenue was recognized during the three and six months ended June 30, 2021 under the 2018 Zai Lab Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zai Lab Clinical Supply Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#x2019;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements). The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab.  The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing service. During the three months ended June 30, 2022 and 2021, the Company recognized revenue of $0.1 million and $0.5 million, respectively, related to the Zai Lab Clinical Supply Agreements. During the six months ended June 30, 2022 and 2021, the Company recognized revenue of $0.3 million and $1.6 million, respectively, related to the Zai Lab Clinical Supply Agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Zai Lab Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates the Company&#x2019;s DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by the Company. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while the Company receives commercial rights in all other territories. Under the Lead Program, Zai Lab received an option upon reaching a predefined clinical milestone to convert the regional arrangement into a global 50/50 profit share. If Zai Lab elects such option, Zai Lab is to pay the Company $85.0&#160;million plus any research costs incurred by both parties as of the option election date. Zai Lab also obtained exclusive, global licenses from the Company to develop, manufacture and commercialize two additional molecules. Zai Lab granted the Company a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2021 Zai Lab Agreement, the Lead Program includes joint research and development services by both the Company and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with the Company to perform research and development services in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0&#160;million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into the Stock Purchase Agreement whereby Zai Lab paid the Company approximately $30.0 million to purchase shares of the Company&#x2019;s common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assuming successful development and commercialization of the Programs, the Company could receive up to approximately $800.0&#160;million in development and regulatory milestones and $600.0&#160;million in commercial milestones. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of low double digit teens on annual net sales of certain specified products and of mid-single digits to low double digit teens on annual net sales of other specified products in Zai Lab&#x2019;s territory, which may be subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, the Company may also receive reimbursements from Zai Lab for certain research and development costs incurred by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#x2019;s territory for each Program and (ii) certain research and development activities for the Lead Program. The Company determined that for the Lead Program, the license is not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#x2019;s significant expertise in this area and as such, the research and development services are expected to significantly modify and customize the license. Therefore, for the Lead Program, the license and the services were combined into a single performance obligation. Since the other programs each represent distinct intellectual property and there are no other services included in the 2021 Zai Lab Agreement related to these licenses, each license is considered to be a distinct performance obligation. As such, there are four performance obligations included in the 2021 Zai Lab Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the estimated transaction price is $40.4 million, consisting of the $25.0 million upfront payment, the $10.4 million premium related to the purchase of the Company&#x2019;s common stock, and the $5.0 million estimated reimbursement by Zai Lab for research and development activities for the Lead Program. The potential milestone payments were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company will re-assess the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price of $40.4 million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believes a market participant is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#x2019;s estimate of the probability of success for each Program. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue related to the Lead Program license and related research and development services performance obligation is being recognized over time as the research and development activities are performed. The Company will utilize a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in June 2021.  During the three months ended June 30, 2022 and 2021, the Company recognized revenue of $14.7 million and $14.4 million, respectively, under the 2021 Zai Lab Agreement. During the six months ended June 30, 2022 and 2021, the Company recognized revenue of $15.0 million and $14.4 million, respectively, under the 2021 Zai Lab Agreement. As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022, $1.8 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; revenue was deferred under the agreement, all of which was current. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; December&#160;31, 2021, $16.1 million in revenue was deferred, all of which was current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen Biotech, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company entered into a research collaboration and license agreement with Janssen Biotech, Inc. (Janssen) to develop a novel DART molecule (Janssen Agreement).  The research collaboration will incorporate the Company&#x2019;s proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the Janssen Agreement, Janssen paid the Company an upfront payment of $20.0&#160;million and will be responsible for funding all research and development expenses. The Company will also be eligible to receive up to $312.0&#160;million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales. &lt;/span&gt;&lt;span style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of this agreement, the Company granted Janssen an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term. The Company evaluated the Janssen Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i)  a license to develop the preclinical bispecific molecule and (ii) performing certain research and development activities during the research term. The Company determined that the license and research and development activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as Janssen could benefit from the license on its own without the Company&#x2019;s involvement during the research term.  The Company determined that the transaction price of the Janssen Agreement at inception was $22.2&#160;million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for research and development activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;considering similar collaboration and license agreements as well as current market conditions. The standalone selling price for agreed-upon research and development activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. This variable consideration is fully constrained until the Company begins its work under the performance obligation.  The potential milestone payments are &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Janssen and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:42pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized the $20.0&#160;million allocated to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license when it satisfied its performance obligation and transferred the license to Janssen in December 2020. The $2.2&#160;million allocated to the research and development activities is being recognized over the Company&#x2019;s involvement in the research term, which is estimated to be less than two years. During the three months ended June 30, 2022 and 2021, the Company recognized revenue of  $0.2 million and $0.6&#160;million, respectively, for research and development activities performed under the Janssen Agreement.  During the six months ended June 30, 2022, and 2021 the Company recognized revenue of $0.6 million and $0.9&#160;million, respectively, for research and development activities performed under the Janssen Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;I-Mab Biopharma&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;I-Mab License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab License Agreement).  I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the I-Mab License Agreement, I-Mab paid the Company an upfront payment of $15.0 million.  Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $135.0 million in development and regulatory milestones, of which $5.0&#160;million has been earned from the inception of the I-Mab License Agreement through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In addition, I-Mab would pay the Company tiered royalties ranging from mid-teens to 20% on annual net sales in I-Mab's territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the I-Mab License Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i) an exclusive license to develop and commercialize enoblituzumab in I-Mab&#x2019;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $15.0 million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $1.0 million. I-Mab paid the Company for the cost of this study as the costs were incurred and I-Mab received a one-time credit of eighty percent of the total amount of such costs against the milestone achieved during 2021. The Company reassessed the transaction price as it became probable that a significant reversal of cumulative revenue would not occur for a $5.0&#160;million milestone ($4.5&#160;million after netting a one-time credit as described above) related to development progress of enoblituzumab, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue during 2021. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Revenue under the I-Mab License Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligations.  During the three months ended June &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30, 2022 and 2021, the Company recognized revenue of $0.6 million and $1.9 million, respectively, under the I-Mab License Agreement. During the six months ended June 30, 2022 and 2021, the Company recognized revenue of $0.7 million and $2.5 million, respectively, under the I-Mab License Agreement. As of June&#160;30, 2022, $3.8 million in revenue was deferred under the I-Mab License Agreement, all of which was current. As of December&#160;31, 2021, $4.5 million in revenue was deferred under the I-Mab License Agreement, all of which was current.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;I-Mab Clinical Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the Company entered into an agreement under which the Company is to perform development and manufacturing services for I-Mab&#x2019;s clinical needs of enoblituzumab (I-Mab Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of enoblituzumab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the three and six months ended June 30, 2022, the Company recognized revenue of $0.3&#160;million and $1.1 million, respectively, for research and development activities performed under the I-Mab Clinical Supply Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Manufacturing Services Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incyte &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Incyte (Incyte Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Incyte bulk drug substance over a three-year period at one of the Company&#x2019;s manufacturing facilities. Under the terms of the Incyte Manufacturing and Clinical Supply Agreement, the Company received an upfront payment of $10.0&#160;million and is eligible to receive annual fixed payments paid quarterly over the term of the contract totaling $14.4&#160;million. The Company will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Incyte Manufacturing and Clinical Supply Agreement under the provisions of ASC 606 and identified one performance obligation to provide manufacturing runs to Incyte, as and when requested by Incyte, over the term of the contract that is part of a series of goods and services. The Company determined that the transaction price at inception consists of the upfront payment received of $10.0&#160;million and the annual fixed payments totaling $14.4&#160;million.   The Company will recognize revenue over time on a straight-line basis as the manufacturing services are provided to Incyte, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Incyte will be allocated to the related manufacturing activities and will be recognized as revenue as those activities occur.  Materials purchased by the Company to manufacture the product for Incyte are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized revenue of $4.0&#160;million under the Incyte Manufacturing and Clinical Supply Agreement during each of the three and six month periods ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$9.5&#160;million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in revenue was deferred under this agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.3&#160;million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which was current and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$6.2&#160;million &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of which was non-current.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Government Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NIAID Contract&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a contract with National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, MGD014 and MGD020 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of June&#160;30, 2022 is $25.1&#160;million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in July 2023. During the three months ended June 30, 2022 and 2021, the Company recognized revenue under the NIAID Contract of $0.5 million and $0.4 million, respectively.   During the six months ended June 30, 2022 and 2021, the Company recognized revenue under the NIAID Contract of $0.9 million and $1.2 million, respectively.</mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock>
    <mgnx:NonRefundableUpfrontFees
      contextRef="id672cb9284434e3a9202e6f51f077bac_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNjc5_f400404f-acfd-41a8-892e-4452a4f37e28"
      unitRef="usd">150000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i00c0c8a5e81842d6ad36655e19d61684_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTk3OA_07a677c4-2e0a-45bd-aacd-1d3e1ce38c02"
      unitRef="usd">435000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="i00c0c8a5e81842d6ad36655e19d61684_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjAzMg_920f7115-fa64-49e1-8f3e-02662d52d95b"
      unitRef="usd">330000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i8b2a073d3c794192a595450d0028cae4_D20180101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjE1MQ_315918c6-a00a-4355-a87e-bef90e350fb5"
      unitRef="usd">70000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:TwoAdditionalMilestoneIncyteLicenseAgreement
      contextRef="i96f7ff3791204451aedc226872ae5fcb_I20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNDA1OTM_5aed2386-df07-4091-a339-dddc7ff1ed72"
      unitRef="usd">30000000</mgnx:TwoAdditionalMilestoneIncyteLicenseAgreement>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i5d06233b12574a07a62e6512ccf7e4fb_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjMyNg_7fc96a79-882c-4a95-bf5b-2f237727f3f3"
      unitRef="number">0.15</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i61b3c4379d88468da27af3737a110d8c_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjMzMg_aa1c1242-b575-4dd2-a922-c522027e0a5b"
      unitRef="number">0.24</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NumberOfPerformanceObligations
      contextRef="i00c0c8a5e81842d6ad36655e19d61684_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjk3Nw_3d5c8416-b25f-4bfa-a6d1-d2c8bcc139d6"
      unitRef="performanceobligation">2</mgnx:NumberOfPerformanceObligations>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i00c0c8a5e81842d6ad36655e19d61684_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzc2NA_2cdca3a3-c59c-4bee-871e-8780dfe74787"
      unitRef="usd">154000000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i8b2a073d3c794192a595450d0028cae4_D20180101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTM0Mw_315918c6-a00a-4355-a87e-bef90e350fb5"
      unitRef="usd">70000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="i5c253e1b8d354889a4ce47f6161201e6_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTY0OQ_37272679-8d81-4c73-9f00-c5924d28b2e3"
      unitRef="usd">150000000</us-gaap:Revenues>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="idf96f2f2d3bb4019aab8b83995fbefb6_D20170101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTc3Mw_caf74ba3-62fa-4c8d-9859-a9c0c52ecdb8"
      unitRef="usd">4000000</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <us-gaap:Revenues
      contextRef="id33701a0fbcb45c99cf26d0167b17df9_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODUxNTEw_ae720bae-3518-4d4f-ad92-cdb9bf2b56a5"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i76d65ceb505a48e1acdee1cd35c24fd7_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODUxNTEw_e9bb9f30-3447-4a83-aee9-6f5219d050aa"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8427f430b14a43c5a0c839c84cd2fac8_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODUxNTAz_2c0bdd1e-ad99-4854-b62b-028e9cfedad4"
      unitRef="usd">5000000</us-gaap:Revenues>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i3d2a0a32c3bf4466ba347ecd77c315eb_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTk3Nw_d4251426-5d83-421f-bfa4-a8da6a1cf6f7"
      unitRef="usd">15000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="i252d416a130b4aef83acef014a242473_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNzEzNw_482fe0aa-7f08-4ec0-b800-6482338d39f9"
      unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i868d68accdbb4b1baea1ef30a6c728af_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNzE0NA_3456ac5d-a124-45f3-97cf-ed86873ef485"
      unitRef="usd">700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie30a746971b840fa954d23a4bd59f89e_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ3NDI0_b597ccf5-c6a8-4b90-b171-f76171a3a751"
      unitRef="usd">500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6171432917614920af3bc0adaae45923_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ3NDMy_0d4a4467-dd63-4313-8d04-b9058c22877f"
      unitRef="usd">800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib69d294a237f46dbb406c9df90ddc345_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ3MjQ5_c1445df8-cbca-4c2e-8df0-7132dc3ec0dd"
      unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1434bddbeff34ada94d5f3a35035e034_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ3NDU5_8f8d5eb1-e8ee-44b3-aa12-1acb16212362"
      unitRef="usd">2800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib07fdf3f2fc0440ca7f2e21164cc1d94_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ3NDg1_6d35627b-e534-4137-8d71-d654e53c00d5"
      unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if65110ca3e22439a98fecb99c1d702d2_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ3NDk0_720996c7-ff27-43d2-bafe-0efbb8cd8146"
      unitRef="usd">5900000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i1b2807234912469ba06c538de023e4f5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfOTQyMw_7caf07d1-8fda-4e4c-8973-97f3ae7cc5e0"
      unitRef="usd">25000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding
      contextRef="i1b2807234912469ba06c538de023e4f5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfOTQyNw_675ff960-7be6-4904-8d67-83ea948f8cc1"
      unitRef="usd">22500000</mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding>
    <mgnx:NonrefundablePaymentTaxWithholding
      contextRef="i1b2807234912469ba06c538de023e4f5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfOTQ3Ng_74169b4c-904c-4699-99f4-8188d073057c"
      unitRef="usd">2500000</mgnx:NonrefundablePaymentTaxWithholding>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i27227311568a45f2b51cd61543ae9030_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfOTYyMg_b80efafe-65df-4080-b062-7f6d269dd74a"
      unitRef="usd">140000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ic8e1dffc03b44a83ab8e292584fd3d5b_D20200701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfOTY5OQ_e5ee53fa-c867-4b50-9339-f412768dcb4a"
      unitRef="usd">9000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="id5b94f0e0eeb4a01aea4900a9c756dd1_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfOTgxMA_66fd1980-872a-47a5-9094-efef93bb1775"
      unitRef="number">0.20</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="icb889204b9fb4dcc80d0bb9f95f21240_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfOTkzMw_17e67937-e5c7-4987-a769-fb44b42b80b3"
      unitRef="number">0.10</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding
      contextRef="i1b2807234912469ba06c538de023e4f5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTEyMzg_675ff960-7be6-4904-8d67-83ea948f8cc1"
      unitRef="usd">22500000</mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ic8e1dffc03b44a83ab8e292584fd3d5b_D20200701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTI2MTQ_e5ee53fa-c867-4b50-9339-f412768dcb4a"
      unitRef="usd">9000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ic8e1dffc03b44a83ab8e292584fd3d5b_D20200701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTI3NDM_e5ee53fa-c867-4b50-9339-f412768dcb4a"
      unitRef="usd">9000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:MillstoneRevenueRecognized
      contextRef="ic6983323f60e4a67818ce6a331b74360_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTI3NDc_c64386df-d4fe-4182-ba12-e12aad50fc5a"
      unitRef="usd">5000000</mgnx:MillstoneRevenueRecognized>
    <us-gaap:Revenues
      contextRef="i3fbf626084c549ea9aa5a07ec92ed81d_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ4NjEx_d11ebc05-7fdb-40be-b43e-2c82fbd315ec"
      unitRef="usd">400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic6983323f60e4a67818ce6a331b74360_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODUxODkx_b7d22d93-6bbc-4b26-badc-0107edb2b19b"
      unitRef="usd">5400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7c76ddf33fdb445c8361740c1a5a1d36_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTI3OTI_697f1e7b-4294-44ba-ba25-fa24d0245fc8"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i20167305bd354a7886c63d0edbe908a2_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTI3OTI_99c7f746-d10e-4b29-902e-4acb3d7da6da"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icba2317be6d9465d9e494fbbc525bc2c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTM5ODU_d6807320-04e0-4783-a21c-f5797b4eca43"
      unitRef="usd">100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i55649e5833464f0ca12e4ad111b17c07_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTM5OTI_fc56fce2-94ce-4885-a19d-774d166235e0"
      unitRef="usd">500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ca75e3ff4904b2a89f832e75c1ca3da_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ3NzYx_2d41180a-5231-4d85-8cb2-00d1eb5802eb"
      unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea8d6ea8007a4fedb1d035394ed7db3f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ3NzY5_49f3a62a-c20a-4a19-8062-de6777d765d5"
      unitRef="usd">1600000</us-gaap:Revenues>
    <mgnx:OptInFee
      contextRef="i8862965ac7c74eaa91fbf299dcefad53_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTUwNjU_3219d673-3573-491b-b296-e86d32b904c7"
      unitRef="usd">85000000</mgnx:OptInFee>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i6417b05cf7d64d0bb5cc9aa0b049314b_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTU4MjU_bb2de008-f42e-48fc-8182-3aa7a8bef68e"
      unitRef="usd">25000000</mgnx:NonRefundableUpfrontFees>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i6417b05cf7d64d0bb5cc9aa0b049314b_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTYwNTM_1654a8e2-386d-4e81-8aef-bfdb45e97215"
      unitRef="usd">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTYxMTY_8b30ca84-6404-4d48-9b96-b8228d6e491e"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i8862965ac7c74eaa91fbf299dcefad53_I20210615"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTYxNDA_972312f8-bb52-4500-967a-6a5c6158dca1"
      unitRef="usdPerShare">31.3</us-gaap:SaleOfStockPricePerShare>
    <mgnx:PremiumReceivedOnStockPurchase
      contextRef="ibbbb27e355214928b77e2fc758f95088_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTYxNjM_c0781a70-2663-47df-a039-9ccb7ebe5ad7"
      unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i8862965ac7c74eaa91fbf299dcefad53_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTYzNTE_0c101153-1a15-42cd-b512-8e45d6296d22"
      unitRef="usd">800000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="i8862965ac7c74eaa91fbf299dcefad53_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTYzOTk_6e1cc9ed-2670-4657-beab-03dfeb1a1edc"
      unitRef="usd">600000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i8862965ac7c74eaa91fbf299dcefad53_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTgxNTI_86bd2e68-fc13-4baf-8ebe-9645618caf9a"
      unitRef="usd">40400000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i6417b05cf7d64d0bb5cc9aa0b049314b_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTgxNzQ_4bcbb36f-994d-4612-9dfb-10c29a4154ae"
      unitRef="usd">25000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PremiumReceivedOnStockPurchase
      contextRef="ibbbb27e355214928b77e2fc758f95088_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTgxOTg_07d56a3f-7f51-4442-881b-3bcea7d28d3b"
      unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="i6417b05cf7d64d0bb5cc9aa0b049314b_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTgyNzI_b1a55e7e-8755-4f23-a3ab-1530ca25dab4"
      unitRef="usd">5000000</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i8862965ac7c74eaa91fbf299dcefad53_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMTkxNDQ_bd3116a6-7e59-4b9a-a80a-6ac6ea09bc9a"
      unitRef="usd">40400000</mgnx:CollaborativeAgreementTransactionPrice>
    <us-gaap:Revenues
      contextRef="i3c3f1cf70f6e49f2a38e855d5b0e46c2_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjc0ODc3OTEwNDg1OA_d5c02f43-5e16-49ca-a4cb-87d77ede8048"
      unitRef="usd">14700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i66ee9789245a4404aaebbe85e877994a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjc0ODc3OTEwNDg2Ng_41217e69-e5e1-4a03-a9c2-4d721af9456c"
      unitRef="usd">14400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i94bc3a3ceb5941fb8aa911e2ffb733eb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjc0ODc3OTEwNDk0OA_8c660914-c543-40e9-a0ab-7166b31d757e"
      unitRef="usd">15000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i70ebe69ee2214b73974336b7a5727cc9_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjc0ODc3OTEwNDk1Ng_bf016e66-33f6-4573-876e-7818f6e9a3f5"
      unitRef="usd">14400000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="iaa61f3996c3c405984b11d51d65bf3ae_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjA0OTc_b250bcc5-d3c5-43e7-bc9b-825f85a1e122"
      unitRef="usd">1800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i05e7befa8e9d45b6893dabb2ea11e658_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjA1ODE_9e656788-3d80-4c08-9456-3096b55a98d5"
      unitRef="usd">16100000</us-gaap:ContractWithCustomerLiability>
    <mgnx:NonRefundableUpfrontFees
      contextRef="iae3a758cac9b4c67ac48b3d949bb81ab_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjExMTI_7aaaa680-87f3-4cec-809d-a2ac98a2b452"
      unitRef="usd">20000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialMilestonePaymentsAndRoyaltiesOnProductSales
      contextRef="i98ee39cd1bfe4c6fadfe480718e3ef13_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjEyNDE_dd067549-0a31-4c1e-8d0b-76fc55a2f608"
      unitRef="usd">312000000</mgnx:PotentialMilestonePaymentsAndRoyaltiesOnProductSales>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="iae3a758cac9b4c67ac48b3d949bb81ab_D20201201-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjEzMDY_4eedd710-e892-4ce6-8d58-ccd83ddb53f4"
      unitRef="number">0.10</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i98ee39cd1bfe4c6fadfe480718e3ef13_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjIzODU_1c579e4f-0434-4abd-9edc-b3b5fde07453"
      unitRef="usd">22200000</mgnx:CollaborativeAgreementTransactionPrice>
    <us-gaap:Revenues
      contextRef="i8f16bac8141c4383a00685b230199498_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjQwMDA_c74fb630-21b1-4c1b-8ed6-46a7e4308346"
      unitRef="usd">20000000</us-gaap:Revenues>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="iae3a758cac9b4c67ac48b3d949bb81ab_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjQxMzQ_6bf40b98-0db6-41b8-afee-9898b13f3017"
      unitRef="usd">2200000</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <us-gaap:Revenues
      contextRef="i613268f3651e4fae832a1050b7bc8c75_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ4ODM5_5c00daa7-48d1-4fdb-903c-825b793ae2c0"
      unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i702fa2d64613432cba42480b770b9427_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ4ODQ4_85551497-75a9-46c9-870f-3fb0790fe403"
      unitRef="usd">600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i460b9af7b2724b7e931ef3fcbb896107_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ5MTgw_a9adddd9-e45c-4bbc-b72c-a6ef69c620ce"
      unitRef="usd">600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8c06d5991f5342a9bc4118c142fb5a68_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ4MDQ2_a44ec199-9860-438e-be45-8f0357e6db34"
      unitRef="usd">900000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="ie6784addc67c4bffab8c458f3a96daaf_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjUxODQ_defba850-5a76-413c-84a4-da0d3835d641"
      unitRef="usd">15000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i118a870a47a847ab9a59d307cf7a8dec_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjUyOTM_6485fd6c-f92c-4d55-a3a6-f561b545063c"
      unitRef="usd">135000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ief27732f4ac54730a699b2393bb54497_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjUzNDc_4d7211fe-0a46-492d-965e-57770bed8139"
      unitRef="usd">5000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="ibcd59b18a37243bfb09019e459954829_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjU1MTM_509a0e49-ec4b-436d-a964-cf81831fbd6a"
      unitRef="number">0.20</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NonRefundableUpfrontFees
      contextRef="ie6784addc67c4bffab8c458f3a96daaf_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjYzMjA_defba850-5a76-413c-84a4-da0d3835d641"
      unitRef="usd">15000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount
      contextRef="ie6784addc67c4bffab8c458f3a96daaf_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjY3MzU_d6608013-55ff-4f4c-bd81-9621dc5eb8d5"
      unitRef="usd">1000000</mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i8c7222aea8cc4fe58941ee0a062a32d5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjcwODg_36237875-7c46-425d-9631-bcf6d6d37d08"
      unitRef="usd">5000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:OneTimeMillstoneCredit
      contextRef="ia7f623bc792547a1a41b06a0787a398e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjcxMDI_282fd9cc-3c0f-462d-aecb-6e6f6faebf36"
      unitRef="usd">4500000</mgnx:OneTimeMillstoneCredit>
    <us-gaap:Revenues
      contextRef="i20c8da099331485ba579926bf66c0d17_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ4MzI5_66cb7a9c-6cb6-4d6d-87a1-2f35695f087c"
      unitRef="usd">600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2497d88ae95c4519b39b87d1ba7cdeb7_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ4MzMz_f9fc1529-f56d-4d3f-8109-86eaa2405c96"
      unitRef="usd">1900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ief27732f4ac54730a699b2393bb54497_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjg0Nzc_c7d77ede-bf8a-4582-aea9-67ac2a423b81"
      unitRef="usd">700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic969da273e7b44dba3060478dc9568ab_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjg0ODQ_74ca725a-a927-494a-9cf6-b7ae7c507c7e"
      unitRef="usd">2500000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i9e4dca55397644a2849eaef94593433c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjg1NDc_c2181c18-57a3-4103-99c0-81aa92b539d8"
      unitRef="usd">3800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ia7f623bc792547a1a41b06a0787a398e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMjg2NDU_8d31441b-62f8-4b57-8454-2c0ecc7ea14f"
      unitRef="usd">4500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Revenues
      contextRef="i63be51e66fd743578dd0ea8c55b930fc_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODUxOTI1_43490112-8872-4e90-9672-be7ff3b78bea"
      unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9537b5eb6ae949c28d9293e9e3ce85f9_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ4MzM5_48c58e4f-c625-4aea-99b7-483fcfc12be6"
      unitRef="usd">1100000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i427113310e024f5eb793d1e86f25cad4_D20220101-20220731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzAzNDM_ce09b26e-a9da-4732-beb9-3b7619816408"
      unitRef="usd">10000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:TotalAnnualFixedPayments
      contextRef="ic55bd316cd91463e82b7d37fc8a0975a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzA0NDk_ed0d3122-b9f4-4e70-9101-f9bcd567f500"
      unitRef="usd">14400000</mgnx:TotalAnnualFixedPayments>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i427113310e024f5eb793d1e86f25cad4_D20220101-20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzEwMDg_1568fd57-9e94-4d90-a7e5-7499e51ebd11"
      unitRef="usd">10000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:TotalAnnualFixedPayments
      contextRef="ic55bd316cd91463e82b7d37fc8a0975a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzEwNTA_ca217ec8-4401-455f-ae70-5930c6e3167c"
      unitRef="usd">14400000</mgnx:TotalAnnualFixedPayments>
    <us-gaap:Revenues
      contextRef="i7ee85754d5014401ad61235f662351ae_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ4MzQ1_8edf5d7b-8498-4c9d-828d-21992150b213"
      unitRef="usd">4000000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ic55bd316cd91463e82b7d37fc8a0975a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzIwMjg_997403e0-2c37-41bf-a99a-feb00d40898a"
      unitRef="usd">9500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ic55bd316cd91463e82b7d37fc8a0975a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzIwNzc_2db20a13-acb2-451d-bbc3-1ae32d6d19de"
      unitRef="usd">3300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ic55bd316cd91463e82b7d37fc8a0975a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzIxMDU_ccf66020-3579-4de3-b10f-bfce8b98c9e9"
      unitRef="usd">6200000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement
      contextRef="i096d5137725d40148157656180087db8_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzIzNjQ_5a90fa90-e00e-4c73-9c07-93be2aec44c0"
      unitRef="molecule">2</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement>
    <mgnx:TotalPotentialValueUnderAgreement
      contextRef="i772a42253ce1405785340b3edb6899da_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzMwNzY_ac226585-68ba-40e5-8b26-56e1dc86f4e1"
      unitRef="usd">25100000</mgnx:TotalPotentialValueUnderAgreement>
    <us-gaap:Revenues
      contextRef="ib4a0eb4c0fe649c482ed64bbcf0d0b11_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ4NDc4_c44ee503-1e92-492b-9b61-9c78b050c515"
      unitRef="usd">500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f9782aefce248e491b1017c418c61ad_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfNTQ5NzU1ODQ4NDc0_2352e710-4074-4f83-a501-c232cbfff82b"
      unitRef="usd">400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i655cea49e809491ba22491fc3a7a1477_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzMyODM_cec48d56-74fa-41e1-9140-9c0f1ebf556d"
      unitRef="usd">900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d1bdfd0b85f4ac79e062c9afd027395_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81Mi9mcmFnOjE3MzM3Y2NmMzUyOTQ0ZThhNjdkMzAzNGI0ZjViNGZhL3RleHRyZWdpb246MTczMzdjY2YzNTI5NDRlOGE2N2QzMDM0YjRmNWI0ZmFfMzMyOTM_a452e580-40c3-4a0b-bc6a-48486b757cd5"
      unitRef="usd">1200000</us-gaap:Revenues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNTI2OQ_10bfd651-9990-4de0-bcc0-8ed70c2d5e7c">Stock-Based Compensation&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, the Company&#x2019;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#x2019;s common stock on the last day of the offering period.  During the six months ended June&#160;30, 2022, 65,125 shares of common stock were purchased under the 2016 ESPP.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Option Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of June&#160;30, 2022, under the 2003 Plan, there were options to purchase an aggregate of 105,282 shares of common stock outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2013, the Company implemented the 2013 Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&#160;&#160;The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Company's Board of Directors. During the six months ended June&#160;30, 2022, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 15,816,949.&#160;&#160; If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards.  As of June&#160;30, 2022, there were options to purchase an aggregate of 10,395,473 shares of common stock outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation expense was recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.8% -89.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.2% - 86.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4% - 3.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6% - 1.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the six months ended June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;&#160;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,373,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,721)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(267,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,500,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of June 30, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,930,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,719,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of options granted during the six months ended June&#160;30, 2022 and 2021 was $6.96 and $15.11, respectively. The total intrinsic value of options exercised during the six months ended June&#160;30, 2022 and 2021 was approximately $0.5 million and $1.8 million, respectively.  The total cash received for options exercised during the six months ended June&#160;30, 2022 and 2021 was $0.3 million and $4.6 million, respectively. The total fair value of shares vested in the six months ended June&#160;30, 2022 and 2021 was approximately $9.4 million and $8.1 million, respectively. As of June&#160;30, 2022, the total unrecognized compensation expense related to unvested stock options, net of related forfeiture estimates, was approximately $33.9 million, which the Company expects to recognize over a weighted-average period of approximately 1.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants restricted stock units (RSUs) under the 2013 Plan to employees from time to time as a component of their compensation. During the six months ended June 30, 2022, the Company awarded RSUs to employees in conjunction with the annual performance review process. Each RSU vests over a two-year period and entitles the holder to receive one share of the Company's common stock when the RSU vests. Compensation expense is recognized on a straight-line basis over the vesting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the six months ended June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,099)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2022, there was $2.4 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of approximately 1.3 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i5806f140f2fb4121a04208d77d725e5d_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNDI3_46b2ec8d-da86-4411-ad69-b484b4140ce8"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i0bb8e7382f584403b0bd73897bfafdc4_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNjI2_d2c330b5-5538-48d8-98c5-44ff4ede28d7"
      unitRef="number">0.10</mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent>
    <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="id5c46189a60a4d9e98d6758e10e520b4_D20170501-20170531"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNzY5NjU4MTM5OTkxMg_94fc549e-5e23-4bd6-bbd7-dd55da615d4f">P6M</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i0bb8e7382f584403b0bd73897bfafdc4_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfODcy_2449551a-3c35-44a3-98d1-ac50156d3658"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i164a86dfd80c4e50a7e23e302c1c0bf0_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfMTAwMg_5d9d58ec-e003-4498-94fe-040948e161b0"
      unitRef="shares">65125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i43fa69d5c22045ddbb94dd1e3a59d966_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfMTkyMw_99816722-a687-4ea1-be85-5e3b021d37eb"
      unitRef="shares">105282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance
      contextRef="i978da7f614aa4ea690dbff8c9356eb6d_I20131031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfMjM2MA_cb485ef2-1f60-415d-aa2a-65aa033cf483"
      unitRef="shares">1960168</mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance>
    <mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan
      contextRef="idf3d70a2fb43424cb1591bef0c3534e4_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfMjM3NQ_84d47d59-97ae-456d-b452-02bdc49d1993"
      unitRef="number">0.04</mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i3d1a4774b1f345f19d161adf566fb6fd_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfMjcyNw_33146162-fd45-45b7-9652-7cfdfa2d77ff"
      unitRef="shares">15816949</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i3d1a4774b1f345f19d161adf566fb6fd_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfMzMwMw_3835582c-cd44-42f6-a3cd-4aaf2a680626"
      unitRef="shares">10395473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNTI2Mw_ea0ff56d-5474-4ae4-8412-5d505c297235">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation expense was recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5499db67d8414a0fbbfbf13e986ae6dd_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfMi0xLTEtMS00NjMzOA_d5c7d1a6-b107-4cff-a39a-55d4cdc049d2"
      unitRef="usd">2658000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibb0c8219b14e42c7aad0de17683ccf63_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfMi0zLTEtMS00NjMzOA_722c6eea-569f-4faa-ab01-83b251fefcf5"
      unitRef="usd">3058000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if743a9b99df64882ac59cc7cf3cb3f2b_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfMi01LTEtMS00NjMzOA_97117709-502b-44bd-976e-6f5832e1a3c1"
      unitRef="usd">5050000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i133be2faddae4492b069093a43dfefae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfMi03LTEtMS00NjMzOA_b94ff3a0-d5e9-4193-a41a-4e535e62005e"
      unitRef="usd">5785000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id2c0a615ad08480184a8698a62ebdc4b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfMy0xLTEtMS00NjMzOA_8dc60c1e-7a2b-4a0f-ab92-28e40f83c9b9"
      unitRef="usd">2642000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia1253c83d5764ca2869c6ae3052e19ad_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfMy0zLTEtMS00NjMzOA_088bc569-b3b7-4292-bd13-82daee6fe481"
      unitRef="usd">3012000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6e41bc1a29374b0f95aa6bf490e51d76_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfMy01LTEtMS00NjMzOA_402aa959-d140-4a0c-a464-fe967f0c302f"
      unitRef="usd">5524000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i39128793661549b8bdf32a8a1cc51c91_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfMy03LTEtMS00NjMzOA_48dd5cbb-469c-4d6c-8087-02ac5bbdb3e1"
      unitRef="usd">5571000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfNC0xLTEtMS00NjMzOA_eedbbaf7-ceff-459f-960e-302bb4ca3cc2"
      unitRef="usd">5300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if05a3aa8af26496aabc4fd6c1bd31cc5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfNC0zLTEtMS00NjMzOA_4af2f7c2-e3bc-43bd-9457-a0910ba230f8"
      unitRef="usd">6070000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfNC01LTEtMS00NjMzOA_d77d4a19-7bcb-436d-8c75-50615ce71f9f"
      unitRef="usd">10574000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjAxZDUwYjZiODA4NzQ1Nzg5ZGQ1MmY1YzBjMjJjMjFkL3RhYmxlcmFuZ2U6MDFkNTBiNmI4MDg3NDU3ODlkZDUyZjVjMGMyMmMyMWRfNC03LTEtMS00NjMzOA_339d2f7f-65f3-466a-9b44-a964a4fa9236"
      unitRef="usd">11356000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNTI2NA_19a25646-03a6-4993-a21d-5bd8b6908dee">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.8% -89.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.2% - 86.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4% - 3.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6% - 1.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfMi0xLTEtMS00NjMzOA_cb810ff9-6a88-4e56-afe4-1caace2ad277"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfMi0zLTEtMS00NjMzOA_cdc95cab-b50d-4c0a-a113-46b4e597cf6c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic7ffcf2243504d388387524c69d636c3_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfMy0xLTEtMS00NjMzOC90ZXh0cmVnaW9uOjI4N2EyMjhiYzUxZDRlNTQ5YmNmZTU2MDA2MGMyMjE1XzQ_1fdd7296-b6e6-4a76-8e46-4e002b8ca5e1"
      unitRef="number">0.878</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i424f99869a384d90912972e1c1b09528_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfMy0xLTEtMS00NjMzOC90ZXh0cmVnaW9uOjI4N2EyMjhiYzUxZDRlNTQ5YmNmZTU2MDA2MGMyMjE1Xzg_440543a7-5e70-4452-9765-611847543c4a"
      unitRef="number">0.897</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ibd329807983e4f3cb3e69df9ae058545_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfMy0zLTEtMS00NjMzOC90ZXh0cmVnaW9uOmFhYzQzZWRmZjA1ZDRhOTM5MjhmZjU0N2IwMjkyMzNlXzQ_303ccca9-8231-4200-a87a-fb33d9085b3d"
      unitRef="number">0.862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id5649fb8ec294f408a306886c4a94ba6_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfMy0zLTEtMS00NjMzOC90ZXh0cmVnaW9uOmFhYzQzZWRmZjA1ZDRhOTM5MjhmZjU0N2IwMjkyMzNlXzk_d1f0cdad-e450-4420-a5df-6b078b6e26f3"
      unitRef="number">0.867</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic7ffcf2243504d388387524c69d636c3_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfNC0xLTEtMS00NjMzOC90ZXh0cmVnaW9uOmMwOWY3OGZhODMyMzQ0MDFhNTc0MjlkODY1MGE4Y2JlXzQ_1ca21082-665c-4ba0-834e-7c4475637650"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i424f99869a384d90912972e1c1b09528_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfNC0xLTEtMS00NjMzOC90ZXh0cmVnaW9uOmMwOWY3OGZhODMyMzQ0MDFhNTc0MjlkODY1MGE4Y2JlXzk_631c6318-0594-441d-9f11-e914f3456792"
      unitRef="number">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ibd329807983e4f3cb3e69df9ae058545_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfNC0zLTEtMS00NjMzOC90ZXh0cmVnaW9uOmQwYWRmMGEzMDdkYjRkMjBhMmI3ZDYyNzNjYjIwMDIwXzQ_8d73f795-e5af-4345-b207-da4f424ef8f7"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id5649fb8ec294f408a306886c4a94ba6_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfNC0zLTEtMS00NjMzOC90ZXh0cmVnaW9uOmQwYWRmMGEzMDdkYjRkMjBhMmI3ZDYyNzNjYjIwMDIwXzk_7ae2cfb0-bc28-4fcf-b501-c3da12f520d6"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfNS0xLTEtMS00NjMzOA_d4b8a82a-9077-4d12-984d-4d4504884ef5">P5Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmVlYWJhMDRlM2Q0MjRmMDc4NmQzMDg0ZWYzMjMzZGNkL3RhYmxlcmFuZ2U6ZWVhYmEwNGUzZDQyNGYwNzg2ZDMwODRlZjMyMzNkY2RfNS0zLTEtMS00NjMzOA_b505cc6b-9b0c-4b91-bce9-6dd42d6b23f6">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNTI2Ng_eac2cccb-7a88-409f-ba1d-0146b853803c">&lt;div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the six months ended June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;&#160;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,373,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,721)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(267,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,500,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of June 30, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,930,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,719,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfMS0xLTEtMS00NjMzOA_911e8d08-952c-4e89-9b0c-6dd79ab4c8ea"
      unitRef="shares">8373921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i111ca364d8d9452c98412cfc77554d5c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfMS0zLTEtMS00NjMzOA_48076a0c-329f-4790-880f-5a08614cd863"
      unitRef="usdPerShare">21.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="iacfa9386b3a3414bbb61ae3690fcdc16_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfMS01LTEtMS00NjMzOA_c086019e-fceb-4ceb-aa5a-afc3b3434b1c">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfMi0xLTEtMS00NjMzOA_5d0f41aa-3a6e-4447-a11b-eacb62354f7d"
      unitRef="shares">2685197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfMi0zLTEtMS00NjMzOA_be168c78-4c64-45e9-aa64-3274ca3d40de"
      unitRef="usdPerShare">9.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfMy0xLTEtMS00NjMzOA_47f748c9-506c-4d1b-bd04-3eac82fb6439"
      unitRef="shares">80721</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfMy0zLTEtMS00NjMzOA_be0ac180-61d3-4272-92e2-17099e27d34c"
      unitRef="usdPerShare">1.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfNC0xLTEtMS00NjMzOA_f11b322c-e8d9-4119-869a-9f1d316d3255"
      unitRef="shares">267563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfNC0zLTEtMS00NjMzOA_2fdd1d59-8348-4a8b-a501-c1e91a3ebec2"
      unitRef="usdPerShare">16.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfNS0xLTEtMS00NjMzOA_eb85dbd5-29d2-4468-9a10-8d028b897c2e"
      unitRef="shares">210079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfNS0zLTEtMS00NjMzOA_e71a9234-8cc1-42f4-ac54-cedee8ae0ce3"
      unitRef="usdPerShare">23.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfNi0xLTEtMS00NjMzOA_33913b6a-0c98-4714-9cfc-1c1ae8932567"
      unitRef="shares">10500755</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfNi0zLTEtMS00NjMzOA_57e9c4b1-cd5a-4666-b7d8-b0b5e8b02c94"
      unitRef="usdPerShare">18.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfNi01LTEtMS00NjMzOA_d14dcf11-aefd-4cae-91de-3dec91045f3a">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfNi03LTEtMS00NjMzOA_35652972-784d-4dfc-82f8-54268cbbddca"
      unitRef="usd">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfOC0xLTEtMS00NjMzOA_8363e41c-c2b7-4a18-8428-90423341c0a7"
      unitRef="shares">5930958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfOC0zLTEtMS00NjMzOA_7450098e-bedb-411f-898a-d4fe5357546b"
      unitRef="usdPerShare">22.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfOC01LTEtMS00NjMzOA_fe8adfb7-b9eb-488b-ba3f-7f08fd951171">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfOC03LTEtMS00NjMzOA_57290eae-baa3-4bfa-886e-0890379de3ce"
      unitRef="usd">74000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfOS0xLTEtMS00NjMzOA_0c322fe4-1bcb-4e55-910d-5b1e4f963705"
      unitRef="shares">9719165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfOS0zLTEtMS00NjMzOA_45bd125a-9c2e-44ed-8ebe-e19e221c5d91"
      unitRef="usdPerShare">19.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfOS01LTEtMS00NjMzOA_c9f2bd8f-bc75-4b8e-8e5f-2ed3a71aa1fa">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOmYwMzNlNGM4ZDdjMzQ5YjNhYTY2YWEzNjgyMzdhMzQ4L3RhYmxlcmFuZ2U6ZjAzM2U0YzhkN2MzNDliM2FhNjZhYTM2ODIzN2EzNDhfOS03LTEtMS00NjMzOA_93d528a4-8a54-469e-8877-c4f440a6f4f5"
      unitRef="usd">79000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfMzg0Nw_4d38e973-62fb-4c45-869b-001c28084bc0"
      unitRef="usdPerShare">6.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfMzg1NA_f7aedc5d-fd69-4f88-90f9-d7cee32ea4de"
      unitRef="usdPerShare">15.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfMzk3NA_fd3d8831-bd70-4370-b6da-80a12b3fd5d9"
      unitRef="usd">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfMzk4MQ_b378caba-c1ba-40e4-9788-2dad65ed6968"
      unitRef="usd">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNTQ5NzU1ODE5MjY1_524b4583-8b79-4a80-bc3b-a7e0f27fc26e"
      unitRef="usd">300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNDA5Ng_74ef6109-073f-45cd-b7b7-d36fee4b0a18"
      unitRef="usd">4600000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNDIzOQ_341b6f02-1167-4502-bc44-b9357ea52ff4"
      unitRef="usd">9400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="iad530b0c716c4f599b97763de395ad0e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNDI0Ng_3dfb1ce9-2b9a-4ffc-986f-a1dd2f33e44a"
      unitRef="usd">8100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i19ba873ecda04a69b9b0b78f7944a57b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNDQwOA_6f00b646-e65f-441f-ae80-6feae0a88a13"
      unitRef="usd">33900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNDQ5OQ_3809698e-515f-4cce-a3bf-6f79b56a1b96">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1104b4f510e448a6aafaae0d08700a68_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNTI2Mg_cc5281f1-b4f5-48f1-87f2-f6b93336fea6">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward
      contextRef="i1104b4f510e448a6aafaae0d08700a68_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNDg1NA_13eec218-a126-4688-933b-4dc0f078af07"
      unitRef="shares">1</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNTI2OA_ccf3e73e-bf75-4857-89d9-13bda5726f44">&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the six months ended June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,099)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4a101c2276a549c7b6f9656b0b6d6551_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjBkMWIxNWEyNTRlZTQ4ZWY5NzNlMzg0YzBkZjRhNTExL3RhYmxlcmFuZ2U6MGQxYjE1YTI1NGVlNDhlZjk3M2UzODRjMGRmNGE1MTFfMS0xLTEtMS00NjMzOA_b98da7ca-8af5-4544-ad92-cef7f5559db9"
      unitRef="shares">21500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i4a101c2276a549c7b6f9656b0b6d6551_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjBkMWIxNWEyNTRlZTQ4ZWY5NzNlMzg0YzBkZjRhNTExL3RhYmxlcmFuZ2U6MGQxYjE1YTI1NGVlNDhlZjk3M2UzODRjMGRmNGE1MTFfMS0zLTEtMS00NjMzOA_bb5d5728-b2a6-4a40-b1bd-a07135d08296"
      unitRef="usdPerShare">25.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1104b4f510e448a6aafaae0d08700a68_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjBkMWIxNWEyNTRlZTQ4ZWY5NzNlMzg0YzBkZjRhNTExL3RhYmxlcmFuZ2U6MGQxYjE1YTI1NGVlNDhlZjk3M2UzODRjMGRmNGE1MTFfMi0xLTEtMS00NjMzOA_9c5dccfd-0e0a-4624-9925-ca897eb7919d"
      unitRef="shares">314372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1104b4f510e448a6aafaae0d08700a68_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjBkMWIxNWEyNTRlZTQ4ZWY5NzNlMzg0YzBkZjRhNTExL3RhYmxlcmFuZ2U6MGQxYjE1YTI1NGVlNDhlZjk3M2UzODRjMGRmNGE1MTFfMi0zLTEtMS00NjMzOA_7404ffaf-e2e5-469a-8f7f-03681376808c"
      unitRef="usdPerShare">10.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="i1104b4f510e448a6aafaae0d08700a68_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjBkMWIxNWEyNTRlZTQ4ZWY5NzNlMzg0YzBkZjRhNTExL3RhYmxlcmFuZ2U6MGQxYjE1YTI1NGVlNDhlZjk3M2UzODRjMGRmNGE1MTFfMy0xLTEtMS00NjMzOA_f647dcba-d652-4dbd-94c7-5562de9cbfd7"
      unitRef="shares">8465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1104b4f510e448a6aafaae0d08700a68_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjBkMWIxNWEyNTRlZTQ4ZWY5NzNlMzg0YzBkZjRhNTExL3RhYmxlcmFuZ2U6MGQxYjE1YTI1NGVlNDhlZjk3M2UzODRjMGRmNGE1MTFfMy0zLTEtMS00NjMzOA_a27f1546-0a9e-4ce9-983f-2b766e4006d4"
      unitRef="usdPerShare">26.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i1104b4f510e448a6aafaae0d08700a68_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjBkMWIxNWEyNTRlZTQ4ZWY5NzNlMzg0YzBkZjRhNTExL3RhYmxlcmFuZ2U6MGQxYjE1YTI1NGVlNDhlZjk3M2UzODRjMGRmNGE1MTFfNC0xLTEtMS00NjMzOA_d849919f-511f-42f5-9864-a5c5230c8670"
      unitRef="shares">20099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i1104b4f510e448a6aafaae0d08700a68_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjBkMWIxNWEyNTRlZTQ4ZWY5NzNlMzg0YzBkZjRhNTExL3RhYmxlcmFuZ2U6MGQxYjE1YTI1NGVlNDhlZjk3M2UzODRjMGRmNGE1MTFfNC0zLTEtMS00NjMzOA_33bb24d4-b2d0-4c50-bee9-7f72b8a05e7a"
      unitRef="usdPerShare">10.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0fd134611cfd4590aae18ff1ca79c965_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjBkMWIxNWEyNTRlZTQ4ZWY5NzNlMzg0YzBkZjRhNTExL3RhYmxlcmFuZ2U6MGQxYjE1YTI1NGVlNDhlZjk3M2UzODRjMGRmNGE1MTFfNS0xLTEtMS00NjMzOA_4c0a0aba-8893-4f58-9843-40c37f488f81"
      unitRef="shares">307308</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i0fd134611cfd4590aae18ff1ca79c965_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RhYmxlOjBkMWIxNWEyNTRlZTQ4ZWY5NzNlMzg0YzBkZjRhNTExL3RhYmxlcmFuZ2U6MGQxYjE1YTI1NGVlNDhlZjk3M2UzODRjMGRmNGE1MTFfNS0zLTEtMS00NjMzOA_03193949-61bf-4e8c-a7c6-6f261006dd6a"
      unitRef="usdPerShare">10.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i0fd134611cfd4590aae18ff1ca79c965_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNTA5NA_d5fb7e70-cc84-498f-9991-1a1007229dba"
      unitRef="usd">2400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i1104b4f510e448a6aafaae0d08700a68_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81NS9mcmFnOmViZTVjZDYzOWFhMzRmMTQ5OWE3OTJlZWJhMzRhZjE5L3RleHRyZWdpb246ZWJlNWNkNjM5YWEzNGYxNDk5YTc5MmVlYmEzNGFmMTlfNTI2MA_8fa52f1c-fe9a-46c4-b81a-5f97c940fc85">P1Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDY3ZWNlZDkwZDQ1MTQ4ODU0OGRmYmI5MDc3OTIyL3NlYzowMTA2N2VjZWQ5MGQ0NTE0ODg1NDhkZmJiOTA3NzkyMl81OC9mcmFnOjMwNmRmOTBiY2IwYTQwOGRhNDVhMmIwMmEwYjJlOTU0L3RleHRyZWdpb246MzA2ZGY5MGJjYjBhNDA4ZGE0NWEyYjAyYTBiMmU5NTRfMTI5Mg_87d566d7-944c-4b23-8c9b-895ee9f6f407">Commitments and ContingenciesOn September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland (District Court) by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#x2019;s SOPHIA trial. On August 17, 2020, the Employees&#x2019; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint. The amended complaint asserts a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020. On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice. On October 28, 2021 the Lead Plaintiff filed a Notice of Appeal.  The appeal is now pending in the Fourth Circuit. The Company intends to vigorously defend against this action. However, the outcome of this legal proceeding is uncertain at this time and the Company cannot reasonably estimate a range of loss, if any. Accordingly, the Company has not accrued any liability associated with this action.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>46
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" "8@ A5&\R[=]0%  #/'@  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+69:W/B-A2&_XJ&=CKM3 B6#.32A!GB)%O:39:$]++M](.P!7C6MEQ9AN3?
M]\B G:3R@7J6+XEOYT6/CBZOI(N55%^RA1":/,=1DEVV%EJGYYU.YB]$S+-C
MF8H$WLRDBKF&6S7O9*D2/"B"XJC#'*??B7F8M 87Q;.Q&ES(7$=A(L:*9'D<
M<_5R)2*YNFS1UO;!8SA?:/.@,[A(^5Q,A/XU'2NXZY0J01B+) ME0I287;:&
M]-QSF0DHOO@M%*OLU34Q*%,IOYB;47#9<DR)1"1\;20X_%L*3T2148)R_+,1
M;96_:0)?7V_5;PMX@)GR3'@R^CT,].*R==HB@9CQ/-*/<O63V #UC)XOHZSX
M2U;K;[O=%O'S3,MX$PPEB,-D_9\_;RKB=8!3$\ V >Q= *W[!7<3X!:@ZY(5
M6-=<\\&%DBNBS->@9BZ*NBFB@29,3!HG6L';$.+TP)-+H<@8,D;:)%MP);*+
MC@9A\[KC;T2NUB*L1J1/[F2B%QFY20(1O(WO0('*4K%MJ:X8*OASGAP3USDB
MS&',4AX/#Q_F\V/BN+;P-\5QRTIR"ST7K:2_AM-,*VAW?]MJ:*W0M2N8SGB>
MI=P7ERWH;9E02]$:?/<-[3L_VO"^DM@;V&X)V\74!]?2SZ&?:O+TD@H;*1Y.
MG?:##0F-:HC4*Y%Z^R$]Y%QIH:(7\BA2J;0-#Y?2*K=5BH=&-<3KEWC]_?#&
M0H4R,+V0P&!@31ZN5/:[VHZ'QC?D/"DY3_9LF8K#/%), _5YQ+5F/,JLB43#
M&@*>EH"G:*%N$AWJ%W(;1H+<Y_%4*!L8KN$XM.WV*;5F#PUM"'=6PIWM _<H
MYJ$91B&-]SRVME%<YV[H/7[Z<',_\B9'9'3O'=M 48F&H-2IYE1G']11XDL%
MS9.;EGI$)AKZ))&*>#)/M'J!_X&5?X?Z]8V-& ]JBOS*1M!]D)_X,QD%T$?#
M6>@7W$A#WB'I]-NT=T;[U+7RHL%->5G%R_;A'08!J&='VPOR$;XCGQ)[7G')
MLQ.G2^Y$ !47$0_J$#S'M0*3:\5'M9KB5X:(HA;D/_B>N8.F_217B14=EWN4
M_I=E&$5VU$.X(5K9(8H;FO>H93<>*[D,$]^>:ESS[MH*>@B/1"N31'%K\QYT
M+#,-+?'/,*T?J7!%YISV'"OI(>P2K?P2Q6U.T5J'L.JM!\,%7(=:L0[ACFAE
MCRCN:3Y*,W*,%S+![,,.$=:C[1X]L=H'/+0I7^6.*&YMGD(-QDC."&7?3W\@
M$^'G"C)IA<25/!G',#5--(P[1R3EBBQYE ORK7/L4)+"P%LLA:UU< @/12L3
M17'W ]8W"),YF;S$4QE9T7?8IP_W?UBY#F&96&69&&YJMLDD-\_^@B=S4>L.
M=PC=#R?70^L*% ]L2E@Y)+:70_)RI<P:9KUP*5()$TINW779H?C9NE?CX5%-
M.2MGQ/9R1B/C7]:;=&8QRK?@5DY<L8[S$!:(51:([66!S&(-+#UX@KE4UK%H
MA\Y'KJ"U#WU?@!#(!&M)*_$AG!"KG!#;RPE-8AY%Y"K/X'5F;[>X3MT>"A[6
M%*_R/VPO_W,3"S4W_?(#*.@%6(0XY8D]L[A@[1X#'M<4M+(_#'<OVSPN!.01
MP\-EZO$.88-898,8[F"V ^V;.7Y2;&V33[D&4YN8*=1*_)4,SJ8>UFJ]0LV<
MIRP'?=KMG9Z<@2E>VA@K*\1P S.,11(4>V&W$;>CX +UR3N$OV&5OV&X/2GW
M^&[#S+C9SP+,V2T\M \TN%CMZ<$AO(Y;>1UWQP;..\;-MFTMY0ZY!RLC'M24
ML7([[GYN!S 5((Z20#R37X1UG-DAY3@.I:SG=GM6SD.X';=R.R[N3;9V[G5S
MQ?;?=\BUVY2U7>OB$H_\OZ"=5T>&9L(K3E(SXINMR?7I8?FT/*T=%F>4G>KS
M]5'O'3?S948B,8-0Y_@$!CRU/CU=WVB9%@>04ZFUC(O+A>"!4.8#>#^34F]O
MS ^49]B#?P%02P,$%     @ F( (51.\-3FF!0  \!8  !@   !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6RUF&USFS@0Q[^*QM>YAQDGEL2C<XYG$B>=]J9M
M,G5Z]UH!.68"R)6$W=RGOP43P""P.Y-[T0;,[O)?/>R/U6PGY+-:<Z[1CR1.
MU>5HK?7F8C)1P9HG3)V+#4_AR4K(A&FXE4\3M9&<A853$D\HQNXD85$ZFL^*
MW^[E?"8R'4<IOY=(94G"Y,LUC\7N<D1&KS]\C9[6.O]A,I]MV!-?<OUM<R_A
M;E)%":.$IRH2*9)\=3FZ(A<+ZN<.A<7?$=^IQC7*4WD4XCF_^1A>CG"NB,<\
MT'D(!G^V?,'C.(\$.KZ704?5.W/'YO5K]/=%\I#,(U-\(>)_HE"O+T?^"(5\
MQ;)8?Q6[#[Q,R,GC!2)6Q?]H5]KB$0HRI452.H.")$KW?]F/<B :#L3N<:"E
M SW5P2H=K"+1O;(BK1NFV7PFQ0[)W!JBY1?%V!3>D$V4YM.XU!*>1N"GYXN[
M+\N[3Q]OKAYN;]#UU:>K+XM;M/QP>_NP1&?HV_(&_?[N#_0.12EZ6(M,L314
MLXF&-^?^DZ!\R_7^+;3G+7]EZ3FR\!A13*G!?3'L?L,#<">%.SETGT"^5=*T
M2IH6\:R^I#,I>:H14XIK=6'*9Q_ -@?(]]:%VK" 7XY@\R@NMWPT__47XN(_
M3=F]4;"#7*TJ5VLH^GS!U!K!K*$@O^#?LVC+8DC>.(O[4&X1*B\ VSDEMCN=
M3;;-=+I6A%I-LP.A=B74'A3ZF<EGKMECS)'B028C'7&CR'T8I_EZ0JE'6BH-
M9A03VS.K="J5SJ#*JR 0&8P>E+" PU""7)-&I_MRW_*=ED2#%;9\UZS0K12Z
M@PH_IEN87B%?QBCEVB3.[;R63NWV)'>-;,OWS=*\2IHW*.U>\@V+0L1_ (44
M5\6Z%'K-)92ZYI8TJ?8,\^DX;=E=*TJ(A\VZ_4JW/ZC[06@6GR#1[TIT/=>R
M6AJ[9M2;.FZ/R&DE<GID<('M4L.TYYM\DQ1287R56.D=D[QW.4P[<BR[*-,'
MH@U6'B1GUDQPC1\\J/JNF/T4@'Y\>,M0A^/;7)0E2PQF/L8]Y8DT2$E.6 4#
M\HAA[?G8;D^_P<ZR'&H[/0)KJI'3L!9'[#&*B_II9!MY4[B]5;3#I&N\D6&^
M505YPU[ZJG$9XF!F7-PN'08KXCBX9UN2FFMD&&R@4&9\L.HU9LRHO\LRBT!A
M:2=@,+,\IV]=U<@CP\R[X2L..D-@'J E,P^Q@67$<=O$,YA1[-I]9:1F'AF&
MWB<.G_)'A]' M*F-VQ(-5J[7\]E :O218?8=,N28TB[&'.PW1)12NV:>[7@]
ME"8U[L@P[]H37J #B54E?R-DWH09I7?IYI+N4NU:]>VSFG]D&("=-?!3LKM\
M(SYU[;;NKAG%WI28M=,:@_1G,7ADA= NY*C3)N$1HT.M-0?I*1P\IJ\+.:A$
M;ONKPF &7T*T9[?11H,WC,*E%L'S6L0AE^JWXH-(OYC[O+=M]/X/%M*:A?1(
MKR>2!):0RI,?HW?X'!/ HD30\64<G9TA^&(>8XSS?TBMX:,08)3IM9#1OSP<
M(Y>,;<<?>U-<, IN+>R-;>J_&HM,*PV/HO0),8V@K>=[^:^]?>$'[3I/'KDL
M'Y5]^QBJB=KPXM@F?C'.11? +FD3Q&AD]:R7FM'T"*/#,,I+ RSLO$,YBV C
MLDT$"]THU-1;4LOW.F)-AL3"F/8(KIE,C_:A69+%3//J6T(DL*C6^0G;%LJ@
M4.9]V07PF47=MFZ#E=M7Y&I(TV%(-S6'?!4%D;$?H5T GQ'L$]=O4\1D.?6L
MJ=7S/4%K6M-3:*T,5<2HV-";VM3VVT<2!CMJ35W25Y)K8--3&M1&2=YW?J?*
M]PW'/H;&Q6!G;%PFC>/(_"SX,Y-/4:I0S%?@B,\]& "Y/U[=WVBQ*4XH'X76
M(BDNUYR![-P GJ^$T*\W^:%G=<@]_P]02P,$%     @ F( (524-+3V( @
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M""W8,MZFY3U__,3V@IR*;\Y34?]%CWNL-4+SK2AYMC>6(\B2O/D?_]@[XLA
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MNE%I"U:LK<(F7_*"Q6GR'UN@52R[W[=52-XAGLO)MV.BK+97.$$=($&IFIT
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M[+W90;4"4-'$J7KH_"@O@#W="V" C@Y#;GU/QIVB-PFH7D#':Q!8674:E!?
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M1Q0G%'E<<2IMSL??<\>-^?WY"2K:%!4M04436&CZPX*4[1"X;8=>CPNR+8&
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MF^= ?RF;IEQM7BZR5 J;-D#^_[8LFV]OVD=+[Y]N?O$'4$L#!!0    ( )B
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MA@7=5F@Y@+[GQOC=A FZ^V_Z!U!+ P04    " "8@ A5Y(V]4]4&  !K$@
M&    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;+58:V_;.!;]*X2GF&T QP_)
M3=PT"9"DF]T93(&BF<Y^6.P'6KJVV5"D2E)Q_>_W7%)6E(?3HHO]8I$T[^&Y
M;TJG&^MN_9HHB&^5-OYLL ZA/AF/?;&F2OJ1K<G@GZ5UE0R8NM78UXYD&84J
M/<XFDZ-Q)949G)_&M8_N_-0V02M#'YWP355)M[TD;3=G@^E@M_!)K=:!%\;G
MI[5<T0V%S_5'A]FX0RE51<8K:X2CY=G@8GIR.>/]<<-?BC:^-Q:LR<+:6Y[\
M5IX-)DR(-!6!$20>=W1%6C,0:'QM,0?=D2S8'^_0KZ/NT&4A/5U9_2]5AO79
M8#X0)2UEH\,GN_DGM?J\8;S":A]_Q2;MS8\&HFA\L%4K# :5,NDIO[5VZ G,
M)WL$LE8@B[S309'E>QGD^:FS&^%X-]!X$%6-TB"G##OE)CC\JR 7SJ^E<N(O
MJ1L2=BFNE9&F4%*+WXP/KH'U@S\=!QS$V\=%"WJ90+,]H$?B@S5A[<7?34GE
M0_DQ"'8LLQW+R^Q%P-\;,Q+Y9"BR29:]@)=W6N<1+_^^UN^5+[3UC2,O_GVQ
M@-8(E/\\IW."G#T/R<ESXFM9T-D V>')W='@_-=?ID>3=R\0GG6$9R^A_ZR;
M_F=0\>>:Q)6M:FFV?_-BV>U1O3V%18[ZP""%]&LA39D&]+51=U+SIB&"UMU2
MD M-PE/1.!4485D6A6T8Q5%!V(W_>XNUW$8)AL2B:Z@4] T5R9,?17*%=&ZK
MS$K(BD68Q,]#"NE(K,B0DUIODV(E.>P(5BP(@-&W)DBN)7Q66!.,B,6:8GT1
M2S;J'1O50Z*0C>_M\VOKPF$@5PDC V)NU#?P/4<46R;?.!<U U-CS>']ROTA
MHB+)P9L\H4S$<"6\1*@D8<T']UQ[D4Y@C)L 7.E*+RXM'N+U]<7-Y<'S.ZYL
MJ9:JD+&0OKZXN3H0\PSIV(N@#WT>S+B?6"S"$@<CT8ZX<B(<?4^5H2#/\:%0
MS0#15W*MX!%7K+?1,M)[:@_12BZ4CJ&TLP2\&AZ@\C['H<A,X&G)14F4/7IR
M@7:USZC)13O:]TR<-+<^FO=K(T%ARVYVM&,4I\K4#<=^(MU4-1L0<P1%R<YB
MZ9(X'N"A:%P(]7@\H+Y';4X ]5CK-EX+#2%XCO\VG<[I;&MV@0FC:C1G=GE8
M.^*<"K2R0/4GXM=?YEEV]$[\07>DQ50<)J>G4Y3OZ -TL85BC-(867Y![\+:
MU\;RHW:J(+866'*.R3NI=$Q#M>O,;8%(P8^L0PP6B-CGM1X]XI7]$*_D#F&A
MLV,NIM-J#\T2AB\"*@%3,O>S!==WIC]"L8R8!<"4*713TB,P5L>K"NKNC=RG
M-H#,4Y3O&85Q$$</D$;B$VD9HLL[HE)[V[$-:T1$%Y%LOS8276LH9L#6JVQ)
M&L'KFP(UGD^#A9&RR(1 B<Q6D4;M;]#\6BOR<1R(UCF[L"XR6?0MV!(5)6XO
MC[V:?\>KK4J=NQK3PTU5,SPY^L%YG[OJ[&D'I\R=U:R 5RL3RQ[:"J/Y9O&E
MK?)?FG*52EU*M$K"D@"7W")0X]E>["R4@4-!H]5HV%%/%5W(NG86I@4MD;*%
M\1A.QCR-S6P)9\(/T?E:*Q2"DB'A?ENHJ%"L\5*L0,KL^NKV85>AY%/JM^\]
M =1JR"SVM1B^2?=Z$V[$*AJA\TRL*'WM=/0E7+19*T0.]K9E:<M;*T$2J_=F
MJ\DI6[(*/7^GD.Q*8>BI![Q*WM+SWI&1&V^_=V9!]Z6YB_N^=QX5X V2@%+4
MMT):I>;:5O GO2':'S(;_C$X'[W"+\GQC2!L")Z*-H%ZC4M5EUJU<3U)%PR"
M!:X?N^OY#O>\2^+9TK>U'2TXDK6-ATK^X&1_ZPX"MVWJ;MOB3QO 8%<H=^7V
M(C(ZX8L^=3FU;( M7HGY<'J4]9Z<U=/LG?@\NH%I7#QNV[L%BNGDS7">'W?/
MG<"5=77,7/AG$?H21\-9/NOVI5EB^K*M7LL#$)KB\C++<QY-\^';MV\Q2A@O
MF.4];I/5 @4QGT;33'_&--/C(43[@^\:9SX=3O-L]]AM_X>](V>8W*&O<:FP
MK"L'CD/:\57V>'C<LU":[;=G#CKS2;>]G?Z011?1HK-\F,_F&+V=#W,<]4K,
MW@PGTUFT^(_@/ F\MD'Y5$R^*;R"$YKOJ_DHPYLPRF&L"%PV4@KO???@!.$4
MX^N\U:I,G4#J6 KBJ_,H:O&#+)_&P3ZF6?Y_H/K<V^2X]P&@(K>*GSGXQ0Q-
M)'T+Z%:[+RD7Z0/"_?;T&>:#="N\W*%"+2$Z&1V_&0B7/FVD2;!U_)RPL"'8
M*@[7A/;G> /^7UK<6]H)']!]7SK_+U!+ P04    " "8@ A5^$J%WO\#  #6
M"0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6R=5MMNVS@0_15"771C
M0+&NOC2U#3CI=8$"09/L/A3[0$MCBPA%JB1EU_WZ'5*R8KN.M^V+1'(X9\Y<
M..1D(]6C+@ ,^59RH:=>84QU%00Z*Z"DNB\K$"A92E52@U.U"G2E@.9.J>1!
M'(;#H*1,>+.)6[M5LXFL#6<";A71=5E2M;T&+C=3+_)V"Y_9JC!V(9A-*KJ"
M.S /U:W"6="AY*P$H9D41,%RZLVCJ^O4[G<;_F:PT7MC8CU92/EH)Q_SJ1=:
M0L A,Q:!XF\--\"Y!4(:7UM,KS-I%??'._1WSG?T94$UW$C^#\M-,?7&'LEA
M26MN/LO-!VC]&5B\3'+MOF33[!V@Q:S61I:M,LY+)IH__=;&84]A'#ZC$+<*
ML>/=&'(LWU!#9Q,E-T39W8AF!\Y5IXWDF+!)N3,*I0SUS.P358]@Z((#N8.L
M5LPPT)/ (+3=$&0MS'4#$S\#,R2?I#"%)F]%#OFA?H"4.E[QCM=U?!;PKUKT
M21+Z) [C^ Q>TOF9.+SD&;R/8@W:8#49[9,WL#"$BIR\_5HSL]WSG'R9+[11
M6"O_G@I"8R,];<.>GRM=T0RF'AX0#6H-WNSEBV@8OC[C0=IYD)Y#__E,G84Y
M3?(D-KDO@"PEQW/+Q(HXL6Y/+_L.Q*#X1I85%=L_-=9D!Y';\.HGG LF<+.L
M-89<]ZX(YA:ZW))Y*95!O)R\5U+K]ON.,D4>^G=]<H^]1M=JNX_X!XG"H1^E
M(QR]?#&.H_@UCBZ2*.PYV< ?)R,DIRJIJ/F1T=!/TU>=YD4TZ-FE)"7WTE!N
M(:+8'[P:'L''@UXKBT<15E$&Y0(422+G2O2;KHPC/QJGAZ8&<:^5)#%Y+]>@
MA*W=2UU)H:5""S@#52FF$6/DCY(]=Y"E74G/!  IQ^/!DTK::Y:BIPC$H1^'
MXT-:PZC7BFSLYYP3NJ:,VZQ?X@5QJ2FF_TPE%,!S0C61RZ,BL(?QQW@6-"<9
M]A5['FMDA4UXAX0(6(T:ZXH*(A%J"U3U'244'9;FKW'$8D7(6F"NN,LEMTFL
MI&;--?+3[#>@P*$=(2")/>YF WR-A%S[[).'0[O64W'*@6/6OTA+2-1F*\&6
M+*.B:89.@!5ECS??DKS&(RY)AB1735B8+3GLHL26%+91)C)>Y[8W-.$D&18F
M0^#F>> [5&NIA<+]]@"@:^U&K-Y'2UW+C"$D4F"F0'7(+*\]]S"Q62:5M<6W
M/F(2:ML2%1FX<+9X;<04<(>&)O^W$([CN*%6W]I"@%-=.]B[:TM0*_>BT%BF
MM3#-M=NM=H^6>7-7/VUO7CS8=5=,:"R&):J&_=' PY"X5T0S,;)R-_="&GP'
MN&&!D05E-Z!\*:793:R![BDW^P]02P,$%     @ F( (5>3H_:>= @  O04
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M72A+[>ZW!<U7U"Z _+E2=G-P"=J)/?T#4$L#!!0    ( )B "%5O&3&F^P0
M ,X+   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;)56;6_;-A#^*P<W
MZ O@R;+L.&F3&'#2#.O0=D'<;,"&?:"EDT6$$E62LI-_OSM25N0LR;HOMOAR
M#^_E>8X\W6IS:PM$!W>EJNS9H'"N_C :V;3 4MA(UUC12JY-*1P-S7ID:X,B
M\T:E&B5Q/!N50E:#^:F?NS+S4]TX)2N\,F";LA3F_AR5WIX-QH/=Q+5<%XXG
M1O/36JQQB>ZFOC(T&G4HF2RQLE)78# _&RS&'\ZGO-]O^%WBUO:^@2-9:7W+
M@T_9V2!FAU!AZAA!T-\&+U I!B(WOK>8@^Y(-NQ_[]!_]K%3+"MA\4*K/V3F
MBK/!\0 RS$6CW+7>_H)M/(>,EVIE_2]LP]Z$3DP;ZW39&M.XE%7X%W=M'GH&
MQ_$S!DEKD'B_PT'>RX_"B?FIT5LPO)O0^,.'ZJW).5EQ49;.T*HD.S=?.IW>
M%EIE:.P;N/S>2'=_.G*$S.NCM$4Y#RC),R@S^*(K5UBXK#+,]NU'Y%'G5K)S
MZSQY$?#7IHI@$@\AB9/D!;Q)%^;$XTV>P0N!P5^+E76&F/#W4S$&B.G3$*R.
M#[86*9X-B/X6S08'\]>OQK/XY 4'IYV#TY?0?[@._Q\%/E7P56^P7*'A=%)2
M78%PH<M:5/> E4.#&<C*:1!@A4(+8FT027H.WB[]Q&(W\8[XZ0H0I*<UKY,1
M24P-(3>Z!$=ZY2G^'X(M!"4*= [264AU69(,+;L(A=C(:AU@"'HM'+9'UT:F
MR#9-S4@'XSB.8F*^4BQB5QC=K/WYKU\=)TE\(IP/ASK*+;4PG>=H"-DOCD_@
M[>+;%_BMG7P'PK)B*6D<+UPW"F$Z/H2&6&L\S!+3QD@G.>24X6#\?C(9LJ&@
M\(G<$7RC?6UHKJ#CMY0_L)3T/LY^UL(>:6U#)XLJ"]OKQMA&A"3V2O+&$CRJ
MG'K>6C)=??NRCG+DL6C #0F6/TU:!\B[7"J"]K7QYU]>\+ZN[E.OI#B"CPUG
MPN^Q\@[*(%L?&9#H<">Z\3Y+O+^3X2Q)AN/C6:^R>U4E7P2%RHV0X]R@(9*T
M%:W)"V_&5@?)432C@PB$NB<[1.6HJ'ZUT2EBYJ%%3:,[29T7U3T<O#^.DAT/
MAGXSDX0SON6*$48F;:J;BKC&*6;/*..T.XPUQ6,Z@@#>T;UFT4:LCP7YJ)X(
M>T\<"R: K\!7'<%X5[5_E;J0:4$6*=V1UG,$B3OL%SO<0V>.CH].'BG#5S0E
M?J]:4JWN]US:*8 E%23XP+H^V5M%[BFL"_X_1*9_T&S2-PO"V+E9$"<K[4((
MGD%/4\:@$DR6'\^O\"!]KB81+*AQ"--E.*6B2\I*D X]7?RL86):6!O27#CR
M3R'ALUC!S1(^?[[H99*N5256N@5@^B@*G?C2:XT9VM3(%2&5FFB=-XIH*EET
ME+.C(5SC!JL&]QG%4(].?=R!D2+Q_= GB)I$2LG$O9[L5ZYV*[WF3,?[S#"5
M([AIXY$6GC,9/O:F%C+;]WA?AI-'3.G\>W]X/)S.CDB96\Y#Z'4/5=]O<'T.
M#+ETL!&J03@@=-*@;R2YO".$CG,'DW$TB5MY&?1WL*^C8/Y&T\XI6BEE4P+U
MOE#,T'9:H"J0ZIET0$9A1D_=YZ/>&ZM$L_8O20Z$A!V>6]UL]UA=A#?:P_;P
MTOTBS%I25U*8DVD<'1T. C=W Z=K_V);:4?O/_]9T(,;#6^@]5P3Q=H!'] ]
MX>?_ %!+ P04    " "8@ A5=HMJGX4;   ?A0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6SM/6MSVS:V?X7C=5M[AK8EV7FT33+C).VVW62;B=-[
M9^Z=^P$B(0D-26@)TK+ZZ^\Y!P\"?$EVXZ2;S8>FMD0"Y_T&_&0CR_=JQ7D5
MW>19H9X>K*IJ_=W9F4I6/&?J5*YY =\L9)FS"GXMEV=J77*6TDMY=C:;3!Z>
MY4P4!\^>T&=ORF=/9%UEHN!ORDC5><[*[7.>R<W3@^F!_>"M6*XJ_.#LV9,U
M6_(K7OVV?E/";V=NE53DO%!"%E')%T\/+J??/;_ Y^F!_Q)\H[R?(\1D+N5[
M_.7G].G!! 'B&4\J7('!_Z[Y"YYEN!" \2^SYH';$E_T?[:K_TBX RYSIO@+
MF?VW2*O5TX/'!U'*%ZS.JK=R\Q,W^#S ]1*9*?HWVNAG+^#AI%:5S,W+ $$N
M"OU_=F/HX+WP>#+PPLR\,".X]48$Y4M6L6=/2KF)2GP:5L,?"%5Z&X 3!3+E
MJBKA6P'O5<_>\FM>U/S)606+X4=GB7GQN7YQ-O#BP^BU+*J5BGXH4IZ&[Y\!
M$ Z2F87D^6QTP5_JXC0ZG\31;#*;C:QW[C [I_7.!]8#/F5L+DNFN5^DT2N1
M@#3QZ')9<@Z"5:GH?R_GJBI!-/ZOCP)Z@XO^#5!=OE-KEO"G!Z /BI?7_.#9
MUW^;/IQ\/P+^A0/_8FSU,<;L]6+DX7_-"?]?JQ4O?>Q_+I)MA4^6:TLG\U&'
M5/ %,&;Z*(Y@$7@C7[-B&\$7O.1I)(I*PA81OTFR6N%^RTS.618E'29D9F7F
M5MZ(:M4'RI'^[#@"TP/Z7XD% V1S-H]Q*U%<<U6))3T+.^6RD$E&/[*B$G.9
M;@%45L&#*S$7@.VZE,N2Y3G FX 5 -UEL#%\6G%11-/HZ,W+D^FQW;9+@N-3
M"^6*J4C.*S!YL%:#,]B?+ 7UY5&)MD 1X$BN%%B2R35ABS1()$!1)H)EX@^-
MJUP$& +0$0,019&*A)Y0<;19B8P'Y(=7  9%G]&6$;#!;!81RF+-43XBIA2'
MWV%9V'LN"KTK4=[?]S3Z#;19 PV<S14"AK\,T22VWZR92 /8@$7U>E&"C8#O
MMH0ZK'4X?3 YG8 ARS($0&BA0L)&O]39%G5_ZM9D12'K(N&I9B2N_N/+2Z ^
M")Q2-7S.:+N,P\-ON5I+A.T5KP#TZ.C%VU?'@-R2E:DHED2.YT)F<BD2U2"R
M7F>&PM'1\U>776$#TL$V:Q 2D"H0K@I<7T7HX),L!>L/"%:"%(H(FLD$> <4
M2*\900_/Y< I5<%C"?B=FN6R5EH($P9R4,B<64HSE. $_[7B]O7?'L^FC[Y7
MCAZTNQ&--G%2CGPCP:3/69H*HR$I^(>(E3PJ.$_Q>Y054!LT@)46K 2$!5;-
MHCDO^$)4';FT$JWJ>2ZJBE3?BFA,LDV[&@9N@'8EOP9/BAP@Z7C[BI[:R#I+
MHU0H<'$* +JI(E7QM:&@0<;I&^RF^+]J0!O(BD^D);A[Y.@/=0GQ"<@:\QB)
M0$*$\1X AVU97:UD.:1H%J&&K?!$PZ+=W"%C@*Q%6@!;0.GJ4M6XLZ_V/0KN
M9"I#35X*X@/ >,(+-L]P 575J> *N+&50+2])2>&Y<$H:;DO6N+Y^NKGDQ48
M"S#>J02Y+(5^+>%E'+WF0+:LO0%RK # 5(Y&B;[,:EA;O^4H ;BS3,F]"= Q
M13DHDP!U1J.<UDF%&Z0"Y!9H *8D#VP:&8W+=2DRBACBEO5)+53\AB<U<@>E
M!$!)"1P0_C&[AM^#ZH#F@ZD"/R/!AJ*H_'9Z=8JR5LIKH%J?U8[4FB=B 8K>
M:(96#*E=!;@'(!H:[DB20P;>UQFK9*G!#IQ%LA+P:]YPK[U?M0*J*\#+WXYH
MA>@UP&-04.TTYW>P_V@>D:H\=79[(U! ($.P4<"(')Q&EV#*<Y+V.DFX4HLZ
MV\-ASK=FMY#O"=F5DB<<'7*]1JH?7IP_"'U.>WF/ XYBBKXQ*YR?M[Q6 Y#W
MQFGTHR4\Z!]?6X,S+FBK4M:@C1#^<A?^1B%6*[*CB5P6X@\0Y,-'DV%\/ 1J
MQ\MA?GN.=UB%%G5)DFH8O5-S(+'"K"M*5JQ8<H0]TYY**YT7#UA-:)$]#'*(
MF8!VFPF-=)L5C970H %N;?541G7)&(12A>+K[ZH=U!P4)Q-+,<? 2SJY G.*
M46\IMPP,%B<MF3[X"A^977P5D<)OK? 7D%DKEJ%XO+O/V"T. FD?-U2N,*1I
MD;C],&Y/NQZI8_ E"T('U'/EQ4$>+(JB"DM:DBD;=L0M5O;@G+.B7D &5N,:
ML$%IU68.YA&W@5>!QM\T*853/56#U]]2/*/:AB7&J.%WE$(C=8JO&04ZW058
MHP\^BSC8^-J$6","WZ@9$D HH@A <YF -2HH!KFJ@.00B"I8.T7GH'GX3J[!
M3SR</(PCF[61 +^ J!F34F/S7U 9@)<J.KJ\>H'/'Q,+(=. Y1?" +B 7$OJ
M2&L#3IB75+(!0P2Y2F82)=\H.*R_BX[$,7UDD[.V8\/=CH1Y*%BY46$7.U*A
M19!>6./&HGDI.%A"GJP*C,$A-RM9H18 "BPG9!I2OAW%^K"1YO;LA3+H>#R$
M_9PGK%84[&[IC82M&6HWRANGF 7B,+#>E8YF\1'[B7:W*#^0]=Y4UK(GAED:
M PNEB0J!ZQG%#A"WZS!<5%OTF3I4!!'5+R ,<1!1"C#V*"A%I6$4F483XSF-
M'$+K"$%AG(I]JRV4CYWW$D"-=&Q(AU(FZ\K7U6]PIVN9Z>#C^T"-S5)&[+QU
MTKJT@7Z+O3J+RAFE9B@T$M)W4&O@SV[.TUI,5_$@WM-B-ZJ2E/9;#XQ9".2=
M%XWSB'%_16Q=>FQ4H%"F]@ V ]+M9!7Z!%@(-:[**._!<(X<G$LB?!'%:@AL
MD*,T]FZ!+_7JC$2WXVBLR=,E 0(#T;A,K&?E#.USK]Q3W3)%OP1@B%+[8W1D
MGH0JB.J1'+2ZWG3H6XN/11=!\?A6*RL$+/T=3!=\I+,Q\BE*:0ZAMT"(+5$H
M A3 (%;N4S52.T"T+*$7TI-Z+0<L5$CM85SX#<3UB$LBE0>^HZR%G94ERH0.
M1]I!')ES'?6#H4( -!J-6]TG-&W"'31/$"]G6R(C"(D&&I;*6@Z>\D&RR"Q(
M*RPOF\4%5<KF9#=<0F^BSR:%UMZJ%=@UBU *4$A\46&%1&=&GDW#%4H(B^B;
M'/UD$.+"IXN:0@)M/XQE0\.(8<B*@?#..2]L2I4V.4]'52#%T"3PE,\#G&*S
M$\W'5AC:!'B$SYS[(&Y67/L#NQ8M%,DDJ4M*B\C';#AZ$,^H2?,\P,8A_X80
MBJH:AH)6SI> A('/%<-TA JQM2S!5Q )*-W>GPYA_'FBU9&K 2.+%@Y%O.04
ME*%J&5M>&.Q-4KE928P9Z@HB*^.(@>WH.ZCVI>7=Y@(8*8@RJ7-4W<02S*1.
ML\GT\6!&!"X3W7?.&_G4TMPO6.AEZKPVELY*K([K43)I7[(3 ^E3)2M&%B7,
MMSS1:0Q*J*F>?6EIB,ND=&VP+R/VBS>M J! #71U+!:] 9L")&I% 1$QVLH)
M&4&E),2[VGKY:D!.)$T;^*S+2GOD@=@>9J*ZOD>$;4N7>P:7;95] [\5>!*4
M*H'Y4B44!;:4"?4[-3).)LPHS49VH49O7(D9P3N\&(.BSS^T$ :Z@>!1!(<-
M'X$"3"K>>! 3!.&F!"+*]&GT3]F(8+CD[BP]B*M6\"&MJ\0--CVP!:>S\D!?
M3J-#O^B!+P 3AO+GCPG:-$;K@,X4]#+;NNKA"TO]*YV4M5M/C\=;3[W]I-B@
MT(WE!+E^P[6.UVUR4@I++*?16+14TLE,;Q+JFDF#R!WOD7(.4T9C9Y+"=DY(
MD4*_ZO0F@1X]',8M\S5.)QOF6G!-=MVI^/4'M, 1/TRE. M-'ECITG8K='4D
MW!F@*NNE*QE3"14_P*8!N1@=.HA LN4UXB]R;AQU@S%Z+\KCJ:)IOO7).-\&
M@I1*> G]28(=!$ZBB*43+8;X6P:"6F@O5"O>*;Y@7(C)0@$[))S<FJN-V$J9
MC69].!+3^=*D814?(RS7-:!&LUU<*XHU9'XYAPPPM84[^UV+!4>-8T+_7I=(
M+W0H=6XJ:A2U1Y!+EHH"9E3^XTZ4V*M<I]'+MBD9MF[&L*(MJ?J]CK5HV'.<
MG,Y"0S@Y?=2D@KXQBHG23A8:H]ZQA(,Z&> Q;J-OB\6#-A:/[Q$+UY!WQ;)^
MNSR;W,$NZQ81T]7B7N/L\NRQ"B&^LZ,JV&GG'NU&[!C;(. :5:3#=A)>SLI,
M8(O,]D9:18@Q0E'V /H@2NQ)&/M&O[M@KN56/%NMS8"7B^Q3UM_M4T; _9A>
M)30&VNBT.7D'!\*BA;B!'_4W  !\58&489FOSMZW/(2I GAREOZ'^XR>?/=>
M74;XVJ=Q&6!0ST,+._L %G98SSZHI^@"_^#TVWL%_G^8B%Z!07TE<H&LHMS=
M?GBKX'W_*;'VGD?F@^,@SK=/N1$MG*[0(S [^\IF<@NS(W@WPX=>K, %Q-%/
M$ECU#_@GCEZSA-6TP#LF-J"(%@YGOP&]4F M0 \487\E9^625_5-,\&6Y\#C
M$[D&FZ*S:;"Q)S_]\';6-\P6FP8,G\N*VS&X:"[<N,'+R[?OOO[;]-'%]_ Z
MJ&2=8;R.I1&M1\9  <X2)Z+0[LPA 7[/4HHO</A-3TE>_OWDO+$>/8-/5'N@
M*B<-R\@,1[_J7):Z:H9CPY4>M,+V.-!V68#U =<5VT:2.*;YL ('@#))E3<<
M_3AQR+Q[^_/+'_[YKL$$VQX@[C9>\1EYU"]YQXV(-@,)O0MH1ZZXVXWXCY4'
MQ\9F+32]HO#Z'U:F;;MBJTMS*6!BIZP 2XF-P)IW]FW8223W!OZ\^B$O2JF+
MV\*6\!UDUE$9+X\/F<JIO]4:))FPTL4X;YO!D8]^JL;NHWTG_F9^U>'H<#;S
MX]@%]H,*7A'<B $_,?4H=D,JOY(9>@^EEVI>/;[KX BL$VJBSP+K9]OBM\>0
MR?1B9"AC<,@D1GBZ 3 *&02<J+F'WWK+]I9&6PUW)_0$)8:.@92V1Q= :,$#
M@+6M&.AS2;-62".1GE2<%U0FF4V^(NETHPQM*B*^@R8P]A;KK.)3?VP1(N&T
M#XX^?NV 1Q,\!]+,N3\FH/M59KS2#G)AT=0O6(\%UP,^<'!"H#_$KH)F/I9C
MJ:P+[^9"!0F UVPBPE"]WM"$A@ Z<W1QR#<2^(8%>A(@&.3V*JI^_268G;&H
MA7OMYB=Y-#L_@"/TK$Q6/4-PMAH[WBHFY/T6K-^<V6-U;6LQ+'<=?VJF8,;#
M"C*<+KCWV_R9"4;(? 6]]-:DA(9G#RPO=9LKM#H]G7'%&Z%0*SNQI"=SFN@*
MX_9L,&ES8M/A'\#1V\<8$Z#]IC"(K%I6R1W=^U1&O[8ZVK6RC8XUT;SRR&\=
M,X1P5CMI/*L7!*]MIW]"=UT,3>B$P "?+12[YR30+(;^M>V/B?#6/E'+6%2U
M)0?:'\BSMX,3$7-N6E.Z0=O?-63.*(,68$YKIY,;4Q4[[=QCK,&9LJ&)GGL9
M;1C:[1...OQ%9P2\J?_/>$A@=!* !B0_WD" U=__D(F V>333@0,#X@W P)>
MC/Z)FN^_HHJ"6@;I0APV@8??3_<M1/64W';WHL>*5A?MHM7%4-&JB7K[H^RQ
M'OL=NM1[[&<_&NRB*$LM6.';D0H8^K?&W._9LQ[I4;>C[FZ3>C2&.]J-V&C;
MNH.*G^?T!"Y;+WAE>F@:S18>KU--_&K#J4ZV-!(<8#!.D0IL9-^_2TNBV]&V
MF=88(>_>Z?[2W?Z\NMOWVMR>MMO"#X9,: O4W6I^C\WL5K=B>OKP T)-!KRW
M%T$P=\'\LPV)WZZB5Z]>1$?XHH6\OV4!0JC'U3!*P+A61:Z)H2?N::X_ ,"<
M7%<^)">R@"W<-\'.&K<WYKMCP(Z.T2A2BP7(;Y.B4Q-"PF*)/I;1E,"/^HEH
M+/]"E*JRVP.X&&(!X:C([FH<+H$V!_$3<[J?!Y/1SDUA!P,KU1699L1U+@H\
M,_/RW([4^RV#BDRO69LTLL3@E?("=Y(TZ$X<O4+P#%T,(@H$M$B[F-C5*>W5
M?122PM! 0I2JC9<NQ1"]FQ*L*1$KOZ?=-)C^3B:UM/VE7Q@LJ*WY/R!X9+WG
M_<?6P[.Y.K*V538J)C7E?1_[#I!$7JE/3-",0HDNC@Y04V;"%^2SG2MLTC@<
MA,7C'&5ELA_3;/.+DT:OS+#&@\G9@PG2"X^8JQ4X)3JL9R&B*UM,$J<A:J U
M,5"KJGWXV(]SUUFM(DTO(X@M4P\\I,-E9@;?KUEH KA+8[3G<1D7)E?=BQ]B
MBY=13=6D7*[L[JJG<3C.TBVE;J1_:-_I8P.%2P7]WDMS^41LDM7MR0)4%H^Z
MG/16<U'L,:3 908*HIU"C)/ZP9Y1G\F(.])GZT@J^ET*2M$&JJ(N<+$L"QM.
MJ=W,Z:$]7='114@%G=6CZ:"EQ%EJ<U@'06WN'O"X9@/%W1":BIBN2%!/!BA<
M&#ER2^O3Z-[\TA#)_DR;[32Z=!*$W@#D&T5]^!P2Z:TV)#V%!C\3&N9O#U=:
M60X\=%7)Y'WT!H(K&EWW1J30'0*3A]'&*MH-Y<? OO L<$5W#N@ER9PX@6R[
M&-0U/*R#8,1(%%.UAX!D B$!U0[\R2&D[/GT]'QBTK&2TU4_1"$&48N?P,(W
MN:AS$WVO#"AVH6(<?U-POVM+T_?WNYN5+5H^GMRE=:GCMH?M=P=.QM]#BS*3
M&\A/:DPI4K$$3Z);C!2P%;5_\MH_IMIT]4Q.I1$Q+4^3:])ZY&ENMXDV/CU;
MW*T?V2QD3#IP M<C:?,F*(=5\S1Z<UL[;=F X)##L[(#X6H^AUVY=]3>KD&'
M&7<U\KI>./ IPP6%@7#^P[95=>^SXRK5;7QWTP8=9WG3=;,.\2[M4&>Z?=<Z
MWB;J>R,."LU"];1 _:KV'H#%0:N#W!XKP=(H4F#@4'?Z)FRV]9ENOZ2+V3>$
M;HJ[*U 81LQ>]3\V,._RVFBAW=%.5+EFEPRSH50LM$O3=_%9+AMJ!<7>W;2U
MJ(5'AV[5KSV-K@1-K'9"'5>:UP[*;Y""F<> MM;2CJ3;6EA0CJGK;6U7$\Z$
MG;X!'0R3<]6H31SVXX5R,J&?QEI? ^,0LGXGW(!*^>M0P6\_J$,=L8TOKY,Z
M5HG'(OO%Q*]3=P^3AT-/K7!-RT1_[-"^*<4&"GN%,U:\@J)_@TI@OR,OUM(S
M\G_&W#2]R9X&I.EX\=PQ_DL[\DL[<F<[DC!S/<F_1$>ROP*-.8)O$*CY5.'>
MG?QYU'9]_$D&[>A!=)##<HZV'W7H>Y^-096T,8MC.^OR.S8'=@]%Q(W'<J,4
MI%J-,;:[SWF&)D!?)$+K4?TF$6M43J%U@1;1!2+75C"]DV;H75/.7<^!I'#$
M#W4.8WI'%]U-4+'69P8_4/+H1?[^B'*KANQ?"^'H8D%LV_7VS2':N@FZ/ 9'
MKG5VV(DB3]TU0BTC%]1>_&AD9U#7/B;0GE;J:[]TVD_[.!?F'Z+NL00U. B,
MOABE$>:^AJ"]@ZU#?=<G5;<ZIT?-W4\@-/H#3YJQD:]?\91\X:ZJJ4J9:1N@
M;':/=4C$L#$WL3XT4##-9<?+W^MTJ=V^T-28P\8 ,U/H*O!F'N0+F3BYH3NB
M].GWK=6' 0T>/'!O'5W'^K3B12IVK*G^AM$28J,/IWG(>S9?^<9>>)V4>VQN
M32^:DYJF3W2QWX1 ?]AW3]VL:?>H_9\"\Y),2FN&XG#:G$:**$%L1AU2VU3J
M.8(7Z\: '3/'QTDIFHU>0H*?S^&]\ZD]H7\X?>CU%0=V&UOY%Y A,.IXY2Y>
M^D5W6U$5R&VVZ^BH7[W?LQO7O^F1^?@XF&$&YP<_Z9Z3RSWMHYUVUP L9)F\
MOE:O,<>4JQ2\8I#WARTN-$(%>18EL&/%"H[7N^K6DTTG-K*GZZ4;/N2GV9K7
M>*\P9< X<XF'?&P_;[!2WT$T=A_M77&>M*2^B47I*F:Z-1%=U +AQXB  KH!
M5T -==6>\:8E31#9>Q6CO:!S.@O+D*,9":4(/7<XZL7PE 'RUMWF;0,(<XOC
M57BOH$=6K$/T%]-LO&QI[(_8-PV;.9 &"=6=N=^O\M0$']ZYL*'"BJ:M[6_<
MINQDIJF87Y^TKR$UQDIY';G[*(<CS+F&OL,,^U*.BG/^S7NW)U@0"G4)M>O2
MPWVCJ'^?2Q"M,"1F^DO?.>X21'<;I3Z,)S=%WTV%WNU([K["/T'QP<L&NY+;
MO65P-FNNFOC+7#*XC]Q\N71PKTE\%-H-7G_>A#IV&VRG"R\P'[V9T+^5\ [L
M^22W%()SNP;W1(8B%#+X9I^*WIPO\?)?5&7\2SV^X1^H_NXL+7ZY__#SO_^P
M"9D^[^,. ]F\;B=\]-OS+-5%*V,S]^C-_"N5VO#L8]&&ZT8[/+LHNE[==M"%
M"HHZ*+#Z&A\@/2526WCG(]\T-3C6NJ]K[KN?HQ.+W**T$3N4]L/H81NCT6M%
M/B!&/Y^\9G/,Y=<K!O)K?A_ZRU1CYRMN,=#;WO2(/@A+!YWLBQ>H6%7]1SUT
MMP=^6(F3YX].?CH?^U-5_1.RWX1%A!^3Z%>]L(DCFUO576GA:(!:QY:N'_%R
M%-KP&_]2E'B/*SD"HK8OY'"7B>@DUO8!]*%S,XUI_WJ.&73LF3@9^F,G_:2+
MS1?[_ZFK8"+OKJ-=+>$*PYJ^BRCN]-=.O(LH@O8QQH/:O^KK*!;#?^%D0#WW
MN;-"O[OG.!A&KC3(CJ!T[JGHF\P"(G1D</2.M %4/F*IXM97,'34A9#HC!Z1
MXOBUC%L5,IB[OL=.#X-I!?Z" @-T-\(<(D#-V]ZNN.$'DI_E70VW:[MYF-[Q
M8H?=Y _;%KU7!6A%^&07!?36/&Y!NY &=!0-\X4^8@Q),<:4W5DXUTG3BHP0
MT)4]07]\(%LF--G0R),=C0HG=*>^)QGP0I96E/G;<K3&P2B"[HGJBRML8Q1!
MUPLVYT!0BTZH'YC (_JO -)?M]W:.5QWQPPU3DW#7C>F[6$+ML0_]5.U\F*3
M>7NW9&/_,$Q]3%8V=$.$_N,I]W/NFX7.KX'[Z/!B\-JJ+KVH.J.24LR1G'/(
M:X)C@L'%7+;YV^OIFUM#/LHQ\@Y3OMPY\67(BQ[7)N)S+\'8Z1GO(LR!2'#X
MU/&7^10WGW*/999646(Z7)38R<M[/./<FEV9#9_,W@/*_J&0\UL-A0QFMG<9
M$?$]XKULK5\9_;L0OR:5-*7)T1/=_CWD'_Y/0@295O>RC3 U.]J!ULC5&OY\
MP;_-WWX(L/_RQQ\^\XN\^V_'>')6/7MR)A3\D\!_I=S OVK%>?625>S9DYR7
M2_Z"9QFN"2'7TX/I@?<IPO;TX'+ZW>7LX S>;!Y_]F0-_NPU*ZFUF/$%O IV
M]\&!)J/]I9)K7!*/$%<RIQ]7G($>X /P_4)"H&M^P0VP/TG@/?M_4$L#!!0
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MV8 *;(, SBMC_&81#&S?;M._ %!+ P04    " "8@ A5:SJZ7Z\&   >$0
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M=M2V&ZNK9KPMM:5AV2PW]#J!<0:D7VEM[S<N0/_>S?\ 4$L#!!0    ( )B
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MABF6"]20]+RE!P_4W 2'2JL4C8'W$'?BI$=KTAG&0[C@DE,;9+!4*C-PTAM
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MLG3O==TE_=% S08T/U?*[@?LH/_K<O4W4$L#!!0    ( )B "%4G;.2K\P4
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M!.CY!>?JK6/*6_>:I;\!4$L#!!0    ( )B "%5PI@DAJ@0  %(?   9
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M$0(%[25\WB9\KDWXM41R1Y!:ZCZI7_E?-AO"DVP[E%LMY]2Z  GS(&$^)"R
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MB?DD%I!82&(1B<4D)D@L@;!&7SE][BNG[_TJWBG96DC,)C&'Q%P2\TC,)[&
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MRWPZELK&06;-KE#-1C4'U5Q4\U#-1[4 U<)*:[Y&.U O5LC",:H)5$LHK=E
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MM "4%D+1VA[?%;),?2%+MPQK=DM*H\X2FYY_LB=!ZU,]%X!Q9XD--*8/2@M
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M/SB>ULL^?<"#\?X,/0$+00'UBJ(;;[EH[LDQZQ+"\H,_;CST1N6%*6]5C(7
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M/MHLVXF:G0BZ5WLS'ZD0-%:'.X(#PM(&\O<-I>)TDG9PW@\\_Q]02P,$%
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MOV#V*@"#82\8M<"H.@?^J-:!/Z)WX*IY8'<Q;RX?[XFV_FFT#;KC88MEJ]:
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M"'-!?U]RKHX;(Z <TF?_ E!+ P04    " "8@ A5#JZN#BT#  #J$@  #0
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M2)*X]^#!^RC>O*?B[:];X]]02P,$%     @ F( (59>*NQS     $P(   L
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M==:JY'QH8XFXE33?'ZCN#X.O?@-02P,$%     @ F( (5> ]"5=H 0  2A0
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M(&@7/F@/0?OP012CC+& I 76 K0FY)H$>$T(-@D0FY!L$F V(=HD0&U"MDF
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M              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ F( (51O,NW?4!0  SQX  !@              ("!#@@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( )B "%43O#4YI@4  / 6   8
M              " @1@.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " "8@ A5)0TM/8@"  "5!@  &               @('T$P  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ F( (595DUFD>!P
MW2@  !@              ("!LA8  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( )B "%5<1:YE4PH  .E<   8              " @08>
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "8@ A5>?!7
M[J8&   Q'   &               @(&/*   >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ F( (5>]$KK:-"@  \!@  !@
M ("!:R\  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( )B
M"%68K+>)" ,   L'   8              " @2XZ  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " "8@ A5Y(V]4]4&  !K$@  &
M        @(%L/0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ F( (5?A*A=[_ P  U@D  !D              ("!=T0  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " "8@ A5Y.C]IYT"  "]!0
M&0              @(&M2   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( )B "%5O&3&F^P0  ,X+   9              " @8%+  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ F( (57:+:I^%
M&P  'X4  !D              ("!LU   'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " "8@ A56SR^: (+  ! '@  &0
M@(%O;   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( )B
M"%4?JX:!>P0  ,<)   9              " @:AW  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ F( (56LZNE^O!@  'A$  !D
M         ("!6GP  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " "8@ A5QID)A8D#  #M"   &0              @(% @P  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( )B "%5O8GTJ% ,  /L&
M   9              " @0"'  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ F( (5465G(.K @  O@4  !D              ("!2XH
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " "8@ A5- H(
MT2$%  #&#   &0              @($MC0  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( )B "%4G;.2K\P4  %@N   9
M  " @862  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
MF( (564*YKI:!   .!8  !D              ("!KY@  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " "8@ A5.D0;GXX"  #9!@  &0
M            @(% G0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( )B "%5PI@DAJ@0  %(?   9              " @06@  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ F( (5526 JTX#P
M&^\  !D              ("!YJ0  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " "8@ A5H\+H?0L+  "@A   &0              @(%5
MM   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( )B "%4V
M".+&0 4  &<F   9              " @9>_  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ F( (57\XGC6#!@  9CD  !D
M     ("!#L4  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )B "%67)GT;100  + /   9              "
M@4+C  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ F( (
M50ZNK@XM P  ZA(   T              ( !ON<  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " "8@ A5EXJ[',     3 @  "P              @ $6ZP
M7W)E;',O+G)E;'-02P$"% ,4    " "8@ A5QO("Z%(#  "0%@  #P
M        @ '_ZP  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ F( (5> ]
M"5=H 0  2A0  !H              ( !?N\  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ F( (51R:"5V, 0  YQ0  !,
M     ( !'O$  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "D *0 6"P
&V_(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>200</ContextCount>
  <ElementCount>207</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/NatureofOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104103 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107104 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110105 - Disclosure - Inventory, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNet</Role>
      <ShortName>Inventory, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113106 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2115107 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121108 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2127109 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/FairValueofFinancialInstruments</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecurities</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2311303 - Disclosure - Inventory, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNetTables</Role>
      <ShortName>Inventory, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/InventoryNet</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockBasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/FairValueofFinancialInstrumentsTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Inventory, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNetDetails</Role>
      <ShortName>Inventory, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/InventoryNetTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2414404 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockholdersEquity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2416405 - Disclosure - Collaboration and Other Agreements - Incyte Corporation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails</Role>
      <ShortName>Collaboration and Other Agreements - Incyte Corporation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2417406 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails</Role>
      <ShortName>Collaboration and Other Agreements - Zai Lab (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Collaboration and Other Agreements - Janssen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails</Role>
      <ShortName>Collaboration and Other Agreements - Janssen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails</Role>
      <ShortName>Collaboration and Other Agreements - I-Mab Biopharma (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails</Role>
      <ShortName>Collaboration and Other Agreements - NIAID Contract (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2423410 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Option Pricing Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mgnx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Stock-based Compensation - Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-based Compensation - Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="mgnx-20220630.htm">mgnx-20220630.htm</File>
    <File>exhibit101-incyte2ndamend.htm</File>
    <File>exhibit31-1q22022.htm</File>
    <File>exhibit31-2q22022.htm</File>
    <File>exhibit32-1q22022.htm</File>
    <File>exhibit32-2q22022.htm</File>
    <File>mgnx-20220630.xsd</File>
    <File>mgnx-20220630_cal.xml</File>
    <File>mgnx-20220630_def.xml</File>
    <File>mgnx-20220630_lab.xml</File>
    <File>mgnx-20220630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="464">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>51
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mgnx-20220630.htm": {
   "axisCustom": 0,
   "axisStandard": 14,
   "contextCount": 200,
   "dts": {
    "calculationLink": {
     "local": [
      "mgnx-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mgnx-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mgnx-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mgnx-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgnx-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mgnx-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 330,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 32,
   "keyStandard": 175,
   "memberCustom": 28,
   "memberStandard": 18,
   "nsprefix": "mgnx",
   "nsuri": "http://macrogenics.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://macrogenics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107104 - Disclosure - Marketable Securities",
     "role": "http://macrogenics.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110105 - Disclosure - Inventory, Net",
     "role": "http://macrogenics.com/role/InventoryNet",
     "shortName": "Inventory, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113106 - Disclosure - Stockholders' Equity",
     "role": "http://macrogenics.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115107 - Disclosure - Revenue",
     "role": "http://macrogenics.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121108 - Disclosure - Stock-Based Compensation",
     "role": "http://macrogenics.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127109 - Disclosure - Commitments and Contingencies",
     "role": "http://macrogenics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Marketable Securities (Tables)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311303 - Disclosure - Inventory, Net (Tables)",
     "role": "http://macrogenics.com/role/InventoryNetTables",
     "shortName": "Inventory, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i19ba873ecda04a69b9b0b78f7944a57b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i19ba873ecda04a69b9b0b78f7944a57b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://macrogenics.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i19ba873ecda04a69b9b0b78f7944a57b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406401 - Disclosure - Fair Value of Financial Instruments (Details)",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
     "shortName": "Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7c140531ab074f03aea8d010a367b9b3_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i19ba873ecda04a69b9b0b78f7944a57b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - Marketable Securities (Details)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesDetails",
     "shortName": "Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i19ba873ecda04a69b9b0b78f7944a57b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i19ba873ecda04a69b9b0b78f7944a57b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWorkInProcess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412403 - Disclosure - Inventory, Net (Details)",
     "role": "http://macrogenics.com/role/InventoryNetDetails",
     "shortName": "Inventory, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i19ba873ecda04a69b9b0b78f7944a57b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWorkInProcess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i111ca364d8d9452c98412cfc77554d5c_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414404 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://macrogenics.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "ia1adbba07b474f27be0bcec58c6f439a_D20210601-20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416405 - Disclosure - Collaboration and Other Agreements - Incyte Corporation (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
     "shortName": "Collaboration and Other Agreements - Incyte Corporation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "id672cb9284434e3a9202e6f51f077bac_D20180101-20180930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417406 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
     "shortName": "Collaboration and Other Agreements - Zai Lab (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i1b2807234912469ba06c538de023e4f5_D20180101-20181231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - Collaboration and Other Agreements - Janssen (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
     "shortName": "Collaboration and Other Agreements - Janssen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "iae3a758cac9b4c67ac48b3d949bb81ab_D20201201-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419408 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
     "shortName": "Collaboration and Other Agreements - I-Mab Biopharma (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "ie6784addc67c4bffab8c458f3a96daaf_D20200101-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
     "shortName": "Collaboration and Other Agreements - NIAID Contract (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i096d5137725d40148157656180087db8_D20150915-20150915",
      "decimals": "INF",
      "lang": "en-US",
      "name": "mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "molecule",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i19ba873ecda04a69b9b0b78f7944a57b_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i19ba873ecda04a69b9b0b78f7944a57b_I20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "id5c46189a60a4d9e98d6758e10e520b4_D20170501-20170531",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423410 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "role": "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "id5c46189a60a4d9e98d6758e10e520b4_D20170501-20170531",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)",
     "role": "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Option Pricing Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i111ca364d8d9452c98412cfc77554d5c_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Stock-based Compensation - Restricted Stock Unit Activity (Details)",
     "role": "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails",
     "shortName": "Stock-based Compensation - Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i4a101c2276a549c7b6f9656b0b6d6551_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "if4f71af33da3443e9442ee9c7100c75d_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "ie4e23f5d9b7e42e6af2e22c7b835b9ef_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "id01dffdb96844c10acb64f346aef127a_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of Operations",
     "role": "http://macrogenics.com/role/NatureofOperations",
     "shortName": "Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104103 - Disclosure - Fair Value of Financial Instruments",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20220630.htm",
      "contextRef": "i7ade49b6f8ab438fb3f5537df9497b99_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 49,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mgnx_A2003StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A2003StockIncentivePlanMember",
        "terseLabel": "2003 Stock Incentive Plan"
       }
      }
     },
     "localname": "A2003StockIncentivePlanMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Zai Lab Collaboration And License Agreement",
        "label": "2018 Zai Lab Collaboration And License Agreement [Member]",
        "terseLabel": "2018 Zai Lab Agreement"
       }
      }
     },
     "localname": "A2018ZaiLabCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_A2021ZaiLabAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Zai Lab Agreements",
        "label": "2021 Zai Lab Agreements [Member]",
        "terseLabel": "2021 Zai Lab Agreements"
       }
      }
     },
     "localname": "A2021ZaiLabAgreementsMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At the Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Collaboration and License Agreements [Abstract]",
        "terseLabel": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://macrogenics.com/20220630",
     "xbrltype": "stringItemType"
    },
    "mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration And Other Agreements Disclosure [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "CollaborationAndOtherAgreementsDisclosureTextBlock",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_CollaborativeAgreementTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "CollaborativeAgreementTransactionPrice",
        "terseLabel": "Collaborative agreement transaction price"
       }
      }
     },
     "localname": "CollaborativeAgreementTransactionPrice",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance",
        "terseLabel": "Potential annual increase in shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_CommonStockMaximumAmountAvailableForIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Maximum Amount Available For Issuance",
        "label": "Common Stock, Maximum Amount Available For Issuance",
        "terseLabel": "Maximum amount available for issuance"
       }
      }
     },
     "localname": "CommonStockMaximumAmountAvailableForIssuance",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Maximum Amount Available For Issuance, Increase",
        "label": "Common Stock, Maximum Amount Available For Issuance, Increase",
        "terseLabel": "Maximum amount available for issuance, increase"
       }
      }
     },
     "localname": "CommonStockMaximumAmountAvailableForIssuanceIncrease",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ContractManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Manufacturing",
        "label": "Contract Manufacturing [Member]",
        "terseLabel": "Contract Manufacturing"
       }
      }
     },
     "localname": "ContractManufacturingMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_CostOfManufacturingServices": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of manufacturing services",
        "label": "Cost of manufacturing services",
        "terseLabel": "Cost of manufacturing services"
       }
      }
     },
     "localname": "CostOfManufacturingServices",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "label": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "terseLabel": "Development and regulatory milestones recognized"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
        "terseLabel": "Payroll deduction percentage"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab Biopharma Collaboration And License Agreement Clinical Supply",
        "label": "I-Mab Biopharma Collaboration And License Agreement Clinical Supply [Member]",
        "terseLabel": "I-Mab Biopharma Collaboration And License Agreement Clinical Supply"
       }
      }
     },
     "localname": "IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab Biopharma Collaboration And License Agreement",
        "label": "I-Mab Biopharma Collaboration And License Agreement [Member]",
        "terseLabel": "I-Mab Biopharma Collaboration and License Agreement"
       }
      }
     },
     "localname": "IMabBiopharmaCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IMabBiopharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab Biopharma",
        "label": "I-Mab Biopharma [Member]",
        "terseLabel": "I-Mab"
       }
      }
     },
     "localname": "IMabBiopharmaMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncyteCorporationMember",
        "terseLabel": "Incyte Corporation"
       }
      }
     },
     "localname": "IncyteCorporationMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementClinicalActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncyteMGA012AgreementClinicalActivitiesMember",
        "terseLabel": "Incyte MGA012 Agreement - Clinical activities"
       }
      }
     },
     "localname": "IncyteMGA012AgreementClinicalActivitiesMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncyteMGA012AgreementMember",
        "terseLabel": "Incyte MGA012 Agreement"
       }
      }
     },
     "localname": "IncyteMGA012AgreementMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012ClinicalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte MGA012 Clinical Services",
        "label": "Incyte MGA012 Clinical Services [Member]",
        "terseLabel": "Incyte MGA012 Clinical Services"
       }
      }
     },
     "localname": "IncyteMGA012ClinicalServicesMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012SupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte MGA012 Supply Agreement",
        "label": "Incyte MGA012 Supply Agreement [Member]",
        "terseLabel": "Incyte MGA012 Supply Agreement"
       }
      }
     },
     "localname": "IncyteMGA012SupplyAgreementMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_JanssenBiotechIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Biotech Inc",
        "label": "Janssen Biotech Inc [Member]",
        "terseLabel": "Janssen Biotech Inc"
       }
      }
     },
     "localname": "JanssenBiotechIncMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_JanssenCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Collaboration And License Agreement",
        "label": "Janssen Collaboration And License Agreement [Member]",
        "terseLabel": "Janssen Collaboration and License Agreement"
       }
      }
     },
     "localname": "JanssenCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_MillstoneRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Millstone Revenue Recognized",
        "label": "Millstone Revenue Recognized",
        "terseLabel": "Millstone Revenue Recognized"
       }
      }
     },
     "localname": "MillstoneRevenueRecognized",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
        "terseLabel": "NIAID"
       }
      }
     },
     "localname": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_NonRefundableUpfrontFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "NonRefundableUpfrontFees",
        "terseLabel": "Non-refundable upfront payment"
       }
      }
     },
     "localname": "NonRefundableUpfrontFees",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonrefundablePaymentTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrefundable Payment Tax Withholding",
        "label": "Nonrefundable Payment Tax Withholding",
        "terseLabel": "Nonrefundable payment tax withholding"
       }
      }
     },
     "localname": "NonrefundablePaymentTaxWithholding",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrefundable Upfront Fees, Net Of Tax Withholding",
        "label": "Nonrefundable Upfront Fees, Net Of Tax Withholding",
        "terseLabel": "Non-refundable upfront payment, net of tax withholding"
       }
      }
     },
     "localname": "NonrefundableUpfrontFeesNetOfTaxWithholding",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
        "terseLabel": "Number of commercialized molecules"
       }
      }
     },
     "localname": "NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_NumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Performance Obligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "NumberOfPerformanceObligations",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_OneTimeMillstoneCredit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Time Millstone Credit",
        "label": "One Time Millstone Credit",
        "terseLabel": "One Time Millstone Credit"
       }
      }
     },
     "localname": "OneTimeMillstoneCredit",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_OptInFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opt-in Fee",
        "label": "Opt-in Fee",
        "terseLabel": "Opt-in fee"
       }
      }
     },
     "localname": "OptInFee",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan",
        "terseLabel": "Potential annual increase in shares reserved for future issuance as percentage of outstanding share"
       }
      }
     },
     "localname": "PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_PotentialCommercialMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PotentialCommercialMilestonePaymentsUnderAgreement",
        "terseLabel": "Potential commercial milestone payments under agreement"
       }
      }
     },
     "localname": "PotentialCommercialMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
        "terseLabel": "Potential development and regulatory milestone payments under agreement"
       }
      }
     },
     "localname": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Milestone Payments and Royalties On Product Sales",
        "label": "Potential Milestone Payments and Royalties On Product Sales",
        "terseLabel": "Potential milestone payments and royalties on product sales"
       }
      }
     },
     "localname": "PotentialMilestonePaymentsAndRoyaltiesOnProductSales",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PremiumReceivedOnStockPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PremiumReceivedOnStockPurchase",
        "label": "PremiumReceivedOnStockPurchase",
        "terseLabel": "Premium received on stock purchase"
       }
      }
     },
     "localname": "PremiumReceivedOnStockPurchase",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ProceedsfromRoyaltiesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ProceedsfromRoyaltiesPercent",
        "terseLabel": "Potential proceeds from royalties (percent)"
       }
      }
     },
     "localname": "ProceedsfromRoyaltiesPercent",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
        "verboseLabel": "Proceeds from stock option exercises and ESPP Purchases"
       }
      }
     },
     "localname": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenueFromCollaborativeAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenueFromCollaborativeAgreementsMember",
        "terseLabel": "Collaborative and other agreements"
       }
      }
     },
     "localname": "RevenueFromCollaborativeAgreementsMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromGovernmentAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenueFromGovernmentAgreementsMember",
        "terseLabel": "Government agreements"
       }
      }
     },
     "localname": "RevenueFromGovernmentAgreementsMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Performance Of The Research And Development Activities",
        "label": "Revenue From Performance Of The Research And Development Activities [Member]",
        "terseLabel": "Revenue From Performance of the Research and Development Activities"
       }
      }
     },
     "localname": "RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Information Used To Assess Variable Consideration, Amount",
        "label": "Revenue, Information Used To Assess Variable Consideration, Amount",
        "terseLabel": "Estimated variable consideration"
       }
      }
     },
     "localname": "RevenueInformationUsedToAssessVariableConsiderationAmount",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount",
        "label": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount",
        "terseLabel": "Variable consideration recognized",
        "verboseLabel": "Clinical trial activities selling price amount"
       }
      }
     },
     "localname": "RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenuesFromCMOAgreementsMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RevenuesFromCMOAgreementsMember",
        "label": "RevenuesFromCMOAgreementsMember [Member]",
        "terseLabel": "RevenuesFromCMOAgreementsMember"
       }
      }
     },
     "localname": "RevenuesFromCMOAgreementsMemberMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesFromGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenuesFromGrantsMember",
        "terseLabel": "Revenues From Grants"
       }
      }
     },
     "localname": "RevenuesFromGrantsMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesFromLicenseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenuesFromLicenseAgreementsMember",
        "terseLabel": "Revenues From License Agreements"
       }
      }
     },
     "localname": "RevenuesFromLicenseAgreementsMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number Of Shares Received For Each Vested Award",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number Of Shares Received For Each Vested Award",
        "terseLabel": "Number of shares per employee"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReceivedForEachVestedAward",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mgnx_StockIncentivePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "StockIncentivePlan2013Member",
        "terseLabel": "Stock Incentive Plan 2013"
       }
      }
     },
     "localname": "StockIncentivePlan2013Member",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_StockIssuedDuringPeriodSharesStockPlanActivity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued due to stock plan related activity.",
        "label": "Stock Issued During Period Shares Stock Plan Activity",
        "terseLabel": "Stock plan activity (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockPlanActivity",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_StockIssuedDuringPeriodValueStockPlanActivity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued due to stock plan related activity.",
        "label": "Stock Issued During Period Value Stock Plan Activity",
        "terseLabel": "Stock plan related activity"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockPlanActivity",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_TotalAnnualFixedPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Annual Fixed Payments",
        "label": "Total Annual Fixed Payments",
        "terseLabel": "Annual Fixed Payments"
       }
      }
     },
     "localname": "TotalAnnualFixedPayments",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_TotalPotentialValueUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "TotalPotentialValueUnderAgreement",
        "terseLabel": "Total potential value"
       }
      }
     },
     "localname": "TotalPotentialValueUnderAgreement",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Additional Milestone Incyte License Agreement",
        "label": "Two Additional Milestone Incyte License Agreement",
        "terseLabel": "Two Additional Incyte License Agreement Milestone"
       }
      }
     },
     "localname": "TwoAdditionalMilestoneIncyteLicenseAgreement",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
        "terseLabel": "2016 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabClinicalSupplyAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab Clinical Supply Agreements",
        "label": "Zai Lab Clinical Supply Agreements [Member]",
        "terseLabel": "Zai Lab Clinical Supply Agreements"
       }
      }
     },
     "localname": "ZaiLabClinicalSupplyAgreementsMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab",
        "label": "Zai Lab [Member]",
        "terseLabel": "Zai Labs"
       }
      }
     },
     "localname": "ZaiLabMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement, Margetuximab",
        "label": "Zai Labs Collaboration And License Agreement, Margetuximab [Member]",
        "terseLabel": "Zai Lab Agreement, Margetuximab"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement, TRIDENT molecule",
        "label": "Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member]",
        "terseLabel": "Zai Lab Agreement, TRIDENT molecule"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember",
     "nsuri": "http://macrogenics.com/20220630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r33",
      "r35",
      "r79",
      "r80",
      "r181",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r167",
      "r180",
      "r191",
      "r228",
      "r229",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r357",
      "r381",
      "r383",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r167",
      "r180",
      "r191",
      "r228",
      "r229",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r357",
      "r381",
      "r383",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r122",
      "r165",
      "r166",
      "r216",
      "r218",
      "r360",
      "r380",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r122",
      "r165",
      "r166",
      "r216",
      "r218",
      "r360",
      "r380",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r159",
      "r164",
      "r165",
      "r166",
      "r167",
      "r180",
      "r191",
      "r219",
      "r228",
      "r229",
      "r259",
      "r260",
      "r261",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r357",
      "r381",
      "r383",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r159",
      "r164",
      "r165",
      "r166",
      "r167",
      "r180",
      "r191",
      "r219",
      "r228",
      "r229",
      "r259",
      "r260",
      "r261",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r357",
      "r381",
      "r383",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r34",
      "r35",
      "r79",
      "r80",
      "r181",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27",
      "r325"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r125",
      "r126"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of premiums and discounts on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r271",
      "r272",
      "r273",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r232",
      "r275",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r38",
      "r41",
      "r47",
      "r48",
      "r49",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r11",
      "r77",
      "r111",
      "r114",
      "r120",
      "r141",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r287",
      "r290",
      "r311",
      "r323",
      "r325",
      "r362",
      "r372"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r26",
      "r77",
      "r141",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r287",
      "r290",
      "r311",
      "r323",
      "r325"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r130",
      "r148"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r128",
      "r131",
      "r148",
      "r364"
     ],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "verboseLabel": "Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property, equipment and software included in accounts payable or accruals"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r9",
      "r69"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r64",
      "r69",
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r64",
      "r312"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaboration And Other Agreements [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r168",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r82",
      "r83",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14",
      "r325"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value -- 125,000,000 shares authorized, 61,458,790 and 61,307,428 shares outstanding at June\u00a030, 2022 and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r43",
      "r45",
      "r46",
      "r52",
      "r366",
      "r378"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r214",
      "r215",
      "r217"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r214",
      "r215",
      "r217"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r214",
      "r215",
      "r217"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r220",
      "r227",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r56",
      "r360"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r132",
      "r148",
      "r151",
      "r152"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit loss related to available-for-sale debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Available-for-sale Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r67",
      "r110"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r234",
      "r235",
      "r265",
      "r266",
      "r268",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r53",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r95",
      "r97",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r297",
      "r298",
      "r367",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per common share (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r53",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r97",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r297",
      "r298",
      "r367",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per common share (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense recognition period (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r47",
      "r48",
      "r49",
      "r82",
      "r83",
      "r84",
      "r86",
      "r92",
      "r94",
      "r104",
      "r142",
      "r205",
      "r212",
      "r271",
      "r272",
      "r273",
      "r282",
      "r283",
      "r296",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r322",
      "r384",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r299",
      "r300",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Financial Assets Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r299",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r182",
      "r184",
      "r185",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r300",
      "r330",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r299",
      "r300",
      "r302",
      "r303",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r182",
      "r220",
      "r221",
      "r226",
      "r227",
      "r300",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r182",
      "r184",
      "r185",
      "r220",
      "r221",
      "r226",
      "r227",
      "r300",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r182",
      "r184",
      "r185",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r330",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r305",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value Measurements, Recurring Basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r135",
      "r136",
      "r138",
      "r139",
      "r140",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r149",
      "r150",
      "r153",
      "r154",
      "r183",
      "r203",
      "r294",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r158",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.",
        "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r66",
      "r358"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r66",
      "r321"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other non current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory, Net"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://macrogenics.com/role/InventoryNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r25",
      "r325"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://macrogenics.com/role/InventoryNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net",
        "totalLabel": "Total inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r25",
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Inventory valuation reserves"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://macrogenics.com/role/InventoryNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r137",
      "r361",
      "r370",
      "r390",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28",
      "r77",
      "r115",
      "r141",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r288",
      "r290",
      "r291",
      "r311",
      "r323",
      "r324"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r77",
      "r141",
      "r311",
      "r325",
      "r363",
      "r374"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r30",
      "r77",
      "r141",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r288",
      "r290",
      "r291",
      "r311",
      "r323",
      "r324",
      "r325"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r64",
      "r65",
      "r68"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r42",
      "r44",
      "r49",
      "r51",
      "r68",
      "r77",
      "r85",
      "r87",
      "r88",
      "r89",
      "r90",
      "r93",
      "r94",
      "r98",
      "r111",
      "r113",
      "r116",
      "r119",
      "r121",
      "r141",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r298",
      "r311",
      "r365",
      "r377"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r111",
      "r113",
      "r116",
      "r119",
      "r121"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r3",
      "r81",
      "r107",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Nature of Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/NatureofOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r36",
      "r37",
      "r39"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other non-cash items"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r59",
      "r61",
      "r129"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and software"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r59",
      "r60",
      "r129"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from sale and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r63",
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash received for options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r157",
      "r325",
      "r371",
      "r375"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, equipment and software, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r280",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r280",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r279",
      "r359",
      "r394"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r212",
      "r325",
      "r373",
      "r387",
      "r388"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r82",
      "r83",
      "r84",
      "r86",
      "r92",
      "r94",
      "r142",
      "r271",
      "r272",
      "r273",
      "r282",
      "r283",
      "r296",
      "r384",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r50",
      "r77",
      "r108",
      "r109",
      "r112",
      "r117",
      "r118",
      "r122",
      "r123",
      "r124",
      "r141",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r311",
      "r368"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds of stock sale"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sales of stock purchase price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "License And Collaboration Agreements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r263",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r8",
      "r22",
      "r23",
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r231",
      "r233",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Valuation Assumptions Using the Black-Scholes Option-Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r75",
      "r105",
      "r106",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r198",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of Stock Options Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending Balance (in dollars per share)",
        "periodStartLabel": "Beginning Balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedTerseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based compensation, number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Shares, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Shares, Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Shares, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding, Ending Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Shares, Outstanding, Ending Balance (in shares)",
        "periodStartLabel": "Shares, Outstanding, Beginning Balance (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)",
        "periodStartLabel": "Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)",
        "terseLabel": "Weighted-average exercise price of stock options outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Shares, Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Common stock purchased (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Vested and expected to vest (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock percent of the fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r74",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r32",
      "r47",
      "r48",
      "r49",
      "r82",
      "r83",
      "r84",
      "r86",
      "r92",
      "r94",
      "r104",
      "r142",
      "r205",
      "r212",
      "r271",
      "r272",
      "r273",
      "r282",
      "r283",
      "r296",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r322",
      "r384",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r104",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "auth_ref": [
      "r230",
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock plan related activity"
       }
      }
     },
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r205",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares issued or sold (in shares)",
        "verboseLabel": "Issuance of common stock, net of offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r205",
      "r212",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Shares, Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r205",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r17",
      "r18",
      "r77",
      "r127",
      "r141",
      "r311",
      "r325"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r48",
      "r77",
      "r82",
      "r83",
      "r84",
      "r86",
      "r92",
      "r141",
      "r142",
      "r212",
      "r271",
      "r272",
      "r273",
      "r282",
      "r283",
      "r285",
      "r286",
      "r292",
      "r296",
      "r311",
      "r313",
      "r314",
      "r318",
      "r322",
      "r385",
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r190",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r212",
      "r213",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r319",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r319",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r319",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r135",
      "r136",
      "r138",
      "r139",
      "r140",
      "r183",
      "r203",
      "r294",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r220",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Government-sponsored enterprises"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r78",
      "r220",
      "r227",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r96",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r95",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128088960&loc=d3e3913-113898"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126965701&loc=d3e15009-113911"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r395": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r396": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r397": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r398": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r399": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r400": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r401": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r402": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r403": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r404": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r405": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r406": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r407": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r408": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>52
<FILENAME>0001125345-22-000090-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-22-000090-xbrl.zip
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MC4YK3_W'/? GY-FD=OYC.]S35D;XI49J+]>@\[@578KNS#B;D##C!DJN/YF
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MMZ8.NU4^\J5'<TT?G<3/7T[_"U!+ P04    " "8@ A5D9 2BCL'  !;(P
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MOK_BZF!I NAM)[%EUT!K9VNVYM'$1;9/ RV=;"(2J9%4'.^OWU&RW:19LG;
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MM&41]PB>DJ4I36PWQ\S$[4-:J8N,"QO_V+4K6QIDH;>]PGD8EJCK'=@P3#9
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MS"A1VTV1/[EVW;S]#;"YBXY_ U!+ P04    " "8@ A5WG/F4CJ* 0"(51
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MO1CV>G<T[$[';P.0_^6HM/LQ4D$"L1:THP?G@P><68Q!BD0D+BAM C5KFQF
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M(EH1_5(JN]E+U@1U'6=:>RND5PS4'8K61ALQ!6PF3!!^&0Z^'),&2-!M V@
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M4L@*L8$?6N/O2>I:W?XPY;@9VQV.*W?5]O/^ITJ49B-*K!*EQ1<E5:ZS#7I
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M_EM2<X6T9PP!UY!3?QRRPB1H]8DO<]'$;7=MPNVO^FDHO7R^Y"<G38KK\ J
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M][9SO'_H>(=V3CNOWISL77Z\/#IY>=HYV_GR[M7?[.CRW^EO'\>][CB^LW>
M<2?=M;_U/A!G#94$1:4, N)8+JH#2*@HA,/*Q:C&Z0!8MH'6U33FSGO14^8%
M/*"B-PX*[WZ"=+Z77U)TFZU)>S]HF^V2=9T]CWESLC9.+_*,O>X/\BBV1J-!
MUUY4'N;#?J??R^,8]$_3\#_L9C86AJ/&U*-=$MB[G((]#HJ!5"I7DM,(J(S(
MRJ@0%92Q*)4.1&38FSU6L<)XUSBZ^W//=L'E@LL;78>=T-9*HAT#+;W&-L@H
MN5:$!(7Q8^/R,A017Q+0YE.@+3QH$IE TC.% '.*M+(8R1"DU#Y7V<J'P]N4
ML#;&LST45ABZ"R2N.B3.U3\A1A(A6A$27PV,&DZM]=*!M00TD[=CXBW%+@HX
M-@X<O\S4R*6!4&L$PC$D=)3<(9T+)@<*RCDA):=X8U-+UM9L-E-S[I[.!18+
M+#;@K>>!1<XP#YY2(SB Q-B(A#V6\T0=F,3:/!DL%N2;#_FFTM19P%$!<XCC
M(!'8*)#5GB2SW@)V5DN"73;F"^@5T%L)T)L#\P@ASC !7GD-G#JM@% 77:(#
M/%<"+>;Q\N+@]-%.'96+RDJ$9;:/'3AD3 A(I%6D/996B60?4Z;;@BQ'(&<=
M.A95H4YDS3#D=SP[#[VAR0*Y5PCZKA5,FX=I__?_*$KH'W.NPN85ERUB6BXQ
M-3S6L>++:0XFHR&9:%@18HP%XH-->YJ"R!PET7L<IZM2L%]1FBU_<C$<56<F
M#_O?,XQS<O%N;Y)67(%SA<W;UZ#Y34@,:-@=A8,P^-1UX75Z^;Y_$US_0Z]Z
MRG_,Z44H9*<VLO-U)A;@1<CME#6BBNO<2IXEKD,#HE)P)JU002:NP]N4PJ),
MI\'@M9J@L')[3!%3$=,R;+&8!@B<$,:9!^^5\4Z%(".5%&,F9=EB5WF+G?$G
M6$^%- !(F+S'LJB1Y9PB!\H31;EA!)JWQ_["9]!LEE_N7)\[U^&$1>4V;J57
M[[6JBC&Y14 "B$_3Q\7F/&*Q2MOPC0<IK"::&8^3B>- &V^5="9B:Y5SQ CS
MBYWXVHF*LP^]+V/O_?@TQ8N+0?;95]OI^)1%=?%U$M'61#+EP$5=N^K5CGK=
M<+7$:D4%BHHH!#Y&9-*NBE2(G!(>J<A);)2W!<QF:912B\U6\ON91 T64Y/W
MS]5?3D_A'?W9?E'97#=L%\7.FF='F'9E&@K<4BX0\\$@@("1CEHAZF6PSAC.
M06]LLMG6]JL#,ZNIOBNW&Q0Q%3$MPV98FQ^S;(8/;AY-.QT]-Z;J_ZEU[F7"
M,$;)\*6(.Y;L7R":R-"PW7 =LI3^Z0U"&L9E\*W3_G#82@K8[7T*$^=^R54J
MD:\BII*K5);3,BVG(J8BIJ4XN&4PL=98RJ/0(+DR44=O*0Y$*4<)N0.?O^4$
MUW=:\\IT>[G>XWYO]SNO*6Q^'C9_P]$LPS5CTAI$!<Y=;)5%VBJ/C)>1A"S4
MF'802F</ZS])]_:BNG6K;@VF>%'=1U'=:4.<YC.406ID74B&>!0>:2X%$MKQ
M(!5QC,0&J>XZ9%-TPJBROM<L=:(X:(N82O![W8+?*[><5E-,\Y!!+TRD"GOE
M% /"I 9#(@%IG*5.6GY_,IAVQG'1_LP#2U9X;;SPZVR=(9[[?#K/$*-2(C B
M($V)1AZ,U5@;8FBN&"S: +/5,^>NN%$4N>!M$5/CC.^"MP^&M]-V.!=:AT@8
MDL0;!$((9)(8$9;>84^4- 0W"V_7(1[^K77$GAFXXZN^$7210/@:]XU0(!+V
M<&VUU^"LL49(S2() J2,"JHJ13\[Y5#Z1CPD+.UOSQYC8. D-Q1!S"PP22ZQ
M0$=1 .&-C5K+2,9](QAK8UG7 <%F%&"KT?V_'DH_2TWNI_&EG4(ST&"ZG8)V
M!H0."C$F$T?Q B-MG$;6.I7M0DPXKJ6=PE+"P"KX$=<<KK".D3&1*+CB8*1,
ML(6]PC(XEBYI\=AP50RNVK!LIK*09C)**Y'0-B*@#B,CO$#:$V.HELP;.NXR
MH-I4K">BK1M2S.-T$4X$:2E$A3'@8"SH(-/O C/GN=:W0T4IOK\LF#'C%*>.
M2 F!H(@]1FD14:32_R,N(O?>\V #SJ"15D2;2;UXRD3!BU7!"Q*LBMH[RJV&
MQ"V,B59Z+Z05S*E@GPPO"B3,!PE3J8^21D4]1*0Y=@@(XT@9&1&)0#UGBK(J
M]5$MXK0M8+ $8#!/@)PR%5GZ01@#!=A*'0$8(8%@HAPM9L;RXL-T7 =S'#2S
M@+#W(=D9T2&M5*8, 6.F&(NY7P^1R<H@R^$^78<4S%JKM2]O%+HD"Q0QE93,
M=4O)G(/) "514Z$-=Q:HB0:#X4QK9T+BQ%Y,4D_@*O5$,%Q*R:X(V9DM<<0B
MB=&S@#" SB6. )GL'L$AI(7B H$<+>9MQG&#ZCJ4/68M]Y@BIB*F9=AB(T1)
M3&3,&P; @@:@(6@GTY.<Y+YLL:N\Q<[X$\"PQ+)P1$HRBD!'0#HI =+,<HB1
M1N)9\_;8=<@5K;L(]O*>')\O*]0039@U1.2&O1&4=5$+&9F,/%I%S2\ [K;T
MT#^GT6MK,#"]#R$#WY]?O]_RVGS-'VU]-@._?YYO'+Y*-XZ&N[TQOI4$T]JZ
M3QQNC6;ZF0?0ECB!,,WGSU6H3J(+I+ P-)F34:F$9X3RMB0+5\HN-22:@@0W
M5']9# 9NB8Y4JGQ31<<;"4YA)_-J\U0TU!%*<HHO\B*?8N$\($6J OA$8FW!
M4)^K2:RP'J^"ZW(M\*9VUV7!FX?'F_TI]D P!"HQ1UX1C,!:0-9H0#)**AAP
M87W.OA"KC#BKJ<FEOE\14Q'3*O@;R[[X"#S\\)^)9?TWW;O<@_<8!*A\XM])
M9Q,1MSZ7[_ HL1PP0F&N@>2-<8E:.JY$8M$#%%A?WBA("585,97THG5++UJY
MY53$5,2T%&>0 E9.",V#TQ8 A,I->#P1 213GJD[4/M2I?D1^/Q.XO-[/_)Y
MIBT5/C!$-0D(L#3( G-(1& <)SDRFK:0II2&*JI;M^K68)47U7TDU9TRQ865
M0(FR2"FF$4BJD%'8)-75S#!+.'>Q.:J[#IDZ"Q587UXG8/'5%C&5D/BZA<17
M;CFMIICF(8,0G/.<*^H"!T/2+]0$IAU ##$H?7\R6 K^/A OW!WMC<]*?>>%
M)%KI",MGI*A (*A'5@-!#'O,D[TG::")%Y(VP[-1FM(WJ[&:7 !W*<34#.N[
M .X# NZ4(2Z=$L8 ($ZD2X ;'#+1IZ5LHL2!.AX F@6XZQ 1_U9B_=\7O=!B
M>($*ZY.WGY0_&;_5<Y;FWO<O[&D8ET!9CZ)#-YZTH9RJX+3P(0105FLE+0_:
M$VHI)G!5@^R.!VQ*_?7:06MOYG@,SDUP@U6()::/ .<RI6D;0FD_XA*85]+$
MJ@ [<-66NJXS?W6HT!,'#YX,)1J'L/_U%-*?0^J- LY9\G<_U"PU[)N"J%-'
ME)A*[$QJCT0T&$%"4:2-=HCI&(,QGAHN,Z+R J4-\\_^\LX"^07R:X%\)Y7
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ML+=P \IEPKO&T=W%ZD447%X'7&:$!P.8<ZP!F,)&&:EYC"9RK37CCXW+*W^
MX_% FT^!MI0R4" <6<,) D<8LA$'E(O_J."Q,M16)X^%;!-><TVU9D-W@<15
MA\2Y#@E[X@VG.EA!0#IEG9/2<":9I"80>3LFEL(,RP*.7Z9+3K((GE-#D63
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M8^6")N"X QF]LB&&1#:() *L49.J17<\GE.JMM<.6G_/'*[QVM+ I$,DZHC
M8XP4PPJ91 ]]9,%Q&:NR[82Q-H"LZ<1@'2KTQ,&#)T.)QB'L?SV%].>0>J.
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MO@-EHSZA6ITS7#'IC>OG#V9J'[H\ZG,%M&/AP<V5J+_Z<7WF,\[N1%B)U,5
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M2PSD:QP.6GBZ&3RQ97@J3306%E.6$=,!7"*E-)(4\%E@,HF"E54X"^/_>D
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M*W5!9 (5L)34$DN#2A3SB53QY+E:;578EA5KD>XQ(MT# +I?.0#@AP'=<@"
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MC)MGPK-Z<33JC(]@!0;]V#F/=KC9Z>#HX+OQ4>R\&)S \IS_U^B&P^WV84R
M78VVU>F!NM4Y'8RZ&=2^92)G<1CS<Y>>!<.9F\;X+/8^P]!@QD>CS>H1G0^+
MX\"I]]=-:'D6WSS,_@"> S3?34#__7&^/G]Q.@2L' )!=<(D=L:#CH=!'U8+
MUL7TPS@:=S# <+0!?_O>!/FL7NB.'\;0A0>?PFP"7(!/Q3?5CX+KL>P:3+*^
M<-@=?<))C :^BQIPYZP[/H+; ;!A7',3Q3WW'M@=7M8[W^C<N0QZL_MJ60@M
MZ>U+(@E(<G!F^Q[_?I%GA_K[E<X1^CAE42_^S[OSC_^$4\=EL;/]^Q'(DD\@
MB^3.=CC9W?[C&*YE'[>/3C[NO6'P;OYV[_?CC]N[:??X\.R@D(4J2FE)5&4$
M25*4I/0L$E<&Q7@PL WV!]2K;_?X#O?8>BJ\48;$%/*);R#.%IH$&0I?& J;
MD9X\[P]6%(65#SJV6?:,I#5TU# YC-ET1G2Y4AHL@^>9Q?L15> !BR(:QX 4
MUNU/;#6J.:%="TJ)E<0;D/\M#Z3[.<X*B*.J/'=7+>/I[!;K0&.9C"^^9:6,
MZ#TI WII<>9^'@UGQ9,/@8,!WS\1FV"LO]G>F3T?/?GO184'M)WY]5N>^J5:
MT\5?7JN$_'TLW?];(J0*"5S2A6:Q!*FC)37. 4^8I)CB''",^R?/D=*!D#NG
M\-I! &4"Y"Z20-CL[,WH'+1A&"I*6!3-_<P&HPC*$?#""'61SR"ML8; *(MB
M8)MN=?G) $1]K_LI@IS/6@E^"+^,Y[D(I#$\RD5@DO],NL.X\/B%A[OLILK,
M!"KU>:V;=6$*S<$LX#7H#0Z$/Z@%9T==?P0ZPSD^'-Y9:WSGFZM\UUE5G?,*
M4D8+#?I-,#1(Q619*EF&Y)RA6AO.#V3QY&*R0(OA1]#$2OW=3!-JL]%?:D-B
M49AI&Z(TKDBE=5*4R8FD%%A;R4BCG3$'VUF8,<K(3*HMBK$WL#?]\6!XOMT=
M>4#*R3#NP?-_[PW\IWL61KO=1AB]ZNV>_-$#H7.^\_K5R<?C=R<?_]F!]X03
M>!X8MA_H[M=WQSNOW[ 58?3/![Y_\@&$SINS_7_ ?'W]$<8!PHOOP]C!L-W[
M6^R^WCG;/_YWVMWSXJ#D*5(A-$G,E-B4+Y(2M#^2#'.\X%J "E*I%$!X,6R-
M\P(9K:R1!0],,FNLB\%I 1J%M%8:4$$BR/=3A.GA)#YY/EWS#:"3\8JIN$#&
M:T'AZA<N#I#Z4A2<.2NHD=85H.@P402=CX>B\E,-ZJZH[+T_BF'2BV_3=.XO
M)L,A_+:'@O<7ICAYH)QU .:)E-)K4'&#(,[$DG!E12@++KVTRQ1T,5 M>@78
MIKI7O\"*Y=UMMK]6QT:-.@:OFR0TZX=H),)].UOO7K_<_;@%]AR*L31 U0Z_
MJ]N[1! F($K "%Q\0S^.Y][R%&S1\=%@ A,)HV>_7>5=F:']XVDB4VZ:4M]Z
M Q%6;@IYO0XB-_NNY.)N!EO\D'8GJY<^CDK^Z/CI-#Z?:S1#^&D7XKO:OCS0
M]E@_>:;R/X/A)W0JG@X'/HYNK_O"SW[0>./Y_SRGB;?4E7*JK2()ONG_51'@
MXS@[_$9EMCX[A.># KMS\K?ZN/?O[@Z> 7[=4OO_[)R]W?L XW[#8!R?WF[O
MT^6SPUV8R\[QUOG'[5YO]Y\W7T#9%3O;O:-]N!_&"]]]@#G_+7>/WZWKM)!"
M$EJR2$(9(Y&PD\3HZ$@ADRP*GGWR3Y[S#2YNN0/EM?KU/,JRNRW._;0X=TM1
M$RW.W3G.+0?MQC)X'0#G2J8=F/V4$I>T)SXJQHIHO)-8=F+#\.\N4_FC<.Y7
MR(%[U>UW1T<Q= X'@]"6UOUQ&EBS\*]QW5OPN0GXK-;(]8F*@CI.@G>>R" M
M<1'^M" ]F#8B%<D\>:[9;:5D/:"(U99%[TQY:%GT.UAT):D'N,](*TGRGA.I
M2TU*J0HB':7*%4PDZ9X\E^HA%;'^%9Q1.0E^=L*P@0<.WZB)M5'Q=[0T/P]$
MW[86M1O'K55W6ZB]IIB@TG@8SRA)M&!$FE02RZD@ H2MH[!M"HL)\@TC;]FJ
M>]!)1+?CV&KALH7+'ZS1MG!YNW"YK.0F'U0209(8HP*X])240AJ"H4Q5*ZH2
M[%"Y(<KOMD0? %S^;(?+#W3 ER=B71JO7>\R0<&P&#UUO>PL)!SQ<%*SUD</
M7AT-^->P.QAB9-:'S?>;G5=@SE=90L/)86<KG*"9/QY63WSZ:GOK6<>>G@X'
MGVUO/G +3^RGP1: NW0C1VKEZ%ZX#" 5)@4 G!\=OYS&_BBN9OA<&AM6Y2%-
M _-SD/XHVJ$_R@\-\7/L#4XQ\+AYP6;G_<2-XG\F^!E,$$8_'?S&0D2SBX>P
M8=Z>=L>8;H5OGH65X216,@IFPXR+ 6Q[=0QT=:^SO9RA\"T)6=TJO@WNLWFJ
MP\_Y59W_<_<VA;I02/[;]BKR>E>-Z)KG1L7C%)G?$>SYM]K]BM>^I+O;^^I
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M+[0$9>1#*".[/KI$WUET2>U3F#.;MOKA+;H[IQLT>G Q)FQG&N7U4NQ\W1$
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MF+6ZG$]K_5$7_CR9D>WR^_*9] CF-?^Z*B<#P^2G@T<?QOA*?7KST8?/W=B
MF(7Z3[7"W&:I%T$)K.W(2^@8&R&"IGB2<6KBL:!KFO2N87.Y\_IUBX3KL]HR
MK-SFWQ(01SWUI56Q9*7DH;!!%(52D9E0L*+,<=.LO#@^MG+>-Y"\/9L&S.+=
ME%!W&KKZJ[*M1GG9IZO:&C5K?99[G\3;K0.J;:&UEX1':HE4+A!K?2 LB,A\
M%*6G_,ES*=059LTRB<W!R)3MJV#9^Z:B%U/B;^GF6^CF>.OKSN&!X31IQA3@
M9B&)-)&1,HE(*"\*'A0/1H%>)RX/-:FD;KT;<W2RV7G5R S0F>)I8\E<+B/K
MX-]+5 ^N\+]WB/>K07?WJ0@M8OE1W<_RL)\[[MV$ 4O'+=4B"*^-9(9;9914
M-%#*2V^C7' ^759'(G/B'(QOW0#&WTW'WC+F>L9\R3#1F2G#2E\02Q'0A5+$
MEAKLR)@,C4+1Y-23Y_HJOIS'\SD G\527JBTS?NV+M:#TV28U<U:V[E2_1W&
MU(NH@]?]II?JL,QY51MU=DGL+/J*JSB &S&!*9).26@P7:F4BMD8/.=%J;F-
M*ODF,"F?HUU(^WMG@ZVIAVI*\-7$ZWFW\N=R9^SV%GN[MW.@8/VY* L2$M5$
M4L.(%0+#M(.'?6(Q:'Y5J.,\E30D5-MVU9: /OUFV:H:U197G4P[KTNCUK[0
M(36KSP[LG5[WL(N%.3(E5]HTF/]X7#0<G-M>T\[^0G+LYXS3U<R!@@OA&%=:
M6M3D>"P4X]XG'65R5YP)\*40F2HS#F?_KAG37S"S3(DUL1'^BU';SO'.^>[A
M@4[>%%8;4I;<$VF-(BXI1WCB0FNNDT@"G?\KI/9_<<=OMJL%<\)+P)E0EK(H
M@^7: NP(;1FCH;SJI*?=U6OM*NJPUC+/N.3$*:V(#($3:S@G7@&.<PT&$>JP
M?#6PZ?]VLA?EO+'(,6,PUXU8RO&X]3/)C84#XGGH08M_\1AG2>8M7YQSY/"M
M3T?/-CK=5.6@3/S1W-G/W%A&^22E0;XLY)NCEHTEV;IFSO-ETO!P:=AH]&X
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MK';5SX*X*FUXN?[T]"'YF!@+"E0UC^K3_SD1AD\8CG(?H[KFRL)Y 'R:)ME
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M0 [?9G7Q2Z#E+QQ.2P%74<#N]M8!P(1@/)4$L)T3J2@EIM"6%%9Y6/$R>,L
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MEX]YW<#(]\ (/=AY?:1@G[-<2L*<3 BWB22H8Q.6J,P(H94,;;*RZWHQAO3
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MAV]&QO!GYS&.4K;O[ \ZL&>AH4LC*@'7L*$KZ%G?A29*\0*A'=(D&2 T@L%
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MUVO@AH]?]W<^BX^'5NR=_=G]>(:OO8'K=4%T[J8';X]H8@J7"0 PI1(,B21
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MVV8Y:ZMTQ8;HFZ&*3Z-1V$_=!^P//PAX=2=X>7=5?_-H62E?I>Y5::5!*=W
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MY'4W.'X!;]=4U0U);S6ADY!T$(L(HP?8^,L^ICG<EG::ABK>:(I ]][ODA-
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M5M!EJ:J/>A:I:!6%C&XGAX_E,,ZX7 M8U0>@6C6ZO;R^SZJ#*CH3*#M;T4#
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M7?[&0>?TT<]ZW.X<WP\"RS_KGPXV<-;^T?'>G'43<.VVN]VC/3GK/L&UH5>
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MC5G3<,MSXY;.^B'1AEL>R;)YXGRR*FCJS2&#^P[HVI')U]C_FR>)O2*(W?L
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M&B<H_'R26Q*M(!3GB; NPNE41(X'\NTZG<T B>=CP#<2U1NK0>0.$&FP=:N
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M1/4 UOM"XV3Q=KMWV_-7&1M7L?-7T7283S-WV\?:+U\Y4[UV/AK/@V_K&%&
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M2(Q34.EA!*B:P2UNX O /<B5(7*=,MO26+0MO+)47G'J ")CRT-F0+5!886
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M'5Q<?2QHDBS!AJ/&X=UM>:9,Y$CQ(.U55V4$5585G^(*'+U.TYGI[PUC$\'
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MF7[[CL$584PWG=I.%.IKZ:6AFCDHOZ$*8&S9VCWE6DUC'499BH8F6"D)GRU
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MP8.C=J]_])CEP0MM\..]M*<_G5]<??GP_O/EQ368%9\OVKOV=Q_?K5GC\?N
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M9:HL)\H17@6T;+^=6QEX'#X3Y"1V/*#X$4]%NN"QY2J"'*"E7$>2U/UAZ/'
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MJD!!33E\HZSWN6E6:RN7$;U&L<<;:4@6@<,\[XV]RLMGQ5VB2<ITGT:H1(I
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M4:V3-*Y,C,HNJ4:5#S#QS0C2KF]'&($[3.33XV)U2#N0F]A,!DE0:JA-Q-J
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MYP4[OP]"' SG_=5>8YB>33 ?C][5GFOUJ81^@< V6?ZU-E&9?H^YE&)M#M:
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M'%'DGJ2B@=M,SBJO74=5=5N=YE'P+#UVBRNM6.!0DVG7TL6XL2![R MJTP]
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M0R@.8( DACC0;E06A QBJK>8C&<DS$*7S<1Q_JGM$RU\\%,KP,]F(]B6X9]
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MS3NU-W\;=EWLPP '6\C[GQ=8KH2E*>:?WZ$-+"_4]JAHX$24M_H&=K..7.W
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MIKY.5LV;O%!ROGK4+_PZ8P(1GB@24ZAH$NO-"H>0A22#L22!B*F,*.=M5LW
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MHJE(>1AP"=,HH!"+1+M2.,X@QTJA6" 2X]31E>J'9&H[?&O!KE'?@ 8WN&^
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MI/BP_&34E7&C] ?>YZ958/W7%[2<EU^,);YI9BQ33(,PHS R/5MQ2 -(:1C
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MU+;953_Z+4]'AR)UZ,--C7M=A_X&[& '+7A3T64+OL?SR#ZL^3I.=)I[W-/
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M$$&%$;0@[?3.*0:[M8L'7@;6(6Z46"N*,X(?40>EY+_<Y4^_ZF_6FD#_L%$
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M1M_/%ZHJV#@C5*=)9G8!*+5D;YI*0#%60!.>Q%!CEC&G@Z%SC4]MZM4QCU;
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MU.AXA=&OJ'50(_W:LR/OBW]?U;[+B6_S[KM:B[EY?):I3.1:(&,P;!'U-->
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M><YR*E)&0 X5!PA!"2C2]F X$U#&L4!YYK6&7>UR<JN/D=C&P%:W(MV*R#L
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MRUU-;0&K>#:6QD;5 D:+G=A^JU$+OFX+1QC4!K;Q%6![4E:.>"5G..-['8M
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M7)!H#=!K;6"\H#L7/0X"Z9Q>Z)CT5KG_Q>?5O?CGRWQM?'A;XG+S:GO9V#V
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MJ/;'1>EC*^/TSB5;LC]>'\Q/__XOS6_,'Y:FY]__Y?\#4$L#!!0    ( )B
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MQ?PZS*<4)"^N">45EG$:4RBCC,TBU?<'0TZ*KN.<R&L!XYG2Q?+L\+'FU=M
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MD J2#VY"@$AB 5GHRRB,;#^D[6%J!G7:#P. C50W"!#^-ON.\VEUGC^?U*J
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M,3J>LS*^\/:5XAO0UZ]'W0YT>]?-L'#W<3Y.^!'G*]Y&R&-VK"!P5V-.1YY
M*-& *&3RLPIH9.NNB0_1TN_QMU<\;2_S86'GY6RZ&),>UAD "<??ZR"=ZQO#
M&UZ4X1P"%[5WAR>/4$L)MJBHHI2H<_-GCTT([#<_8Z\H:ZR=I^1VO9VFVI4+
M1SP8G;A+P)01H)!Y8I4%$%XR'8QPSO#F[M?%ZIVPI8>/K<.(?PBFK7)W?KR_
M.JTWL62CQ[-\?NR_QS]7/UJ,@HN.654O9BD&4A36@J,P&5RM2,K..IE4:YO6
MB;).@#/#!]P>]3$ E%W;21_#_,-\=9>75X-L+GT"GPLOILHJESHD0D?P0D9
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M@9#+JE+=. J]DX2"P?O(N#"Y_0/?S^GJ!LCG^W*R-QT.'9=5NFNV'(56);
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M4R170_-.9O&9=&G>2*>=NC1O(N"^8X'KC81_H\USV3TXH3,J9P58I 3EE8/
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M"N:,MDH,09Y!I)E\*?[1K!D?)+W0Y:!P\^=;Z>>K]2]=WI1AOU@XQYW50F&
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M%.TR]>4LJX!ND/+#DTG8^<G0&+^MZ#,\F/X85-L.(2B:@O7H(K H: NTFK9
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M4$L! A0#%     @ F( (574AGA/A P  Y@X  !4              ( !?B(
M &5X:&EB:70S,BTR<3(R,#(R+FAT;5!+ 0(4 Q0    ( )B "%7><^92.HH!
M (A5$  1              "  9(F  !M9VYX+3(P,C(P-C,P+FAT;5!+ 0(4
M Q0    ( )B "%4(#ME2+@T  *!]   1              "  ?NP 0!M9VYX
M+3(P,C(P-C,P+GAS9%!+ 0(4 Q0    ( )B "%51[K@9QA$  ,V=   5
M          "  5B^ 0!M9VYX+3(P,C(P-C,P7V-A;"YX;6Q02P$"% ,4
M" "8@ A5JEN5480^  !JR0( %0              @ %1T $ ;6=N>"TR,#(R
M,#8S,%]D968N>&UL4$L! A0#%     @ F( (58 7=2 ]EP  [(P& !4
M         ( !" \" &UG;G@M,C R,C V,S!?;&%B+GAM;%!+ 0(4 Q0    (
M )B "%4D2HD=VV   "6/!  5              "  7BF @!M9VYX+3(P,C(P
A-C,P7W!R92YX;6Q02P4&      L "P#A @  A@<#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
